PMID,Outcome,Sub-category,Value,Unit,Summary Statistics,Variation type,Variation value,Interval type,Interval low,Interval high,Subjects n,Population,Pregnancy Stage ,Gestational Age,P-value,Notes,_source_file,_source_folder,_source_sheet_original,_source_sheet_canonical,_row_index,_processed_at
434035.0,birth weight,,3310,grams,mean,SD,545.0,,,,30.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,2,2025-12-02T15:57:10.570299
434035.0,Apgar score 1' <7,,2,,,,,,,,30.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,3,2025-12-02T15:57:10.570299
434035.0,Apgar score 5' <7,,1,,,,,,,,30.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,4,2025-12-02T15:57:10.570299
434035.0,Complications,Small for dates,2,number,frequency,,,,,,30.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,5,2025-12-02T15:57:10.570299
434035.0,Complications,Large for dates,2,number,frequency,,,,,,30.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,6,2025-12-02T15:57:10.570299
434035.0,Complications,Premature,2,number,frequency,,,,,,30.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,7,2025-12-02T15:57:10.570299
434035.0,Complications,Post-term,1,number,frequency,,,,,,30.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,8,2025-12-02T15:57:10.570299
1163360.0,gestational age,,39,weeks,mean,SD,0.4,range,34,43,31.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,9,2025-12-02T15:57:10.570299
1163360.0,birth weight,full term,3087,grams,mean,SD,75.0,range,2130,3920,27.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,10,2025-12-02T15:57:10.570299
1163360.0,birth weight,preterm,1967.5,grams,mean,SD,364.1,range,1730,2510,4.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,11,2025-12-02T15:57:10.570299
1163360.0,Apgar score 1',,7.5,,mean,SD,0.4,range,1,9,31.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,12,2025-12-02T15:57:10.570299
1163360.0,Apgar score 2',,7.6,,mean,SD,0.5,range,1,9,31.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,13,2025-12-02T15:57:10.570299
1163360.0,Apgar score 5',,8.9,,mean,SD,0.2,range,7,10,31.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,14,2025-12-02T15:57:10.570299
1163360.0,Small for gestational age,,3,count,%,11.1,,,,,27.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,15,2025-12-02T15:57:10.570299
1163360.0,birth asphyxia,,3,count,,,,,,,31.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,16,2025-12-02T15:57:10.570299
1163360.0,methadone withdrawal,mild,5,count,%,17,,,,,29.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,17,2025-12-02T15:57:10.570299
1163360.0,methadone withdrawal,moderate,14,count,%,48,,,,,29.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,18,2025-12-02T15:57:10.570299
1163360.0,methadone withdrawal,severe,5,count,%,21,,,,,24.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,19,2025-12-02T15:57:10.570299
1163360.0,methadone withdrawal,any symptoms,25,count,%,86,,,,,29.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,20,2025-12-02T15:57:10.570299
1424407.0,heart rate,baseline,156,beats/min,median,,,range,107,184,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,21,2025-12-02T15:57:10.570299
1424407.0,,5 mMin,159,beats/min,median,,,range,113,188,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,22,2025-12-02T15:57:10.570299
1424407.0,,15 Min,140,beats/min,median,,,range,109,180,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,23,2025-12-02T15:57:10.570299
1424407.0,,30 Min,146,beats/min,median,,,range,108,178,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,24,2025-12-02T15:57:10.570299
1424407.0,,60 Min,151,beats/min,median,,,range,101,187,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,25,2025-12-02T15:57:10.570299
1424407.0,,120 Min,140,beats/min,median,,,range,103,185,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,26,2025-12-02T15:57:10.570299
1424407.0,,240 Min,133,beats/min,median,,,range,108,177,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,27,2025-12-02T15:57:10.570299
1424407.0,,480 Min,140,beats/min,median,,,range,106,180,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,28,2025-12-02T15:57:10.570299
1424407.0,,720 Min,144,beats/min,median,,,range,120,190,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,29,2025-12-02T15:57:10.570299
1424407.0,Mean blood pressure,baseline,62,mmHg,median,,,range,39,95,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,30,2025-12-02T15:57:10.570299
1424407.0,Mean blood pressure,5 mMin,55,mmHg,median,,,range,42,97,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,31,2025-12-02T15:57:10.570299
1424407.0,Mean blood pressure,15 Min,52,mmHg,median,,,range,40,84,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,32,2025-12-02T15:57:10.570299
1424407.0,Mean blood pressure,30 Min,55,mmHg,median,,,range,42,92,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,33,2025-12-02T15:57:10.570299
1424407.0,Mean blood pressure,60 Min,58,mmHg,median,,,range,38,97,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,34,2025-12-02T15:57:10.570299
1424407.0,Mean blood pressure,120 Min,58,mmHg,median,,,range,40,97,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,35,2025-12-02T15:57:10.570299
1424407.0,Mean blood pressure,240 Min,55,mmHg,median,,,range,36,98,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,36,2025-12-02T15:57:10.570299
1424407.0,Mean blood pressure,480 Min,60,mmHg,median,,,range,34,85,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,37,2025-12-02T15:57:10.570299
1424407.0,Mean blood pressure,720 Min,59,mmHg,median,,,range,34,85,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,38,2025-12-02T15:57:10.570299
1424407.0,Oxygen saturation,baseline,97,%,median,,,range,79,99,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,39,2025-12-02T15:57:10.570299
1424407.0,,5 mMin,97,%,median,,,range,78,99,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,40,2025-12-02T15:57:10.570299
1424407.0,,15 Min,96,%,median,,,range,83,99,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,41,2025-12-02T15:57:10.570299
1424407.0,,30 Min,97,%,median,,,range,81,99,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,42,2025-12-02T15:57:10.570299
1424407.0,,60 Min,97,%,median,,,range,80,99,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,43,2025-12-02T15:57:10.570299
1424407.0,,120 Min,97,%,median,,,range,82,99,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,44,2025-12-02T15:57:10.570299
1424407.0,,240 Min,97,%,median,,,range,78,99,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,45,2025-12-02T15:57:10.570299
1424407.0,,480 Min,97,%,median,,,range,77,99,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,46,2025-12-02T15:57:10.570299
1424407.0,,720 Min,97,%,median,,,range,80,90,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,47,2025-12-02T15:57:10.570299
1424407.0,pH,baseline,7.39,,median,,,range,7.3,7.53,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,48,2025-12-02T15:57:10.570299
1424407.0,,5 mMin,,,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,49,2025-12-02T15:57:10.570299
1424407.0,,15 Min,,,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,50,2025-12-02T15:57:10.570299
1424407.0,,30 Min,,,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,51,2025-12-02T15:57:10.570299
1424407.0,,60 Min,,,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,52,2025-12-02T15:57:10.570299
1424407.0,,120 Min,7.38,,median,,,range,7.29,7.55,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,53,2025-12-02T15:57:10.570299
1424407.0,,240 Min,,,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,54,2025-12-02T15:57:10.570299
1424407.0,,480 Min,,,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,55,2025-12-02T15:57:10.570299
1424407.0,,720 Min,7.35,,median,,,range,7.22,7.6,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,56,2025-12-02T15:57:10.570299
1424407.0,,24 Hours,7.35,,median,,,range,7.21,7.47,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,57,2025-12-02T15:57:10.570299
1424407.0,Pco2,baseline,4.8,kPa,median,,,range,3.1,6.3,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,58,2025-12-02T15:57:10.570299
1424407.0,,5 mMin,,kPa,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,59,2025-12-02T15:57:10.570299
1424407.0,,15 Min,,kPa,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,60,2025-12-02T15:57:10.570299
1424407.0,,30 Min,,kPa,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,61,2025-12-02T15:57:10.570299
1424407.0,,60 Min,,kPa,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,62,2025-12-02T15:57:10.570299
1424407.0,,120 Min,4.4,kPa,median,,,range,2.7,6.4,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,63,2025-12-02T15:57:10.570299
1424407.0,,240 Min,,kPa,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,64,2025-12-02T15:57:10.570299
1424407.0,,480 Min,,kPa,median,,,range,,,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,65,2025-12-02T15:57:10.570299
1424407.0,,720 Min,4.9,kPa,median,,,range,3.3,6.9,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,66,2025-12-02T15:57:10.570299
1424407.0,,24 Hours,5.3,kPa,median,,,range,2.7,6.6,21.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,67,2025-12-02T15:57:10.570299
1437393.0,minute ventilation (VE),Meperidine group,222,,ml/kg/min,SD,45.0,,,,8.0,Neonate,Postpartum (PP),day 1; 1-4 hours,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,68,2025-12-02T15:57:10.570299
1437393.0,minute ventilation (VE),Control group,223,,ml/kg/min,,59.0,,,,8.0,Neonate,Postpartum (PP),day 1; 1-4 hours,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,69,2025-12-02T15:57:10.570299
1437393.0,respiratory rate (RR),Meperidine group,46.3,,breaths/min,,6.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,70,2025-12-02T15:57:10.570299
1437393.0,respiratory rate (RR),Control group,57.9,,breaths/min,,17.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,71,2025-12-02T15:57:10.570299
1437393.0,Ti/Ttot (inspiratory time/total duration of respiratory cycle),Meperidine group,0.39,,,,0.02,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,72,2025-12-02T15:57:10.570299
1437393.0,Ti/Ttot (inspiratory time/total duration of respiratory cycle),Control group,0.39,,,,0.03,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,73,2025-12-02T15:57:10.570299
1437393.0,tidal volume (VT),Meperidine group,4.8,,ml/kg,,0.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,74,2025-12-02T15:57:10.570299
1437393.0,tidal volume (VT),Control group,4.1,,ml/kg,,1.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,75,2025-12-02T15:57:10.570299
1437393.0,VT/Ti,Meperidine group,33.1,,ml/s,,7.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,76,2025-12-02T15:57:10.570299
1437393.0,VT/Ti,Control group,32.3,,ml/s,,8.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,77,2025-12-02T15:57:10.570299
1437393.0,compliance of total respiratory system (CRS),Meperidine group,0.71,,ml/cm water/kg,,0.11,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,78,2025-12-02T15:57:10.570299
1437393.0,compliance of total respiratory system (CRS),Control group,0.7,,ml/cm water/kg,,0.09,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,79,2025-12-02T15:57:10.570299
1437393.0,Apnea >10s/100 min during active sleep,Meperidine group,2.25,,count,,2.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,80,2025-12-02T15:57:10.570299
1437393.0,Apnea >10s/100 min during active sleep,Control group,0.25,,count,,0.66,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,81,2025-12-02T15:57:10.570299
1437393.0,Apnea >3s/100 min during active sleep,Meperidine group,37.1,,count,,25.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,82,2025-12-02T15:57:10.570299
1437393.0,Apnea >3s/100 min during active sleep,Control group,11.2,,count,,25.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,83,2025-12-02T15:57:10.570299
1437393.0,Apnea >3s/100 min during quiet sleep,Meperidine group,4.35,,,,25.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,84,2025-12-02T15:57:10.570299
1437393.0,Apnea >3s/100 min during quiet sleep,Control group,2.32,,count,,25.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,85,2025-12-02T15:57:10.570299
1437393.0,Lowest arterial oxygen saturation (SaO2) during active sleep,Meperidine group,81.1,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,86,2025-12-02T15:57:10.570299
1437393.0,Lowest arterial oxygen saturation (SaO2) during active sleep,Control group,89.4,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,87,2025-12-02T15:57:10.570299
1437393.0,Time spent in arterial oxygen saturation (SaO2) <90% during active sleep,Meperidine group,14.3,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,88,2025-12-02T15:57:10.570299
1437393.0,Time spent in arterial oxygen saturation (SaO2) <90% during active sleep,Control group,1.3,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,89,2025-12-02T15:57:10.570299
1437393.0,Time spent in arterial oxygen saturation (SaO2) <90% during quiet sleep,Meperidine group,0.3,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,90,2025-12-02T15:57:10.570299
1437393.0,Time spent in arterial oxygen saturation (SaO2) <90% during quiet sleep,Control group,0,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,91,2025-12-02T15:57:10.570299
1437393.0,Time spent in wakefulness,Meperidine group,21.1,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,92,2025-12-02T15:57:10.570299
1437393.0,Time spent in wakefulness,Control group,13.2,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,93,2025-12-02T15:57:10.570299
1437393.0,Time spent in active sleep,Meperidine group,55.8,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,94,2025-12-02T15:57:10.570299
1437393.0,Time spent in active sleep,Control group,53.5,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,95,2025-12-02T15:57:10.570299
1437393.0,Time spent in quite sleep,Meperidine group,23.1,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,96,2025-12-02T15:57:10.570299
1437393.0,Time spent in quite sleep,Control group,33.1,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,97,2025-12-02T15:57:10.570299
1467165.0,duration of hospital stay,"Group A: : meperidine, morphine, or codeine IM or IV bolus",6.9,days,mean,,2.5,,,,32.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,98,2025-12-02T15:57:10.570299
1467165.0,duration of severe pain,"Group A: : meperidine, morphine, or codeine IM or IV bolus",2,days,mean,,1.8,,,,32.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,99,2025-12-02T15:57:10.570299
1467165.0,duration of hospital stay,Group B: patients receiving CIV morphine,7.1,days,mean,,4.0,,,,34.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,100,2025-12-02T15:57:10.570299
1467165.0,duration of severe pain,Group B: patients receiving CIV morphine,0.9,days,mean,,1.0,,,,34.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,101,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,"Group A: : meperidine, morphine, or codeine IM or IV bolus",9,,count,,,,,,32.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,102,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,"Group A: : meperidine, morphine, or codeine IM or IV bolus",9,,count,,,,,,32.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,103,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,"Group A: : meperidine, morphine, or codeine IM or IV bolus",4,,count,,,,,,32.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,104,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,"Group A: : meperidine, morphine, or codeine IM or IV bolus",8,,count,,,,,,32.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,105,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,"Group A: : meperidine, morphine, or codeine IM or IV bolus",13,,count,,,,,,32.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,106,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,"Group A: : meperidine, morphine, or codeine IM or IV bolus",2,,count,,,,,,32.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,107,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,Group B: patients receiving CIV morphine,5,,count,,,,,,34.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,108,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,Group B: patients receiving CIV morphine,12,,count,,,,,,34.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,109,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,Group B: patients receiving CIV morphine,9,,count,,,,,,34.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,110,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,Group B: patients receiving CIV morphine,4,,count,,,,,,34.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,111,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,Group B: patients receiving CIV morphine,25,,count,,,,,,34.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,112,2025-12-02T15:57:10.570299
1467165.0,frequency of opioid side effects,Group B: patients receiving CIV morphine,3,,count,,,,,,34.0,child,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,113,2025-12-02T15:57:10.570299
1632539.0,convulsive rigidity,,4,count,,,,,,,20.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,114,2025-12-02T15:57:10.570299
1683310.0,Apgar score >7,,40,,count,,,,,,40.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,115,2025-12-02T15:57:10.570299
1765214.0,Sedation,,0,,count,,,,,,16.0,Maternal,Labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,116,2025-12-02T15:57:10.570299
1765214.0,Respiratory depression,,0,,,,,,,,16.0,Maternal,Labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,117,2025-12-02T15:57:10.570299
1765214.0,Apgar score>8 at 1',,16,,,,,,,,16.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,118,2025-12-02T15:57:10.570299
1765214.0,Apgar score>8 at 5',,16,,,,,,,,16.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,119,2025-12-02T15:57:10.570299
2012289.0,adequate analgesia at 24 hours,bupivacaine alone,5,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,120,2025-12-02T15:57:10.570299
2012289.0,adequate analgesia at 24 hours,bupivacaine/morphine,11,count,,,,,,,15.0,children,,,0.01,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,121,2025-12-02T15:57:10.570299
2012289.0,nalbuphine supplemental analgesia at 24 hours,bupivacaine alone,11,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,122,2025-12-02T15:57:10.570299
2012289.0,nalbuphine supplemental analgesia at 24 hours,bupivacaine/morphine,0,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,123,2025-12-02T15:57:10.570299
2012289.0,paracetamol supplemental analgesia at 24 hours,bupivacaine alone,5,count,,,,,,,15.0,children,,,<0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,124,2025-12-02T15:57:10.570299
2012289.0,paracetamol supplemental analgesia at 24 hours,bupivacaine/morphine,3,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,125,2025-12-02T15:57:10.570299
2012289.0,time to awakening,bupivacaine alone,7.5,minutes,median,,,range,1,25,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,126,2025-12-02T15:57:10.570299
2012289.0,time to awakening,bupivacaine/morphine,5,minutes,median,,,,1,25,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,127,2025-12-02T15:57:10.570299
2012289.0,nausea/vomiting,bupivacaine alone,6,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,128,2025-12-02T15:57:10.570299
2012289.0,nausea/vomiting,bupivacaine/morphine,6,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,129,2025-12-02T15:57:10.570299
2012289.0,persistent vomiting,bupivacaine alone,3,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,130,2025-12-02T15:57:10.570299
2012289.0,persistent vomiting,bupivacaine/morphine,4,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,131,2025-12-02T15:57:10.570299
2012289.0,pruritis,bupivacaine alone,0,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,132,2025-12-02T15:57:10.570299
2012289.0,pruritis,bupivacaine/morphine,2,count,,,,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,133,2025-12-02T15:57:10.570299
2012289.0,Ventilatory rates,bupivacaine alone,24.2,breaths/min,mean,SD,4.3,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,134,2025-12-02T15:57:10.570299
2012289.0,Ventilatory rates,bupivacaine/morphine,23.4,breaths/min,mean,SD,3.7,,,,15.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,135,2025-12-02T15:57:10.570299
2078976.0,arterial pressure after infusion,,38.5,mmHg,mean,,4.9,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,136,2025-12-02T15:57:10.570299
2078976.0,arterial pressure after infusion,,37.1,mmHg,mean,,5.7,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,137,2025-12-02T15:57:10.570299
2078976.0,arterial pressure after infusion,,36.8,mmHg,mean,,5.6,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,138,2025-12-02T15:57:10.570299
2078976.0,arterial pressure after infusion,,38.8,mmHg,mean,,5.6,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,139,2025-12-02T15:57:10.570299
2078976.0,arterial pressure after infusion,,38,mmHg,mean,,5.8,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,140,2025-12-02T15:57:10.570299
2078976.0,heart rate after infusion,,139,beats/min,mean,,13.0,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,141,2025-12-02T15:57:10.570299
2078976.0,heart rate after infusion,,139,beats/min,mean,,16.0,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,142,2025-12-02T15:57:10.570299
2078976.0,heart rate after infusion,,140,beats/min,mean,,15.0,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,143,2025-12-02T15:57:10.570299
2078976.0,heart rate after infusion,,137,beats/min,mean,,13.0,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,144,2025-12-02T15:57:10.570299
2078976.0,heart rate after infusion,,136,beats/min,mean,,13.0,,,,10.0,neonate ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,145,2025-12-02T15:57:10.570299
2097341.0,Amnesia,,0,,count,,,,,,13.0,Maternal,Labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,146,2025-12-02T15:57:10.570299
2240676.0,pain VAS score,meperidine (24h),2,,,,,range,0.8,7.6,5.0,maternal,labor,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,147,2025-12-02T15:57:10.570299
2240676.0,pain VAS score,morphine (24h),2,,,,,,1.4,2.8,5.0,maternal,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,148,2025-12-02T15:57:10.570299
2240676.0,pain VAS score,meperidine (48h),1.7,,,,,,0.8,8.7,,maternal,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,149,2025-12-02T15:57:10.570299
2240676.0,pain VAS score,morphine (48h),1.3,,,,,,0.9,1.8,4.0,maternal,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,150,2025-12-02T15:57:10.570299
2240676.0,satisfaction VAS score,meperidine (24h),9.2,,,,,,7.3,9.6,,maternal,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,151,2025-12-02T15:57:10.570299
2240676.0,satisfaction VAS score,morphine (24h),9,,,,,,6.9,9.5,,maternal,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,152,2025-12-02T15:57:10.570299
2240676.0,satisfaction VAS score,meperidine (48h),8.25,,,,,,6.2,9.6,,maternal,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,153,2025-12-02T15:57:10.570299
2240676.0,satisfaction VAS score,morphine (48h),9.75,,,,,,8,9.8,4.0,maternal,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,154,2025-12-02T15:57:10.570299
2240676.0,sex ratio (M/F),meperidine,2022-03-02 00:00:00,,count,,,,,,5.0,neonate,delivery,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,155,2025-12-02T15:57:10.570299
2240676.0,sex ratio (M/F),morphine,2022-02-03 00:00:00,,count,,,,,,5.0,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,156,2025-12-02T15:57:10.570299
2240676.0,Gestational age,meperidine,38.6,,weeks,SD,0.89,,,,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,157,2025-12-02T15:57:10.570299
2240676.0,Gestational age,morphine,39.2,,weeks,,0.84,,,,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,158,2025-12-02T15:57:10.570299
2240676.0,birth weight,meperidine,3.66,,kg,,0.3,,,,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,159,2025-12-02T15:57:10.570299
2240676.0,birth weight,morphine,3.4,,kg,,0.46,,,,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,160,2025-12-02T15:57:10.570299
2240676.0,Time elapsed from nursing to nenatal exam,meperidine,1.6,,hours,,0.9,,,,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,161,2025-12-02T15:57:10.570299
2240676.0,Time elapsed from nursing to nenatal exam,morphine,0.87,,,,0.79,,,,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,162,2025-12-02T15:57:10.570299
2240676.0,Apgar score 1',meperidine,9,,,,,range,8,9,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,163,2025-12-02T15:57:10.570299
2240676.0,Apgar score 1',morphine,9,,,,,,8,9,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,164,2025-12-02T15:57:10.570299
2240676.0,Apgar score 5',meperidine,9,,,,,,9,9,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,165,2025-12-02T15:57:10.570299
2240676.0,Apgar score 5',morphine,9,,,,,,9,9,,neonate,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,166,2025-12-02T15:57:10.570299
2240676.0,NBAS score - alertness,meperidine,2,,,,,,2,3,,neonate,,,0.01,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,167,2025-12-02T15:57:10.570299
2240676.0,NBAS score - alertness,morphine,6,,,,,,4,8,,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,168,2025-12-02T15:57:10.570299
2240676.0,NBAS score - orientation to human face,meperidine,2,,,,,,1,5,,neonate,,,0.045,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,169,2025-12-02T15:57:10.570299
2240676.0,NBAS score - orientation to human face,morphine,6,,,,,,3,7,,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,170,2025-12-02T15:57:10.570299
2240676.0,NBAS score - orientation to human voice,meperidine,3,,,,,,2,5,,neonate,,,0.043,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,171,2025-12-02T15:57:10.570299
2240676.0,NBAS score - orientation to human voice,morphine,5,,,,,,4,6,,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,172,2025-12-02T15:57:10.570299
2240676.0,NBAS score - orientation to both face/voice,meperidine,2,,,,,,1,5,,neonate,,,0.035,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,173,2025-12-02T15:57:10.570299
2240676.0,NBAS score - orientation to both face/voice,morphine,6,,,,,,4,7,,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,174,2025-12-02T15:57:10.570299
2262875.0,Rh hemolytic disease,,4,,count,,,,,,5.0,Fetal,Trimester 3,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,175,2025-12-02T15:57:10.570299
2262875.0,Hydramnios,,1,,count,,,,,,5.0,Maternal,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,176,2025-12-02T15:57:10.570299
2262875.0,Fetal ascites,,1,,count,,,,,,5.0,Fetal,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,177,2025-12-02T15:57:10.570299
2485290.0,Opioid withdrawal symptoms,,1,,count,,,,,,1.0,Maternal,Trimester 3,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,178,2025-12-02T15:57:10.570299
2729393.0,Apgar <7 at 1 min,intravenous,1,,,,,,,,5.0,neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,179,2025-12-02T15:57:10.570299
2729393.0,Apgar <7 at 1 min,gluteus 1,1,,,,,,,,5.0,neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,180,2025-12-02T15:57:10.570299
2729393.0,Apgar >7 at 1 min,intravenous,4,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,181,2025-12-02T15:57:10.570299
2729393.0,Apgar >7 at 1 min,gluteus 1,4,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,182,2025-12-02T15:57:10.570299
2729393.0,Apgar <7 at 5 min,intravenous,0,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,183,2025-12-02T15:57:10.570299
2729393.0,Apgar <7 at 5 min,gluteus 1,0,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,184,2025-12-02T15:57:10.570299
2729393.0,Apgar >7 at 5 min,intravenous,5,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,185,2025-12-02T15:57:10.570299
2729393.0,Apgar >7 at 5 min,gluteus 1,5,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,186,2025-12-02T15:57:10.570299
2729393.0,Weeks gestation,intravenous,40,,weeks,SD,0.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,187,2025-12-02T15:57:10.570299
2729393.0,Weeks gestation,gluteus 1,39.4,,,,1.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,188,2025-12-02T15:57:10.570299
2729393.0,Birth weight,intravenous,3192,,grams,,471.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,189,2025-12-02T15:57:10.570299
2729393.0,Birth weight,gluteus 1,3469,,,,445.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,190,2025-12-02T15:57:10.570299
2729393.0,Apgar <7 at 1 min,deltoid,1,,,,,,,,5.0,neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,191,2025-12-02T15:57:10.570299
2729393.0,Apgar <7 at 1 min,gluteus 2,0,,,,,,,,5.0,neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,192,2025-12-02T15:57:10.570299
2729393.0,Apgar >7 at 1 min,deltoid,4,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,193,2025-12-02T15:57:10.570299
2729393.0,Apgar >7 at 1 min,gluteus 2,5,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,194,2025-12-02T15:57:10.570299
2729393.0,Apgar <7 at 5 min,deltoid,0,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,195,2025-12-02T15:57:10.570299
2729393.0,Apgar <7 at 5 min,gluteus 2,0,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,196,2025-12-02T15:57:10.570299
2729393.0,Apgar >7 at 5 min,deltoid,5,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,197,2025-12-02T15:57:10.570299
2729393.0,Apgar >7 at 5 min,gluteus 2,5,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,198,2025-12-02T15:57:10.570299
2729393.0,Weeks gestation,deltoid,39,,weeks,SD,0.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,199,2025-12-02T15:57:10.570299
2729393.0,Weeks gestation,gluteus 2,39,,,,1.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,200,2025-12-02T15:57:10.570299
2729393.0,Birth weight,deltoid,3485,,,,264.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,201,2025-12-02T15:57:10.570299
2729393.0,Birth weight,gluteus 2,3384,,,,402.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,202,2025-12-02T15:57:10.570299
3214378.0,Apgar score 1' 9-10,,40,,count,,,,,,101.0,neonate,delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,203,2025-12-02T15:57:10.570299
3214378.0,Apgar score 1'  7-8,,44,,,,,,,,,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,204,2025-12-02T15:57:10.570299
3214378.0,Apgar score 1'  5-6,,10,,,,,,,,,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,205,2025-12-02T15:57:10.570299
3214378.0,Apgar score 1'  3-4,,6,,,,,,,,,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,206,2025-12-02T15:57:10.570299
3214378.0,Apgar score 1'  1-2,,1,,,,,,,,,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,207,2025-12-02T15:57:10.570299
3214378.0,Apgar score 5' 9-10,,92,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,208,2025-12-02T15:57:10.570299
3214378.0,Apgar score 5' 7-8,,9,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,209,2025-12-02T15:57:10.570299
3214378.0, Pain at delivery/rectaI pain,,14,,count,,,,,,100.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,210,2025-12-02T15:57:10.570299
3214378.0,Nause/vomiting,,10,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,211,2025-12-02T15:57:10.570299
3214378.0,Disorientation,,3,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,212,2025-12-02T15:57:10.570299
3214378.0,Miscellaneous side effects,,16,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,213,2025-12-02T15:57:10.570299
3214378.0,Analgesia pain relief,,76,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,214,2025-12-02T15:57:10.570299
3214378.0,Elevation in mood,,42,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,215,2025-12-02T15:57:10.570299
3214378.0,Aware of contractions/labor,,34,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,216,2025-12-02T15:57:10.570299
3214378.0,Participation/in control,,27,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,217,2025-12-02T15:57:10.570299
3214378.0,Mobility,,26,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,218,2025-12-02T15:57:10.570299
3214378.0,Able to cope/enjoy,,19,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,219,2025-12-02T15:57:10.570299
3214378.0,Not feeling numb,,17,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,220,2025-12-02T15:57:10.570299
3214378.0,Able to push,,7,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,221,2025-12-02T15:57:10.570299
3214378.0,Miscellaneous,,48,,count,,,,,,,maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,222,2025-12-02T15:57:10.570299
3609434.0,number of patients suffered from mild to moderate pruritus,,11,,,,,,,,13.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,223,2025-12-02T15:57:10.570299
3840338.0,heart rate,skin incision,159,bpm,mean,SD,12.0,,,,9.0,infants,,,<0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,224,2025-12-02T15:57:10.570299
3840338.0,heart rate,skin closure,173,bpm,mean,SD,15.0,,,,9.0,infants,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,225,2025-12-02T15:57:10.570299
3840338.0,heart rate,in NICU,155,bpm,mean,SD,10.0,,,,9.0,infants,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,226,2025-12-02T15:57:10.570299
3840338.0,systolic blood pressure,in NICU,73,mmHg,mean,SD,22.0,,,,9.0,infants,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,227,2025-12-02T15:57:10.570299
3970110.0,<37 weeks gestation,,1,,count,,,,,,12.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,228,2025-12-02T15:57:10.570299
3970110.0,Cord entanglement,,2,,count,,,,,,12.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,229,2025-12-02T15:57:10.570299
3970110.0,Apgar score 1' <7,,2,,count,,,,,,12.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,230,2025-12-02T15:57:10.570299
3970110.0,Apgar score 5' <7,,1,,count,,,,,,12.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,231,2025-12-02T15:57:10.570299
3970110.0,Large for dates,,1,,count,,,,,,12.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,232,2025-12-02T15:57:10.570299
3970110.0,Small for dates,,1,,count,,,,,,12.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,233,2025-12-02T15:57:10.570299
3970110.0,Asphyxia,,2,,count,,,,,,12.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,234,2025-12-02T15:57:10.570299
3970110.0,Seizures,,1,,count,,,,,,12.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,235,2025-12-02T15:57:10.570299
3970110.0,Narcotic antagonist,,1,,count,,,,,,12.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,236,2025-12-02T15:57:10.570299
3981450.0,Apgar score 1' >7,,9,,count,,,,,,9.0,Neonate,Postpartum (PP),,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,237,2025-12-02T15:57:10.570299
3981450.0,Apgar score 5' >7,,9,,count,,,,,,9.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,238,2025-12-02T15:57:10.570299
3981450.0,Neonatal opiate withdrawal,,5,,count,,,,,,9.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,239,2025-12-02T15:57:10.570299
3981450.0,Paregoric for opiate withdrawal for ≤ 5 days,,5,,count,,,,,,9.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,240,2025-12-02T15:57:10.570299
3981450.0,Methadone withdrawal,,3,,count,,,,,,9.0,Maternal,Postpartum (PP),,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,241,2025-12-02T15:57:10.570299
3981450.0,Opioid withdrawal questionnaire score,,40,,,SD,7.0,,,,6.0,Maternal,Phase 1 - 27 weeks gestation,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,242,2025-12-02T15:57:10.570299
3981450.0,Opioid withdrawal questionnaire score,,44,,,,8.0,,,,6.0,,Phase 2 - 37 weeks gestation,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,243,2025-12-02T15:57:10.570299
3981450.0,Opioid withdrawal questionnaire score,,36,,,,7.0,,,,6.0,,Phase 3 - 2 weekspostpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,244,2025-12-02T15:57:10.570299
3981450.0,Opioid withdrawal questionnaire score,,38,,,,5.0,,,,6.0,,Phase 4 - 8 weekspostpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,245,2025-12-02T15:57:10.570299
4072588.0,Vomiting,Group 1,2,count,,,,,,,6.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,246,2025-12-02T15:57:10.570299
4072588.0,Vomiting,Group 2,3,count,,,,,,,11.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,247,2025-12-02T15:57:10.570299
6489427.0,plasma albumin,before bypass,32.4,mM,mean,SD,2.2,,,,5.0,pediatric ,,,<0.001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,248,2025-12-02T15:57:10.570299
6489427.0,plasma albumin,on bypass,15,mM,mean,SD,1.6,,,,5.0,pediatric ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,249,2025-12-02T15:57:10.570299
6896151.0,Residual pain score at 10 mins,,2.5,,,,,,,,25.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,250,2025-12-02T15:57:10.570299
6896151.0,Residual pain score at 25 mins,,1.5,,,,,,,,25.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,251,2025-12-02T15:57:10.570299
6896151.0,Type of delivery,vaginal,23,,,,,,,,25.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,252,2025-12-02T15:57:10.570299
6896151.0,Type of delivery,cesarean,2,,,,,,,,25.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,253,2025-12-02T15:57:10.570299
6896151.0,Apgar score >9,,22,,,,,,,,25.0,fetal,delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,254,2025-12-02T15:57:10.570299
6896151.0,Apgar score <9,misplaced umbilical cords,3,,,,,,,,25.0,fetal,delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,255,2025-12-02T15:57:10.570299
6896151.0,itching,,18,,,,,,,,25.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,256,2025-12-02T15:57:10.570299
6896151.0,somnolence,,15,,,,,,,,25.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,257,2025-12-02T15:57:10.570299
6896151.0,nausea/vomiting,,8,,,,,,,,25.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,258,2025-12-02T15:57:10.570299
6896151.0,urinary retention,,3,,,,,,,,25.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,259,2025-12-02T15:57:10.570299
6896151.0,headache,,4,,,,,,,,25.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,260,2025-12-02T15:57:10.570299
6897154.0,Pruritis,Group A,1,count,,,,,,,12.0,maternal,delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,261,2025-12-02T15:57:10.570299
6897154.0,Pruritis,Group B,2,count,,,,,,,12.0,maternal,delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,262,2025-12-02T15:57:10.570299
7211235.0,time to sustained respiration,Interval  between meperidine injection/delivery <60 min,23,seconds,mean,SD,8.0,,,,28.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,263,2025-12-02T15:57:10.570299
7211235.0,,Interval  between meperidine injection/delivery >60 min,35,seconds,mean,SD,15.0,,,,28.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,264,2025-12-02T15:57:10.570299
7545736.0,pain-intensity score,,,,,,,range,none,mild,2.0,pediatric ,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,265,2025-12-02T15:57:10.570299
7552591.0,change in Adrenaline concentration in plasma (0-6 hours),50 mcg/kg loading dose group,-0.22,nmol/l,median,,,IQR,-0.06,-0.37,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,266,2025-12-02T15:57:10.570299
7552591.0,change in Noradrenaline concentration in plasma (0-6 hours),50 mcg/kg loading dose group,-0.88,nmol/l,median,,,IQR,0.21,-1.26,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,267,2025-12-02T15:57:10.570299
7552591.0,change in Cortisol concentration in plasma (0-6 hours),50 mcg/kg loading dose group,-152,nmol/l,median,,,IQR,11,-209,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,268,2025-12-02T15:57:10.570299
7552591.0,change in Noradrenaline concentration in plasma (0-6 hours),200 mcg/kg loading dose group,-0.09,nmol/l,median,,,IQR,0.06,-0.83,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,269,2025-12-02T15:57:10.570299
7552591.0,change in Cortisol concentration in plasma (0-6 hours),200 mcg/kg loading dose group,-0.93,nmol/l,median,,,IQR,-0.2,-2.71,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,270,2025-12-02T15:57:10.570299
7552591.0,change in Noradrenaline concentration in plasma (0-6 hours),200 mcg/kg loading dose group,-111,nmol/l,median,,,IQR,-18,-457,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,271,2025-12-02T15:57:10.570299
7552591.0,Behavioural activity scores (0-30 minutes),50 mcg/kg loading dose group,9,,count,,,,,,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,272,2025-12-02T15:57:10.570299
7552591.0,Behavioural activity scores (0-30 minutes),50 mcg/kg loading dose group,3,,count,,,,,,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,273,2025-12-02T15:57:10.570299
7552591.0,Respiratory effort scores (0-30 minutes),50 mcg/kg loading dose group,9,,count,,,,,,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,274,2025-12-02T15:57:10.570299
7552591.0,Respiratory effort scores (0-30 minutes),50 mcg/kg loading dose group,4,,count,,,,,,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,275,2025-12-02T15:57:10.570299
7552591.0,Behavioural activity scores (0-30 minutes),200 mcg/kg loading dose group,12,,count,,,,,,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,276,2025-12-02T15:57:10.570299
7552591.0,Behavioural activity scores (0-30 minutes),200 mcg/kg loading dose group,1,,count,,,,,,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,277,2025-12-02T15:57:10.570299
7552591.0,Respiratory effort scores (0-30 minutes),200 mcg/kg loading dose group,7,,count,,,,,,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,278,2025-12-02T15:57:10.570299
7552591.0,Respiratory effort scores (0-30 minutes),200 mcg/kg loading dose group,6,,count,,,,,,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,279,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of blood pressure,50 mcg/kg loading dose group,-2,mmHg,median,,,IQR,-1,-3,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,280,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of heart rate,50 mcg/kg loading dose group,0,bpm,median,,,IQR,3,-10,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,281,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of PH,50 mcg/kg loading dose group,-0.02,,median,,,IQR,-0.008,-0.032,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,282,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of PCO2,50 mcg/kg loading dose group,0.15,kPa,median,,,IQR,-0.025,0.54,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,283,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of PO2,50 mcg/kg loading dose group,0,kPa,median,,,IQR,-1.15,1.15,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,284,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of a:A ratio,50 mcg/kg loading dose group,-0.004,,median,,,IQR,0.002,-0.023,13.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,285,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of blood pressure,200 mcg/kg loading dose group,-2.5,mmHg,median,,,IQR,-1,-6,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,286,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of heart rate,200 mcg/kg loading dose group,-6,bpm,median,,,IQR,-1,-9,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,287,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of PH,200 mcg/kg loading dose group,-0.075,,median,,,IQR,-0.05,-0.09,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,288,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of PCO2,200 mcg/kg loading dose group,0.8,kPa,median,,,IQR,0.35,1.2,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,289,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of PO2,200 mcg/kg loading dose group,-2.05,kPa,median,,,IQR,-0.2,-4.6,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,290,2025-12-02T15:57:10.570299
7552591.0,changes (0-30 minutes) of a:A ratio,200 mcg/kg loading dose group,-0.072,,median,,,IQR,-0.05,-0.099,14.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,291,2025-12-02T15:57:10.570299
7574018.0,Apgar score 1',>8,21,count,frequency,,,,,,21.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,292,2025-12-02T15:57:10.570299
7574018.0,Apgar score 5',>8,21,count,frequency,,,,,,21.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,293,2025-12-02T15:57:10.570299
7574018.0,umbilical arterial pH,,7.26,,mean,SD,0.03,,,,21.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,294,2025-12-02T15:57:10.570299
7574018.0,umbilical venous pH,,7.33,,mean,SD,0.03,,,,21.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,295,2025-12-02T15:57:10.570299
7574018.0,umbilical arterial PO2,,17.6,mmHg,mean,SD,8.4,,,,21.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,296,2025-12-02T15:57:10.570299
7574018.0,umbilical venous PO2,,25,mmHg,mean,SD,5.3,,,,21.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,297,2025-12-02T15:57:10.570299
7574018.0,umbilical arterial PCO2,,53,mmHg,mean,SD,9.9,,,,21.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,298,2025-12-02T15:57:10.570299
7574018.0,umbilical venous PCO2,,44.3,mmHg,mean,SD,3.2,,,,21.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,299,2025-12-02T15:57:10.570299
7589618.0,Number of oocytes retrieved,Midazolam,12.3,count,mean,SD,1.1,,,,15.0,adult,non-pregnant,,>0.05,p for comparing outcomes between the three drugs,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,300,2025-12-02T15:57:10.570299
7589618.0,Number of oocytes fertilized,Midazolam,6.3,count,mean,SD,0.85,,,,15.0,adult,non-pregnant,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,301,2025-12-02T15:57:10.570299
7589618.0,Number of embryos transferred,Midazolam,2.4,count,mean,SD,0.16,,,,15.0,adult,non-pregnant,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,302,2025-12-02T15:57:10.570299
7589618.0,Pregnancy rate,Midazolam,26.7,%,mean,,,,,,15.0,adult,non-pregnant,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,303,2025-12-02T15:57:10.570299
7589618.0,Number of oocytes retrieved,Fentanyl,12,count,mean,SD,1.3,,,,15.0,adult,non-pregnant,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,304,2025-12-02T15:57:10.570299
7589618.0,Number of oocytes fertilized,Fentanyl,6.3,count,mean,SD,0.7,,,,15.0,adult,non-pregnant,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,305,2025-12-02T15:57:10.570299
7589618.0,Number of embryos transferred,Fentanyl,2.3,count,mean,SD,0.13,,,,15.0,adult,non-pregnant,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,306,2025-12-02T15:57:10.570299
7589618.0,Pregnancy rate,Fentanyl,26.7,%,mean,,,,,,15.0,adult,non-pregnant,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,307,2025-12-02T15:57:10.570299
7589618.0,Number of oocytes retrieved,Alfentanil,12.4,count,mean,SD,1.93,,,,13.0,adult,non-pregnant,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,308,2025-12-02T15:57:10.570299
7589618.0,Number of oocytes fertilized,Alfentanil,7.2,count,mean,SD,1.25,,,,13.0,adult,non-pregnant,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,309,2025-12-02T15:57:10.570299
7589618.0,Number of embryos transferred,Alfentanil,2,count,mean,SD,0.11,,,,12.0,adult,non-pregnant,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,310,2025-12-02T15:57:10.570299
7589618.0,Pregnancy rate,Alfentanil,30.8,%,mean,,,,,,13.0,adult,non-pregnant,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,311,2025-12-02T15:57:10.570299
7631952.0,Arterial pH,Bupivacaine,7.25,,,,0.02,,,,13.0,Fetal,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,312,2025-12-02T15:57:10.570299
7631952.0,Arterial PO2,Bupivacaine,18,,mmHg,,2.1,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,313,2025-12-02T15:57:10.570299
7631952.0,Arterial PCO2,Bupivacaine,56,,mmHg,,3.3,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,314,2025-12-02T15:57:10.570299
7631952.0,Arterial HCO2,Bupivacaine,24,,mEq/L,,0.7,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,315,2025-12-02T15:57:10.570299
7631952.0,Venous pH,Bupivacaine,7.37,,,,0.01,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,316,2025-12-02T15:57:10.570299
7631952.0,Venous PO2,Bupivacaine,27,,mmHg,,1.6,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,317,2025-12-02T15:57:10.570299
7631952.0,Venous PCO2,Bupivacaine,40,,mmHg,,1.4,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,318,2025-12-02T15:57:10.570299
7631952.0,Venous HCO2,Bupivacaine,23,,mEq/L,,0.4,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,319,2025-12-02T15:57:10.570299
7631952.0,Arterial pH,Bupivacaine- Sufentanil,7.25,,,,0.03,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,320,2025-12-02T15:57:10.570299
7631952.0,Arterial PO2,Bupivacaine- Sufentanil,18,,mmHg,,1.8,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,321,2025-12-02T15:57:10.570299
7631952.0,Arterial PCO2,Bupivacaine- Sufentanil,60,,mmHg,,4.1,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,322,2025-12-02T15:57:10.570299
7631952.0,Arterial HCO2,Bupivacaine- Sufentanil,26,,mEq/L,,0.7,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,323,2025-12-02T15:57:10.570299
7631952.0,Venous pH,Bupivacaine- Sufentanil,7.32,,,,0.02,,,,9.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,324,2025-12-02T15:57:10.570299
7631952.0,Venous PO2,Bupivacaine- Sufentanil,26,,mmHg,,1.2,,,,9.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,325,2025-12-02T15:57:10.570299
7631952.0,Venous PCO2,Bupivacaine- Sufentanil,49,,mmHg,,2.8,,,,9.0,,,,0.003,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,326,2025-12-02T15:57:10.570299
7631952.0,Venous HCO2,Bupivacaine- Sufentanil,24,,mEq/L,,0.5,,,,9.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,327,2025-12-02T15:57:10.570299
7631952.0,Arterial pH,Bupivacaine- Fentanyl,7.28,,,,0.02,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,328,2025-12-02T15:57:10.570299
7631952.0,Arterial PO2,Bupivacaine- Fentanyl,17,,mmHg,,1.3,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,329,2025-12-02T15:57:10.570299
7631952.0,Arterial PCO2,Bupivacaine- Fentanyl,55,,mmHg,,2.2,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,330,2025-12-02T15:57:10.570299
7631952.0,Arterial HCO2,Bupivacaine- Fentanyl,26,,mEq/L,,0.4,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,331,2025-12-02T15:57:10.570299
7631952.0,Venous pH,Bupivacaine- Fentanyl,7.37,,,,0.01,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,332,2025-12-02T15:57:10.570299
7631952.0,Venous PO2,Bupivacaine- Fentanyl,31,,mmHg,,1.7,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,333,2025-12-02T15:57:10.570299
7631952.0,Venous PCO2,Bupivacaine- Fentanyl,40,,mmHg,,1.2,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,334,2025-12-02T15:57:10.570299
7631952.0,Venous HCO2,Bupivacaine- Fentanyl,23,,mEq/L,,0.5,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,335,2025-12-02T15:57:10.570299
7631952.0,Gestational age,Bupivacaine,39,,wk,SD,0.3,,,,13.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,336,2025-12-02T15:57:10.570299
7631952.0,birth length,Bupivacaine,52,,cm,,1.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,337,2025-12-02T15:57:10.570299
7631952.0,birth weight,Bupivacaine,3689,,gm,,148.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,338,2025-12-02T15:57:10.570299
7631952.0,male,Bupivacaine,6,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,339,2025-12-02T15:57:10.570299
7631952.0,female,Bupivacaine,7,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,340,2025-12-02T15:57:10.570299
7631952.0,Gestational age,Bupivacaine- Sufentanil,39,,wk,,0.4,,,,9.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,341,2025-12-02T15:57:10.570299
7631952.0,birth length,Bupivacaine- Sufentanil,52,,cm,,1.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,342,2025-12-02T15:57:10.570299
7631952.0,birth weight,Bupivacaine- Sufentanil,3569,,gm,,159.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,343,2025-12-02T15:57:10.570299
7631952.0,male,Bupivacaine- Sufentanil,6,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,344,2025-12-02T15:57:10.570299
7631952.0,female,Bupivacaine- Sufentanil,3,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,345,2025-12-02T15:57:10.570299
7631952.0,Gestational age,Bupivacaine-fentanyl,40,,wk,,0.3,,,,14.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,346,2025-12-02T15:57:10.570299
7631952.0,birth length,Bupivacaine-fentanyl,51,,cm,,0.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,347,2025-12-02T15:57:10.570299
7631952.0,birth weight,Bupivacaine-fentanyl,3461,,gm,,197.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,348,2025-12-02T15:57:10.570299
7631952.0,male,Bupivacaine-fentanyl,6,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,349,2025-12-02T15:57:10.570299
7631952.0,female,Bupivacaine-fentanyl,8,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,350,2025-12-02T15:57:10.570299
7631952.0,Apgar <7 at 1 min,Bupivacaine,2,,,,,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,351,2025-12-02T15:57:10.570299
7631952.0,Apgar <7 at 5 min,Bupivacaine,0,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,352,2025-12-02T15:57:10.570299
7631952.0,time to sustained respiration,Bupivacaine,28,,s,,5.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,353,2025-12-02T15:57:10.570299
7631952.0,NACS at 15 min,Bupivacaine,34,,,,1.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,354,2025-12-02T15:57:10.570299
7631952.0,NACS at 2 hrs,Bupivacaine,34.4,,,,0.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,355,2025-12-02T15:57:10.570299
7631952.0,NACS at 24 hrs,Bupivacaine,36.8,,,,0.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,356,2025-12-02T15:57:10.570299
7631952.0,Apgar <7 at 1 min,Bupivacaine- Sufentanil,1,,,,,,,,9.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,357,2025-12-02T15:57:10.570299
7631952.0,Apgar <7 at 5 min,Bupivacaine- Sufentanil,0,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,358,2025-12-02T15:57:10.570299
7631952.0,time to sustained respiration,Bupivacaine- Sufentanil,28,,s,,11.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,359,2025-12-02T15:57:10.570299
7631952.0,NACS at 15 min,Bupivacaine- Sufentanil,32.7,,,,0.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,360,2025-12-02T15:57:10.570299
7631952.0,NACS at 2 hrs,Bupivacaine- Sufentanil,34,,,,0.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,361,2025-12-02T15:57:10.570299
7631952.0,NACS at 24 hrs,Bupivacaine- Sufentanil,37.1,,,,0.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,362,2025-12-02T15:57:10.570299
7631952.0,Apgar <7 at 1 min,Bupivacaine- Fentanyl,0,,,,,,,,14.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,363,2025-12-02T15:57:10.570299
7631952.0,Apgar <7 at 5 min,Bupivacaine- Fentanyl,0,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,364,2025-12-02T15:57:10.570299
7631952.0,time to sustained respiration,Bupivacaine- Fentanyl,34,,s,,10.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,365,2025-12-02T15:57:10.570299
7631952.0,NACS at 15 min,Bupivacaine- Fentanyl,33.4,,,,0.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,366,2025-12-02T15:57:10.570299
7631952.0,NACS at 2 hrs,Bupivacaine- Fentanyl,34.9,,,,0.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,367,2025-12-02T15:57:10.570299
7631952.0,NACS at 24 hrs,Bupivacaine- Fentanyl,34.7,,,,0.8,,,,,,,,0.02, p for B-F vs B/B-S,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,368,2025-12-02T15:57:10.570299
7999650.0,Time to maximum pain relief,Group A - alfentanil group,11.9,min,mean,SD,9.0,,,,12.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,369,2025-12-02T15:57:10.570299
7999650.0,VAS pain score - % reduction at 30 minutes,Group A - alfentanil group,99.6,%,mean,SD,1.2,,,,12.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,370,2025-12-02T15:57:10.570299
7999650.0,VAS pain score - % reduction at 120 minutes,Group A - alfentanil group,97.6,%,mean,SD,7.6,,,,12.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,371,2025-12-02T15:57:10.570299
7999650.0,umbilical pH,Group A - alfentanil group,7.32,,mean,SD,0.06,,,,12.0,fetal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,372,2025-12-02T15:57:10.570299
7999650.0,Respiratory rate,Group A - alfentanil group,51,breaths/min,mean,SD,10.0,,,,12.0,fetal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,373,2025-12-02T15:57:10.570299
7999650.0,FHR- variable deceleration,Group A - alfentanil group,1,count,mean,SD,,,,,12.0,fetal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,374,2025-12-02T15:57:10.570299
7999650.0,Time to maximum pain relief,Group B - fentanyl group,14.6,min,mean,SD,11.8,,,,12.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,375,2025-12-02T15:57:10.570299
7999650.0,VAS pain score - % reduction at 30 minutes,Group B - fentanyl group,84,%,mean,SD,24.8,,,,12.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,376,2025-12-02T15:57:10.570299
7999650.0,VAS pain score - % reduction at 120 minutes,Group B - fentanyl group,89.2,%,mean,SD,21.5,,,,12.0,maternal,labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,377,2025-12-02T15:57:10.570299
7999650.0,umbilical pH,Group B - fentanyl group,7.29,,mean,SD,0.08,,,,12.0,fetal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,378,2025-12-02T15:57:10.570299
7999650.0,Respiratory rate,Group B - fentanyl group,47,breaths/min,mean,SD,8.0,,,,12.0,fetal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,379,2025-12-02T15:57:10.570299
7999650.0,FHR - decrease in baseline/increase in variability,Group B - fentanyl group,1,count,,,,,,,12.0,fetal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,380,2025-12-02T15:57:10.570299
8260056.0,Apgar score 5',,8,,,,,,,,12.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,381,2025-12-02T15:57:10.570299
8442811.0,postoperative serum beta-endorphin concentration,,104,pg/ml,mean,,62.0,range,26,320,20.0,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,382,2025-12-02T15:57:10.570299
8442811.0,serum beta-endorphin content following the conset of morphine therapy,,59,pg/ml,mean,,18.0,range,33,116,20.0,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,383,2025-12-02T15:57:10.570299
8442811.0,serum beta-endorphin content at the time of discontinuation of morphine therapy,,76,pg/ml,mean,,14.0,range,49,97,20.0,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,384,2025-12-02T15:57:10.570299
8706774.0,Birth weight,,3448,,g,SD,358.0,,,,28.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,385,2025-12-02T15:57:10.570299
8706774.0,Apgar score 5',,10,,,,,,,,28.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,386,2025-12-02T15:57:10.570299
8706774.0,Apgar score 1',,8,,,,,,,,1.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,387,2025-12-02T15:57:10.570299
8706774.0,Apgar score 1',,3,,,,,,,,1.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,388,2025-12-02T15:57:10.570299
8706774.0,Dizziness,,11,,%,,,,,,28.0,Maternal,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,389,2025-12-02T15:57:10.570299
8706774.0,Drowsiness,,7,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,390,2025-12-02T15:57:10.570299
8706774.0,Nausea/vomiting,,7,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,391,2025-12-02T15:57:10.570299
8706774.0,Pain relief,,54,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,392,2025-12-02T15:57:10.570299
8839086.0,VAS ,,43,min,mean,,16.0,,,,17.0,adolescent,,,,"blood samples were collected the morning after surgery (Day 1),/the  following morning (Day 2)",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,393,2025-12-02T15:57:10.570299
8839086.0,VAS ,,35.4,min,mean,,20.7,,,,13.0,adolescent,,,,"blood samples were collected the morning after surgery (Day 1),/the  following morning (Day 2)",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,394,2025-12-02T15:57:10.570299
9055894.0,number of infants who sucked the  breast during the nbvxvation (relative frequencies),a “short DDI”  group (1.1-5.3 h),3,,,,,,,,7.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,395,2025-12-02T15:57:10.570299
9055894.0,number of infants who sucked the  breast during the nbvxvation (relative frequencies),“long DDI”  group (8.1-9.9 h),4,,,,,,,,6.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,396,2025-12-02T15:57:10.570299
9055894.0,age at first clenched fist,a “short DDI”  group (1.1-5.3 h),12,min,median,,,IQR,11,20,7.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,397,2025-12-02T15:57:10.570299
9055894.0,age at first Hand-to-mouth movement,a “short DDI”  group (1.1-5.3 h),19,min,median,,,IQR,12,27,7.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,398,2025-12-02T15:57:10.570299
9055894.0,age at first Mouth movement,a “short DDI”  group (1.1-5.3 h),22,min,median,,,IQR,16,24,7.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,399,2025-12-02T15:57:10.570299
9055894.0,age at first Lip movement,a “short DDI”  group (1.1-5.3 h),20,min,median,,,IQR,13,24,7.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,400,2025-12-02T15:57:10.570299
9055894.0,age at first Rooting nioi’ement,a “short DDI”  group (1.1-5.3 h),24,min,median,,,IQR,14,30,7.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,401,2025-12-02T15:57:10.570299
9055894.0,age at first Sucking moveinent ,a “short DDI”  group (1.1-5.3 h),45,min,median,,,IQR,30,68,7.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,402,2025-12-02T15:57:10.570299
9055894.0,age at first Breastfeed,a “short DDI”  group (1.1-5.3 h),66,min,median,,,IQR,56,80,7.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,403,2025-12-02T15:57:10.570299
9055894.0,age at first clenched fist,“long DDI”  group (8.1-9.9 h),8,min,median,,,IQR,4,9,6.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,404,2025-12-02T15:57:10.570299
9055894.0,age at first Hand-to-mouth movement,“long DDI”  group (8.1-9.9 h),14,min,median,,,IQR,11,15,6.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,405,2025-12-02T15:57:10.570299
9055894.0,age at first Mouth movement,“long DDI”  group (8.1-9.9 h),11,min,median,,,IQR,8,14,6.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,406,2025-12-02T15:57:10.570299
9055894.0,age at first Lip movement,“long DDI”  group (8.1-9.9 h),10,min,median,,,IQR,6,14,6.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,407,2025-12-02T15:57:10.570299
9055894.0,age at first Rooting nioi’ement,“long DDI”  group (8.1-9.9 h),15,min,median,,,IQR,10,38,6.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,408,2025-12-02T15:57:10.570299
9055894.0,age at first Sucking moveinent ,“long DDI”  group (8.1-9.9 h),17,min,median,,,IQR,14,23,6.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,409,2025-12-02T15:57:10.570299
9055894.0,age at first Breastfeed,“long DDI”  group (8.1-9.9 h),103,min,median,,,IQR,95,111,6.0,infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,410,2025-12-02T15:57:10.570299
9203876.0,umbilical cord arterial pH value,,7.22,,mean,,0.08,,,,40.0,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,411,2025-12-02T15:57:10.570299
9203876.0,umbilical cord venous pH value,,7.29,,mean,,0.06,,,,40.0,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,412,2025-12-02T15:57:10.570299
9203876.0,umbilical cord arterial Po2,,2.3,kPa,mean,,0.2,,,,40.0,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,413,2025-12-02T15:57:10.570299
9203876.0,umbilical cord venous Po2,,4.1,kPa,mean,,0.2,,,,40.0,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,414,2025-12-02T15:57:10.570299
9203876.0,Apgar score at 5 min,,>7,,,,,,,,40.0,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,415,2025-12-02T15:57:10.570299
9203876.0,NACS 2 h  after  delivery,,38,,median,,,IQR,36.5,39.5,40.0,neonate,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,416,2025-12-02T15:57:10.570299
9585276.0,Time to oral intake,,25.4,hours,mean,,27.0,,,,26.0,Infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,417,2025-12-02T15:57:10.570299
9585276.0,Side effects,,20,,count,,,,,,26.0,Infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,418,2025-12-02T15:57:10.570299
9585276.0,Side effects,,5,,count,,,,,,26.0,Infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,419,2025-12-02T15:57:10.570299
9585276.0,Side effects,,1,,count,,,,,,26.0,Infant,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,420,2025-12-02T15:57:10.570299
9637638.0,Arterial pH,,7.36,,,SD,0.03,range,7.32,7.42,16.0,Maternal,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,421,2025-12-02T15:57:10.570299
9637638.0,Arterial PaCO2,,36.8,,mmHg,,3.1,,29,42,16.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,422,2025-12-02T15:57:10.570299
9637638.0,Arterial PaO2,,171,,mmHg,,38.8,,91,94,16.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,423,2025-12-02T15:57:10.570299
9637638.0,Arterial SaO2,,98.9,,%,,0.7,,97,99.5,14.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,424,2025-12-02T15:57:10.570299
9637638.0,Hypotension,,1,,count,,,,,,17.0,Maternal,Labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,425,2025-12-02T15:57:10.570299
9637638.0,Exessive sedation,,2,,count,,,,,,17.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,426,2025-12-02T15:57:10.570299
9637638.0,Dizziness,,1,,count,,,,,,17.0,Maternal,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,427,2025-12-02T15:57:10.570299
9637638.0,Exessive sedation,,4,,count,,,,,,17.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,428,2025-12-02T15:57:10.570299
9637638.0,umbilical vein pH,,7.27,,,SD,0.6,range,7.07,7.34,16.0,Fetal,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,429,2025-12-02T15:57:10.570299
9637638.0,umbilical vein PaCO2,,51.1,,mmHg,,7.6,,42,70.6,16.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,430,2025-12-02T15:57:10.570299
9637638.0,umbilical vein PaO2,,29.8,,mmHg,,5.1,,20,36,16.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,431,2025-12-02T15:57:10.570299
9637638.0,umbilical vein SaO2,,46.9,,%,,12.6,,25.5,64.7,15.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,432,2025-12-02T15:57:10.570299
9637638.0,umbilical artery pH,,7.22,,,,0.06,,7.02,7.28,16.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,433,2025-12-02T15:57:10.570299
9637638.0,umbilical artery PaCO2,,60.6,,mmHg,,11.2,,41,84,16.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,434,2025-12-02T15:57:10.570299
9637638.0,umbilical artery PaO2,,15.1,,mmHg,,4.8,,5.3,26.5,16.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,435,2025-12-02T15:57:10.570299
9637638.0,umbilical artery SaO2,,14.9,,%,,7.2,,2.2,27.3,14.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,436,2025-12-02T15:57:10.570299
9637638.0,Apgar score 1',,8,,,% >7,84.0,range,4,9,17.0,Neonate,delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,437,2025-12-02T15:57:10.570299
9637638.0,Apgar score 5',,9,,,,100.0,,8,9,17.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,438,2025-12-02T15:57:10.570299
9637638.0,Apgar score 10',,9,,,,100.0,,9,10,17.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,439,2025-12-02T15:57:10.570299
9637638.0,Apgar score 20',,9,,,,100.0,,9,10,17.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,440,2025-12-02T15:57:10.570299
9637638.0,NACS score 30',,37,,,% >35,100.0,range,35,39,17.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,441,2025-12-02T15:57:10.570299
9637638.0,NACS score 60',,35,,,,82.0,,34,39,17.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,442,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery pH,control group,7.28,,,,,range,7.1,7.35,60.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,443,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery PO2,control group,1.7,,kPa,,,,0.7,3.3,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,444,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery base excess,control group,-6.7,,mM,,,,-2.7,-16.5,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,445,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery pH,control group,7.35,,,,,,7.12,7.45,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,446,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery PO2,control group,3.4,,kPa,,,,2,6.3,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,447,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery base excess,control group,-7.5,,mM,,,,-1.8,-12,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,448,2025-12-02T15:57:10.570299
9667297.0,Apgar score 1',control group,9,,,,,,1,10,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,449,2025-12-02T15:57:10.570299
9667297.0,Apgar score 5',control group,10,,,,,,6,10,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,450,2025-12-02T15:57:10.570299
9667297.0,NACS at 2h,control group,36,,,,,,32,38,56.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,451,2025-12-02T15:57:10.570299
9667297.0,NACS at 24h,control group,37,,,,,,33,39,50.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,452,2025-12-02T15:57:10.570299
9667297.0,NACS <35 at 2h,control group,7,,count,,,,,,56.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,453,2025-12-02T15:57:10.570299
9667297.0,NACS <35 at 24h,control group,3,,,,,,,,50.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,454,2025-12-02T15:57:10.570299
9667297.0,tcPCO2 intercept,control group,5.2,,kPa,SD,1.5,,,,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,455,2025-12-02T15:57:10.570299
9667297.0,tcPCO2 gradient,control group,-0.07,,Kpa/h,,0.13,,,,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,456,2025-12-02T15:57:10.570299
9667297.0,tcPCO2 at 20 min,control group,5.2,,kPa,,1.2,,,,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,457,2025-12-02T15:57:10.570299
9667297.0,tcPCO2 at 90 min,control group,5,,kPa,,0.8,,,,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,458,2025-12-02T15:57:10.570299
9667297.0,tcPO2 intercept,control group,8.3,,kPa,,2.1,,,,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,459,2025-12-02T15:57:10.570299
9667297.0,tcPO2 gradient,control group,0.14,,Kpa/h,,0.27,,,,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,460,2025-12-02T15:57:10.570299
9667297.0,tcPO2 at 20 min,control group,8.5,,kPa,,1.9,,,,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,461,2025-12-02T15:57:10.570299
9667297.0,tcPO2 at 90 min,control group,9.1,,kPa,,2.9,,,,60.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,462,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery pH,fentanyl group,7.22,,,,,range,7.09,7.32,54.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,463,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery PO2,fentanyl group,2.1,,kPa,,,,1,4.3,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,464,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery base excess,fentanyl group,-7.6,,mM,,,,-2,-18.3,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,465,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery pH,fentanyl group,7.29,,,,,,7.18,7.41,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,466,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery PO2,fentanyl group,3.8,,kPa,,,,1.9,5.6,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,467,2025-12-02T15:57:10.570299
9667297.0,Umbilical artery base excess,fentanyl group,-7.7,,mM,,,,-1.8,-13.1,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,468,2025-12-02T15:57:10.570299
9667297.0,Apgar score 1',fentanyl group,9,,,,,,3,10,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,469,2025-12-02T15:57:10.570299
9667297.0,Apgar score 5',fentanyl group,10,,,,,,8,10,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,470,2025-12-02T15:57:10.570299
9667297.0,NACS at 2h,fentanyl group,35,,,,,,29,39,50.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,471,2025-12-02T15:57:10.570299
9667297.0,NACS at 24h,fentanyl group,37,,,,,,31,39,48.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,472,2025-12-02T15:57:10.570299
9667297.0,NACS <35 at 2h,fentanyl group,9,,count,,,,,,50.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,473,2025-12-02T15:57:10.570299
9667297.0,NACS <35 at 24h,fentanyl group,6,,,,,,,,48.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,474,2025-12-02T15:57:10.570299
9667297.0,tcPCO2 intercept,fentanyl group,5,kPa,mean,SD,1.1,,,,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,475,2025-12-02T15:57:10.570299
9667297.0,tcPCO2 gradient,fentanyl group,-0.03,Kpa/h,,,0.15,,,,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,476,2025-12-02T15:57:10.570299
9667297.0,tcPCO2 at 20 min,fentanyl group,5.1,kPa,,,0.8,,,,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,477,2025-12-02T15:57:10.570299
9667297.0,tcPCO2 at 90 min,fentanyl group,5.1,kPa,,,0.8,,,,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,478,2025-12-02T15:57:10.570299
9667297.0,tcPO2 intercept,fentanyl group,8,kPa,,,2.6,,,,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,479,2025-12-02T15:57:10.570299
9667297.0,tcPO2 gradient,fentanyl group,0.08,Kpa/h,,,0.33,,,,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,480,2025-12-02T15:57:10.570299
9667297.0,tcPO2 at 20 min,fentanyl group,7.9,kPa,,,1.9,,,,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,481,2025-12-02T15:57:10.570299
9667297.0,tcPO2 at 90 min,fentanyl group,8.5,kPa,,,2.0,,,,54.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,482,2025-12-02T15:57:10.570299
10064669.0,akathesia,,1,,count,,,,,,11.0,children,,,,both side effects occurred in the same child,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,483,2025-12-02T15:57:10.570299
10064669.0,anxiety,,1,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,484,2025-12-02T15:57:10.570299
10518075.0,Sedation,,9,,count,,,,,,10.0,preterm,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,485,2025-12-02T15:57:10.570299
10518075.0,Sedation,,15,,,,,,,,16.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,486,2025-12-02T15:57:10.570299
10518075.0,Sedation,,10,,,,,,,,15.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,487,2025-12-02T15:57:10.570299
10518075.0,Sedation,,1,,,,,,,,7.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,488,2025-12-02T15:57:10.570299
10518075.0,Mechanical ventilation,,9,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,489,2025-12-02T15:57:10.570299
10518075.0,Mechanical ventilation,,16,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,490,2025-12-02T15:57:10.570299
10518075.0,Mechanical ventilation,,15,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,491,2025-12-02T15:57:10.570299
10518075.0,Mechanical ventilation,,6,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,492,2025-12-02T15:57:10.570299
10518075.0,NFCS score,"PCA 1, 24-27 weeks",18.3,,,SD,5.0,,,,,,,,," The Pearson product-moment correlation between PCA/facial activity was r = 0.44 (P < .01). The correlation between morphine serum concentrations/change in NFCS was not significant (r = 0.16, P > .05).",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,493,2025-12-02T15:57:10.570299
10518075.0,NFCS score,"PCA 2, 28-31 weeks",15.5,,,,8.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,494,2025-12-02T15:57:10.570299
10518075.0,NFCS score,"PCA 3, 32-35 weeks",26.2,,,,8.9,,,,,,,,<0.01,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,495,2025-12-02T15:57:10.570299
10518075.0,NFCS score,"PCA 4, 36-39 weeks",28.6,,,,13.2,,,,,,,,<0.01,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,496,2025-12-02T15:57:10.570299
10839874.0,Deaths,,3,,count,,,,,,38.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,497,2025-12-02T15:57:10.570299
10942481.0,Biophysical profile score,"morphine group, before fetal blood sampling",9.6,,,SD,0.84,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,498,2025-12-02T15:57:10.570299
10942481.0,Fetal heart rate,"morphine group, before fetal blood sampling",146.3,,bpm,,14.02,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,499,2025-12-02T15:57:10.570299
10942481.0,systolic/diastolic ratio,"morphine group, before fetal blood sampling",2.32,,,,0.43,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,500,2025-12-02T15:57:10.570299
10942481.0,resistance index,"morphine group, before fetal blood sampling",0.56,,,,0.07,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,501,2025-12-02T15:57:10.570299
10942481.0,pulsatility index,"morphine group, before fetal blood sampling",0.84,,,,0.13,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,502,2025-12-02T15:57:10.570299
10942481.0,Biophysical profile score,"morphine group, after fetal blood sampling",6.4,,,,1.84,,,,8.0,,,,0.001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,503,2025-12-02T15:57:10.570299
10942481.0,Fetal heart rate,"morphine group, after fetal blood sampling",140.2,,,,13.74,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,504,2025-12-02T15:57:10.570299
10942481.0,systolic/diastolic ratio,"morphine group, after fetal blood sampling",2.31,,,,0.34,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,505,2025-12-02T15:57:10.570299
10942481.0,resistance index,"morphine group, after fetal blood sampling",0.57,,,,0.005,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,506,2025-12-02T15:57:10.570299
10942481.0,pulsatility index,"morphine group, after fetal blood sampling",0.86,,,,0.1,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,507,2025-12-02T15:57:10.570299
10942481.0,Biophysical profile score,"control group, before fetal blood sampling",8,,,,1.79,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,508,2025-12-02T15:57:10.570299
10942481.0,Fetal heart rate,"control group, before fetal blood sampling",140.33,,,,8.71,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,509,2025-12-02T15:57:10.570299
10942481.0,systolic/diastolic ratio,"control group, before fetal blood sampling",3.44,,,,0.7,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,510,2025-12-02T15:57:10.570299
10942481.0,resistance index,"control group, before fetal blood sampling",0.78,,,,0.21,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,511,2025-12-02T15:57:10.570299
10942481.0,pulsatility index,"control group, before fetal blood sampling",1.06,,,,0.25,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,512,2025-12-02T15:57:10.570299
10942481.0,Biophysical profile score,"control group, after fetal blood sampling",8.67,,,,1.03,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,513,2025-12-02T15:57:10.570299
10942481.0,Fetal heart rate,"control group, after fetal blood sampling",145.83,,,,15.14,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,514,2025-12-02T15:57:10.570299
10942481.0,systolic/diastolic ratio,"control group, after fetal blood sampling",2.92,,,,0.54,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,515,2025-12-02T15:57:10.570299
10942481.0,resistance index,"control group, after fetal blood sampling",0.66,,,,0.1,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,516,2025-12-02T15:57:10.570299
10942481.0,pulsatility index,"control group, after fetal blood sampling",1.03,,,,0.22,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,517,2025-12-02T15:57:10.570299
10962165.0,Mean BP - 1 hours,morphine group,38,,mmHg,SD,7.0,,,,14.0,preterm,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,518,2025-12-02T15:57:10.570299
10962165.0,Mean BP - 2 hours,morphine group,38,,,,6.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,519,2025-12-02T15:57:10.570299
10962165.0,Mean BP - 12 hours,morphine group,37,,,,6.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,520,2025-12-02T15:57:10.570299
10962165.0,PCO2-Kpa - 1 hours,morphine group,5.5,,,,0.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,521,2025-12-02T15:57:10.570299
10962165.0,PCO2-Kpa - 2 hours,morphine group,5.8,,,,1.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,522,2025-12-02T15:57:10.570299
10962165.0,PCO2-Kpa - 12 hours,morphine group,5.6,,,,0.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,523,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 5",morphine group,-10.8,,breaths/min,,29.7,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,524,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 4",morphine group,0.8,,,,9.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,525,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 3",morphine group,5.3,,,,18.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,526,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 2",morphine group,-3.3,,,,17.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,527,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 1",morphine group,1.6,,,,14.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,528,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 5",morphine group,-13.3,,,,28.3,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,529,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 4",morphine group,-6.7,,,,15.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,530,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 3",morphine group,1.3,,,,19.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,531,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 2",morphine group,-2.9,,,,15.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,532,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 1",morphine group,4,,,,9.39,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,533,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 5",morphine group,-12,,,,21.8,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,534,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 4",morphine group,-19.3,,,,19.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,535,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 3",morphine group,-14.8,,,,24.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,536,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 2",morphine group,-2.2,,,,28.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,537,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 1",morphine group,-7,,,,20.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,538,2025-12-02T15:57:10.570299
10962165.0,Mean BP - 1 hours,control group,38,,mmHg,SD,7.0,,,,26.0,preterm,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,539,2025-12-02T15:57:10.570299
10962165.0,Mean BP - 2 hours,control group,38,,,,7.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,540,2025-12-02T15:57:10.570299
10962165.0,Mean BP - 12 hours,control group,38,,,,7.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,541,2025-12-02T15:57:10.570299
10962165.0,PCO2-Kpa - 1 hours,control group,5.2,,,,0.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,542,2025-12-02T15:57:10.570299
10962165.0,PCO2-Kpa - 2 hours,control group,5.4,,,,1.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,543,2025-12-02T15:57:10.570299
10962165.0,PCO2-Kpa - 12 hours,control group,5.3,,,,0.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,544,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 5",control group,-1.5,,breaths/min,,14.0,,,,26.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,545,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 4",control group,1.1,,,,13.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,546,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 3",control group,0.3,,,,17.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,547,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 2",control group,-3.2,,,,16.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,548,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-1h, sensitivity 1",control group,3.1,,,,10.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,549,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 5",control group,-1.7,,,,17.4,,,,26.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,550,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 4",control group,2.5,,,,10.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,551,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 3",control group,3.2,,,,15.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,552,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 2",control group,1.6,,,,17.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,553,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-2h, sensitivity 1",control group,3.1,,,,10.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,554,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 5",control group,0.1,,,,12.2,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,555,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 4",control group,5,,,,16.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,556,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 3",control group,9.6,,,,17.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,557,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 2",control group,3.3,,,,17.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,558,2025-12-02T15:57:10.570299
10962165.0,"Triggered respiratory rate, 0-12h, sensitivity 1",control group,7.6,,,,20.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,559,2025-12-02T15:57:10.570299
10976547.0,Deaths,,2,,count,,,,,,31.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,560,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,Baseline,75.8,,mmHg,SD,20.0,,,,8.0,infants,,0-2 months,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,561,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,1 min after infusion,73.5,,,,20.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,562,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,2 min after infusion,70,,,,20.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,563,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,3 min after infusion,70.6,,,,17.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,564,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,4 min after infusion,69.5,,,,15.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,565,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,5 min after infusion,66.6,,,,18.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,566,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,10 min after infusion,76.3,,,,14.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,567,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,Baseline,89.3,,,,9.8,,,,10.0,infants,,0.17-2 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,568,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,1 min after infusion,82,,,,19.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,569,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,2 min after infusion,75.1,,,,14.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,570,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,3 min after infusion,73.4,,,,13.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,571,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,4 min after infusion,75,,,,13.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,572,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,5 min after infusion,81.5,,,,18.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,573,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,10 min after infusion,88.4,,,,14.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,574,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,Baseline,101.9,,,,20.4,,,,8.0,children,,2-6 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,575,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,1 min after infusion,96.9,,,,22.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,576,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,2 min after infusion,86.6,,,,23.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,577,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,3 min after infusion,86.6,,,,24.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,578,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,4 min after infusion,86.3,,,,19.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,579,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,5 min after infusion,89.1,,,,19.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,580,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,10 min after infusion,98.5,,,,16.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,581,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,Baseline,104.3,,,,9.3,,,,8.0,children,,7-12 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,582,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,1 min after infusion,99.3,,,,14.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,583,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,2 min after infusion,93.4,,,,11.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,584,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,3 min after infusion,88.1,,,,13.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,585,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,4 min after infusion,88.3,,,,13.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,586,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,5 min after infusion,92.3,,,,9.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,587,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,10 min after infusion,97.5,,,,12.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,588,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,Baseline,99.2,,,,12.5,,,,5.0,adolescents,,13-16 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,589,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,1 min after infusion,91,,,,4.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,590,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,2 min after infusion,84.6,,,,14.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,591,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,3 min after infusion,84.8,,,,15.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,592,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,4 min after infusion,86.2,,,,11.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,593,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,5 min after infusion,85.4,,,,15.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,594,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,10 min after infusion,90,,,,6.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,595,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,Baseline,105.7,,,,21.8,,,,3.0,adolescents,,16-18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,596,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,1 min after infusion,93.3,,,,15.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,597,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,2 min after infusion,89.3,,,,14.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,598,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,3 min after infusion,94,,,,19.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,599,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,4 min after infusion,92.7,,,,21.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,600,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,5 min after infusion,97.7,,,,19.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,601,2025-12-02T15:57:10.570299
11726413.0,systolic blood pressure,10 min after infusion,99.3,,,,9.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,602,2025-12-02T15:57:10.570299
11726413.0,heart rate,Baseline,154.5,,bpm,,14.7,,,,8.0,infants,,0-2 months,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,603,2025-12-02T15:57:10.570299
11726413.0,heart rate,1 min after infusion,148.3,,,,15.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,604,2025-12-02T15:57:10.570299
11726413.0,heart rate,2 min after infusion,142,,,,16.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,605,2025-12-02T15:57:10.570299
11726413.0,heart rate,3 min after infusion,140.5,,,,18.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,606,2025-12-02T15:57:10.570299
11726413.0,heart rate,4 min after infusion,142.3,,,,20.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,607,2025-12-02T15:57:10.570299
11726413.0,heart rate,5 min after infusion,146.3,,,,23.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,608,2025-12-02T15:57:10.570299
11726413.0,heart rate,10 min after infusion,149.4,,,,27.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,609,2025-12-02T15:57:10.570299
11726413.0,heart rate,Baseline,144.9,,,,17.9,,,,10.0,infants,,0.17-2 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,610,2025-12-02T15:57:10.570299
11726413.0,heart rate,1 min after infusion,132.3,,,,18.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,611,2025-12-02T15:57:10.570299
11726413.0,heart rate,2 min after infusion,127.3,,,,17.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,612,2025-12-02T15:57:10.570299
11726413.0,heart rate,3 min after infusion,121.5,,,,16.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,613,2025-12-02T15:57:10.570299
11726413.0,heart rate,4 min after infusion,119.8,,,,21.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,614,2025-12-02T15:57:10.570299
11726413.0,heart rate,5 min after infusion,128.1,,,,15.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,615,2025-12-02T15:57:10.570299
11726413.0,heart rate,10 min after infusion,130.2,,,,14.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,616,2025-12-02T15:57:10.570299
11726413.0,heart rate,Baseline,127.3,,,,24.0,,,,8.0,children,,2-6 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,617,2025-12-02T15:57:10.570299
11726413.0,heart rate,1 min after infusion,106.4,,,,27.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,618,2025-12-02T15:57:10.570299
11726413.0,heart rate,2 min after infusion,102.6,,,,26.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,619,2025-12-02T15:57:10.570299
11726413.0,heart rate,3 min after infusion,102.4,,,,24.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,620,2025-12-02T15:57:10.570299
11726413.0,heart rate,4 min after infusion,102.4,,,,24.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,621,2025-12-02T15:57:10.570299
11726413.0,heart rate,5 min after infusion,101.9,,,,23.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,622,2025-12-02T15:57:10.570299
11726413.0,heart rate,10 min after infusion,104.8,,,,21.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,623,2025-12-02T15:57:10.570299
11726413.0,heart rate,Baseline,108.5,,,,23.3,,,,8.0,children,,7-12 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,624,2025-12-02T15:57:10.570299
11726413.0,heart rate,1 min after infusion,98.3,,,,22.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,625,2025-12-02T15:57:10.570299
11726413.0,heart rate,2 min after infusion,93.3,,,,22.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,626,2025-12-02T15:57:10.570299
11726413.0,heart rate,3 min after infusion,89.9,,,,26.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,627,2025-12-02T15:57:10.570299
11726413.0,heart rate,4 min after infusion,89.4,,,,24.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,628,2025-12-02T15:57:10.570299
11726413.0,heart rate,5 min after infusion,88.9,,,,24.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,629,2025-12-02T15:57:10.570299
11726413.0,heart rate,10 min after infusion,89,,,,17.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,630,2025-12-02T15:57:10.570299
11726413.0,heart rate,Baseline,101.4,,,,10.8,,,,5.0,adolescents,,13-16 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,631,2025-12-02T15:57:10.570299
11726413.0,heart rate,1 min after infusion,88,,,,16.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,632,2025-12-02T15:57:10.570299
11726413.0,heart rate,2 min after infusion,82.8,,,,16.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,633,2025-12-02T15:57:10.570299
11726413.0,heart rate,3 min after infusion,79.4,,,,118.3,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,634,2025-12-02T15:57:10.570299
11726413.0,heart rate,4 min after infusion,79.6,,,,17.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,635,2025-12-02T15:57:10.570299
11726413.0,heart rate,5 min after infusion,83.4,,,,21.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,636,2025-12-02T15:57:10.570299
11726413.0,heart rate,10 min after infusion,81.4,,,,16.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,637,2025-12-02T15:57:10.570299
11726413.0,heart rate,Baseline,95,,,,15.7,,,,3.0,adolescents,,16-18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,638,2025-12-02T15:57:10.570299
11726413.0,heart rate,1 min after infusion,81,,,,9.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,639,2025-12-02T15:57:10.570299
11726413.0,heart rate,2 min after infusion,80.7,,,,12.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,640,2025-12-02T15:57:10.570299
11726413.0,heart rate,3 min after infusion,76,,,,4.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,641,2025-12-02T15:57:10.570299
11726413.0,heart rate,4 min after infusion,80,,,,11.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,642,2025-12-02T15:57:10.570299
11726413.0,heart rate,5 min after infusion,82.3,,,,11.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,643,2025-12-02T15:57:10.570299
11726413.0,heart rate,10 min after infusion,87,,,,20.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,644,2025-12-02T15:57:10.570299
12535033.0,Time from infusion start to CO2 response study,,18,,hours,,,IQR,16,19,10.0,infants,,,,cyanotic infants,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,645,2025-12-02T15:57:10.570299
12535033.0,PaCO2 (mmHg) during spontaneous ventilation,,36.5,,mmHg,,,,31.5,47.3,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,646,2025-12-02T15:57:10.570299
12535033.0,CO2 response slope,,9.1,,ml/min/mmHg PeCO2/kg,,,,5.3,17.5,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,647,2025-12-02T15:57:10.570299
12535033.0,Time to extubation from infusion decrease,,6.9,,hours,,,,1.8,16.6,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,648,2025-12-02T15:57:10.570299
12535033.0,MIPS comfort scale ≥15,,74,,%,,,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,649,2025-12-02T15:57:10.570299
12535033.0,MIPS comfort scale <12,,17,,%,,,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,650,2025-12-02T15:57:10.570299
12535033.0,Time from infusion start to CO2 response study,,20,,,,,,16,27,9.0,,,,,acyanotic infants,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,651,2025-12-02T15:57:10.570299
12535033.0,PaCO2 (mmHg) during spontaneous ventilation,,43.5,,,,,,32.8,49.3,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,652,2025-12-02T15:57:10.570299
12535033.0,CO2 response slope,,13.2,,,,,,6.3,16.8,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,653,2025-12-02T15:57:10.570299
12535033.0,Time to extubation from infusion decrease,,5.8,,,,,,4.5,14.8,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,654,2025-12-02T15:57:10.570299
12535033.0,MIPS comfort scale ≥15,,84,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,655,2025-12-02T15:57:10.570299
12535033.0,MIPS comfort scale <12,,11,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,656,2025-12-02T15:57:10.570299
12873948.0,Sensation at incision at 4 hrs,,-0.73,,,,,,,,120.0,maternal,labor,,<0.0001,p<0.0001 for all values,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,657,2025-12-02T15:57:10.570299
12873948.0,Sensation at incision at 24 hrs,,-0.64,,,,,,,,120.0,,,,<0.0001,Change from baseline is shown as the postoperative value minus the preoperative baseline,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,658,2025-12-02T15:57:10.570299
12873948.0,Pain at incision at 4 hrs,,-0.66,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,659,2025-12-02T15:57:10.570299
12873948.0,Pain at incision at 24 hrs,,-0.67,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,660,2025-12-02T15:57:10.570299
12873948.0,Sensation at clavicle at 4 hrs,,-0.53,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,661,2025-12-02T15:57:10.570299
12873948.0,Sensation at clavicle at 24 hrs,,-0.49,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,662,2025-12-02T15:57:10.570299
12873948.0,Pain at clavicle at 4 hrs,,-0.68,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,663,2025-12-02T15:57:10.570299
12873948.0,Pain at clavicle at 24 hrs,,-0.69,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,664,2025-12-02T15:57:10.570299
12873948.0,Pain rating at incision at 4 hrs,,-0.61,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,665,2025-12-02T15:57:10.570299
12873948.0,Pain rating at incision at 24 hrs,,-0.61,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,666,2025-12-02T15:57:10.570299
12873948.0,Pain rating at claviicle at 4 hrs,,-0.7,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,667,2025-12-02T15:57:10.570299
12873948.0,Pain rating at claviicle at 24 hrs,,-0.68,,,,,,,,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,668,2025-12-02T15:57:10.570299
12873948.0,time to rescue analgesia with tramadol/diclofenac,,197,,min,,,IQR,70,1000,120.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,669,2025-12-02T15:57:10.570299
12873948.0,time to rescue analgesia with tramadol/placebo,,48,,min,,,,25,90,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,670,2025-12-02T15:57:10.570299
12873948.0,time to rescue analgesia with diclofenac/placebo,,113,,min,,,,25,270,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,671,2025-12-02T15:57:10.570299
12873948.0,time to rescue analgesia with double placebo,,55,,min,,,,30,100,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,672,2025-12-02T15:57:10.570299
12873948.0,pain score at time of rescue analgesia,,3,,,,,,2,3,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,673,2025-12-02T15:57:10.570299
12873948.0,rescue morphine ≤24 hrs postop with tramadol/diclofenac,,28,,mg,,,95% CI,24,33,120.0,,,,<0.005,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,674,2025-12-02T15:57:10.570299
12873948.0,rescue morphine ≤24 hrs postop with tramadol/placebo,,35,,mg,,,,32,38,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,675,2025-12-02T15:57:10.570299
12873948.0,rescue morphine ≤24 hrs postop with diclofenacl/placebo,,31,,mg,,,,26,36,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,676,2025-12-02T15:57:10.570299
12873948.0,rescue morphine ≤24 hrs postop with double placebo,,38,,mg,,,,35,41,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,677,2025-12-02T15:57:10.570299
12873948.0,nausea with tramadol/diclofenac,,4,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,678,2025-12-02T15:57:10.570299
12873948.0,nausea with tramadol/placebo,,8,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,679,2025-12-02T15:57:10.570299
12873948.0,nausea with diclofenacl/placebo,,6,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,680,2025-12-02T15:57:10.570299
12873948.0,nausea with double placebo,,5,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,681,2025-12-02T15:57:10.570299
12873948.0,vomiting with tramadol/diclofenac,,6,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,682,2025-12-02T15:57:10.570299
12873948.0,vomiting with tramadol/placebo,,3,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,683,2025-12-02T15:57:10.570299
12873948.0,vomiting with diclofenacl/placebo,,2,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,684,2025-12-02T15:57:10.570299
12873948.0,vomiting with double placebo,,2,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,685,2025-12-02T15:57:10.570299
12873948.0,Sleepiness/drowsiness with tramadol/diclofenac,,21,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,686,2025-12-02T15:57:10.570299
12873948.0,Sleepiness/drowsiness with tramadol/placebo,,26,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,687,2025-12-02T15:57:10.570299
12873948.0,Sleepiness/drowsiness with diclofenacl/placebo,,25,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,688,2025-12-02T15:57:10.570299
12873948.0,Sleepiness/drowsiness with double placebo,,28,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,689,2025-12-02T15:57:10.570299
12873948.0,Dizziness with tramadol/diclofenac,,3,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,690,2025-12-02T15:57:10.570299
12873948.0,Dizziness with tramadol/placebo,,1,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,691,2025-12-02T15:57:10.570299
12873948.0,Dizziness with diclofenacl/placebo,,11,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,692,2025-12-02T15:57:10.570299
12873948.0,Dizziness with double placebo,,3,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,693,2025-12-02T15:57:10.570299
12873948.0,Headache with tramadol/diclofenac,,5,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,694,2025-12-02T15:57:10.570299
12873948.0,Headache with tramadol/placebo,,0,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,695,2025-12-02T15:57:10.570299
12873948.0,Headache with diclofenacl/placebo,,9,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,696,2025-12-02T15:57:10.570299
12873948.0,Headache with double placebo,,4,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,697,2025-12-02T15:57:10.570299
12873948.0,any side effect with tramadol/diclofenac,,16,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,698,2025-12-02T15:57:10.570299
12873948.0,any side effect with tramadol/placebo,,21,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,699,2025-12-02T15:57:10.570299
12873948.0,any side effect with diclofenacl/placebo,,20,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,700,2025-12-02T15:57:10.570299
12873948.0,any side effect with double placebo,,18,,count,,,,,,120.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,701,2025-12-02T15:57:10.570299
12897995.0,Heart rate,,137,bpm,mean,SD,13.0,,,,49.0,neonate,,,,Age ≤7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,702,2025-12-02T15:57:10.570299
12897995.0,Heart rate,,151,bpm,mean,SD,2.0,,,,16.0,neonate,,,<0.001,Age >7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,703,2025-12-02T15:57:10.570299
12897995.0,Mean arterial blood pressure,,49,mmHg,mean,SD,7.0,,,,49.0,neonate,,,,Age ≤7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,704,2025-12-02T15:57:10.570299
12897995.0,Mean arterial blood pressure,,58,mmHg,mean,SD,9.0,,,,16.0,neonate,,,<0.001,Age >7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,705,2025-12-02T15:57:10.570299
12897995.0,Comfort behavioral score,,12.6,,mean,SD,2.6,,,,49.0,neonate,,,,Age ≤7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,706,2025-12-02T15:57:10.570299
12897995.0,Comfort behavioral score,,13.3,,mean,SD,2.1,,,,16.0,neonate,,,,Age >7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,707,2025-12-02T15:57:10.570299
12897995.0,Visual analogue score,,1.3,,mean,SD,0.7,,,,49.0,neonate,,,,Age ≤7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,708,2025-12-02T15:57:10.570299
12897995.0,Visual analogue score,,1.7,,mean,SD,0.7,,,,16.0,neonate,,,,Age >7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,709,2025-12-02T15:57:10.570299
12897995.0,Visual analogue score ≥4,,5.1,,% of cases,,,,,,49.0,neonate,,,,Age ≤7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,710,2025-12-02T15:57:10.570299
12897995.0,Visual analogue score ≥4,,7.8,,% of cases,,,,,,16.0,neonate,,,,Age >7 days,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,711,2025-12-02T15:57:10.570299
15001964.0,Mean O2 saturation,oral morphine,93.4,,%,SD,5.3,,,,24.0,children,,,0.01,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,712,2025-12-02T15:57:10.570299
15001964.0,Mean heart rate,oral morphine,102.5,,bpm,,16.7,,,,,,,,0.38,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,713,2025-12-02T15:57:10.570299
15001964.0,Mean end-tidal CO2,oral morphine,38.5,,mmHg,,3.9,,,,,,,,0.73,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,714,2025-12-02T15:57:10.570299
15001964.0,Mean respiration rate,oral morphine,27.3,,breaths/min,,4.4,,,,,,,,0.45,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,715,2025-12-02T15:57:10.570299
15001964.0,Mean O2 saturation,CIV morphine,96.8,,,,2.5,,,,26.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,716,2025-12-02T15:57:10.570299
15001964.0,Mean heart rate,CIV morphine,98.3,,,,14.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,717,2025-12-02T15:57:10.570299
15001964.0,Mean end-tidal CO2,CIV morphine,38,,,,4.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,718,2025-12-02T15:57:10.570299
15001964.0,Mean respiration rate,CIV morphine,25.6,,,,8.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,719,2025-12-02T15:57:10.570299
15001964.0,O2 saturation,"oral morphine, ACS",90.9,,,,5.4,,,,12.0,,,,0.01,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,720,2025-12-02T15:57:10.570299
15001964.0,Heart rate,"oral morphine, ACS",108.6,,,,15.0,,,,,,,,0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,721,2025-12-02T15:57:10.570299
15001964.0,End-tidal CO2,"oral morphine, ACS",38,,,,2.9,,,,,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,722,2025-12-02T15:57:10.570299
15001964.0,Respiration rate,"oral morphine, ACS",29.3,,,,2.7,,,,,,,,0.01,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,723,2025-12-02T15:57:10.570299
15001964.0,O2 saturation,"oral morphine, no ACS",96.8,,,,2.9,,,,9.0,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,724,2025-12-02T15:57:10.570299
15001964.0,Heart rate,"oral morphine, no ACS",94.4,,,,16.0,,,,,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,725,2025-12-02T15:57:10.570299
15001964.0,End-tidal CO2,"oral morphine, no ACS",39.4,,,,5.4,,,,,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,726,2025-12-02T15:57:10.570299
15001964.0,Respiration rate,"oral morphine, no ACS",24,,,,4.9,,,,,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,727,2025-12-02T15:57:10.570299
15001964.0,O2 saturation,"CIV morphine, ACS",94.5,,,,3.6,,,,4.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,728,2025-12-02T15:57:10.570299
15001964.0,Heart rate,"CIV morphine, ACS",103.8,,,,20.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,729,2025-12-02T15:57:10.570299
15001964.0,End-tidal CO2,"CIV morphine, ACS",37.2,,,,1.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,730,2025-12-02T15:57:10.570299
15001964.0,Respiration rate,"CIV morphine, ACS",28.5,,,,8.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,731,2025-12-02T15:57:10.570299
15001964.0,O2 saturation,"CIV morphine, no ACS",97.3,,,,2.0,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,732,2025-12-02T15:57:10.570299
15001964.0,Heart rate,"CIV morphine, no ACS",97,,,,13.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,733,2025-12-02T15:57:10.570299
15001964.0,End-tidal CO2,"CIV morphine, no ACS",38.3,,,,5.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,734,2025-12-02T15:57:10.570299
15001964.0,Respiration rate,"CIV morphine, no ACS",24.7,,,,8.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,735,2025-12-02T15:57:10.570299
15321955.0,Treated for NAS,,12,,count,%,48.0,,,,25.0,infants,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,736,2025-12-02T15:57:10.570299
15321955.0,Age at NAS treatment,,35,,hours,,,range,7,84,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,737,2025-12-02T15:57:10.570299
15321955.0,Length of NAS treatment,,15,,days,,,,11,28,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,738,2025-12-02T15:57:10.570299
15321955.0,NAS score at 24 hrs in treated,,6,,,,,,,,12.0,,,,0.002,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,739,2025-12-02T15:57:10.570299
15321955.0,NAS score at 24 hrs in untreated,,3,,,,,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,740,2025-12-02T15:57:10.570299
15321955.0,Length of stay in treated,,20,,days,,,,14,34,12.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,741,2025-12-02T15:57:10.570299
15321955.0,Length of stay in untreated,,6,,,,,,4,10,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,742,2025-12-02T15:57:10.570299
15448532.0,VAS score 15 mins after sufentanil,,0.3,,mm,SD,0.7,,,,91.0,Maternal,Labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,743,2025-12-02T15:57:10.570299
15448532.0,Duration of analgesia - parity 1,,97.5,,min,,28.3,,,,,,,,<0.09,p<0.09 compared to parity 2,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,744,2025-12-02T15:57:10.570299
15448532.0,Duration of analgesia - parity 2,,92,,min,,45.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,745,2025-12-02T15:57:10.570299
15448532.0,Duration of analgesia over 24 hours,,93,,min,,3.8,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,746,2025-12-02T15:57:10.570299
15448532.0,Peak analgesia at midnight,,0.78,,hours,,0.6,,,,,,,,<0.02,p<0.02 for 12 hour rhythm,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,747,2025-12-02T15:57:10.570299
15448532.0,Peak analgesia at noon,,12.78,,hours,,0.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,748,2025-12-02T15:57:10.570299
15448532.0,Duration of analgesia at peak rhythm,,109.1,,min,,5.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,749,2025-12-02T15:57:10.570299
15448532.0,Duration of analgesia at trough rhythm,,76.9,,min,,5.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,750,2025-12-02T15:57:10.570299
15448532.0,Pruritis,,70,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,751,2025-12-02T15:57:10.570299
15448532.0,Transient uterine hyperactivity,,4,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,752,2025-12-02T15:57:10.570299
15448532.0,Fetal heart rate abnormalities,,4,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,753,2025-12-02T15:57:10.570299
15502029.0,Itchy nose,,2,,count,,,,,,10.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,754,2025-12-02T15:57:10.570299
15502029.0,Postop vomiting,,5,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,755,2025-12-02T15:57:10.570299
15960639.0,Elevated ALT,,2,,count,,,,,,22.0,infants,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,756,2025-12-02T15:57:10.570299
16007420.0,NACS,,37.8,,points,,1.5,,,,22.0,,post partum,,,"measured 69±27 min (range: 20–126 min) post-partum, 312±127 min after the first dose/241±66 min after the last treatment dose, respectively",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,757,2025-12-02T15:57:10.570299
16007420.0,1-min. Apgar score,,8,,,,1.7,,,,47.0,,post partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,758,2025-12-02T15:57:10.570299
16007420.0,5-min. Apgar score,,9.1,,,,1.2,,,,47.0,,post partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,759,2025-12-02T15:57:10.570299
16007420.0,1-min. Apgar score (100mg group),,7.9,,,,1.8,,,,21.0,,post partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,760,2025-12-02T15:57:10.570299
16007420.0,1-min. Apgar score (150mg group),,8.5,,,,0.9,,,,18.0,,post partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,761,2025-12-02T15:57:10.570299
16007420.0,1-min. Apgar score (≥200mg group),,7.4,,,,2.4,,,,8.0,,post partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,762,2025-12-02T15:57:10.570299
16007420.0,maternal without any adverse event,,55.1,,%,,,,,,27.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,763,2025-12-02T15:57:10.570299
16007420.0,maternal with an adverse event,,44.9,,%,,,,,,22.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,764,2025-12-02T15:57:10.570299
16007420.0,Body as a whole,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,765,2025-12-02T15:57:10.570299
16007420.0,Acute pain,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,766,2025-12-02T15:57:10.570299
16007420.0,Digestive system,,4.08,,%,,,,,,2.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,767,2025-12-02T15:57:10.570299
16007420.0,Vomiting,,4.08,,%,,,,,,2.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,768,2025-12-02T15:57:10.570299
16007420.0,Nausea,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,769,2025-12-02T15:57:10.570299
16007420.0,Nervous system,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,770,2025-12-02T15:57:10.570299
16007420.0,Carpal tunnel syndrome,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,771,2025-12-02T15:57:10.570299
16007420.0,Urogenital system,,36.73,,%,,,,,,18.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,772,2025-12-02T15:57:10.570299
16007420.0,Post-partum haemorrhage,,10.2,,%,,,,,,5.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,773,2025-12-02T15:57:10.570299
16007420.0,Prolonged 2nd stage,,10.2,,%,,,,,,5.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,774,2025-12-02T15:57:10.570299
16007420.0,3rd degree perineal laceration,,4.08,,%,,,,,,2.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,775,2025-12-02T15:57:10.570299
16007420.0,"Long labor, unspecified",,4.08,,%,,,,,,2.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,776,2025-12-02T15:57:10.570299
16007420.0,3rd stage haemorrhage,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,777,2025-12-02T15:57:10.570299
16007420.0,Disruption of obstetric perineal wound,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,778,2025-12-02T15:57:10.570299
16007420.0,Failure of cervical dilatation,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,779,2025-12-02T15:57:10.570299
16007420.0,Haematoma of obstetric wound,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,780,2025-12-02T15:57:10.570299
16007420.0,labor/delivery complicated by fetal distress,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,781,2025-12-02T15:57:10.570299
16007420.0,Obstructed labor due to foeto–pelvic disproportion,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,782,2025-12-02T15:57:10.570299
16007420.0,Retained placenta without haemorrhage,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,783,2025-12-02T15:57:10.570299
16007420.0,Retention of urine,,2.04,,%,,,,,,1.0,,post partum,,,a total of 49 subjects,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,784,2025-12-02T15:57:10.570299
16021436.0,Apgar score 5',,10,,,,,,,,10.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,785,2025-12-02T15:57:10.570299
16130057.0,Bispectral index,30 min postinduction,42,,,,11.0,,,,15.0,infants,,,0.02,"BIS decreased significantly with induction, the mean falling from 88 ± 20 to 42 ± 11 (p = 0.02).",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,786,2025-12-02T15:57:10.570299
16130057.0,Bispectral index,Sternotomy,41,,,,10.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,787,2025-12-02T15:57:10.570299
16130057.0,Bispectral index,Aortic cannulation,37,,,,14.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,788,2025-12-02T15:57:10.570299
16130057.0,Bispectral index,4 min on CPB,28,,,,14.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,789,2025-12-02T15:57:10.570299
16130057.0,Bispectral index,30 min on CPB,9,,,,11.0,,,,,,,,0.03,"From aortic cannulation to 30 minutes on CPB, change in BIS was inversely related to change in fentanyl (p = 0.03), although temperature (p = 0.61), MAP (p = 0.38),/flow rate (p = 0.77) were not significant predictors of change in BIS.",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,790,2025-12-02T15:57:10.570299
16130057.0,Bispectral index,60 min on CPB,5,,,,8.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,791,2025-12-02T15:57:10.570299
16130057.0,Bispectral index,1 min off CPB,29,,,,9.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,792,2025-12-02T15:57:10.570299
16130057.0,Bispectral index,30 min off CPB,35,,,,10.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,793,2025-12-02T15:57:10.570299
16130057.0,Temperature,30 min postinduction,35,,celsius,,0.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,794,2025-12-02T15:57:10.570299
16130057.0,Temperature,Sternotomy,34,,,,1.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,795,2025-12-02T15:57:10.570299
16130057.0,Temperature,Aortic cannulation,32.9,,,,1.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,796,2025-12-02T15:57:10.570299
16130057.0,Temperature,4 min on CPB,26,,,,5.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,797,2025-12-02T15:57:10.570299
16130057.0,Temperature,30 min on CPB,16.7,,,,4.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,798,2025-12-02T15:57:10.570299
16130057.0,Temperature,60 min on CPB,18.2,,,,6.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,799,2025-12-02T15:57:10.570299
16130057.0,Temperature,1 min off CPB,36.2,,,,1.4,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,800,2025-12-02T15:57:10.570299
16130057.0,Temperature,30 min off CPB,34.9,,,,0.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,801,2025-12-02T15:57:10.570299
16130057.0,Mean arterial pressure,30 min postinduction,55.3,,mmHg,,9.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,802,2025-12-02T15:57:10.570299
16130057.0,Mean arterial pressure,Sternotomy,55.3,,,,11.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,803,2025-12-02T15:57:10.570299
16130057.0,Mean arterial pressure,Aortic cannulation,46.3,,,,10.2,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,804,2025-12-02T15:57:10.570299
16130057.0,Mean arterial pressure,4 min on CPB,43.6,,,,17.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,805,2025-12-02T15:57:10.570299
16130057.0,Mean arterial pressure,30 min on CPB,23.1,,,,17.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,806,2025-12-02T15:57:10.570299
16130057.0,Mean arterial pressure,60 min on CPB,25.2,,,,28.5,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,807,2025-12-02T15:57:10.570299
16130057.0,Mean arterial pressure,1 min off CPB,42.8,,,,6.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,808,2025-12-02T15:57:10.570299
16130057.0,Mean arterial pressure,30 min off CPB,50,,,,6.7,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,809,2025-12-02T15:57:10.570299
16130057.0,CPB flow rate,4 min on CPB,160,,ml/kg/min,,25.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,810,2025-12-02T15:57:10.570299
16130057.0,CPB flow rate,30 min on CPB,44,,,,43.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,811,2025-12-02T15:57:10.570299
16130057.0,CPB flow rate,60 min on CPB,38,,,,42.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,812,2025-12-02T15:57:10.570299
16261362.0,Male sex,,4,,count,,,,,,9.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,813,2025-12-02T15:57:10.570299
16261362.0,Female sex,,5,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,814,2025-12-02T15:57:10.570299
16261362.0,Premature by 21 days,,1,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,815,2025-12-02T15:57:10.570299
16261362.0,Length of gestation,,39.7,,week,SD,10.0,range,37,42,,,,,,Unit for SD/range is days/not weeks,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,816,2025-12-02T15:57:10.570299
16261362.0,Cesarean delivery,,2,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,817,2025-12-02T15:57:10.570299
16261362.0,Birth weight,,3094,,g,,368.0,range,2535,3705,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,818,2025-12-02T15:57:10.570299
16261362.0,NAS,,4,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,819,2025-12-02T15:57:10.570299
16261362.0,Special care duration,,,,days,,,range,0.5,28,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,820,2025-12-02T15:57:10.570299
16394684.0,"Systolic arterial pressure, maximum",Remifentanil,127,,mmHg,SD,12.6,,,,20.0,maternal,Labor,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,821,2025-12-02T15:57:10.570299
16394684.0,"Mean arterial pressure, maximum",Remifentanil,98,,mmHg,,8.6,,,,20.0,,,,<0.0001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,822,2025-12-02T15:57:10.570299
16394684.0,"Heart rate, maximum",Remifentanil,112,,beats/min,,8.4,,,,20.0,,,,0.0008,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,823,2025-12-02T15:57:10.570299
16394684.0,"Systolic arterial pressure, minimum",Remifentanil,85,,mmHg,,11.4,,,,20.0,,,,0.001,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,824,2025-12-02T15:57:10.570299
16394684.0,"Mean arterial pressure, minimum",Remifentanil,55,,mmHg,,16.5,,,,20.0,,,,0.0002,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,825,2025-12-02T15:57:10.570299
16394684.0,"Heart rate, minimum",Remifentanil,76,,beats/min,,8.2,,,,20.0,,,,0.35,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,826,2025-12-02T15:57:10.570299
16394684.0,Increased intravenous infusion,Remifentanil,2,,count,%,10.0,,,,20.0,,,,1,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,827,2025-12-02T15:57:10.570299
16394684.0,Ephedrine required,Remifentanil,0,,,,,,,,20.0,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,828,2025-12-02T15:57:10.570299
16394684.0,Atropine required,Remifentanil,0,,,,,,,,20.0,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,829,2025-12-02T15:57:10.570299
16394684.0,Apgar score 1' 7-10,Remifentanil,12,,,%,60.0,,,,20.0,Neonate,Delivery,,0.5,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,830,2025-12-02T15:57:10.570299
16394684.0,Apgar score 1' 6,Remifentanil,6,,,,30.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,831,2025-12-02T15:57:10.570299
16394684.0,Apgar score 1' 5,Remifentanil,2,,,,10.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,832,2025-12-02T15:57:10.570299
16394684.0,Apgar score 1' <5,Remifentanil,0,,,,0.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,833,2025-12-02T15:57:10.570299
16394684.0,Apgar score 5' 8-10,Remifentanil,20,,,,100.0,,,,20.0,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,834,2025-12-02T15:57:10.570299
16394684.0,Apgar score 5' <8,Remifentanil,0,,,,0.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,835,2025-12-02T15:57:10.570299
16394684.0,Time to sustained respiration,Remifentanil,75,,sec,,,range,0,240,20.0,,,,0.28,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,836,2025-12-02T15:57:10.570299
16394684.0,Tactile stimulation,Remifentanil,10,,,%,50.0,,,,20.0,,,,0.2,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,837,2025-12-02T15:57:10.570299
16394684.0,Bag-mask ventilation,Remifentanil,7,,,,35.0,,,,20.0,,,,0.29,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,838,2025-12-02T15:57:10.570299
16394684.0,Tracheal intubation,Remifentanil,0,,,,0.0,,,,20.0,,,,1,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,839,2025-12-02T15:57:10.570299
16394684.0,Naloxone,Remifentanil,2,,,,10.0,,,,20.0,,,,0.49,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,840,2025-12-02T15:57:10.570299
16394684.0,Admitted to NICU,Remifentanil,3,,,,15.0,,,,20.0,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,841,2025-12-02T15:57:10.570299
16394684.0,NICU for respiratory depression,Remifentanil,2,,,,10.0,,,,20.0,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,842,2025-12-02T15:57:10.570299
16394684.0,NICU for maternal medical condition,Remifentanil,1,,,,5.0,,,,20.0,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,843,2025-12-02T15:57:10.570299
16394684.0,"Systolic arterial pressure, maximum",control,165,,mmHg,SD,23.0,,,,20.0,maternal,Labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,844,2025-12-02T15:57:10.570299
16394684.0,"Mean arterial pressure, maximum",control,123,,mmHg,,15.9,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,845,2025-12-02T15:57:10.570299
16394684.0,"Heart rate, maximum",control,126,,beats/min,,15.4,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,846,2025-12-02T15:57:10.570299
16394684.0,"Systolic arterial pressure, minimum",control,102,,mmHg,,19.5,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,847,2025-12-02T15:57:10.570299
16394684.0,"Mean arterial pressure, minimum",control,75,,mmHg,,13.9,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,848,2025-12-02T15:57:10.570299
16394684.0,"Heart rate, minimum",control,79,,beats/min,,15.7,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,849,2025-12-02T15:57:10.570299
16394684.0,Increased intravenous infusion,control,1,,count,%,5.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,850,2025-12-02T15:57:10.570299
16394684.0,Ephedrine required,control,0,,,,,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,851,2025-12-02T15:57:10.570299
16394684.0,Atropine required,control,0,,,,,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,852,2025-12-02T15:57:10.570299
16394684.0,Apgar score 1' 7-10,control,15,,,%,75.0,,,,20.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,853,2025-12-02T15:57:10.570299
16394684.0,Apgar score 1' 6,control,3,,,,15.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,854,2025-12-02T15:57:10.570299
16394684.0,Apgar score 1' 5,control,2,,,,10.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,855,2025-12-02T15:57:10.570299
16394684.0,Apgar score 1' <5,control,0,,,,0.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,856,2025-12-02T15:57:10.570299
16394684.0,Apgar score 5' 8-10,control,20,,,,100.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,857,2025-12-02T15:57:10.570299
16394684.0,Apgar score 5' <8,control,0,,,,0.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,858,2025-12-02T15:57:10.570299
16394684.0,Time to sustained respiration,control,25,,sec,,,range,0,180,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,859,2025-12-02T15:57:10.570299
16394684.0,Tactile stimulation,control,6,,,%,30.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,860,2025-12-02T15:57:10.570299
16394684.0,Bag-mask ventilation,control,4,,,,20.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,861,2025-12-02T15:57:10.570299
16394684.0,Tracheal intubation,control,0,,,,0.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,862,2025-12-02T15:57:10.570299
16394684.0,Naloxone,control,0,,,,0.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,863,2025-12-02T15:57:10.570299
16394684.0,Admitted to NICU,control,3,,,,15.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,864,2025-12-02T15:57:10.570299
16394684.0,NICU for respiratory depression,control,0,,,,0.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,865,2025-12-02T15:57:10.570299
16394684.0,NICU for maternal medical condition,control,3,,,,15.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,866,2025-12-02T15:57:10.570299
16394684.0,Arterial pH,Remifentanil,7.29,,,,,,,,20.0,Neonate,delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,867,2025-12-02T15:57:10.570299
16394684.0,Arterial PCO2,Remifentanil,56,,mmHg,SD,0.05,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,868,2025-12-02T15:57:10.570299
16394684.0,Arterial PO2,Remifentanil,26,,mmHg,,5.8,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,869,2025-12-02T15:57:10.570299
16394684.0,Arterial base excess,Remifentanil,-1.1,,mM,,9.6,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,870,2025-12-02T15:57:10.570299
16394684.0,Arterial total HgB,Remifentanil,14.1,,g/dl,,2.1,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,871,2025-12-02T15:57:10.570299
16394684.0,Arterial O2 content,Remifentanil,10.5,,ml/dl,,1.4,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,872,2025-12-02T15:57:10.570299
16394684.0,Arterial pH,control,7.29,,,,2.8,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,873,2025-12-02T15:57:10.570299
16394684.0,Arterial PCO2,control,54,,mmHg,,0.04,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,874,2025-12-02T15:57:10.570299
16394684.0,Arterial PO2,control,21,,mmHg,,6.1,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,875,2025-12-02T15:57:10.570299
16394684.0,Arterial base excess,control,-2.6,,mM,,6.7,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,876,2025-12-02T15:57:10.570299
16394684.0,Arterial total HgB,control,14.5,,g/dl,,2.4,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,877,2025-12-02T15:57:10.570299
16394684.0,Arterial O2 content,control,9.2,,ml/dl,,1.3,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,878,2025-12-02T15:57:10.570299
16394684.0,Venous pH,Remifentanil,7.33,,,,3.9,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,879,2025-12-02T15:57:10.570299
16394684.0,Venous PCO2,Remifentanil,49,,mmHg,,0.04,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,880,2025-12-02T15:57:10.570299
16394684.0,Venous PO2,Remifentanil,38,,mmHg,,5.6,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,881,2025-12-02T15:57:10.570299
16394684.0,Venous base excess,Remifentanil,-1.1,,mM,,9.5,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,882,2025-12-02T15:57:10.570299
16394684.0,Venous total HgB,Remifentanil,14.6,,g/dl,,1.9,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,883,2025-12-02T15:57:10.570299
16394684.0,Venous O2 content,Remifentanil,15.7,,ml/dl,,1.4,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,884,2025-12-02T15:57:10.570299
16394684.0,Venous pH,control,7.35,,,,2.7,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,885,2025-12-02T15:57:10.570299
16394684.0,Venous PCO2,control,46,,mmHg,,0.03,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,886,2025-12-02T15:57:10.570299
16394684.0,Venous PO2,control,36,,mmHg,,3.4,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,887,2025-12-02T15:57:10.570299
16394684.0,Venous base excess,control,-1.9,,mM,,10.0,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,888,2025-12-02T15:57:10.570299
16394684.0,Venous total HgB,control,14.8,,g/dl,,1.5,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,889,2025-12-02T15:57:10.570299
16394684.0,Venous O2 content,control,15.2,,ml/dl,,1.2,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,890,2025-12-02T15:57:10.570299
16802855.0,Vomiting,,3,,count,,,,,,30.0,pediatric,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,891,2025-12-02T15:57:10.570299
16802855.0,Dizziness,,1,,,,,,,,30.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,892,2025-12-02T15:57:10.570299
16802855.0,Itching in the nose,,1,,,,,,,,30.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,893,2025-12-02T15:57:10.570299
16949720.0,1-min. Apgar score ≤7,,20,,number,,,,,,20.0,,post partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,894,2025-12-02T15:57:10.570299
16949720.0,Resuscitation needed-Oxygen by mask,,14,,number,,,,,,14.0,,post partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,895,2025-12-02T15:57:10.570299
16949720.0,Resuscitation needed-Bag/mask/positive pressure,,6,,number,,,,,,6.0,,post partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,896,2025-12-02T15:57:10.570299
16949720.0,Resuscitation needed-Mask/valve/positive pressure,,1,,number,,,,,,1.0,,post partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,897,2025-12-02T15:57:10.570299
17478871.0,Apgar score 1',,8.3,,,,,,,,12.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,898,2025-12-02T15:57:10.570299
17478871.0,Apgar score 5',,8.9,,,,,,,,12.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,899,2025-12-02T15:57:10.570299
17478871.0,Neonatal abstinence syndrome,,1,,count,,,,,,12.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,900,2025-12-02T15:57:10.570299
17478871.0,Duration of NAS treatment,,6,,days,,,,,,12.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,901,2025-12-02T15:57:10.570299
17564645.0,Recovery - 25% to T1,sevoflurane,18,min,mean,SD,5.2,,,,12.0,children,,,0.0033,p is for difference between the sevoflurane/fentanyl,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,902,2025-12-02T15:57:10.570299
17564645.0,Recovery - 10% to TR,sevoflurane,43.6,min,mean,SD,13.3,,,,12.0,children,,,0.0095,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,903,2025-12-02T15:57:10.570299
17564645.0,Recovery - 25% to T2,fentanyl group,10.8,min,mean,SD,5.4,,,,12.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,904,2025-12-02T15:57:10.570299
17564645.0,Recovery - 10% to TR,fentanyl group,29.9,min,mean,SD,11.2,,,,12.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,905,2025-12-02T15:57:10.570299
17934758.0,CHIPPS pain score before piritramide,,2.8,,,SD,2.8,,,,20.0,children,,,,spontaneously breathing patients,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,906,2025-12-02T15:57:10.570299
17934758.0,CHIPPS pain score 60 min after piritramide,,0.2,,,,0.4,,,,20.0,,,,<0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,907,2025-12-02T15:57:10.570299
17934758.0,CHIPPS pain score 120 min after piritramide,,1.6,,,,2.9,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,908,2025-12-02T15:57:10.570299
17934758.0,Rescue medication,,31,,%,,,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,909,2025-12-02T15:57:10.570299
17934758.0,Acetaminophen co-analgesia,,26,,%,,,,,,20.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,910,2025-12-02T15:57:10.570299
17934758.0,Hartwig pain score>13 60 min after piritramide,,>50,,%,,,,,,19.0,,,,,ventilated patients,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,911,2025-12-02T15:57:10.570299
17934758.0,Rescue medication,,60,,%,,,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,912,2025-12-02T15:57:10.570299
17934758.0,Acetaminophen co-analgesia,,55,,%,,,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,913,2025-12-02T15:57:10.570299
18166563.0,Apgar score 1',Breastfed,9,,median,,,IQR,1,,8.0,Neonate,Postpartum (PP),,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,914,2025-12-02T15:57:10.570299
18166563.0,Apgar score 5',Breastfed,9,,median,,,IQR,0,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,915,2025-12-02T15:57:10.570299
18166563.0,Day 3 NAS score,Breastfed,4.5,,median,,,IQR,3.9,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,916,2025-12-02T15:57:10.570299
18166563.0,Highest NAS score,Breastfed,6.5,,median,,,IQR,4.5,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,917,2025-12-02T15:57:10.570299
18166563.0,Infants requiring NAS pharmacotherapy,Breastfed,1,,count,,,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,918,2025-12-02T15:57:10.570299
18166563.0,Total time of NAS therapy,Breastfed,6,,days (d),,,IQR,0,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,919,2025-12-02T15:57:10.570299
18166563.0,Apgar score 1',Formula-fed,9,,,,,IQR,0.5,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,920,2025-12-02T15:57:10.570299
18166563.0,Apgar score 5',Formula-fed,9,,,,,IQR,0,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,921,2025-12-02T15:57:10.570299
18166563.0,Day 3 NAS score,Formula-fed,6.8,,,,,IQR,1.2,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,922,2025-12-02T15:57:10.570299
18166563.0,Highest NAS score,Formula-fed,11,,,,,IQR,5,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,923,2025-12-02T15:57:10.570299
18166563.0,Infants requiring NAS pharmacotherapy,Formula-fed,4,,count,,,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,924,2025-12-02T15:57:10.570299
18166563.0,Total time of NAS therapy,Formula-fed,13.5,,days (d),,,IQR,10.5,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,925,2025-12-02T15:57:10.570299
18294329.0,Apgar score 1' <7,Tramadol group,9,,,,,IQR,9,10,75.0,Neonate,Postpartum (PP),,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,926,2025-12-02T15:57:10.570299
18294329.0,Apgar score 5' <7,Tramadol group,9,,,,,,9,10,75.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,927,2025-12-02T15:57:10.570299
18294329.0,Assessment day post birth,Tramadol group,4,,days (d),,,,3,4,75.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,928,2025-12-02T15:57:10.570299
18294329.0,Total NAC score,Tramadol group,36,,,,,,33,38,67.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,929,2025-12-02T15:57:10.570299
18294329.0,Neurologic score,Tramadol group,28,,,,,,26,29,67.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,930,2025-12-02T15:57:10.570299
18294329.0,Adaptive capacity score,Tramadol group,9,,,,,,8,10,67.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,931,2025-12-02T15:57:10.570299
18294329.0,Apgar score 1' <7,Control group,9,,,,,,9,10,75.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,932,2025-12-02T15:57:10.570299
18294329.0,Apgar score 5' <7,Control group,9,,,,,,9,10,75.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,933,2025-12-02T15:57:10.570299
18294329.0,Assessment day post birth,Control group,3,,days (d),,,,2,4,75.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,934,2025-12-02T15:57:10.570299
18294329.0,Total NAC score,Control group,37,,,,,,33,40,67.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,935,2025-12-02T15:57:10.570299
18294329.0,Neurologic score,Control group,27,,,,,,26,30,67.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,936,2025-12-02T15:57:10.570299
18294329.0,Adaptive capacity score,Control group,10,,,,,,8,10,67.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,937,2025-12-02T15:57:10.570299
18381513.0,AST,hypothermic,56,,IU/l,,,range,25,170,10.0,neonates,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,938,2025-12-02T15:57:10.570299
18381513.0,ALT,hypothermic,34,,IU/l,,,,8,84,,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,939,2025-12-02T15:57:10.570299
18381513.0,LDH,hypothermic,1152,,IU/l,,,,459,2344,,,,,0.04,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,940,2025-12-02T15:57:10.570299
18381513.0,CK,hypothermic,237,,IU/l,,,,59,1035,,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,941,2025-12-02T15:57:10.570299
18381513.0,Creatinine,hypothermic,62,,umol/l,,,,24,87,,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,942,2025-12-02T15:57:10.570299
18381513.0,Urine output,hypothermic,3.5,,ml/kg/h,,,,2.6,6.2,,,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,943,2025-12-02T15:57:10.570299
18381513.0,Encephalopathy score on day 4,hypothermic,8.5,,,,,,3,12,,,,,0.26,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,944,2025-12-02T15:57:10.570299
18381513.0,Rectal temperature,hypothermic,33.4,,celsius,SD,0.65,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,945,2025-12-02T15:57:10.570299
18381513.0,Seizures,hypothermic,4,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,946,2025-12-02T15:57:10.570299
18381513.0,AST,normothermic,118,,IU/l,,,range,53,365,6.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,947,2025-12-02T15:57:10.570299
18381513.0,ALT,normothermic,75,,IU/l,,,,11,878,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,948,2025-12-02T15:57:10.570299
18381513.0,LDH,normothermic,2487,,IU/l,,,,1084,4667,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,949,2025-12-02T15:57:10.570299
18381513.0,CK,normothermic,605,,IU/l,,,,236,2602,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,950,2025-12-02T15:57:10.570299
18381513.0,Creatinine,normothermic,100,,umol/l,,,,52,114,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,951,2025-12-02T15:57:10.570299
18381513.0,Urine output,normothermic,3.5,,ml/kg/h,,,,0.5,4.4,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,952,2025-12-02T15:57:10.570299
18381513.0,Encephalopathy score on day 4,normothermic,5.5,,,,,,0,15,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,953,2025-12-02T15:57:10.570299
18381513.0,Rectal temperature,normothermic,36.7,,celsius,SD,0.33,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,954,2025-12-02T15:57:10.570299
18381513.0,Death,normothermic,1,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,955,2025-12-02T15:57:10.570299
18381513.0,Seizures,normothermic,3,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,956,2025-12-02T15:57:10.570299
18454213.0,Apgar score 1',Group 1,6,,score,,,range,7,8,50.0,neonates,postpartum,,0.51,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,957,2025-12-02T15:57:10.570299
18454213.0,Apgar score 1',Group 2,8,,,,,,7,9,50.0,neonates,postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,958,2025-12-02T15:57:10.570299
18454213.0,Apgar score 5',Group 1,9,,score,,,,7,10,,,,,0.61,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,959,2025-12-02T15:57:10.570299
18454213.0,Apgar score 5',Group 2,9,,,,,,8,10,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,960,2025-12-02T15:57:10.570299
18454213.0,Supplemental bottle feeding,Group 1,20,,count,,,,,,,,,,0.63,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,961,2025-12-02T15:57:10.570299
18454213.0,Supplemental bottle feeding,Group 2,14,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,962,2025-12-02T15:57:10.570299
18454213.0,PIBBS at 24 hours,Group 1,35,,score,,,,,,,,,,0.03,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,963,2025-12-02T15:57:10.570299
18454213.0,PIBBS at 24 hours,Group 2,34,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,964,2025-12-02T15:57:10.570299
18454213.0,No response to breast,Group 1,12,,count,,,,,,,,,,0.18,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,965,2025-12-02T15:57:10.570299
18454213.0,No response to breast,Group 2,10,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,966,2025-12-02T15:57:10.570299
18454213.0,Infant slips of breast,Group 1,10,,,,,,,,,,,,0.15,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,967,2025-12-02T15:57:10.570299
18454213.0,Infant slips of breast,Group 2,8,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,968,2025-12-02T15:57:10.570299
18454213.0,No rooting occurs,Group 1,15,,,,,,,,,,,,0.47,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,969,2025-12-02T15:57:10.570299
18454213.0,No rooting occurs,Group 2,7,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,970,2025-12-02T15:57:10.570299
18454213.0,"Mouth closed, points forward",Group 1,14,,,,,,,,,,,,0.36,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,971,2025-12-02T15:57:10.570299
18454213.0,"Mouth closed, points forward",Group 2,13,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,972,2025-12-02T15:57:10.570299
18454213.0,Lower lip turned in,Group 1,10,,,,,,,,,,,,0.7,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,973,2025-12-02T15:57:10.570299
18454213.0,Lower lip turned in,Group 2,4,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,974,2025-12-02T15:57:10.570299
18454213.0,Cannot see infant’s tongue,Group 1,3,,,,,,,,,,,,0.9,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,975,2025-12-02T15:57:10.570299
18454213.0,Cannot see infant’s tongue,Group 2,2,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,976,2025-12-02T15:57:10.570299
18454213.0,Cheek tense or pulled in,Group 1,12,,,,,,,,,,,,0.94,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,977,2025-12-02T15:57:10.570299
18454213.0,Cheek tense or pulled in,Group 2,9,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,978,2025-12-02T15:57:10.570299
18454213.0,Rapid sucks,Group 1,8,,,,,,,,,,,,0.67,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,979,2025-12-02T15:57:10.570299
18454213.0,Rapid sucks,Group 2,3,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,980,2025-12-02T15:57:10.570299
18454213.0,Can hear smacking or clicking,Group 1,5,,,,,,,,,,,,0.11,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,981,2025-12-02T15:57:10.570299
18454213.0,Can hear smacking or clicking,Group 2,6,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,982,2025-12-02T15:57:10.570299
18454213.0,Infant does not latch on,Group 1,20,,,,,,,,,,,,0.89,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,983,2025-12-02T15:57:10.570299
18454213.0,Infant does not latch on,Group 2,29,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,984,2025-12-02T15:57:10.570299
18454213.0,Infant falls asleep,Group 1,8,,,,,,,,,,,,0.97,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,985,2025-12-02T15:57:10.570299
18454213.0,Infant falls asleep,Group 2,7,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,986,2025-12-02T15:57:10.570299
18454213.0,Infant not sucking well,Group 1,9,,,,,,,,,,,,1,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,987,2025-12-02T15:57:10.570299
18454213.0,Infant not sucking well,Group 2,9,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,988,2025-12-02T15:57:10.570299
18474065.0,Length of hospital stay,,25,,days,SD,19.0,range,3,125,58.0,infants,,,0.006,"The infants’ (n = 29) urinary norbuprenophine concentrations on day 1 correlated with the length of hospital stay (r = 0.496, p = 0.006; Fig. 1), but not with the duration of morphine treatment.",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,989,2025-12-02T15:57:10.570299
18474065.0,Length of hospital stay,Compliant group,28,,,,13.0,,4,57,,,,,0.012,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,990,2025-12-02T15:57:10.570299
18474065.0,Length of hospital stay,Non-compliant group,19,,,,13.0,,3,125,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,991,2025-12-02T15:57:10.570299
18474065.0,Length of morphine treatment for NAS,Compliant group,20,,days,,10.0,,7,48,38.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,992,2025-12-02T15:57:10.570299
18474065.0,Length of morphine treatment for NAS,Non-compliant group,18,,,,12.0,,7,48,,,,,0.009,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,993,2025-12-02T15:57:10.570299
18474065.0,Length of morphine treatment for NAS,,10,,,,12.0,,7,42,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,994,2025-12-02T15:57:10.570299
18474065.0,Age at morphine initiation,,2.4,,days,,1.1,,1,6,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,995,2025-12-02T15:57:10.570299
18474065.0,Day 1 Finnegan score,with maternal on IV buprenorphine,6.8,,score,SD,2.7,,,,,,,,0.002,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,996,2025-12-02T15:57:10.570299
18474065.0,Day 1 Finnegan score,with maternal on SL buprenorphine,4.7,,,,2.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,997,2025-12-02T15:57:10.570299
18474065.0,Excessive jerking,,10,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,998,2025-12-02T15:57:10.570299
18474065.0,Abnormal EEG,,2,,,,,,,,10.0,infants,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,999,2025-12-02T15:57:10.570299
18474065.0,Small for gestational age,,5,,count,%,9.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1000,2025-12-02T15:57:10.570299
18474065.0,Preterm birth,,3,,,5,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1001,2025-12-02T15:57:10.570299
18701886.0,Female sex,,6,,count,,,,,,10.0,neonates,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1002,2025-12-02T15:57:10.570299
18701886.0,Apgar score 1',,8.1,,,SD,0.2,range,7,9,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1003,2025-12-02T15:57:10.570299
18701886.0,Apgar score 5',,8.7,,,,0.2,,8,9,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1004,2025-12-02T15:57:10.570299
18701886.0,Gestational age at birth,,38.6,,weeks,,0.5,,37,41,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1005,2025-12-02T15:57:10.570299
18701886.0,Birth weight,,3248,,grams,,161.5,range,2730,4340,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1006,2025-12-02T15:57:10.570299
18701886.0,Head circumference,,34.2,,cm,,0.6,,31,38,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1007,2025-12-02T15:57:10.570299
18701886.0,Length,,50.7,,cm,,1.0,,48,58,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1008,2025-12-02T15:57:10.570299
18701886.0,Length of hospital stay,,5.8,,days,,0.9,,4,11,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1009,2025-12-02T15:57:10.570299
18701886.0,Treated for NAS,,2,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1010,2025-12-02T15:57:10.570299
18701886.0,Time to onset,,56.6,,h,,19.4,,3,205,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1011,2025-12-02T15:57:10.570299
18701886.0,Peak NAS score,,7.7,,,,1.0,,3,13,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1012,2025-12-02T15:57:10.570299
18701886.0,Time-to-peak NAS score,,97.9,,h,,18.7,,28,204,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1013,2025-12-02T15:57:10.570299
18701886.0,Duration,,113.1,,h,,19.9,,7,208,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1014,2025-12-02T15:57:10.570299
18701886.0,% Of scores >4,,24.1,,%,,5.8,,0,58,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1015,2025-12-02T15:57:10.570299
18806024.0,End-tidal CO2 before intubation,Remi-2,23,,%,SD,9.0,,,,47.0,children,,,0.1,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1016,2025-12-02T15:57:10.570299
18806024.0,End-tidal CO2 before intubation,Remi-3,23,,,,9.0,,,,48.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1017,2025-12-02T15:57:10.570299
18806024.0,End-tidal CO2 before intubation,Saline-2,26,,,,9.0,,,,47.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1018,2025-12-02T15:57:10.570299
18806024.0,End-tidal CO2 before intubation,Saline-3,26,,,,10.0,,,,46.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1019,2025-12-02T15:57:10.570299
18806024.0,End-tidal CO2 after intubation,Remi-2,36,,,,8.0,,,,47.0,,,,0.9,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1020,2025-12-02T15:57:10.570299
18806024.0,End-tidal CO2 after intubation,Remi-3,38,,,,7.0,,,,48.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1021,2025-12-02T15:57:10.570299
18806024.0,End-tidal CO2 after intubation,Saline-2,36,,,,11.0,,,,47.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1022,2025-12-02T15:57:10.570299
18806024.0,End-tidal CO2 after intubation,Saline-3,37,,,,10.0,,,,46.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1023,2025-12-02T15:57:10.570299
19260034.0,Nausea,,4,,count,,,,,,7.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1024,2025-12-02T15:57:10.570299
19260034.0,Vomiting,,4,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1025,2025-12-02T15:57:10.570299
19260034.0,Dizziness,,1,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1026,2025-12-02T15:57:10.570299
19260034.0,Sedation,,1,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1027,2025-12-02T15:57:10.570299
19260034.0,Difficult urination,,1,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1028,2025-12-02T15:57:10.570299
19260034.0,constipation,,2,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1029,2025-12-02T15:57:10.570299
19260034.0,Pruritis,,,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1030,2025-12-02T15:57:10.570299
19330322.0,Apgar score 5',,10,,median,,,,,,10.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1031,2025-12-02T15:57:10.570299
19996953.0,Onset of relief,,5,,min,,3.5,,,,52.0,Maternal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1032,2025-12-02T15:57:10.570299
19996953.0,Dermatome at 5 min,,T6,,,,3.2,,,,52.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1033,2025-12-02T15:57:10.570299
19996953.0,Dermatome at 10 min,,T4,,,,3.2,,,,52.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1034,2025-12-02T15:57:10.570299
19996953.0,Cervical dilation,,3.5,,cm,,1.3,,,,52.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1035,2025-12-02T15:57:10.570299
19996953.0,Block duration,,99.2,,min,,41.0,,,,52.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1036,2025-12-02T15:57:10.570299
20216119.0,Male sex,,3,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1037,2025-12-02T15:57:10.570299
20216119.0,Female sex,,3,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1038,2025-12-02T15:57:10.570299
20216119.0,birth weight,,3133.3,,grams,SD,159.3,,,,6.0,neonates,postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1039,2025-12-02T15:57:10.570299
20216119.0,head circumference,,34,,cm,,1.0,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1040,2025-12-02T15:57:10.570299
20216119.0,length,,50,,cm,,0.9,,,,6.0,,,,0.009,"NBUP/NBUP-Gluc ratio correlated negatively with newborn length (p=0.009, r=−0.99, n=4)",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1041,2025-12-02T15:57:10.570299
20216119.0,gestational age at delivery,,38.3,,weeks,,0.6,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1042,2025-12-02T15:57:10.570299
20216119.0,Apgar score 1',,8,,,,0.3,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1043,2025-12-02T15:57:10.570299
20216119.0,Apgar score 5',,8.8,,,,0.2,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1044,2025-12-02T15:57:10.570299
20216119.0,Length of hospital stay,,5,,days,,0.6,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1045,2025-12-02T15:57:10.570299
20216119.0,Peak NAS score,,6.3,,,,0.9,,,,6.0,,,,0.023,"NBUP/NBUP-Gluc ratio correlated positively with maximum NAS score (p=0.023, r=0.87, n=6)",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1046,2025-12-02T15:57:10.570299
20216119.0,Time to peak NAS,,108.5,,hours,,28.0,,,,6.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1047,2025-12-02T15:57:10.570299
20216119.0,Time to NAS onset,,58,,hours,,37.1,,,,5.0,,,,0.0009,Placenta NBUP-Gluc concentration correlated positively with time to NAS onset,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1048,2025-12-02T15:57:10.570299
20216119.0,Duration NAS,,116.7,,hours,,32.9,,,,5.0,,,,0.042,Placenta NBUP-Gluc concentration correlated negatively with duration of NAS,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1049,2025-12-02T15:57:10.570299
20216119.0,NAS score >4,,21.4,,%,,8.6,,,,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1050,2025-12-02T15:57:10.570299
20854338.0,Gestational age at birth,,38,,weeks,,,,,,18.0,infants,postpartum,,0.007,in infants with opioid positive meconium,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1051,2025-12-02T15:57:10.570299
20854338.0,Preterm birth,,38.9,,%,,,,,,,,,,0.005,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1052,2025-12-02T15:57:10.570299
20854338.0,Birth weight,,2823,,g,SD,554.0,,,,,,,,0.068,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1053,2025-12-02T15:57:10.570299
20854338.0,Length,,48,,cm,,3.6,,,,,,,,0.085,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1054,2025-12-02T15:57:10.570299
20854338.0,Head circumference,,32.5,,cm,,1.6,,,,,,,,0.306,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1055,2025-12-02T15:57:10.570299
20854338.0,Length of hospital stay,,8.5,,days,,,,,,,,,,0.018,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1056,2025-12-02T15:57:10.570299
20854338.0,Peak NAS score,,10.2,,,,5.7,,,,,,,,0.523,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1057,2025-12-02T15:57:10.570299
20854338.0,Day of peak NAS score,,3.5,,day,,,,,,,,,,0.035,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1058,2025-12-02T15:57:10.570299
20854338.0,Treatment for NAS,,33.3,,%,,,,,,,,,,0.879,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1059,2025-12-02T15:57:10.570299
20854338.0,Gestational age at birth,,40,,weeks,,,,,,31.0,infants,postpartum,,,in infants with opioid negative meconium,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1060,2025-12-02T15:57:10.570299
20854338.0,Preterm birth,,6.5,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1061,2025-12-02T15:57:10.570299
20854338.0,Birth weight,,3154,,g,SD,621.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1062,2025-12-02T15:57:10.570299
20854338.0,Length,,49.7,,cm,,3.1,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1063,2025-12-02T15:57:10.570299
20854338.0,Head circumference,,33.1,,cm,,1.9,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1064,2025-12-02T15:57:10.570299
20854338.0,Length of hospital stay,,4.5,,days,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1065,2025-12-02T15:57:10.570299
20854338.0,Peak NAS score,,9.4,,,,3.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1066,2025-12-02T15:57:10.570299
20854338.0,Day of peak NAS score,,3,,day,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1067,2025-12-02T15:57:10.570299
20854338.0,Treatment for NAS,,35.5,,%,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1068,2025-12-02T15:57:10.570299
21245372.0,Estimated gestational age at birth,,36.3,,weeks,SD,3.4,,,,19.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1069,2025-12-02T15:57:10.570299
21245372.0,Birth weight,,3027.6,,grams,,816.3,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1070,2025-12-02T15:57:10.570299
21245372.0,Head circumference,,32.8,,cm,,2.4,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1071,2025-12-02T15:57:10.570299
21245372.0,Length,,48.3,,m,,3.3,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1072,2025-12-02T15:57:10.570299
21245372.0,Apgar score 1',,8.3,,,,0.7,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1073,2025-12-02T15:57:10.570299
21245372.0,Apgar score 5',,8.8,,,,0.4,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1074,2025-12-02T15:57:10.570299
21245372.0,Time to NAS onset,,30.9,,hours,,28.6,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1075,2025-12-02T15:57:10.570299
21245372.0,Peak NAS score,,9.5,,,,3.8,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1076,2025-12-02T15:57:10.570299
21245372.0,Time to peak NAS score,,65.7,,hours,,49.8,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1077,2025-12-02T15:57:10.570299
21245372.0,NAS duration,,131.1,,hours,,148.5,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1078,2025-12-02T15:57:10.570299
21245372.0,NAS score >4,,47.1,,%,,28.0,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1079,2025-12-02T15:57:10.570299
21343764.0,Preterm birth < 37 weeks gestation,,7,,count,%,19.0,,,,30.0,Maternal,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1080,2025-12-02T15:57:10.570299
21343764.0,Birth weight <1500 g,,3,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1081,2025-12-02T15:57:10.570299
21398109.0,time from last meperidine to NACS ,,105,minute,median,,,IQR,25,269,20.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1082,2025-12-02T15:57:10.570299
21398109.0,NACS,,33.5,,median,,,IQR,30,36,20.0,Neonate,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1083,2025-12-02T15:57:10.570299
21642610.0,Supplemental oxygen,Group E,6,,count,,,,,,15.0,Maternal,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1084,2025-12-02T15:57:10.570299
21642610.0,O2 saturation <93%,Group E,5,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1085,2025-12-02T15:57:10.570299
21642610.0,Hypotension,Group E,6,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1086,2025-12-02T15:57:10.570299
21642610.0,Vomiting at 1 hour,Group E,1,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1087,2025-12-02T15:57:10.570299
21642610.0,Vomiting at 4 hours,Group E,4,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1088,2025-12-02T15:57:10.570299
21642610.0,Vomiting at 8 hours,Group E,4,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1089,2025-12-02T15:57:10.570299
21642610.0,Vomiting at 24 hours,Group E,3,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1090,2025-12-02T15:57:10.570299
21642610.0,Nausea 0-72 hours,Group E,8,,,%,53.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1091,2025-12-02T15:57:10.570299
21642610.0,Vomiting 0-24 hours,Group E,10,,,,67.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1092,2025-12-02T15:57:10.570299
21642610.0,Antiemetic use,Group E,10,,,,67.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1093,2025-12-02T15:57:10.570299
21642610.0,Anti-pruritic medication,Group E,4,,,,27.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1094,2025-12-02T15:57:10.570299
21642610.0,Analgesia satisfaction 0-72 hours (0-100),Group E,91,,,SD,16.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1095,2025-12-02T15:57:10.570299
21642610.0,Time to hospital discharge,Group E,3.5,,days,,0.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1096,2025-12-02T15:57:10.570299
21642610.0,Hypotension,Group SE,6,,,,,,,,14.0,Maternal,Postpartum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1097,2025-12-02T15:57:10.570299
21642610.0,Vomiting at 4 hours,Group SE,2,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1098,2025-12-02T15:57:10.570299
21642610.0,Vomiting at 24 hours,Group SE,1,,,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1099,2025-12-02T15:57:10.570299
21642610.0,Nausea 0-72 hours,Group SE,5,,,%,36.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1100,2025-12-02T15:57:10.570299
21642610.0,Vomiting 0-24 hours,Group SE,2,,,,14.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1101,2025-12-02T15:57:10.570299
21642610.0,Antiemetic use,Group SE,3,,,,21.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1102,2025-12-02T15:57:10.570299
21642610.0,Anti-pruritic medication,Group SE,5,,,,36.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1103,2025-12-02T15:57:10.570299
21642610.0,Analgesia satisfaction 0-72 hours (0-100),Group SE,92,,,SD,14.0,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1104,2025-12-02T15:57:10.570299
21642610.0,Time to hospital discharge,Group SE,3.5,,,,0.6,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1105,2025-12-02T15:57:10.570299
21743375.0,Estimated gestational age at birth,,36.3,,weeks,SD,3.4,,,,19.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1106,2025-12-02T15:57:10.570299
21743375.0,Birth weight,,3027.6,,grams,,816.3,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1107,2025-12-02T15:57:10.570299
21743375.0,Head circumference,,32.8,,cm,,2.4,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1108,2025-12-02T15:57:10.570299
21743375.0,Length,,48.3,,m,,3.3,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1109,2025-12-02T15:57:10.570299
21743375.0,Apgar score 1',,8.3,,,,0.7,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1110,2025-12-02T15:57:10.570299
21743375.0,Apgar score 5',,8.8,,,,0.4,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1111,2025-12-02T15:57:10.570299
21743375.0,Time to NAS onset,,30.9,,hours,,28.6,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1112,2025-12-02T15:57:10.570299
21743375.0,Peak NAS score,,9.5,,,,3.8,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1113,2025-12-02T15:57:10.570299
21743375.0,Time to peak NAS score,,65.7,,hours,,49.8,,,,19.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1114,2025-12-02T15:57:10.570299
21743375.0,NAS duration,,131.1,,hours,,148.5,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1115,2025-12-02T15:57:10.570299
21743375.0,NAS score >4,,47.1,,%,,28.0,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1116,2025-12-02T15:57:10.570299
21819795.0,Apgar score 1',,8,,,,,,,,5.0,Neonate,Postpartum (PP),,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1117,2025-12-02T15:57:10.570299
21819795.0,Apgar score 5',,9,,,,,,,,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1118,2025-12-02T15:57:10.570299
21819795.0,Length of hospital stay,,5,,days,,,,,,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1119,2025-12-02T15:57:10.570299
21819795.0,Peak NAS score,,6,,,,,,,,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1120,2025-12-02T15:57:10.570299
21819795.0,Time to peak NAS score,,122,,h,,,,,,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1121,2025-12-02T15:57:10.570299
21819795.0,Time to NAS onset,,31.5,,h,,,,,,4.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1122,2025-12-02T15:57:10.570299
21819795.0,Duration NAS,,129.5,,h,,,,,,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1123,2025-12-02T15:57:10.570299
21819795.0,NAS scores>4,,19,,%,,,,,,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1124,2025-12-02T15:57:10.570299
22448718.0,Pain relief 10' after last oxycodone dose,,6,,,,,range,3,10,14.0,Maternal,Labor,,0.01,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1125,2025-12-02T15:57:10.570299
22448718.0,Time to epidural analgesia after last oxycodone dose,,89,,min,,,,15,309,14.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1126,2025-12-02T15:57:10.570299
22448718.0,Sedation,,6,,count,,,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1127,2025-12-02T15:57:10.570299
22448718.0,Light headedness,,2,,count,,,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1128,2025-12-02T15:57:10.570299
22448718.0,Nausea,,1,,count,,,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1129,2025-12-02T15:57:10.570299
22448718.0,Transient O2 desaturation to 93%,,1,,count,,,,,,10.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1130,2025-12-02T15:57:10.570299
22448718.0,Apgar score 1',Oxycodone group,9,,,,,range,4,9,14.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1131,2025-12-02T15:57:10.570299
22448718.0,Apgar score 5',Oxycodone group,9,,,,,,7,9,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1132,2025-12-02T15:57:10.570299
22448718.0,NACS,Oxycodone group,34,,,,,,27,37,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1133,2025-12-02T15:57:10.570299
22448718.0,NACS time from birth,Oxycodone group,43,,min,,,,27,68,,,,,0.034,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1134,2025-12-02T15:57:10.570299
22448718.0,Ua-pH,Oxycodone group,7.2,,,,,,7,7.3,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1135,2025-12-02T15:57:10.570299
22448718.0,Uv-pH,Oxycodone group,7.3,,,,,,7.1,7.4,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1136,2025-12-02T15:57:10.570299
22448718.0,Ua-BE,Oxycodone group,-6.4,,,,,,-10,1,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1137,2025-12-02T15:57:10.570299
22448718.0,Uv-BE,Oxycodone group,-6.7,,,,,,-9.5,-0.4,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1138,2025-12-02T15:57:10.570299
22448718.0,Apgar score 1',Control group,9,,,,,,5,10,30.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1139,2025-12-02T15:57:10.570299
22448718.0,Apgar score 5',Control group,9,,,,,,9,10,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1140,2025-12-02T15:57:10.570299
22448718.0,NACS,Control group,34,,,,,,30,38,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1141,2025-12-02T15:57:10.570299
22448718.0,NACS time from birth,Control group,54,,,,,,23,153,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1142,2025-12-02T15:57:10.570299
22448718.0,Ua-pH,Control group,7.3,,,,,,7.1,7.5,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1143,2025-12-02T15:57:10.570299
22448718.0,Uv-pH,Control group,7.4,,,,,,7.3,7.5,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1144,2025-12-02T15:57:10.570299
22448718.0,Ua-BE,Control group,-5,,,,,,-12.6,-1.3,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1145,2025-12-02T15:57:10.570299
22448718.0,Uv-BE,Control group,-4.9,,,,,,-10.1,-0.9,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1146,2025-12-02T15:57:10.570299
22486937.0,pain scores,,2.9,,mean,SD,2.9,,,,35.0,child,,,,Non-Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1147,2025-12-02T15:57:10.570299
22486937.0,pain scores,,3,,mean,SD,2.6,,,,33.0,child,,,0.84,Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1148,2025-12-02T15:57:10.570299
22486937.0,peak agitation score,,1.5,,mean,SD,1.0,,,,35.0,child,,,,Non-Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1149,2025-12-02T15:57:10.570299
22486937.0,peak agitation score,,1.4,,mean,SD,0.9,,,,33.0,child,,,0.56,Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1150,2025-12-02T15:57:10.570299
22486937.0,any hydromorphone rescue boluses,,14,,n,,,,,,35.0,child,,,,Non-Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1151,2025-12-02T15:57:10.570299
22486937.0,any hydromorphone rescue boluses,,16,,n,,,,,,33.0,child,,,0.48,Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1152,2025-12-02T15:57:10.570299
22486937.0,any side effect,,7,,n,,,,,,35.0,child,,,,Non-Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1153,2025-12-02T15:57:10.570299
22486937.0,any side effect,,19,,n,,,,,,33.0,child,,,0.001,Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1154,2025-12-02T15:57:10.570299
22486937.0,emesis,,1,,n,,,,,,35.0,child,,,,Non-Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1155,2025-12-02T15:57:10.570299
22486937.0,emesis,,7,,n,,,,,,33.0,child,,,0.025,Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1156,2025-12-02T15:57:10.570299
22486937.0,pruritus,,3,,n,,,,,,35.0,child,,,,Non-Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1157,2025-12-02T15:57:10.570299
22486937.0,pruritus,,12,,n,,,,,,33.0,child,,,0.006,Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1158,2025-12-02T15:57:10.570299
22486937.0,respiratory depression,,3,,n,,,,,,35.0,child,,,,Non-Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1159,2025-12-02T15:57:10.570299
22486937.0,respiratory depression,,8,,n,,,,,,33.0,child,,,0.079,Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1160,2025-12-02T15:57:10.570299
22486937.0,hospitalization for side effects,,0,,n,,,,,,35.0,child,,,,Non-Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1161,2025-12-02T15:57:10.570299
22486937.0,hospitalization for side effects,,4,,n,,,,,,33.0,child,,,0.05,Latino,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1162,2025-12-02T15:57:10.570299
24269714.0,side effects,,4.4,,mean,,3.0,,,,8.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1163,2025-12-02T15:57:10.570299
24269714.0,side effects,,4.3,,mean,,3.8,,,,97.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1164,2025-12-02T15:57:10.570299
24269714.0,side effects,,5,,mean,,4.9,,,,44.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1165,2025-12-02T15:57:10.570299
24269714.0,side effects,,5.3,,mean,,5.9,,,,7.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1166,2025-12-02T15:57:10.570299
24269714.0,pain index,,4.8,,mean,,2.3,,,,8.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1167,2025-12-02T15:57:10.570299
24269714.0,pain index,,4.3,,mean,,2.5,,,,97.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1168,2025-12-02T15:57:10.570299
24269714.0,pain index,,4.5,,mean,,2.1,,,,44.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1169,2025-12-02T15:57:10.570299
24269714.0,pain index,,4.9,,mean,,2.5,,,,7.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1170,2025-12-02T15:57:10.570299
24269714.0,pain index,,5,,median,,,range,0,8,8.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1171,2025-12-02T15:57:10.570299
24269714.0,pain index,,4,,median,,,range,0,10,97.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1172,2025-12-02T15:57:10.570299
24269714.0,pain index,,4.5,,median,,,range,1,9,44.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1173,2025-12-02T15:57:10.570299
24269714.0,pain index,,4,,median,,,range,1,9,7.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1174,2025-12-02T15:57:10.570299
26385675.0,Fatigue,,5,,count,,,,,,15.0,Maternal,Labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1175,2025-12-02T15:57:10.570299
26385675.0,Mild sedation,,2,,count,,,,,,15.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1176,2025-12-02T15:57:10.570299
26385675.0,Achieved analgesia,,10,,count,,,,,,15.0,,,,,between 33/140 mins after last dose at 0.5 ng/ml cocentration,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1177,2025-12-02T15:57:10.570299
26701799.0,Apgar score 1',,9,,,,,,,,1.0,Neonate,Delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1178,2025-12-02T15:57:10.570299
26701799.0,Apgar score 5',,9,,,,,,,,1.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1179,2025-12-02T15:57:10.570299
26701799.0,LATCH score,,2,,,,,,,,1.0,,,,,the latching ability/audible swallowing were rated at 2 (normal),Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1180,2025-12-02T15:57:10.570299
27138295.0,Total number of children with TEAEs,,11,,,,,,,,37.0,pediatric ,,7–11 Years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1181,2025-12-02T15:57:10.570299
27138295.0,Total number of adolescents with TEAEs,,18,,,,,,,,38.0,pediatric ,,12–17 Years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1182,2025-12-02T15:57:10.570299
27140798.0,Vomiting,single-dose study,23,,%,,,,,,,12-16 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1183,2025-12-02T15:57:10.570299
27140798.0,Vomiting,single-dose study,6,,,,,,,,,7-11 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1184,2025-12-02T15:57:10.570299
27140798.0,Vomiting,multiple-dose study,38,,,,,,,,,7-11 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1185,2025-12-02T15:57:10.570299
27140798.0,Vomiting,multiple-dose study,31,,,,,,,,,12-16 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1186,2025-12-02T15:57:10.570299
27140798.0,Headache,multiple-dose study,25,,,,,,,,,7-11 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1187,2025-12-02T15:57:10.570299
27140798.0,Headache,multiple-dose study,31,,,,,,,,,12-16 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1188,2025-12-02T15:57:10.570299
27140798.0,Discontinued tramadol,,1,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1189,2025-12-02T15:57:10.570299
27572136.0,VAS pain score at 72h in methadone users,,2.6,,,,,,,,12.0,adults,,,0.04,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1190,2025-12-02T15:57:10.570299
27572136.0,VAS pain score at 72h in controls,,4.7,,,,,,,,12.0,adults,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1191,2025-12-02T15:57:10.570299
27572136.0,Overall VAS pain score in methadone users,,4.1,,,,,,,,12.0,adults,,,>0.05,"Using a repeated measures model, adjusted for age, sex,/time, there was no significant difference between the methadone/control groups",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1192,2025-12-02T15:57:10.570299
27572136.0,Overall VAS pain score in controls,,4.8,,,,,,,,12.0,adults,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1193,2025-12-02T15:57:10.570299
27572136.0,Pain relief score in methadone users,,5.7,,,,,,,,12.0,adults,,,>0.05,"Using a repeated measures model treating pain relief as a continuous value, adjusted for age, sex,/time, there was no significant difference in pain relief between the methadone/control groups",Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1194,2025-12-02T15:57:10.570299
27572136.0,Pain relief score in controls,,5.4,,,,,,,,12.0,adults,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1195,2025-12-02T15:57:10.570299
27572136.0,Cumulative opioid consumption in methadone users,,469,,mg,SD,139.0,,,,12.0,adults,,,0.499,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1196,2025-12-02T15:57:10.570299
27572136.0,Cumulative opioid consumption in controls,,570,,,,537.0,,,,12.0,adults,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1197,2025-12-02T15:57:10.570299
27572136.0,Cumulative opioid consumption in methadone users,,255,,,,155.0,,,,12.0,children,,,>0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1198,2025-12-02T15:57:10.570299
27572136.0,Cumulative opioid consumption in controls,,309,,,,135.0,,,,12.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1199,2025-12-02T15:57:10.570299
28320034.0,Total duration of NAS treatment ,,44,days,median,,,range,8,134,11.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1200,2025-12-02T15:57:10.570299
28320034.0,Length of hospital stay,Infants requiring NAS treatment,19,days,median,,,range,10,42,11.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1201,2025-12-02T15:57:10.570299
28320034.0,Length of hospital stay,Infants not requiring NAS treatment,7,days,median,,,range,5,11,10.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1202,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 1 min,patients undergoing elective CS were administered anesthesia at short I-D intervals,4,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1203,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 1 min,patients undergoing elective CS were administered anesthesia at short I-D intervals,9,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1204,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 1 min,patients undergoing elective CS were administered anesthesia at short I-D intervals,7,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1205,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 1 min,patients undergoing elective CS were administered anesthesia at  long I-D intervals,5,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1206,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 1 min,patients undergoing elective CS were administered anesthesia at  long I-D intervals,9,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1207,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 1 min,patients undergoing elective CS were administered anesthesia at  long I-D intervals,6,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1208,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 5 min,patients undergoing elective CS were administered anesthesia at short I-D intervals,14,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1209,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 5 min,patients undergoing elective CS were administered anesthesia at short I-D intervals,6,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1210,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 5 min,patients undergoing elective CS were administered anesthesia at short I-D intervals,0,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1211,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 5 min,patients undergoing elective CS were administered anesthesia at  long I-D intervals,12,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1212,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 5 min,patients undergoing elective CS were administered anesthesia at  long I-D intervals,7,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1213,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 5 min,patients undergoing elective CS were administered anesthesia at  long I-D intervals,1,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1214,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 10 min,patients undergoing elective CS were administered anesthesia at short I-D intervals,20,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1215,2025-12-02T15:57:10.570299
28805611.0,Apgar scores at 10 min,patients undergoing elective CS were administered anesthesia at  long I-D intervals,20,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1216,2025-12-02T15:57:10.570299
28805611.0,NACS,patients undergoing elective CS were administered anesthesia at short I-D intervals,7,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1217,2025-12-02T15:57:10.570299
28805611.0,NACS,patients undergoing elective CS were administered anesthesia at short I-D intervals,16,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1218,2025-12-02T15:57:10.570299
28805611.0,NACS,patients undergoing elective CS were administered anesthesia at short I-D intervals,20,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1219,2025-12-02T15:57:10.570299
28805611.0,NACS,patients undergoing elective CS were administered anesthesia at  long I-D intervals,8,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1220,2025-12-02T15:57:10.570299
28805611.0,NACS,patients undergoing elective CS were administered anesthesia at  long I-D intervals,15,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1221,2025-12-02T15:57:10.570299
28805611.0,NACS,patients undergoing elective CS were administered anesthesia at  long I-D intervals,20,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1222,2025-12-02T15:57:10.570299
28805611.0,Resuscitative measures,patients undergoing elective CS were administered anesthesia at short I-D intervals,13,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1223,2025-12-02T15:57:10.570299
28805611.0,Resuscitative measures,patients undergoing elective CS were administered anesthesia at short I-D intervals,5,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1224,2025-12-02T15:57:10.570299
28805611.0,Resuscitative measures,patients undergoing elective CS were administered anesthesia at short I-D intervals,0,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1225,2025-12-02T15:57:10.570299
28805611.0,Resuscitative measures,patients undergoing elective CS were administered anesthesia at  long I-D intervals,11,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1226,2025-12-02T15:57:10.570299
28805611.0,Resuscitative measures,patients undergoing elective CS were administered anesthesia at  long I-D intervals,4,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1227,2025-12-02T15:57:10.570299
28805611.0,Resuscitative measures,patients undergoing elective CS were administered anesthesia at  long I-D intervals,0,,,,,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1228,2025-12-02T15:57:10.570299
29943508.0,Time from epidural placement to birth ,Adrenaline group,311,minutes,median,,,IQR,227,491,19.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1229,2025-12-02T15:57:10.570299
29943508.0,Time from epidural placement to birth ,Control group (w/o adrenaline),348,minutes,median,,,IQR,268,486,20.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1230,2025-12-02T15:57:10.570299
29943508.0,Birth weight ,Adrenaline group,3520,g,median,,,IQR,3200,3760,19.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1231,2025-12-02T15:57:10.570299
29943508.0,Birth weight ,Control group (w/o adrenaline),3602,g,median,,,IQR,3384,3809,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1232,2025-12-02T15:57:10.570299
29943508.0,Apgar-score at 1 min,Adrenaline group,9,,median,,,IQR,9,9,19.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1233,2025-12-02T15:57:10.570299
29943508.0,Apgar-score at 1 min,Control group (w/o adrenaline),9,,median,,,IQR,8.25,9,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1234,2025-12-02T15:57:10.570299
29943508.0,Apgar-score at 5 min,Adrenaline group,10,,median,,,IQR,10,10,19.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1235,2025-12-02T15:57:10.570299
29943508.0,Apgar-score at 5 min,Control group (w/o adrenaline),10,,median,,,IQR,9,10,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1236,2025-12-02T15:57:10.570299
29943508.0,Apgar-score at 10 min,Adrenaline group,10,,median,,,IQR,10,10,19.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1237,2025-12-02T15:57:10.570299
29943508.0,Apgar-score at 10 min,Control group (w/o adrenaline),10,,median,,,IQR,9,10,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1238,2025-12-02T15:57:10.570299
29943508.0,pH umbilical vein at birth,Adrenaline group,7.33,,median,,,IQR,7.3,7.35,19.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1239,2025-12-02T15:57:10.570299
29943508.0,pH umbilical vein at birth,Control group (w/o adrenaline),7.35,,median,,,IQR,7.3,7.39,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1240,2025-12-02T15:57:10.570299
29943508.0,Base excess umbilical vein at birth,Adrenaline group,-4.5,,mean,,1.8,,,,19.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1241,2025-12-02T15:57:10.570299
29943508.0,Base excess umbilical vein at birth,Control group (w/o adrenaline),-4.9,,mean,,1.6,,,,20.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1242,2025-12-02T15:57:10.570299
29943508.0,Total dose of epidural solution administered ,Adrenaline group,36,mL,median,,,IQR,33,66,19.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1243,2025-12-02T15:57:10.570299
29943508.0,Total dose of epidural solution administered ,Control group (w/o adrenaline),47,mL,median,,,IQR,36,69,20.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1244,2025-12-02T15:57:10.570299
29943508.0,Total number of boluses administered epidurally,Adrenaline group,2.8,,mean,,2.6,,,,19.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1245,2025-12-02T15:57:10.570299
29943508.0,Total number of boluses administered epidurally,Control group (w/o adrenaline),3.4,,mean,,2.9,,,,20.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1246,2025-12-02T15:57:10.570299
29943508.0,Modified Bromage-score at 60 min,Adrenaline group,0,,median,,,25th; 75th percentile,0,0,19.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1247,2025-12-02T15:57:10.570299
29943508.0,Modified Bromage-score at 60 min,Control group (w/o adrenaline),0,,median,,,25th; 75th percentile,0,0,20.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1248,2025-12-02T15:57:10.570299
29943508.0,No. of mechanically assisted deliveries,Adrenaline group,3,,mean,,,,,,19.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1249,2025-12-02T15:57:10.570299
29943508.0,No. of mechanically assisted deliveries,Control group (w/o adrenaline),8,,mean,,,,,,20.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1250,2025-12-02T15:57:10.570299
29943508.0,No. of cesarean deliveries,Adrenaline group,1,,mean,,,,,,19.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1251,2025-12-02T15:57:10.570299
29943508.0,No. of cesarean deliveries,Control group (w/o adrenaline),2,,mean,,,,,,20.0,pregnant ,post-partum,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1252,2025-12-02T15:57:10.570299
31213888.0,Visual analog scale,SPID4 scores,106.28,,mean,,75.35,,,,20.0,pediatric ,,12-<18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1253,2025-12-02T15:57:10.570299
31213888.0,McGrath color analog scale,SPID4 scores,8.93,,mean,,6.35,,,,20.0,pediatric ,,12-<18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1254,2025-12-02T15:57:10.570299
31213888.0,McGrath color analog scale,SPID4 scores,9.7,,mean,,7.61,,,,22.0,pediatric ,,6-<12 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1255,2025-12-02T15:57:10.570299
31213888.0,Faces pain scale-revised,SPID4 scores,8.72,,mean,,6.87,,,,22.0,pediatric ,,6-<12 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1256,2025-12-02T15:57:10.570299
31213888.0,Faces pain scale-revised,SPID4 scores,17.65,,mean,,14.67,,,,11.0,pediatric ,,3-<6 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1257,2025-12-02T15:57:10.570299
31213888.0,"Face, legs, activity, cry,/consolability score",SPID4 scores,11.61,,mean,,8.33,,,,12.0,pediatric ,,3-<6 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1258,2025-12-02T15:57:10.570299
31213888.0,"Face, legs, activity, cry,/consolability score",SPID4 scores,12.48,,mean,,8.96,,,,4.0,pediatric ,,2-<3 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1259,2025-12-02T15:57:10.570299
31213888.0,supplemental analgesic medication,,12,,number,,,,,,21.0,pediatric ,,12-<18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1260,2025-12-02T15:57:10.570299
31213888.0,opioids,supplemental analgesic medication,3,,number,,,,,,21.0,pediatric ,,12-<18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1261,2025-12-02T15:57:10.570299
31213888.0,nonopioids,supplemental analgesic medication,12,,number,,,,,,21.0,pediatric ,,12-<18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1262,2025-12-02T15:57:10.570299
31213888.0,supplemental analgesic medication,,18,,number,,,,,,28.0,pediatric ,,6-<12 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1263,2025-12-02T15:57:10.570299
31213888.0,opioids,supplemental analgesic medication,3,,number,,,,,,28.0,pediatric ,,6-<12 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1264,2025-12-02T15:57:10.570299
31213888.0,nonopioids,supplemental analgesic medication,18,,number,,,,,,28.0,pediatric ,,6-<12 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1265,2025-12-02T15:57:10.570299
31213888.0,supplemental analgesic medication,,15,,number,,,,,,17.0,pediatric ,,2-<6 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1266,2025-12-02T15:57:10.570299
31213888.0,opioids,supplemental analgesic medication,8,,number,,,,,,17.0,pediatric ,,2-<6 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1267,2025-12-02T15:57:10.570299
31213888.0,nonopioids,supplemental analgesic medication,15,,number,,,,,,17.0,pediatric ,,2-<6 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1268,2025-12-02T15:57:10.570299
31303784.0,TEAE,,12,,n of patients with >=1 TEAE,,,,,,30.0,pediatric ,,12–<18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1269,2025-12-02T15:57:10.570299
31303784.0,TEAE,,8,,n of patients with >=1 TEAE,,,,,,14.0,pediatric ,,6–<18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1270,2025-12-02T15:57:10.570299
31303784.0,TEAE,,20,,n of patients with >=1 TEAE,,,,,,44.0,pediatric ,,6–<18 years,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1271,2025-12-02T15:57:10.570299
31688081.0,CRP,control,0.85,,ug/ml,SD,1.3,,,,18.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1272,2025-12-02T15:57:10.570299
31688081.0,CRP,OSAS,1.78,,,,3.8,,,,9.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1273,2025-12-02T15:57:10.570299
31688081.0,CRP,Obese/OSAS. The values were significantly different from control/OSAS groups,4.53,,,,4.2,,,,8.0,,,,<0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1274,2025-12-02T15:57:10.570299
31688081.0,IL-1beta,control,0.22,,pg/ml,,0.41,,,,12.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1275,2025-12-02T15:57:10.570299
31688081.0,IL-1beta,OSAS,0.17,,,,0.07,,,,7.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1276,2025-12-02T15:57:10.570299
31688081.0,IL-1beta,Obese/OSAS,0.18,,,,0.16,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1277,2025-12-02T15:57:10.570299
31688081.0,IL-10,control,0.46,,pg/ml,,0.16,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1278,2025-12-02T15:57:10.570299
31688081.0,IL-10,OSAS,0.59,,,,0.17,,,,7.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1279,2025-12-02T15:57:10.570299
31688081.0,IL-10,Obese/OSAS. The values were significantly different from control group,1,,,,0.7,,,,8.0,,,,<0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1280,2025-12-02T15:57:10.570299
31688081.0,IL-6,control,0.59,,pg/ml,,0.26,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1281,2025-12-02T15:57:10.570299
31688081.0,IL-6,OSAS,0.74,,,,0.29,,,,7.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1282,2025-12-02T15:57:10.570299
31688081.0,IL-6,Obese/OSAS. The values were significantly different from control group,1.02,,,,0.25,,,,8.0,,,,<0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1283,2025-12-02T15:57:10.570299
31688081.0,Insulin,control,10.2,,uU/ml,,10.4,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1284,2025-12-02T15:57:10.570299
31688081.0,Insulin,OSAS. The values were significantly different from control group,3.6,,,,2.8,,,,9.0,,,,<0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1285,2025-12-02T15:57:10.570299
31688081.0,Insulin,Obese/OSAS,7.6,,,,3.6,,,,13.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1286,2025-12-02T15:57:10.570299
31688081.0,Leptin,control,7.4,,ng/ml,,8.8,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1287,2025-12-02T15:57:10.570299
31688081.0,Leptin,OSAS,4.5,,,,2.1,,,,7.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1288,2025-12-02T15:57:10.570299
31688081.0,Leptin,Obese/OSAS. The values were significantly different from control/OSAS groups,28.8,,,,21.3,,,,13.0,,,,<0.05,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1289,2025-12-02T15:57:10.570299
31688081.0,TNF-alpha,control,3,,pg/ml,,1.2,,,,18.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1290,2025-12-02T15:57:10.570299
31688081.0,TNF-alpha,OSAS,2.6,,,,0.7,,,,7.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1291,2025-12-02T15:57:10.570299
31688081.0,TNF-alpha,Obese/OSAS,3.5,,,,1.1,,,,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1292,2025-12-02T15:57:10.570299
32044215.0,labor duration ,Intranasal fentanyl,6.8,h,mean,,3.5,,,,13.0,pregnant ,delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1293,2025-12-02T15:57:10.570299
32044215.0,Naloxone use,Intranasal fentanyl,0,,count,,,,,,13.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1294,2025-12-02T15:57:10.570299
32044215.0,Neonatal time to establish breathing of <1 min,Intranasal fentanyl,11,,count,,,,,,13.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1295,2025-12-02T15:57:10.570299
32044215.0,Apgar score at 1 min,Intranasal fentanyl,8,,median,,,IQR,7,8,13.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1296,2025-12-02T15:57:10.570299
32044215.0,Apgar score at 5 min,Intranasal fentanyl,9,,median,,,IQR,9,9,13.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1297,2025-12-02T15:57:10.570299
32044215.0,labor duration ,Subcutaneous fentanyl,5.9,h,mean,,3.0,,,,17.0,pregnant ,delivery,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1298,2025-12-02T15:57:10.570299
32044215.0,Naloxone use,Subcutaneous fentanyl,0,,count,,,,,,17.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1299,2025-12-02T15:57:10.570299
32044215.0,Neonatal time to establish breathing of <1 min,Subcutaneous fentanyl,17,,count,,,,,,17.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1300,2025-12-02T15:57:10.570299
32044215.0,Apgar score at 1 min,Subcutaneous fentanyl,9,,median,,,IQR,8,9,17.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1301,2025-12-02T15:57:10.570299
32044215.0,Apgar score at 5 min,Subcutaneous fentanyl,9,,median,,,IQR,9,,17.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1302,2025-12-02T15:57:10.570299
32052397.0,1 minute Apgar’s score,NAS,9,,median,,,range,1,9,16.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1303,2025-12-02T15:57:10.570299
32052397.0,1 minute Apgar’s score,No NAS,9,,median,,,range,7,9,4.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1304,2025-12-02T15:57:10.570299
32052397.0,Peak Finnegan’s Score,NAS,13,,median,,,range,10,20,16.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1305,2025-12-02T15:57:10.570299
32052397.0,Peak Finnegan’s Score,No NAS,9,,median,,,range,7,10,4.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1306,2025-12-02T15:57:10.570299
32052397.0,Number of days in hospital,NAS,29,,median,,,range,19,55,16.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1307,2025-12-02T15:57:10.570299
32052397.0,Number of days in hospital,No NAS,6,,median,,,range,5,6,4.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1308,2025-12-02T15:57:10.570299
32052397.0,Peak morphine dose,NAS,0.05,mg/day/kg,median,,,range,0.02,0.61,16.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1309,2025-12-02T15:57:10.570299
32052397.0,Total cumulative morphine dose,NAS,5.64,mg/kg,median,,,range,1.02,17.53,16.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1310,2025-12-02T15:57:10.570299
32363420.0,nausea,,5,,count,,,,,,7.0,Maternal,Labor,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1311,2025-12-02T15:57:10.570299
32363420.0,vomiting,,3,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1312,2025-12-02T15:57:10.570299
32363420.0,pruritis,,3,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1313,2025-12-02T15:57:10.570299
32363420.0,hypotension,,1,,count,,,,,,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1314,2025-12-02T15:57:10.570299
33481403.0,corrected QT interval - preoperative,,416,,ms,,,range,397,427,38.0,children,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1315,2025-12-02T15:57:10.570299
33481403.0,corrected QT interval - postoperative,,431,,,,,,414,440,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1316,2025-12-02T15:57:10.570299
33481403.0,Average pain score,,3.53,,,,,,2.73,4.8,,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1317,2025-12-02T15:57:10.570299
33481403.0,R-EDDP/pain score,,0.042,,,,,,,,,,,,0.028,Only signifcant correlation between outcomes/PK or demographic parameters are presented here,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1318,2025-12-02T15:57:10.570299
33481403.0,S-EDDP/pain score,,0.038,,,,,,,,,,,,0.038,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1319,2025-12-02T15:57:10.570299
33481403.0,Total EDDP/pain score,,0.04,,,,,,,,,,,,0.033,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1320,2025-12-02T15:57:10.570299
33481403.0,AAG/pain score,,0.069,,,,,,,,,,,,0.008,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1321,2025-12-02T15:57:10.570299
33481403.0,Average AAG/pain score,,0.065,,,,,,,,,,,,0.037,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1322,2025-12-02T15:57:10.570299
33481403.0,AAG/postoperative QTc,,0.175,,,,,,,,,,,,0.042,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1323,2025-12-02T15:57:10.570299
33481403.0,Biological sex/postoperative QTc,,0.126,,,,,,,,,,,,0.034,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1324,2025-12-02T15:57:10.570299
33481403.0,Morphine equivalent dose mg/kg/day/nausea/vomiting,,2.92,,,,,95% CI,1.27,8.15,,,,,0.021,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1325,2025-12-02T15:57:10.570299
33481403.0,Type of surgery/nausea/vomiting,,0.21,,,,,95% CI,0.04,0.89,,,,,0.039,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1326,2025-12-02T15:57:10.570299
33542653.0,Treatment-Emergent Adverse Events,Tapentadol Oral Solution Single Dose Trial,3,,count,,,,,,8.0,pediatric ,,6 m to<2 y,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1327,2025-12-02T15:57:10.570299
33542653.0,Treatment-Emergent Adverse Events,Tapentadol Oral Solution Single Dose Trial,3,,count,,,,,,6.0,pediatric ,,1 to<6 m,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1328,2025-12-02T15:57:10.570299
33542653.0,Treatment-Emergent Adverse Events,Tapentadol Oral Solution Single Dose Trial,2,,count,,,,,,5.0,pediatric ,,birth to <1m,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1329,2025-12-02T15:57:10.570299
33542653.0,Treatment-Emergent Adverse Events,Tapentadol Intravenous Single Dose Trial,1,,count,,,,,,10.0,pediatric ,,7 m to<2 y,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1330,2025-12-02T15:57:10.570299
33542653.0,Treatment-Emergent Adverse Events,Tapentadol Intravenous Single Dose Trial,3,,count,,,,,,11.0,pediatric ,,2 to<6 m,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1331,2025-12-02T15:57:10.570299
33542653.0,Treatment-Emergent Adverse Events,Tapentadol Intravenous Single Dose Trial,5,,count,,,,,,9.0,pediatric ,,birth to <1m,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1332,2025-12-02T15:57:10.570299
33542653.0,Treatment-Emergent Adverse Events,Tapentadol Intravenous Single Dose Trial,2,,count,,,,,,8.0,pediatric ,,preterm neonates,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1333,2025-12-02T15:57:10.570299
33542653.0,Treatment-Emergent Adverse Events,Tapentadol Oral Solution Multiple Dose Trial,6,,count,,,,,,11.0,pediatric ,,from birth to <2 y,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1334,2025-12-02T15:57:10.570299
33864131.0,NICU admission,,31.6,percentage,,,,,,,19.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1335,2025-12-02T15:57:10.570299
33864131.0,Neonatal opioid withdrawal syndrome diagnosis,,10.5,percentage,,,,,,,19.0, neonatal,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1336,2025-12-02T15:57:10.570299
34784012.0,Face Pain Scale (FPS) -revised,,8,,count,,,,,,8.0,pediatric/adolescent,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1337,2025-12-02T15:57:10.570299
34784012.0,Baseline FPS,,1,,,,,range,0,4,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1338,2025-12-02T15:57:10.570299
34784012.0,Final FPS,,0,,,,,,0,4,8.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1339,2025-12-02T15:57:10.570299
34784012.0,Pain Visual analog scale (VAS) score,,5,,count,,,,,,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1340,2025-12-02T15:57:10.570299
34784012.0,Baseline VAS score,,20,,,,,,0,70,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1341,2025-12-02T15:57:10.570299
34784012.0,Final VAS score,,0,,,,,,0,52,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1342,2025-12-02T15:57:10.570299
34784012.0,Change in VAS score,,-14.6,,,SD,8.3,,,,5.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1343,2025-12-02T15:57:10.570299
34784012.0,Dose of rescue analgesia,,11,,count,,,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1344,2025-12-02T15:57:10.570299
34784012.0,Baseline rescue analgesia dose,,0,,mg,,,range,0,2.16,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1345,2025-12-02T15:57:10.570299
34784012.0,Final rescue analgesia dose,,0,,,,,,0,52.5,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1346,2025-12-02T15:57:10.570299
34784012.0,Baseline pain severity - none,,2,,count,%,18.2,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1347,2025-12-02T15:57:10.570299
34784012.0,Baseline pain severity - mild,,9,,,,81.8,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1348,2025-12-02T15:57:10.570299
34784012.0,Baseline pain severity - moderate,,0,,,,0.0,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1349,2025-12-02T15:57:10.570299
34784012.0,Baseline pain severity - severe,,0,,,,0.0,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1350,2025-12-02T15:57:10.570299
34784012.0,Final pain severity - none,,7,,,,63.6,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1351,2025-12-02T15:57:10.570299
34784012.0,Final pain severity - mild,,2,,,,18.2,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1352,2025-12-02T15:57:10.570299
34784012.0,Final pain severity - moderate,,2,,,,18.2,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1353,2025-12-02T15:57:10.570299
34784012.0,Final pain severity - severe,,0,,,,0.0,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1354,2025-12-02T15:57:10.570299
34784012.0,Play performance scale,,11,,count,,,,,,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1355,2025-12-02T15:57:10.570299
34784012.0,Baseline PPS,,60,,,,,range,30,90,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1356,2025-12-02T15:57:10.570299
34784012.0,Final PPS,,70,,,,,,20,100,11.0,,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1357,2025-12-02T15:57:10.570299
34784012.0,Platelet count decreased,,1,,count,%,25.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1358,2025-12-02T15:57:10.570299
34784012.0,Platelet count decreased,,5,,,,71.4,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1359,2025-12-02T15:57:10.570299
34784012.0,Vomiting,,1,,,,25.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1360,2025-12-02T15:57:10.570299
34784012.0,Vomiting,,3,,,,42.9,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1361,2025-12-02T15:57:10.570299
34784012.0,AST increased,,1,,,,25.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1362,2025-12-02T15:57:10.570299
34784012.0,AST increased,,2,,,,28.6,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1363,2025-12-02T15:57:10.570299
34784012.0,Neutrophil % decreased,,1,,,,25.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1364,2025-12-02T15:57:10.570299
34784012.0,Neutrophil % decreased,,2,,,,28.6,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1365,2025-12-02T15:57:10.570299
34784012.0,Somnolence,,3,,,,75.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1366,2025-12-02T15:57:10.570299
34784012.0,Febrile neutropenia,,2,,,,28.6,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1367,2025-12-02T15:57:10.570299
34784012.0,Pruritis - application site,,1,,,,25.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1368,2025-12-02T15:57:10.570299
34784012.0,Pruritis - application site,,1,,,,14.3,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1369,2025-12-02T15:57:10.570299
34784012.0,Pyrexia,,2,,,,28.6,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1370,2025-12-02T15:57:10.570299
34784012.0,ALT increased,,1,,,,25.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1371,2025-12-02T15:57:10.570299
34784012.0,ALT increased,,1,,,,14.3,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1372,2025-12-02T15:57:10.570299
34784012.0,GGT increased,,2,,,,28.6,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1373,2025-12-02T15:57:10.570299
34784012.0,WBC count decreased,,2,,,,28.6,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1374,2025-12-02T15:57:10.570299
34784012.0,Headache,,1,,,,25.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1375,2025-12-02T15:57:10.570299
34784012.0,Headache,,1,,,,14.3,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1376,2025-12-02T15:57:10.570299
34784012.0,Pruritis,,1,,,,25.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1377,2025-12-02T15:57:10.570299
34784012.0,Pruritis,,1,,,,14.3,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1378,2025-12-02T15:57:10.570299
34784012.0,Drug-related adverse event,,3,,,,75.0,,,,4.0,2-5 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1379,2025-12-02T15:57:10.570299
34784012.0,Drug-related adverse event,,2,,,,28.6,,,,7.0,6-19 years,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1380,2025-12-02T15:57:10.570299
7059414.0,respiratory depression,,6,count,frequency,,,,,,30.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1381,2025-12-02T15:57:10.570299
7059414.0,treated with naloxone,0.03-0.04 mg im,4,count,frequency,,,,,,30.0,newborn,,,,,Combined PK ONLY Opioids Data Curation 10.2023.xlsx,Aditi,Outcomes (summary),Outcomes_summary,1382,2025-12-02T15:57:10.570299
26723196.0,Heartburn,Placebo,3,,Frequency,%,30,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,2,2025-12-02T15:57:20.877366
26723196.0,Heartburn,Pravastatin,4,,Frequency,%,36,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,3,2025-12-02T15:57:20.877366
26723196.0,Musculoskeletal pain,Placebo,1,,Frequency,%,10,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,4,2025-12-02T15:57:20.877366
26723196.0,Musculoskeletal pain,Pravastatin,4,,Frequency,%,34,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,5,2025-12-02T15:57:20.877366
26723196.0,Dizziness,Placebo,2,,Frequency,%,20,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,6,2025-12-02T15:57:20.877366
26723196.0,Dizziness,Pravastatin,3,,Frequency,%,27,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,7,2025-12-02T15:57:20.877366
26723196.0,Chest Pain,Placebo,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,8,2025-12-02T15:57:20.877366
26723196.0,Chest Pain,Pravastatin,2,,Frequency,%,18,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,9,2025-12-02T15:57:20.877366
26723196.0,Diarrhea,Placebo,1,,Frequency,%,10,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,10,2025-12-02T15:57:20.877366
26723196.0,Diarrhea,Pravastatin,2,,Frequency,%,18,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,11,2025-12-02T15:57:20.877366
26723196.0,Headache,Placebo,3,,Frequency,%,30,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,12,2025-12-02T15:57:20.877366
26723196.0,Headache,Pravastatin,2,,Frequency,%,18,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,13,2025-12-02T15:57:20.877366
26723196.0,Cough,Placebo,1,,Frequency,%,10,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,14,2025-12-02T15:57:20.877366
26723196.0,Cough,Pravastatin,2,,Frequency,%,18,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,15,2025-12-02T15:57:20.877366
26723196.0,Swelling,Placebo,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,16,2025-12-02T15:57:20.877366
26723196.0,Swelling,Pravastatin,2,,Frequency,%,18,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,17,2025-12-02T15:57:20.877366
26723196.0,Nausea,Placebo,1,,Frequency,%,10,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,18,2025-12-02T15:57:20.877366
26723196.0,Nausea,Pravastatin,1,,Frequency,%,9,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,19,2025-12-02T15:57:20.877366
26723196.0,Fever,Placebo,2,,Frequency,%,20,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,20,2025-12-02T15:57:20.877366
26723196.0,Fever,Pravastatin,1,,Frequency,%,9,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,21,2025-12-02T15:57:20.877366
26723196.0,Flatulence,Placebo,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,22,2025-12-02T15:57:20.877366
26723196.0,Flatulence,Pravastatin,1,,Frequency,%,9,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,23,2025-12-02T15:57:20.877366
26723196.0,Fatigue,Placebo,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,24,2025-12-02T15:57:20.877366
26723196.0,Fatigue,Pravastatin,1,,Frequency,%,9,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,25,2025-12-02T15:57:20.877366
26723196.0,Wheezing,Placebo,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,26,2025-12-02T15:57:20.877366
26723196.0,Wheezing,Pravastatin,1,,Frequency,%,9,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,27,2025-12-02T15:57:20.877366
26723196.0,Vomiting,Placebo,1,,Frequency,%,10,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,28,2025-12-02T15:57:20.877366
26723196.0,Vomiting,Pravastatin,0,,Frequency,,,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,29,2025-12-02T15:57:20.877366
26723196.0,Influenza-like symptoms,Placebo,2,,Frequency,%,20,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,30,2025-12-02T15:57:20.877366
26723196.0,Influenza-like symptoms,Pravastatin,0,,Frequency,,,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,31,2025-12-02T15:57:20.877366
26723196.0,"Maternal, fetal, or infant death",Placebo,0,,Frequency,,,,,,10,maternal/fetal/infant,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,32,2025-12-02T15:57:20.877366
26723196.0,"Maternal, fetal, or infant death",Pravastatin,0,,Frequency,,,,,,11,maternal/fetal/infant,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,33,2025-12-02T15:57:20.877366
26723196.0,Rhabdomyolysis,Placebo,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,34,2025-12-02T15:57:20.877366
26723196.0,Rhabdomyolysis,Pravastatin,0,,Frequency,,,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,35,2025-12-02T15:57:20.877366
26723196.0,Liver injury,Placebo,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,36,2025-12-02T15:57:20.877366
26723196.0,Liver injury,Pravastatin,0,,Frequency,,,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,37,2025-12-02T15:57:20.877366
26723196.0,Congenital anomalies,Placebo,Polydactyly; Ventriculomegaly,,,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,38,2025-12-02T15:57:20.877366
26723196.0,Congenital anomalies,Pravastatin,Hypospadias; Coarctation of aorta,,,,,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,39,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: HTN/BP exacerbation,Placebo,3,,Frequency,%,30,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,40,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: HTN/BP exacerbation,Pravastatin,2,,Frequency,%,18,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,41,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Preeclampsia workup,Placebo,1,,Frequency,%,10,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,42,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Preeclampsia workup,Pravastatin,0,,Frequency,,,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,43,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Vaginal bleeding,Placebo,1,,Frequency,%,10,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,44,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Vaginal bleeding,Pravastatin,0,,Frequency,,,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,45,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Influenza infection,Placebo,1,,Frequency,%,10,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,46,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Influenza infection,Pravastatin,0,,Frequency,,,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,47,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Migraine,Placebo,1,,Frequency,%,10,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,48,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Migraine,Pravastatin,0,,Frequency,,,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,49,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Syncope,Placebo,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,50,2025-12-02T15:57:20.877366
26723196.0,Hospitalization >24 hours: Syncope,Pravastatin,1,,Frequency,%,9,,,,11,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,51,2025-12-02T15:57:20.877366
26723196.0,Preeclampsia,Placebo Group,4,,Frequency,%,40,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,52,2025-12-02T15:57:20.877366
26723196.0,Maternal - severe features,Placebo Group,3,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,53,2025-12-02T15:57:20.877366
26723196.0,Preeclampsia,Pravastatin Group,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,54,2025-12-02T15:57:20.877366
26723196.0,Maternal - severe features,Pravastatin Group,0,,Frequency,,,,,,10,maternal,"trimester 2/3, postpartum",,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,55,2025-12-02T15:57:20.877366
26723196.0,Postpartum preeclampsia,Placebo Group,1,,Frequency,%,10,,,,10,maternal,postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,56,2025-12-02T15:57:20.877366
26723196.0,Postpartum preeclampsia,Pravastatin Group,0,,Frequency,,,,,,10,maternal,postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,57,2025-12-02T15:57:20.877366
26723196.0,Gestational hypertension,Placebo Group,1,,Frequency,%,10,,,,10,maternal,trimester 2/3,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,58,2025-12-02T15:57:20.877366
26723196.0,Gestational hypertension,Pravastatin Group,1,,Frequency,%,10,,,,10,maternal,trimester 2/3,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,59,2025-12-02T15:57:20.877366
26723196.0,Gestational age at delivery,Placebo Group,36.7,weeks,Mean,SD,2.1,,,,10,maternal,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,60,2025-12-02T15:57:20.877366
26723196.0,Gestational age at delivery,Pravastatin Group,37.7,weeks,Mean,SD,0.9,,,,10,maternal,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,61,2025-12-02T15:57:20.877366
26723196.0,Indicated preterm delivery less than 37 weeks,Placebo Group,5,,Frequency,%,50,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,62,2025-12-02T15:57:20.877366
26723196.0,Indicated preterm delivery less than 37 weeks,Pravastatin Group,1,,Frequency,%,10,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,63,2025-12-02T15:57:20.877366
26723196.0,Indicated preterm delivery less than 34 weeks,Placebo Group,1,,Frequency,%,10,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,64,2025-12-02T15:57:20.877366
26723196.0,Indicated preterm delivery less than 34 weeks,Pravastatin Group,0,,Frequency,,,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,65,2025-12-02T15:57:20.877366
26723196.0,Blood transfusion,Placebo Group,1,,Frequency,%,10,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,66,2025-12-02T15:57:20.877366
26723196.0,Blood transfusion,Pravastatin Group,1,,Frequency,%,10,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,67,2025-12-02T15:57:20.877366
26723196.0,Length of hospital stay,Placebo Group,4,days,Median,Range,2–43,IQR,3.0,7.0,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,68,2025-12-02T15:57:20.877366
26723196.0,Length of hospital stay,Pravastatin Group,3,days,Median,Range,1–6,IQR,3.0,4.0,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,69,2025-12-02T15:57:20.877366
26723196.0,Birth weight,Placebo Group,2877,grams,Mean,SD,630,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,70,2025-12-02T15:57:20.877366
26723196.0,Birth weight,Pravastatin Group,3018,grams,Mean,SD,260,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,71,2025-12-02T15:57:20.877366
26723196.0,Highest level of care - Well baby/routine,Placebo Group,5,count,Frequency,%,50,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,72,2025-12-02T15:57:20.877366
26723196.0,Highest level of care - Intermediate (Level 2),Placebo Group,2,count,Frequency,%,20,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,73,2025-12-02T15:57:20.877366
26723196.0,Highest level of care - NICU,Placebo Group,3,count,Frequency,%,30,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,74,2025-12-02T15:57:20.877366
26723196.0,Highest level of care - Well baby/routine,Pravastatin Group,8,count,Frequency,%,80,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,75,2025-12-02T15:57:20.877366
26723196.0,Highest level of care - Intermediate (Level 2),Pravastatin Group,1,count,Frequency,%,10,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,76,2025-12-02T15:57:20.877366
26723196.0,Highest level of care - NICU,Pravastatin Group,1,count,Frequency,%,10,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,77,2025-12-02T15:57:20.877366
26723196.0,NICU length of stay ≥ 48 hours,Placebo Group,3,count,Frequency,%,30,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,78,2025-12-02T15:57:20.877366
26723196.0,NICU length of stay ≥ 48 hours,Pravastatin Group,0,count,Frequency,,,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,79,2025-12-02T15:57:20.877366
26723196.0,Respiratory Distress Syndrome,Placebo Group,2,count,Frequency,%,20,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,80,2025-12-02T15:57:20.877366
26723196.0,Respiratory Distress Syndrome,Pravastatin Group,1,count,Frequency,%,10,,,,10,maternal,delivery/postpartum,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,81,2025-12-02T15:57:20.877366
26635169.0,stillborn,720 grams weight,1,count,Frequency,,,,,,28,fetal,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,82,2025-12-02T15:57:20.877366
26635169.0,neonatal death,1000-1500 grams weight,1,count,Frequency,,,,,,28,neonate,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,83,2025-12-02T15:57:20.877366
26635169.0,live births,1000-1500 grams weight,7,count,Frequency,,,,,,28,neonate,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,84,2025-12-02T15:57:20.877366
26635169.0,live births,1000-1500 grams weight,8,count,Frequency,,,,,,28,neonate,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,85,2025-12-02T15:57:20.877366
26635169.0,live births,1000-1500 grams weight,8,count,Frequency,,,,,,28,neonate,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,86,2025-12-02T15:57:20.877366
26635169.0,live births,1000-1500 grams weight,3,count,Frequency,,,,,,28,neonate,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,87,2025-12-02T15:57:20.877366
26635169.0,perinatal mortality,,7.1,%,,,,,,,28,neonate,pregnancy/delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,88,2025-12-02T15:57:20.877366
26635169.0,postnatal mortality,,3.57,%,,,,,,,28,neonate,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,89,2025-12-02T15:57:20.877366
26635169.0,amniotic fluid lecithin/spingomyelin ratio,28 weeks ga,na,,,,,,,,1,fetal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,90,2025-12-02T15:57:20.877366
26635169.0,amniotic fluid lecithin/spingomyelin ratio,29 weeks ga,na,,,,,,,,1,fetal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,91,2025-12-02T15:57:20.877366
26635169.0,amniotic fluid lecithin/spingomyelin ratio,31 weeks ga,,,,,,range,3.0,6.4,5,fetal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,92,2025-12-02T15:57:20.877366
26635169.0,amniotic fluid lecithin/spingomyelin ratio,32 weeks ga,5,,,,,,,,1,fetal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,93,2025-12-02T15:57:20.877366
26635169.0,amniotic fluid lecithin/spingomyelin ratio,33 weeks ga,,,,,,range,3.4,7.0,4,fetal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,94,2025-12-02T15:57:20.877366
26635169.0,amniotic fluid lecithin/spingomyelin ratio,34 weeks ga,,,,,,range,8.4,9.5,5,fetal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,95,2025-12-02T15:57:20.877366
26635169.0,amniotic fluid lecithin/spingomyelin ratio,35 weeks ga,,,,,,range,6.0,8.6,6,fetal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,96,2025-12-02T15:57:20.877366
26635169.0,amniotic fluid lecithin/spingomyelin ratio,36 weeks ga,,,,,,range,7.4,9.5,4,fetal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,97,2025-12-02T15:57:20.877366
26635169.0,Respiratory Distress Syndrome,,2,count,Frequency,,,,,,27,neonates,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,98,2025-12-02T15:57:20.877366
26635169.0,asphyxia,,4,count,Frequency,,,,,,27,neonates,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,99,2025-12-02T15:57:20.877366
26635169.0,necrotizing enterocolitis,,2,count,Frequency,,,,,,27,neonates,delivery,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,100,2025-12-02T15:57:20.877366
26635169.0,postural hyoptension,,2,count,Frequency,,,,,,25,maternal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,101,2025-12-02T15:57:20.877366
26635169.0,lethargy,,1,count,Frequency,,,,,,25,maternal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,102,2025-12-02T15:57:20.877366
26635169.0,scalp tingling,,1,count,Frequency,,,,,,25,maternal,pregnancy,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,103,2025-12-02T15:57:20.877366
18507654.0,Abdominal cramping,Domperidone 30 mg daily,1,count,Frequency,,,,,,6,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,104,2025-12-02T15:57:20.877366
18507654.0,Abdominal cramping,Domperidone 60 mg daily,2,count,Frequency,,,,,,5,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,105,2025-12-02T15:57:20.877366
18507654.0,Constipation,Domperidone 30 mg daily,0,count,Frequency,,,,,,6,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,106,2025-12-02T15:57:20.877366
18507654.0,Constipation,Domperidone 60 mg daily,1,count,Frequency,,,,,,5,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,107,2025-12-02T15:57:20.877366
18507654.0,Dry mouth,Domperidone 30 mg daily,3,count,Frequency,,,,,,6,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,108,2025-12-02T15:57:20.877366
18507654.0,Dry mouth,Domperidone 60 mg daily,5,count,Frequency,,,,,,5,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,109,2025-12-02T15:57:20.877366
18507654.0,Depressed mood,Domperidone 30 mg daily,0,count,Frequency,,,,,,6,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,110,2025-12-02T15:57:20.877366
18507654.0,Depressed mood,Domperidone 60 mg daily,1,count,Frequency,,,,,,5,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,111,2025-12-02T15:57:20.877366
18507654.0,Headache,Domperidone 30 mg daily,1,count,Frequency,,,,,,6,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,112,2025-12-02T15:57:20.877366
18507654.0,Headache,Domperidone 60 mg daily,3,count,Frequency,,,,,,5,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,113,2025-12-02T15:57:20.877366
18507654.0,amount of milk produced,run-in phase,8.7,gram/hour,,SD,3.1,,,,4,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,114,2025-12-02T15:57:20.877366
18507654.0,amount of milk produced,phase 1,23.6,gram/hour,,SD,3.9,,,,4,maternal,lactation,,0.0217,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,115,2025-12-02T15:57:20.877366
18507654.0,amount of milk produced,phase 2,29.4,gram/hour,,SD,6.6,,,,4,maternal,lactation,,0.0047,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,116,2025-12-02T15:57:20.877366
18507654.0,pre-pumping prolactin levels,Domperidone 30 mg daily,433,%,,,,,,,6,maternal,lactation,,<0.007,compared to pre-pumping run-in values,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,117,2025-12-02T15:57:20.877366
18507654.0,pre-pumping prolactin levels,Domperidone 60 mg daily,405,%,,,,,,,6,maternal,lactation,,<0.01,compared to pre-pumping run-in values,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,118,2025-12-02T15:57:20.877366
3882143.0,prolactin level,domperidone 20 mg single dose,255,ng/ml,mean,,,,,,5,maternal,lactation,,<0.05,2 hours after dose,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,119,2025-12-02T15:57:20.877366
3882143.0,prolactin level,placebo,150,ng/ml,mean,,,,,,5,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,120,2025-12-02T15:57:20.877366
3882143.0,premature,before randomization,4,count,Frequency,,,,,,6,neonate,delivery,,,among 6 mothers delivered by cesarean section,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,121,2025-12-02T15:57:20.877366
3882143.0,small for gestational age,before randomization,2,count,Frequency,,,,,,6,neonate,delivery,,,among 6 mothers delivered by cesarean section,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,122,2025-12-02T15:57:20.877366
3882143.0,postmature,before randomization,1,count,Frequency,,,,,,6,neonate,delivery,,,among 6 mothers delivered by cesarean section,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,123,2025-12-02T15:57:20.877366
37565541.0,any treatment-emergent adverse event (TEAE),,4,count,frequency,%,50,,,,8,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,124,2025-12-02T15:57:20.877366
37565541.0,treatment-related TEAE,,2,count,frequency,%,25,,,,8,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,125,2025-12-02T15:57:20.877366
37565541.0,serious TEAE,,0,count,frequency,%,0,,,,8,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,126,2025-12-02T15:57:20.877366
37565541.0,TEAEs leading to early discontinuation,,0,count,frequency,%,0,,,,8,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,127,2025-12-02T15:57:20.877366
37565541.0,headache,,2,count,frequency,%,25,,,,8,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,128,2025-12-02T15:57:20.877366
37565541.0,breast pain,,2,count,frequency,%,25,,,,8,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,129,2025-12-02T15:57:20.877366
37565541.0,abdominal discomfort,,1,count,frequency,%,12.5,,,,8,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,130,2025-12-02T15:57:20.877366
37565541.0,diarrhea,,1,count,frequency,%,12.5,,,,8,maternal,lactation,,,,PRGLAC PK curations_AS.xlsx,Aditi,Outcomes (summary),Outcomes_summary,131,2025-12-02T15:57:20.877366
16449615.0,no relapse,,115,n,,,,,,,201.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,60,2025-12-02T15:59:45.299042
16449615.0,,,61,n,,,,,,,82.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,61,2025-12-02T15:59:45.299042
16449615.0,,,11,n,,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,62,2025-12-02T15:59:45.299042
16449615.0,,,22,n,,,,,,,34.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,63,2025-12-02T15:59:45.299042
16449615.0,,,21,n,,,,,,,65.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,64,2025-12-02T15:59:45.299042
16449615.0,relapse (all),,86,n,,,,,,,201.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,65,2025-12-02T15:59:45.299042
16449615.0,,,21,n,,,,,,,82.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,66,2025-12-02T15:59:45.299042
16449615.0,,,9,n,,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,67,2025-12-02T15:59:45.299042
16449615.0,,,12,n,,,,,,,34.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,68,2025-12-02T15:59:45.299042
16449615.0,,,44,n,,,,,,,65.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,69,2025-12-02T15:59:45.299042
16449615.0,first tri relapse,,44,n,,,,,,,201.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,70,2025-12-02T15:59:45.299042
16449615.0,,,11,n,,,,,,,82.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,71,2025-12-02T15:59:45.299042
16449615.0,,,7,n,,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,72,2025-12-02T15:59:45.299042
16449615.0,,,5,n,,,,,,,34.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,73,2025-12-02T15:59:45.299042
16449615.0,,,21,n,,,,,,,65.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,74,2025-12-02T15:59:45.299042
16449615.0,second tri relapse,,31,n,,,,,,,201.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,75,2025-12-02T15:59:45.299042
16449615.0,,,9,n,,,,,,,82.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,76,2025-12-02T15:59:45.299042
16449615.0,,,2,n,,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,77,2025-12-02T15:59:45.299042
16449615.0,,,3,n,,,,,,,34.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,78,2025-12-02T15:59:45.299042
16449615.0,,,19,n,,,,,,,65.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,79,2025-12-02T15:59:45.299042
16449615.0,third tri relapse,,11,n,,,,,,,201.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,80,2025-12-02T15:59:45.299042
16449615.0,,,1,n,,,,,,,82.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,81,2025-12-02T15:59:45.299042
16449615.0,,,0,n,,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,82,2025-12-02T15:59:45.299042
16449615.0,,,4,n,,,,,,,34.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,83,2025-12-02T15:59:45.299042
16449615.0,,,4,n,,,,,,,65.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,84,2025-12-02T15:59:45.299042
16449615.0,risk of relapse over the course of pregnancy,,1,,Cox Proportional Hazard Ratio,,,,,,82.0,neonate,,,,"Adjusted for clinical center, marital status, number of prior depression episodes, and type of medication therapy (selective serotonin reuptake inhibitor vs other)",PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,85,2025-12-02T15:59:45.299042
16449615.0,,,2.8,,Cox Proportional Hazard Ratio,,,95% CI,1.2,6.3,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,86,2025-12-02T15:59:45.299042
16449615.0,,,1.2,,Cox Proportional Hazard Ratio,,,95% CI,0.6,2.5,34.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,87,2025-12-02T15:59:45.299042
16449615.0,,,5,,Cox Proportional Hazard Ratio,,,95% CI,2.8,9.1,65.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,88,2025-12-02T15:59:45.299042
34587291.0,neonatal/fetal death,,3,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,89,2025-12-02T15:59:45.299042
34587291.0,,,2,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,90,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,91,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,92,2025-12-02T15:59:45.299042
34587291.0,,,1,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,93,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,94,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,95,2025-12-02T15:59:45.299042
34587291.0,,,6,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,96,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,97,2025-12-02T15:59:45.299042
34587291.0,,,11,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,98,2025-12-02T15:59:45.299042
34587291.0,transient tachypnea of the newborn (TTN),,35,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,99,2025-12-02T15:59:45.299042
34587291.0,,,48,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,100,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,101,2025-12-02T15:59:45.299042
34587291.0,,,21,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,102,2025-12-02T15:59:45.299042
34587291.0,,,76,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,103,2025-12-02T15:59:45.299042
34587291.0,,,83,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,104,2025-12-02T15:59:45.299042
34587291.0,,,9,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,105,2025-12-02T15:59:45.299042
34587291.0,,,172,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,106,2025-12-02T15:59:45.299042
34587291.0,,,24,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,107,2025-12-02T15:59:45.299042
34587291.0,,,437,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,108,2025-12-02T15:59:45.299042
34587291.0,newbord intubated,,5,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,109,2025-12-02T15:59:45.299042
34587291.0,,,12,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,110,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,111,2025-12-02T15:59:45.299042
34587291.0,,,6,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,112,2025-12-02T15:59:45.299042
34587291.0,,,15,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,113,2025-12-02T15:59:45.299042
34587291.0,,,18,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,114,2025-12-02T15:59:45.299042
34587291.0,,,2,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,115,2025-12-02T15:59:45.299042
34587291.0,,,30,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,116,2025-12-02T15:59:45.299042
34587291.0,,,4,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,117,2025-12-02T15:59:45.299042
34587291.0,,,84,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,118,2025-12-02T15:59:45.299042
34587291.0,pulmonary hypertension,,0,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,119,2025-12-02T15:59:45.299042
34587291.0,,,2,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,120,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,121,2025-12-02T15:59:45.299042
34587291.0,,,1,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,122,2025-12-02T15:59:45.299042
34587291.0,,,2,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,123,2025-12-02T15:59:45.299042
34587291.0,,,2,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,124,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,125,2025-12-02T15:59:45.299042
34587291.0,,,3,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,126,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,127,2025-12-02T15:59:45.299042
34587291.0,,,10,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,128,2025-12-02T15:59:45.299042
34587291.0,seizures,,1,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,129,2025-12-02T15:59:45.299042
34587291.0,,,2,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,130,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,131,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,132,2025-12-02T15:59:45.299042
34587291.0,,,3,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,133,2025-12-02T15:59:45.299042
34587291.0,,,5,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,134,2025-12-02T15:59:45.299042
34587291.0,,,1,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,135,2025-12-02T15:59:45.299042
34587291.0,,,5,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,136,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,137,2025-12-02T15:59:45.299042
34587291.0,,,15,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,138,2025-12-02T15:59:45.299042
34587291.0,jaundice,,63,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,139,2025-12-02T15:59:45.299042
34587291.0,,,55,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,140,2025-12-02T15:59:45.299042
34587291.0,,,3,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,141,2025-12-02T15:59:45.299042
34587291.0,,,21,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,142,2025-12-02T15:59:45.299042
34587291.0,,,90,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,143,2025-12-02T15:59:45.299042
34587291.0,,,91,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,144,2025-12-02T15:59:45.299042
34587291.0,,,6,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,145,2025-12-02T15:59:45.299042
34587291.0,,,228,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,146,2025-12-02T15:59:45.299042
34587291.0,,,18,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,147,2025-12-02T15:59:45.299042
34587291.0,,,548,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,148,2025-12-02T15:59:45.299042
34587291.0,cardiac malformations,,13,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,149,2025-12-02T15:59:45.299042
34587291.0,,,19,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,150,2025-12-02T15:59:45.299042
34587291.0,,,0,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,151,2025-12-02T15:59:45.299042
34587291.0,,,6,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,152,2025-12-02T15:59:45.299042
34587291.0,,,26,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,153,2025-12-02T15:59:45.299042
34587291.0,,,25,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,154,2025-12-02T15:59:45.299042
34587291.0,,,4,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,155,2025-12-02T15:59:45.299042
34587291.0,,,64,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,156,2025-12-02T15:59:45.299042
34587291.0,,,3,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,157,2025-12-02T15:59:45.299042
34587291.0,,,153,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,158,2025-12-02T15:59:45.299042
34587291.0,5 min apgar <7,,50,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,159,2025-12-02T15:59:45.299042
34587291.0,,,56,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,160,2025-12-02T15:59:45.299042
34587291.0,,,3,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,161,2025-12-02T15:59:45.299042
34587291.0,,,22,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,162,2025-12-02T15:59:45.299042
34587291.0,,,66,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,163,2025-12-02T15:59:45.299042
34587291.0,,,99,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,164,2025-12-02T15:59:45.299042
34587291.0,,,9,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,165,2025-12-02T15:59:45.299042
34587291.0,,,213,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,166,2025-12-02T15:59:45.299042
34587291.0,,,20,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,167,2025-12-02T15:59:45.299042
34587291.0,,,504,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,168,2025-12-02T15:59:45.299042
34587291.0,any adaptation syndrome,,19,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,169,2025-12-02T15:59:45.299042
34587291.0,,,35,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,170,2025-12-02T15:59:45.299042
34587291.0,,,1,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,171,2025-12-02T15:59:45.299042
34587291.0,,,21,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,172,2025-12-02T15:59:45.299042
34587291.0,,,51,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,173,2025-12-02T15:59:45.299042
34587291.0,,,34,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,174,2025-12-02T15:59:45.299042
34587291.0,,,7,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,175,2025-12-02T15:59:45.299042
34587291.0,,,75,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,176,2025-12-02T15:59:45.299042
34587291.0,,,9,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,177,2025-12-02T15:59:45.299042
34587291.0,,,228,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,178,2025-12-02T15:59:45.299042
34587291.0,NICU admission,,91,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,179,2025-12-02T15:59:45.299042
34587291.0,,,105,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,180,2025-12-02T15:59:45.299042
34587291.0,,,3,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,181,2025-12-02T15:59:45.299042
34587291.0,,,55,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,182,2025-12-02T15:59:45.299042
34587291.0,,,172,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,183,2025-12-02T15:59:45.299042
34587291.0,,,162,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,184,2025-12-02T15:59:45.299042
34587291.0,,,16,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,185,2025-12-02T15:59:45.299042
34587291.0,,,384,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,186,2025-12-02T15:59:45.299042
34587291.0,,,33,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,187,2025-12-02T15:59:45.299042
34587291.0,,,943,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,188,2025-12-02T15:59:45.299042
34587291.0,preterm birth,,61,n,,,,,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,189,2025-12-02T15:59:45.299042
34587291.0,,,56,n,,,,,,,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,190,2025-12-02T15:59:45.299042
34587291.0,,,2,n,,,,,,,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,191,2025-12-02T15:59:45.299042
34587291.0,,,32,n,,,,,,,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,192,2025-12-02T15:59:45.299042
34587291.0,,,85,n,,,,,,,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,193,2025-12-02T15:59:45.299042
34587291.0,,,100,n,,,,,,,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,194,2025-12-02T15:59:45.299042
34587291.0,,,8,n,,,,,,,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,195,2025-12-02T15:59:45.299042
34587291.0,,,238,n,,,,,,,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,196,2025-12-02T15:59:45.299042
34587291.0,,,18,n,,,,,,,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,197,2025-12-02T15:59:45.299042
34587291.0,,,559,n,,,,,,,3694.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,198,2025-12-02T15:59:45.299042
34587291.0,any adaptaion syndrom,,ref,,unadjusted OR,,,95% CI,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,199,2025-12-02T15:59:45.299042
34587291.0,,,0.67,,unadjusted OR,,,95% CI,0.3,1.52,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,200,2025-12-02T15:59:45.299042
34587291.0,,,1.37,,unadjusted OR,,,95% CI,0.64,2.93,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,201,2025-12-02T15:59:45.299042
34587291.0,,,0.91,,unadjusted OR,,,95% CI,0.11,7.7,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,202,2025-12-02T15:59:45.299042
34587291.0,,,2.43,,unadjusted OR,,,95% CI,1.07,5.23,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,203,2025-12-02T15:59:45.299042
34587291.0,,,1.32,,unadjusted OR,,,95% CI,0.63,2.74,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,204,2025-12-02T15:59:45.299042
34587291.0,,,0.85,,unadjusted OR,,,95% CI,0.4,1.82,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,205,2025-12-02T15:59:45.299042
34587291.0,,,1.99,,unadjusted OR,,,95% CI,0.7,5.65,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,206,2025-12-02T15:59:45.299042
34587291.0,,,0.65,,unadjusted OR,,,95% CI,0.32,1.33,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,207,2025-12-02T15:59:45.299042
34587291.0,NICU admission,,ref,,unadjusted OR,,,95% CI,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,208,2025-12-02T15:59:45.299042
34587291.0,,,0.87,,unadjusted OR,,,95% CI,0.55,1.37,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,209,2025-12-02T15:59:45.299042
34587291.0,,,1.13,,unadjusted OR,,,95% CI,0.72,1.77,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,210,2025-12-02T15:59:45.299042
34587291.0,,,0.69,,unadjusted OR,,,95% CI,0.19,2.58,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,211,2025-12-02T15:59:45.299042
34587291.0,,,1.96,,unadjusted OR,,,95% CI,1.17,3.31,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,212,2025-12-02T15:59:45.299042
34587291.0,,,1.26,,unadjusted OR,,,95% CI,0.82,1.94,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,213,2025-12-02T15:59:45.299042
34587291.0,,,1.17,,unadjusted OR,,,95% CI,0.76,1.8,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,214,2025-12-02T15:59:45.299042
34587291.0,,,1.23,,unadjusted OR,,,95% CI,0.61,2.49,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,215,2025-12-02T15:59:45.299042
34587291.0,,,0.91,,unadjusted OR,,,95% CI,0.6,1.37,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,216,2025-12-02T15:59:45.299042
34587291.0,any adaptation syndrome,,ref,,adjusted OR,,,95% CI,,,406.0,neonate,,,,"Adjusted logistic regression controlled for maternal age, race, insurance status, and estimated gestational age at birth.",PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,217,2025-12-02T15:59:45.299042
34587291.0,,,1.81,,adjusted OR,,,95% CI,1,3.27,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,218,2025-12-02T15:59:45.299042
34587291.0,,,1.13,,adjusted OR,,,95% CI,0.13,9.54,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,219,2025-12-02T15:59:45.299042
34587291.0,,,3.04,,adjusted OR,,,95% CI,1.54,5.98,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,220,2025-12-02T15:59:45.299042
34587291.0,,,2.26,,adjusted OR,,,95% CI,1.3,3.95,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,221,2025-12-02T15:59:45.299042
34587291.0,,,1.3,,adjusted OR,,,95% CI,0.72,2.34,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,222,2025-12-02T15:59:45.299042
34587291.0,,,2.6,,adjusted OR,,,95% CI,1.01,6.71,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,223,2025-12-02T15:59:45.299042
34587291.0,,,0.96,,adjusted OR,,,95% CI,0.57,1.63,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,224,2025-12-02T15:59:45.299042
34587291.0,,,1.33,,adjusted OR,,,95% CI,0.58,3.06,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,225,2025-12-02T15:59:45.299042
34587291.0,NICU admission,,ref,,adjusted OR,,,95% CI,,,406.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,226,2025-12-02T15:59:45.299042
34587291.0,,,1.41,,adjusted OR,,,95% CI,0.98,2.03,385.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,227,2025-12-02T15:59:45.299042
34587291.0,,,0.98,,adjusted OR,,,95% CI,0.26,3.74,16.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,228,2025-12-02T15:59:45.299042
34587291.0,,,2.04,,adjusted OR,,,95% CI,1.29,3.23,139.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,229,2025-12-02T15:59:45.299042
34587291.0,,,1.68,,adjusted OR,,,95% CI,1.21,2.33,581.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,230,2025-12-02T15:59:45.299042
34587291.0,,,1.34,,adjusted OR,,,95% CI,0.96,1.87,579.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,231,2025-12-02T15:59:45.299042
34587291.0,,,1.64,,adjusted OR,,,95% CI,0.83,3.26,55.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,232,2025-12-02T15:59:45.299042
34587291.0,,,1.08,,adjusted OR,,,95% CI,0.81,1.45,1653.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,233,2025-12-02T15:59:45.299042
34587291.0,,,1.17,,adjusted OR,,,95% CI,0.7,1.94,132.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,234,2025-12-02T15:59:45.299042
34587291.0,adaptation syndrome,,0.62,,adjusted OR,,,95% CI,0.28,1.37,406.0,neonate,early exposure (3+ months before pregnancy),,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,235,2025-12-02T15:59:45.299042
34587291.0,,,0.83,,adjusted OR,,,95% CI,0.43,1.58,385.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,236,2025-12-02T15:59:45.299042
34587291.0,,,2.57,,adjusted OR,,,95% CI,0.26,25.36,16.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,237,2025-12-02T15:59:45.299042
34587291.0,,,2.31,,adjusted OR,,,95% CI,1.11,4.8,139.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,238,2025-12-02T15:59:45.299042
34587291.0,,,1.72,,adjusted OR,,,95% CI,1.09,2.71,581.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,239,2025-12-02T15:59:45.299042
34587291.0,,,0.92,,adjusted OR,,,95% CI,0.52,1.62,579.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,240,2025-12-02T15:59:45.299042
34587291.0,,,1.88,,adjusted OR,,,95% CI,0.62,5.67,55.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,241,2025-12-02T15:59:45.299042
34587291.0,,,0.68,,adjusted OR,,,95% CI,0.46,1.01,1653.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,242,2025-12-02T15:59:45.299042
34587291.0,,,1.4,,adjusted OR,,,95% CI,0.54,3.67,132.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,243,2025-12-02T15:59:45.299042
34587291.0,NICU admission,,0.76,,adjusted OR,,,95% CI,0.5,1.17,406.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,244,2025-12-02T15:59:45.299042
34587291.0,,,1.2,,adjusted OR,,,95% CI,0.82,1.75,385.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,245,2025-12-02T15:59:45.299042
34587291.0,,,0.61,,adjusted OR,,,95% CI,0.06,5.89,16.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,246,2025-12-02T15:59:45.299042
34587291.0,,,2.47,,adjusted OR,,,95% CI,1.4,4.34,139.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,247,2025-12-02T15:59:45.299042
34587291.0,,,1.64,,adjusted OR,,,95% CI,1.21,2.22,581.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,248,2025-12-02T15:59:45.299042
34587291.0,,,1.02,,adjusted OR,,,95% CI,0.74,1.43,579.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,249,2025-12-02T15:59:45.299042
34587291.0,,,0.85,,adjusted OR,,,95% CI,0.32,2.22,55.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,250,2025-12-02T15:59:45.299042
34587291.0,,,0.93,,adjusted OR,,,95% CI,0.75,1.16,1653.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,251,2025-12-02T15:59:45.299042
34587291.0,,,1.03,,adjusted OR,,,95% CI,0.54,1.96,132.0,neonate,early exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,252,2025-12-02T15:59:45.299042
34587291.0,adaptation syndrome,,0.47,,adjusted OR,,,95% CI,0.17,1.3,406.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,253,2025-12-02T15:59:45.299042
34587291.0,,,0.81,,adjusted OR,,,95% CI,0.34,1.91,385.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,254,2025-12-02T15:59:45.299042
34587291.0,,,3.71,,adjusted OR,,,95% CI,0.33,41.62,16.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,255,2025-12-02T15:59:45.299042
34587291.0,,,1.94,,adjusted OR,,,95% CI,0.72,5.25,139.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,256,2025-12-02T15:59:45.299042
34587291.0,,,1.69,,adjusted OR,,,95% CI,0.97,2.95,581.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,257,2025-12-02T15:59:45.299042
34587291.0,,,0.52,,adjusted OR,,,95% CI,0.21,1.3,579.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,258,2025-12-02T15:59:45.299042
34587291.0,,,1.75,,adjusted OR,,,95% CI,0.37,8.21,55.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,259,2025-12-02T15:59:45.299042
34587291.0,,,0.66,,adjusted OR,,,95% CI,0.4,1.07,1653.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,260,2025-12-02T15:59:45.299042
34587291.0,,,0.77,,adjusted OR,,,95% CI,0.18,3.32,132.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,261,2025-12-02T15:59:45.299042
34587291.0,NICU admission,,0.68,,adjusted OR,,,95% CI,0.39,1.17,406.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,262,2025-12-02T15:59:45.299042
34587291.0,,,1.09,,adjusted OR,,,95% CI,0.67,1.79,385.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,263,2025-12-02T15:59:45.299042
34587291.0,,,0.72,,adjusted OR,,,95% CI,0.07,7.56,16.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,264,2025-12-02T15:59:45.299042
34587291.0,,,2.32,,adjusted OR,,,95% CI,1.13,4.77,139.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,265,2025-12-02T15:59:45.299042
34587291.0,,,1.56,,adjusted OR,,,95% CI,1.06,2.28,581.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,266,2025-12-02T15:59:45.299042
34587291.0,,,0.92,,adjusted OR,,,95% CI,0.6,1.43,579.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,267,2025-12-02T15:59:45.299042
34587291.0,,,0.86,,adjusted OR,,,95% CI,0.25,2.92,55.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,268,2025-12-02T15:59:45.299042
34587291.0,,,0.88,,adjusted OR,,,95% CI,0.68,1.15,1653.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,269,2025-12-02T15:59:45.299042
34587291.0,,,1.15,,adjusted OR,,,95% CI,0.54,2.41,132.0,neonate,first trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,270,2025-12-02T15:59:45.299042
34587291.0,adaptation syndrome,,1.29,,adjusted OR,,,95% CI,0.65,2.58,406.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,271,2025-12-02T15:59:45.299042
34587291.0,,,3.02,,adjusted OR,,,95% CI,1.82,5.04,385.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,272,2025-12-02T15:59:45.299042
34587291.0,,,na,,adjusted OR,,,95% CI,na,na,16.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,273,2025-12-02T15:59:45.299042
34587291.0,,,4.76,,adjusted OR,,,95% CI,2.27,9.91,139.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,274,2025-12-02T15:59:45.299042
34587291.0,,,4.2,,adjusted OR,,,95% CI,2.76,6.38,581.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,275,2025-12-02T15:59:45.299042
34587291.0,,,2.08,,adjusted OR,,,95% CI,1.27,3.42,579.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,276,2025-12-02T15:59:45.299042
34587291.0,,,3.26,,adjusted OR,,,95% CI,0.65,16.23,55.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,277,2025-12-02T15:59:45.299042
34587291.0,,,1.56,,adjusted OR,,,95% CI,1.09,2.24,1653.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,278,2025-12-02T15:59:45.299042
34587291.0,,,3.95,,adjusted OR,,,95% CI,1.74,8.97,132.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,279,2025-12-02T15:59:45.299042
34587291.0,NICU admission,,1.51,,adjusted OR,,,95% CI,1.03,2.21,406.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,280,2025-12-02T15:59:45.299042
34587291.0,,,1.61,,adjusted OR,,,95% CI,1.11,2.34,385.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,281,2025-12-02T15:59:45.299042
34587291.0,,,0.52,,adjusted OR,,,95% CI,0.06,4.38,16.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,282,2025-12-02T15:59:45.299042
34587291.0,,,2.71,,adjusted OR,,,95% CI,1.52,4.83,139.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,283,2025-12-02T15:59:45.299042
34587291.0,,,1.93,,adjusted OR,,,95% CI,1.44,2.59,581.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,284,2025-12-02T15:59:45.299042
34587291.0,,,1.45,,adjusted OR,,,95% CI,1.07,1.98,579.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,285,2025-12-02T15:59:45.299042
34587291.0,,,1.81,,adjusted OR,,,95% CI,0.49,6.72,55.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,286,2025-12-02T15:59:45.299042
34587291.0,,,1.15,,adjusted OR,,,95% CI,0.94,1.41,1653.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,287,2025-12-02T15:59:45.299042
34587291.0,,,1.53,,adjusted OR,,,95% CI,0.83,2.81,132.0,neonate,third trimester exposure,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,288,2025-12-02T15:59:45.299042
19452377.0,BNBAS assessment ,age,3.5,days,mean,SD,0.69,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,11,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,age,3.6,days,mean,SD,0.92,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,12,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,habituation,6.46,,mean,SD,1.65,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,13,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,habituation,7.64,,mean,SD,0.84,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,14,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,social-interactive,6.49,,mean,SD,1.63,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,15,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,social-interactive,7.29,,mean,SD,1.12,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,16,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,motor,5.27,,mean,SD,0.69,,,,11,pediatric,,neonate,<0.05,SNRI group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,17,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,motor,6.13,,mean,SD,0.44,,,,18,pediatric,,neonate,<0.05,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,18,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,range,3.55,,mean,SD,0.52,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,19,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,range,3.53,,mean,SD,0.75,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,20,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,regulation,6.09,,mean,SD,1.32,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,21,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,regulation,6.26,,mean,SD,1,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,22,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,autonomic,5.47,,mean,SD,1.59,,,,11,pediatric,,neonate,<0.05,SNRI group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,23,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,autonomic,6.2,,mean,SD,0.68,,,,18,pediatric,,neonate,<0.05,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,24,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,reflexes,0.72,,mean,SD,0.11,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,25,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,reflexes,0.75,,mean,SD,0.07,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,26,2025-12-02T16:05:09.863062
19452377.0,BNBAS assessment ,age,3.5,days,mean,SD,0.69,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,11,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,age,3.6,days,mean,SD,0.92,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,12,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,habituation,6.46,,mean,SD,1.65,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,13,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,habituation,7.64,,mean,SD,0.84,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,14,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,social-interactive,6.49,,mean,SD,1.63,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,15,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,social-interactive,7.29,,mean,SD,1.12,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,16,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,motor,5.27,,mean,SD,0.69,,,,11,pediatric,,neonate,<0.05,SNRI group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,17,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,motor,6.13,,mean,SD,0.44,,,,18,pediatric,,neonate,<0.05,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,18,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,range,3.55,,mean,SD,0.52,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,19,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,range,3.53,,mean,SD,0.75,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,20,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,regulation,6.09,,mean,SD,1.32,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,21,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,regulation,6.26,,mean,SD,1,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,22,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,autonomic,5.47,,mean,SD,1.59,,,,11,pediatric,,neonate,<0.05,SNRI group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,23,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,autonomic,6.2,,mean,SD,0.68,,,,18,pediatric,,neonate,<0.05,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,24,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,reflexes,0.72,,mean,SD,0.11,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,25,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,reflexes,0.75,,mean,SD,0.07,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,26,2025-12-02T16:05:12.251790
19452377.0,BNBAS assessment ,age,3.5,days,mean,SD,0.69,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,11,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,age,3.6,days,mean,SD,0.92,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,12,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,habituation,6.46,,mean,SD,1.65,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,13,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,habituation,7.64,,mean,SD,0.84,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,14,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,social-interactive,6.49,,mean,SD,1.63,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,15,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,social-interactive,7.29,,mean,SD,1.12,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,16,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,motor,5.27,,mean,SD,0.69,,,,11,pediatric,,neonate,<0.05,SNRI group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,17,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,motor,6.13,,mean,SD,0.44,,,,18,pediatric,,neonate,<0.05,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,18,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,range,3.55,,mean,SD,0.52,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,19,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,range,3.53,,mean,SD,0.75,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,20,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,regulation,6.09,,mean,SD,1.32,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,21,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,regulation,6.26,,mean,SD,1,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,22,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,autonomic,5.47,,mean,SD,1.59,,,,11,pediatric,,neonate,<0.05,SNRI group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,23,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,autonomic,6.2,,mean,SD,0.68,,,,18,pediatric,,neonate,<0.05,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,24,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,reflexes,0.72,,mean,SD,0.11,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,25,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,reflexes,0.75,,mean,SD,0.07,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,26,2025-12-02T16:05:16.158507
19452377.0,BNBAS assessment ,age,3.5,days,mean,SD,0.69,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,11,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,age,3.6,days,mean,SD,0.92,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,12,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,habituation,6.46,,mean,SD,1.65,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,13,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,habituation,7.64,,mean,SD,0.84,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,14,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,social-interactive,6.49,,mean,SD,1.63,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,15,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,social-interactive,7.29,,mean,SD,1.12,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,16,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,motor,5.27,,mean,SD,0.69,,,,11,pediatric,,neonate,<0.05,SNRI group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,17,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,motor,6.13,,mean,SD,0.44,,,,18,pediatric,,neonate,<0.05,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,18,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,range,3.55,,mean,SD,0.52,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,19,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,range,3.53,,mean,SD,0.75,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,20,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,regulation,6.09,,mean,SD,1.32,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,21,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,regulation,6.26,,mean,SD,1,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,22,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,autonomic,5.47,,mean,SD,1.59,,,,11,pediatric,,neonate,<0.05,SNRI group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,23,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,autonomic,6.2,,mean,SD,0.68,,,,18,pediatric,,neonate,<0.05,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,24,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,reflexes,0.72,,mean,SD,0.11,,,,11,pediatric,,neonate,,SNRI group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,25,2025-12-02T16:05:22.595023
19452377.0,BNBAS assessment ,reflexes,0.75,,mean,SD,0.07,,,,18,pediatric,,neonate,,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,26,2025-12-02T16:05:22.595023
12709723.0,gestational age at birth,,39,weeks,mean,SD,1.5,,,,11,pediatric,,infants,0.22,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,385,2025-12-02T16:05:09.863062
12709723.0,gestational age at birth,,39,weeks,mean,SD,1.5,,,,10,pediatric,,infants,0.22,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,386,2025-12-02T16:05:09.863062
12709723.0,Apgar score,1 min,7.8,,mean,SD,1.2,,,,11,pediatric,,infants,0.25,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,387,2025-12-02T16:05:09.863062
12709723.0,Apgar score,1 min,8.1,,mean,SD,2.2,,,,10,pediatric,,infants,0.25,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,388,2025-12-02T16:05:09.863062
12709723.0,Apgar score,5 min,8.1,,mean,SD,0.9,,,,11,pediatric,,infants,0.12,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,389,2025-12-02T16:05:09.863062
12709723.0,Apgar score,5 min,8.7,,mean,SD,2.6,,,,10,pediatric,,infants,0.12,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,390,2025-12-02T16:05:09.863062
12709723.0,Apgar score,15 min,8.4,,mean,SD,0.8,,,,11,pediatric,,infants,0.37,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,391,2025-12-02T16:05:09.863062
12709723.0,Apgar score,15 min,7.28,,mean,SD,0.09,,,,10,pediatric,,infants,0.37,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,392,2025-12-02T16:05:09.863062
12709723.0,Umbilical artery pH,,7.25,,mean,SD,0.07,,,,11,pediatric,,infants,0.37,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,393,2025-12-02T16:05:09.863062
12709723.0,Umbilical artery pH,,7.28,,mean,SD,0.09,,,,10,pediatric,,infants,0.37,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,394,2025-12-02T16:05:09.863062
12709723.0,body temperature at birth,,36.8,℃,mean,SD,0.6,,,,11,pediatric,,infants,0.57,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,395,2025-12-02T16:05:09.863062
12709723.0,body temperature at birth,,36.9,℃,mean,SD,0.4,,,,10,pediatric,,infants,0.57,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,396,2025-12-02T16:05:09.863062
12709723.0,sex,female,3,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,397,2025-12-02T16:05:09.863062
12709723.0,sex,male,8,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,398,2025-12-02T16:05:09.863062
12709723.0,sex,female,3,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,399,2025-12-02T16:05:09.863062
12709723.0,sex,male,7,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,400,2025-12-02T16:05:09.863062
12709723.0,delivery mode,Vaginal,8,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,401,2025-12-02T16:05:09.863062
12709723.0,delivery mode,Cesarean section,3,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,402,2025-12-02T16:05:09.863062
12709723.0,delivery mode,Vaginal,8,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,403,2025-12-02T16:05:09.863062
12709723.0,delivery mode,Cesarean section,2,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,404,2025-12-02T16:05:09.863062
12709723.0,malformations,,,,,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,405,2025-12-02T16:05:09.863062
12709723.0,malformations,,,,,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,406,2025-12-02T16:05:09.863062
12709723.0,weight at birth,,3380,g,mean,SD,390,,,,11,pediatric,,infants,0.53,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,407,2025-12-02T16:05:09.863062
12709723.0,weight at birth,,3510,g,mean,SD,550,,,,10,pediatric,,infants,0.53,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,408,2025-12-02T16:05:09.863062
12709723.0,weight at 12 mo,,9760,g,mean,SD,1120,,,,11,pediatric,,infants,0.89,fluoxetine group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,409,2025-12-02T16:05:09.863062
12709723.0,weight at 12 mo,,9830,g,mean,SD,980,,,,10,pediatric,,infants,0.89,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,410,2025-12-02T16:05:09.863062
12709723.0,gestational age at birth,,39,weeks,mean,SD,1.5,,,,11,pediatric,,infants,0.22,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,385,2025-12-02T16:05:12.251790
12709723.0,gestational age at birth,,39,weeks,mean,SD,1.5,,,,10,pediatric,,infants,0.22,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,386,2025-12-02T16:05:12.251790
12709723.0,Apgar score,1 min,7.8,,mean,SD,1.2,,,,11,pediatric,,infants,0.25,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,387,2025-12-02T16:05:12.251790
12709723.0,Apgar score,1 min,8.1,,mean,SD,2.2,,,,10,pediatric,,infants,0.25,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,388,2025-12-02T16:05:12.251790
12709723.0,Apgar score,5 min,8.1,,mean,SD,0.9,,,,11,pediatric,,infants,0.12,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,389,2025-12-02T16:05:12.251790
12709723.0,Apgar score,5 min,8.7,,mean,SD,2.6,,,,10,pediatric,,infants,0.12,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,390,2025-12-02T16:05:12.251790
12709723.0,Apgar score,15 min,8.4,,mean,SD,0.8,,,,11,pediatric,,infants,0.37,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,391,2025-12-02T16:05:12.251790
12709723.0,Apgar score,15 min,7.28,,mean,SD,0.09,,,,10,pediatric,,infants,0.37,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,392,2025-12-02T16:05:12.251790
12709723.0,Umbilical artery pH,,7.25,,mean,SD,0.07,,,,11,pediatric,,infants,0.37,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,393,2025-12-02T16:05:12.251790
12709723.0,Umbilical artery pH,,7.28,,mean,SD,0.09,,,,10,pediatric,,infants,0.37,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,394,2025-12-02T16:05:12.251790
12709723.0,body temperature at birth,,36.8,℃,mean,SD,0.6,,,,11,pediatric,,infants,0.57,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,395,2025-12-02T16:05:12.251790
12709723.0,body temperature at birth,,36.9,℃,mean,SD,0.4,,,,10,pediatric,,infants,0.57,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,396,2025-12-02T16:05:12.251790
12709723.0,sex,female,3,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,397,2025-12-02T16:05:12.251790
12709723.0,sex,male,8,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,398,2025-12-02T16:05:12.251790
12709723.0,sex,female,3,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,399,2025-12-02T16:05:12.251790
12709723.0,sex,male,7,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,400,2025-12-02T16:05:12.251790
12709723.0,delivery mode,Vaginal,8,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,401,2025-12-02T16:05:12.251790
12709723.0,delivery mode,Cesarean section,3,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,402,2025-12-02T16:05:12.251790
12709723.0,delivery mode,Vaginal,8,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,403,2025-12-02T16:05:12.251790
12709723.0,delivery mode,Cesarean section,2,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,404,2025-12-02T16:05:12.251790
12709723.0,malformations,,,,,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,405,2025-12-02T16:05:12.251790
12709723.0,malformations,,,,,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,406,2025-12-02T16:05:12.251790
12709723.0,weight at birth,,3380,g,mean,SD,390,,,,11,pediatric,,infants,0.53,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,407,2025-12-02T16:05:12.251790
12709723.0,weight at birth,,3510,g,mean,SD,550,,,,10,pediatric,,infants,0.53,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,408,2025-12-02T16:05:12.251790
12709723.0,weight at 12 mo,,9760,g,mean,SD,1120,,,,11,pediatric,,infants,0.89,fluoxetine group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,409,2025-12-02T16:05:12.251790
12709723.0,weight at 12 mo,,9830,g,mean,SD,980,,,,10,pediatric,,infants,0.89,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,410,2025-12-02T16:05:12.251790
12709723.0,gestational age at birth,,39,weeks,mean,SD,1.5,,,,11,pediatric,,infants,0.22,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,385,2025-12-02T16:05:16.158507
12709723.0,gestational age at birth,,39,weeks,mean,SD,1.5,,,,10,pediatric,,infants,0.22,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,386,2025-12-02T16:05:16.158507
12709723.0,Apgar score,1 min,7.8,,mean,SD,1.2,,,,11,pediatric,,infants,0.25,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,387,2025-12-02T16:05:16.158507
12709723.0,Apgar score,1 min,8.1,,mean,SD,2.2,,,,10,pediatric,,infants,0.25,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,388,2025-12-02T16:05:16.158507
12709723.0,Apgar score,5 min,8.1,,mean,SD,0.9,,,,11,pediatric,,infants,0.12,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,389,2025-12-02T16:05:16.158507
12709723.0,Apgar score,5 min,8.7,,mean,SD,2.6,,,,10,pediatric,,infants,0.12,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,390,2025-12-02T16:05:16.158507
12709723.0,Apgar score,15 min,8.4,,mean,SD,0.8,,,,11,pediatric,,infants,0.37,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,391,2025-12-02T16:05:16.158507
12709723.0,Apgar score,15 min,7.28,,mean,SD,0.09,,,,10,pediatric,,infants,0.37,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,392,2025-12-02T16:05:16.158507
12709723.0,Umbilical artery pH,,7.25,,mean,SD,0.07,,,,11,pediatric,,infants,0.37,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,393,2025-12-02T16:05:16.158507
12709723.0,Umbilical artery pH,,7.28,,mean,SD,0.09,,,,10,pediatric,,infants,0.37,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,394,2025-12-02T16:05:16.158507
12709723.0,body temperature at birth,,36.8,℃,mean,SD,0.6,,,,11,pediatric,,infants,0.57,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,395,2025-12-02T16:05:16.158507
12709723.0,body temperature at birth,,36.9,℃,mean,SD,0.4,,,,10,pediatric,,infants,0.57,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,396,2025-12-02T16:05:16.158507
12709723.0,sex,female,3,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,397,2025-12-02T16:05:16.158507
12709723.0,sex,male,8,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,398,2025-12-02T16:05:16.158507
12709723.0,sex,female,3,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,399,2025-12-02T16:05:16.158507
12709723.0,sex,male,7,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,400,2025-12-02T16:05:16.158507
12709723.0,delivery mode,Vaginal,8,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,401,2025-12-02T16:05:16.158507
12709723.0,delivery mode,Cesarean section,3,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,402,2025-12-02T16:05:16.158507
12709723.0,delivery mode,Vaginal,8,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,403,2025-12-02T16:05:16.158507
12709723.0,delivery mode,Cesarean section,2,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,404,2025-12-02T16:05:16.158507
12709723.0,malformations,,,,,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,405,2025-12-02T16:05:16.158507
12709723.0,malformations,,,,,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,406,2025-12-02T16:05:16.158507
12709723.0,weight at birth,,3380,g,mean,SD,390,,,,11,pediatric,,infants,0.53,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,407,2025-12-02T16:05:16.158507
12709723.0,weight at birth,,3510,g,mean,SD,550,,,,10,pediatric,,infants,0.53,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,408,2025-12-02T16:05:16.158507
12709723.0,weight at 12 mo,,9760,g,mean,SD,1120,,,,11,pediatric,,infants,0.89,fluoxetine group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,409,2025-12-02T16:05:16.158507
12709723.0,weight at 12 mo,,9830,g,mean,SD,980,,,,10,pediatric,,infants,0.89,control group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,410,2025-12-02T16:05:16.158507
12709723.0,gestational age at birth,,39,weeks,mean,SD,1.5,,,,11,pediatric,,infants,0.22,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,385,2025-12-02T16:05:22.595023
12709723.0,gestational age at birth,,39,weeks,mean,SD,1.5,,,,10,pediatric,,infants,0.22,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,386,2025-12-02T16:05:22.595023
12709723.0,Apgar score,1 min,7.8,,mean,SD,1.2,,,,11,pediatric,,infants,0.25,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,387,2025-12-02T16:05:22.595023
12709723.0,Apgar score,1 min,8.1,,mean,SD,2.2,,,,10,pediatric,,infants,0.25,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,388,2025-12-02T16:05:22.595023
12709723.0,Apgar score,5 min,8.1,,mean,SD,0.9,,,,11,pediatric,,infants,0.12,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,389,2025-12-02T16:05:22.595023
12709723.0,Apgar score,5 min,8.7,,mean,SD,2.6,,,,10,pediatric,,infants,0.12,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,390,2025-12-02T16:05:22.595023
12709723.0,Apgar score,15 min,8.4,,mean,SD,0.8,,,,11,pediatric,,infants,0.37,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,391,2025-12-02T16:05:22.595023
12709723.0,Apgar score,15 min,7.28,,mean,SD,0.09,,,,10,pediatric,,infants,0.37,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,392,2025-12-02T16:05:22.595023
12709723.0,Umbilical artery pH,,7.25,,mean,SD,0.07,,,,11,pediatric,,infants,0.37,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,393,2025-12-02T16:05:22.595023
12709723.0,Umbilical artery pH,,7.28,,mean,SD,0.09,,,,10,pediatric,,infants,0.37,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,394,2025-12-02T16:05:22.595023
12709723.0,body temperature at birth,,36.8,℃,mean,SD,0.6,,,,11,pediatric,,infants,0.57,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,395,2025-12-02T16:05:22.595023
12709723.0,body temperature at birth,,36.9,℃,mean,SD,0.4,,,,10,pediatric,,infants,0.57,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,396,2025-12-02T16:05:22.595023
12709723.0,sex,female,3,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,397,2025-12-02T16:05:22.595023
12709723.0,sex,male,8,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,398,2025-12-02T16:05:22.595023
12709723.0,sex,female,3,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,399,2025-12-02T16:05:22.595023
12709723.0,sex,male,7,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,400,2025-12-02T16:05:22.595023
12709723.0,delivery mode,Vaginal,8,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,401,2025-12-02T16:05:22.595023
12709723.0,delivery mode,Cesarean section,3,,N,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,402,2025-12-02T16:05:22.595023
12709723.0,delivery mode,Vaginal,8,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,403,2025-12-02T16:05:22.595023
12709723.0,delivery mode,Cesarean section,2,,N,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,404,2025-12-02T16:05:22.595023
12709723.0,malformations,,,,,,,,,,11,pediatric,,infants,,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,405,2025-12-02T16:05:22.595023
12709723.0,malformations,,,,,,,,,,10,pediatric,,infants,,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,406,2025-12-02T16:05:22.595023
12709723.0,weight at birth,,3380,g,mean,SD,390,,,,11,pediatric,,infants,0.53,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,407,2025-12-02T16:05:22.595023
12709723.0,weight at birth,,3510,g,mean,SD,550,,,,10,pediatric,,infants,0.53,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,408,2025-12-02T16:05:22.595023
12709723.0,weight at 12 mo,,9760,g,mean,SD,1120,,,,11,pediatric,,infants,0.89,fluoxetine group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,409,2025-12-02T16:05:22.595023
12709723.0,weight at 12 mo,,9830,g,mean,SD,980,,,,10,pediatric,,infants,0.89,control group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,410,2025-12-02T16:05:22.595023
19743889.0,EM and UM paroxetine concentrations decreased over course of pregnancy while IM/PMs increased,,,,,,,,,,74.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,319,2025-12-02T15:59:45.299042
12860776.0,duration or pregnancy,,274,days,mean,,,range,251,291,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,320,2025-12-02T15:59:45.299042
12860776.0,,,279,days,mean,,,range,254,289,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,321,2025-12-02T15:59:45.299042
12860776.0,vaginal delivery,,16,n,,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,322,2025-12-02T15:59:45.299042
12860776.0,,,17,n,,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,323,2025-12-02T15:59:45.299042
12860776.0,cesarean delivery,,4,n,,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,324,2025-12-02T15:59:45.299042
12860776.0,,,3,n,,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,325,2025-12-02T15:59:45.299042
12860776.0,weight at birth,,3455,g,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,326,2025-12-02T15:59:45.299042
12860776.0,,,3534,g,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,327,2025-12-02T15:59:45.299042
12860776.0,body temp at birth,,36.9,deg C,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,328,2025-12-02T15:59:45.299042
12860776.0,,,37,deg C,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,329,2025-12-02T15:59:45.299042
12860776.0,1 min apgar,,8.4,,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,330,2025-12-02T15:59:45.299042
12860776.0,,,8.5,,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,331,2025-12-02T15:59:45.299042
12860776.0,5 min apgar,,8.6,,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,332,2025-12-02T15:59:45.299042
12860776.0,,,9,,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,333,2025-12-02T15:59:45.299042
12860776.0,15 min apgar,,8.8,,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,334,2025-12-02T15:59:45.299042
12860776.0,,,9.4,,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,335,2025-12-02T15:59:45.299042
12860776.0,full breastfeeding,,9,wk,mean,,,range,0,43,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,336,2025-12-02T15:59:45.299042
12860776.0,,,9,wk,mean,,,range,0,26,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,337,2025-12-02T15:59:45.299042
12860776.0,total breastfeeding,,17,wk,mean,,,range,0,52,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,338,2025-12-02T15:59:45.299042
12860776.0,,,24,wk,mean,,,range,2,52,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,339,2025-12-02T15:59:45.299042
12860776.0,infant weight at 2 mo,,5423,g,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,340,2025-12-02T15:59:45.299042
12860776.0,,,5458,g,mean,,,,,,20.0,neonate,,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,341,2025-12-02T15:59:45.299042
12860776.0,systolic blood pressure,,69,mm Hg,mean,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,342,2025-12-02T15:59:45.299042
12860776.0,,,70,mm Hg,mean,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,343,2025-12-02T15:59:45.299042
12860776.0,,,93,mm Hg,mean,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,344,2025-12-02T15:59:45.299042
12860776.0,,,89,mm Hg,mean,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,345,2025-12-02T15:59:45.299042
12860776.0,,,98,mm Hg,mean,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,346,2025-12-02T15:59:45.299042
12860776.0,,,96,mm Hg,mean,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,347,2025-12-02T15:59:45.299042
12860776.0,diastolic blood pressure,,42,mm Hg,mean,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,348,2025-12-02T15:59:45.299042
12860776.0,,,40,mm Hg,mean,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,349,2025-12-02T15:59:45.299042
12860776.0,,,56,mm Hg,mean,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,350,2025-12-02T15:59:45.299042
12860776.0,,,54,mm Hg,mean,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,351,2025-12-02T15:59:45.299042
12860776.0,,,67,mm Hg,mean,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,352,2025-12-02T15:59:45.299042
12860776.0,,,61,mm Hg,mean,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,353,2025-12-02T15:59:45.299042
12860776.0,heart rate,,131,beats/min,mean,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,354,2025-12-02T15:59:45.299042
12860776.0,,,128,beats/min,mean,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,355,2025-12-02T15:59:45.299042
12860776.0,,,153,beats/min,mean,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,356,2025-12-02T15:59:45.299042
12860776.0,,,141,beats/min,mean,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,357,2025-12-02T15:59:45.299042
12860776.0,,,145,beats/min,mean,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,358,2025-12-02T15:59:45.299042
12860776.0,,,139,beats/min,mean,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,359,2025-12-02T15:59:45.299042
12860776.0,body temp,,37.3,deg C,mean,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,360,2025-12-02T15:59:45.299042
12860776.0,,,37.3,deg C,mean,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,361,2025-12-02T15:59:45.299042
12860776.0,,,36.9,deg C,mean,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,362,2025-12-02T15:59:45.299042
12860776.0,,,36.8,deg C,mean,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,363,2025-12-02T15:59:45.299042
12860776.0,,,37,deg C,mean,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,364,2025-12-02T15:59:45.299042
12860776.0,,,37,deg C,mean,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,365,2025-12-02T15:59:45.299042
12860776.0,serotonergic symptom score (SSS): myoclonus,,4,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,366,2025-12-02T15:59:45.299042
12860776.0,,,0,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,367,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,368,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,369,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,370,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,371,2025-12-02T15:59:45.299042
12860776.0,SSS: restlessness,,29,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,372,2025-12-02T15:59:45.299042
12860776.0,,,4,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,373,2025-12-02T15:59:45.299042
12860776.0,,,2,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,374,2025-12-02T15:59:45.299042
12860776.0,,,1,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,375,2025-12-02T15:59:45.299042
12860776.0,,,2,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,376,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,377,2025-12-02T15:59:45.299042
12860776.0,SSS: tremor,,38,sum***,,,,,,,20.0,neonate,day 1-4 postpartum,,,might need to double check this,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,378,2025-12-02T15:59:45.299042
12860776.0,,,7,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,379,2025-12-02T15:59:45.299042
12860776.0,,,2,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,380,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,381,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,382,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,383,2025-12-02T15:59:45.299042
12860776.0,SSS: shivering,,12,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,384,2025-12-02T15:59:45.299042
12860776.0,,,7,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,385,2025-12-02T15:59:45.299042
12860776.0,,,2,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,386,2025-12-02T15:59:45.299042
12860776.0,,,1,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,387,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,388,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,389,2025-12-02T15:59:45.299042
12860776.0,SSS: hyperreflexia,,11,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,390,2025-12-02T15:59:45.299042
12860776.0,,,3,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,391,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,392,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,393,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,394,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,395,2025-12-02T15:59:45.299042
12860776.0,SSS: incoordination,,2,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,396,2025-12-02T15:59:45.299042
12860776.0,,,0,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,397,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,398,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,399,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,400,2025-12-02T15:59:45.299042
12860776.0,,,0,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,401,2025-12-02T15:59:45.299042
12860776.0,SSS: rigidity,,25,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,402,2025-12-02T15:59:45.299042
12860776.0,,,9,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,403,2025-12-02T15:59:45.299042
12860776.0,,,2,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,404,2025-12-02T15:59:45.299042
12860776.0,,,1,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,405,2025-12-02T15:59:45.299042
12860776.0,,,3,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,406,2025-12-02T15:59:45.299042
12860776.0,,,1,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,407,2025-12-02T15:59:45.299042
12860776.0,total SSS,,121,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,408,2025-12-02T15:59:45.299042
12860776.0,,,30,sum,,,,,,,20.0,neonate,day 1-4 postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,409,2025-12-02T15:59:45.299042
12860776.0,,,8,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,410,2025-12-02T15:59:45.299042
12860776.0,,,3,mean,,,,,,,20.0,neonate,2 weeks postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,411,2025-12-02T15:59:45.299042
12860776.0,,,5,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,412,2025-12-02T15:59:45.299042
12860776.0,,,1,mean,,,,,,,20.0,neonate,2 months postpartum,,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,413,2025-12-02T15:59:45.299042
37982307.0,Hamilton Depression Scale,,12.6,,mean,,,range,0,34,87.0,pregnant,1st tri,13 wks 1 d,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,451,2025-12-02T15:59:45.299042
37982307.0,Hamilton Depression Scale,,9.98,,mean,,,range,0,38,87.0,pregnant,2nd tri,13 wks 2 d - 26 wks 2 d,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,452,2025-12-02T15:59:45.299042
37982307.0,Hamilton Depression Scale,,7.91,,mean,,,range,0,28,87.0,pregnant,3rd tri,26 wks 3 d - birth,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,453,2025-12-02T15:59:45.299042
37982307.0,Hamilton Depression Scale,,7.35,,mean,,,range,0,28,87.0,pregnant,postpartum,> 2 mo postpartum,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,454,2025-12-02T15:59:45.299042
37982307.0,Hamilton Anxiety Scale,,15.5,,mean,,,range,1,39,87.0,pregnant,1st tri,13 wks 1 d,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,455,2025-12-02T15:59:45.299042
37982307.0,Hamilton Anxiety Scale,,11.93,,mean,,,range,0,44,87.0,pregnant,2nd tri,13 wks 2 d - 26 wks 2 d,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,456,2025-12-02T15:59:45.299042
37982307.0,Hamilton Anxiety Scale,,10.68,,mean,,,range,0,38,87.0,pregnant,3rd tri,26 wks 3 d - birth,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,457,2025-12-02T15:59:45.299042
37982307.0,Hamilton Anxiety Scale,,10.04,,mean,,,range,0,40,87.0,pregnant,postpartum,> 2 mo postpartum,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,458,2025-12-02T15:59:45.299042
37982307.0,Montgomery-Asberg Depression Scale,,13.78,,mean,,,range,1,38,87.0,pregnant,1st tri,13 wks 1 d,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,459,2025-12-02T15:59:45.299042
37982307.0,Montgomery-Asberg Depression Scale,,11.29,,mean,,,range,0,49,87.0,pregnant,2nd tri,13 wks 2 d - 26 wks 2 d,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,460,2025-12-02T15:59:45.299042
37982307.0,Montgomery-Asberg Depression Scale,,8.85,,mean,,,range,0,36,87.0,pregnant,3rd tri,26 wks 3 d - birth,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,461,2025-12-02T15:59:45.299042
37982307.0,Montgomery-Asberg Depression Scale,,8.15,,mean,,,range,0,36,87.0,pregnant,postpartum,> 2 mo postpartum,,,PRGLAC Data Curation - Sara's Team (1).xlsx,IU team,Outcomes (summary),Outcomes_summary,462,2025-12-02T15:59:45.299042
6113019.0,Apgar score,<6 at 1 min,1,,count,,,,,,29,neonate,,full tern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,10,2025-12-02T16:04:59.615593
6113019.0,Apgar score,<7 at 5 min,0,,count,,,,,,29,neonate,,full tern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,11,2025-12-02T16:04:59.615593
6113019.0,intubated and given IPPV,,0,,count,,,,,,29,neonate,,full tern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,12,2025-12-02T16:04:59.615593
6113019.0,rectal temperature,<36.5 ℃,6,,count,,,,,,29,neonate,,full tern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,13,2025-12-02T16:04:59.615593
6113019.0,rectal temperature,<36.0 ℃,0,,count,,,,,,29,neonate,,full tern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,14,2025-12-02T16:04:59.615593
6113019.0,over 24 hours before feeding established,,7,,count,,,,,,29,neonate,,full tern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,15,2025-12-02T16:04:59.615593
6113019.0,tube feeds,,3,,count,,,,,,29,neonate,,full tern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,16,2025-12-02T16:04:59.615593
6113019.0,Apgar score,<6 at 1 min,4,,count,,,,,,8,neonate,,full tern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,17,2025-12-02T16:04:59.615593
6113019.0,Apgar score,<7 at 5 min,3,,count,,,,,,8,neonate,,full tern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,18,2025-12-02T16:04:59.615593
6113019.0,intubated and given IPPV,,4,,count,,,,,,8,neonate,,full tern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,19,2025-12-02T16:04:59.615593
6113019.0,rectal temperature,<36.5 ℃,5,,count,,,,,,8,neonate,,full tern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,20,2025-12-02T16:04:59.615593
6113019.0,rectal temperature,<36.0 ℃,2,,count,,,,,,8,neonate,,full tern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,21,2025-12-02T16:04:59.615593
6113019.0,over 24 hours before feeding established,,5,,count,,,,,,8,neonate,,full tern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,22,2025-12-02T16:04:59.615593
6113019.0,tube feeds,,4,,count,,,,,,8,neonate,,full tern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,23,2025-12-02T16:04:59.615593
6113019.0,Apgar score,<6 at 1 min,6,,count,,,,,,7,neonate,,pretern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,24,2025-12-02T16:04:59.615593
6113019.0,Apgar score,<7 at 5 min,4,,count,,,,,,7,neonate,,pretern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,25,2025-12-02T16:04:59.615593
6113019.0,intubated and given IPPV,,4,,count,,,,,,7,neonate,,pretern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,26,2025-12-02T16:04:59.615593
6113019.0,rectal temperature,<36.5 ℃,6,,count,,,,,,7,neonate,,pretern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,27,2025-12-02T16:04:59.615593
6113019.0,rectal temperature,<36.0 ℃,3,,count,,,,,,7,neonate,,pretern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,28,2025-12-02T16:04:59.615593
6113019.0,over 24 hours before feeding established,,7,,count,,,,,,7,neonate,,pretern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,29,2025-12-02T16:04:59.615593
6113019.0,tube feeds,,7,,count,,,,,,7,neonate,,pretern,,maternal oral lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,30,2025-12-02T16:04:59.615593
6113019.0,Apgar score,<6 at 1 min,8,,count,,,,,,9,neonate,,pretern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,31,2025-12-02T16:04:59.615593
6113019.0,Apgar score,<7 at 5 min,5,,count,,,,,,9,neonate,,pretern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,32,2025-12-02T16:04:59.615593
6113019.0,intubated and given IPPV,,8,,count,,,,,,9,neonate,,pretern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,33,2025-12-02T16:04:59.615593
6113019.0,rectal temperature,<36.5 ℃,9,,count,,,,,,9,neonate,,pretern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,34,2025-12-02T16:04:59.615593
6113019.0,rectal temperature,<36.0 ℃,6,,count,,,,,,9,neonate,,pretern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,35,2025-12-02T16:04:59.615593
6113019.0,over 24 hours before feeding established,,8,,count,,,,,,9,neonate,,pretern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,36,2025-12-02T16:04:59.615593
6113019.0,tube feeds,,8,,count,,,,,,9,neonate,,pretern,,maternal IV lorazepam,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,37,2025-12-02T16:04:59.615593
42422.0,injection-delivery time,,293,min,mean,,,minmax,180,447,10,maternal,delivery,,,the first stage group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,38,2025-12-02T16:04:59.615593
42422.0,injection-delivery time,,21,min,mean,,,minmax,5,67,12,maternal,delivery,,,the second stage group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,39,2025-12-02T16:04:59.615593
2919760.0,time between induction of anesthesia and delivery,thiopental group,8.1,minutes,median,,,minmax,4,14,20,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,164,2025-12-02T16:04:59.615593
2919760.0,time between induction of anesthesia and delivery,midazolam group,7.5,minutes,median,,,minmax,4,11,20,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,165,2025-12-02T16:04:59.615593
2919760.0,Apgar score at 1 min,,9.3,,mean,,,minmax,5.0,10.0,20,pediatric,,neonates,,thiopental,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,443,2025-12-02T16:05:09.863062
2919760.0,Apgar score at 1 min,,9.6,,mean,,,minmax,5.0,10.0,20,pediatric,,neonates,,Midazolam,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,444,2025-12-02T16:05:09.863062
2919760.0,Apgar score at 5 min,,9.9,,mean,,,minmax,7.0,10.0,20,pediatric,,neonates,,thiopental,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,445,2025-12-02T16:05:09.863062
2919760.0,Apgar score at 5 min,,9.9,,mean,,,minmax,8.0,10.0,20,pediatric,,neonates,,Midazolam,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,446,2025-12-02T16:05:09.863062
2919760.0,Apgar score at 1 min,,9.3,,mean,,,minmax,5.0,10.0,20,pediatric,,neonates,,thiopental,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,443,2025-12-02T16:05:12.251790
2919760.0,Apgar score at 1 min,,9.6,,mean,,,minmax,5.0,10.0,20,pediatric,,neonates,,Midazolam,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,444,2025-12-02T16:05:12.251790
2919760.0,Apgar score at 5 min,,9.9,,mean,,,minmax,7.0,10.0,20,pediatric,,neonates,,thiopental,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,445,2025-12-02T16:05:12.251790
2919760.0,Apgar score at 5 min,,9.9,,mean,,,minmax,8.0,10.0,20,pediatric,,neonates,,Midazolam,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,446,2025-12-02T16:05:12.251790
2919760.0,Apgar score at 1 min,,9.3,,mean,,,minmax,5.0,10.0,20,pediatric,,neonates,,thiopental,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,443,2025-12-02T16:05:16.158507
2919760.0,Apgar score at 1 min,,9.6,,mean,,,minmax,5.0,10.0,20,pediatric,,neonates,,Midazolam,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,444,2025-12-02T16:05:16.158507
2919760.0,Apgar score at 5 min,,9.9,,mean,,,minmax,7.0,10.0,20,pediatric,,neonates,,thiopental,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,445,2025-12-02T16:05:16.158507
2919760.0,Apgar score at 5 min,,9.9,,mean,,,minmax,8.0,10.0,20,pediatric,,neonates,,Midazolam,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,446,2025-12-02T16:05:16.158507
2919760.0,Apgar score at 1 min,,9.3,,mean,,,minmax,5.0,10.0,20,pediatric,,neonates,,thiopental,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,443,2025-12-02T16:05:22.595023
2919760.0,Apgar score at 1 min,,9.6,,mean,,,minmax,5.0,10.0,20,pediatric,,neonates,,Midazolam,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,444,2025-12-02T16:05:22.595023
2919760.0,Apgar score at 5 min,,9.9,,mean,,,minmax,7.0,10.0,20,pediatric,,neonates,,thiopental,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,445,2025-12-02T16:05:22.595023
2919760.0,Apgar score at 5 min,,9.9,,mean,,,minmax,8.0,10.0,20,pediatric,,neonates,,Midazolam,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,446,2025-12-02T16:05:22.595023
30488179.0,cycle delay,total patietns,20,,n,,,,,,22,children ,,,,54 subject-cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,166,2025-12-02T16:04:59.615593
30488179.0,cycle delay,non-dose-adjusted cycles,6,,n,,,,,,8,children ,,,,21no-dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,167,2025-12-02T16:04:59.615593
30488179.0,cycle delay,dose-adjusted cycles,14,,n,,,,,,14,children ,,,0.501,33 dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,168,2025-12-02T16:04:59.615593
30488179.0,any grade hematological toxicity,total patietns,47,,n,,,,,,22,children ,,,,54 subject-cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,169,2025-12-02T16:04:59.615593
30488179.0,any grade hematological toxicity,non-dose-adjusted cycles,18,,n,,,,,,8,children ,,,,21no-dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,170,2025-12-02T16:04:59.615593
30488179.0,any grade hematological toxicity,dose-adjusted cycles,29,,n,,,,,,14,children ,,,0.817,33 dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,171,2025-12-02T16:04:59.615593
30488179.0,grade 3/4 hematological toxicity,total patietns,39,,n,,,,,,22,children ,,,,54 subject-cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,172,2025-12-02T16:04:59.615593
30488179.0,grade 3/4 hematological toxicity,non-dose-adjusted cycles,17,,n,,,,,,8,children ,,,,21no-dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,173,2025-12-02T16:04:59.615593
30488179.0,grade 3/4 hematological toxicity,dose-adjusted cycles,22,,n,,,,,,14,children ,,,0.253,33 dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,174,2025-12-02T16:04:59.615593
30488179.0,any grade non hematological toxicity,total patietns,38,,n,,,,,,22,children ,,,,54 subject-cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,175,2025-12-02T16:04:59.615593
30488179.0,any grade non hematological toxicity,non-dose-adjusted cycles,15,,n,,,,,,8,children ,,,,21no-dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,176,2025-12-02T16:04:59.615593
30488179.0,any grade non hematological toxicity,dose-adjusted cycles,23,,n,,,,,,14,children ,,,0.892,33 dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,177,2025-12-02T16:04:59.615593
30488179.0,grade 3/4 non hematological toxicity,total patietns,16,,n,,,,,,22,children ,,,,54 subject-cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,178,2025-12-02T16:04:59.615593
30488179.0,grade 3/4 non hematological toxicity,non-dose-adjusted cycles,6,,n,,,,,,8,children ,,,,21no-dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,179,2025-12-02T16:04:59.615593
30488179.0,grade 3/4 non hematological toxicity,dose-adjusted cycles,10,,n,,,,,,14,children ,,,0.892,33 dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,180,2025-12-02T16:04:59.615593
30488179.0,any grade AKI,total patietns,2,,n,,,,,,22,children ,,,,54 subject-cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,181,2025-12-02T16:04:59.615593
30488179.0,any grade AKI,non-dose-adjusted cycles,0,,n,,,,,,8,children ,,,,21no-dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,182,2025-12-02T16:04:59.615593
30488179.0,any grade AKI,dose-adjusted cycles,2,,n,,,,,,14,children ,,,0.516,33 dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,183,2025-12-02T16:04:59.615593
30488179.0,grade 3/4 AKI,total patietns,0,,n,,,,,,22,children ,,,,54 subject-cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,184,2025-12-02T16:04:59.615593
30488179.0,grade 3/4 AKI,non-dose-adjusted cycles,0,,n,,,,,,8,children ,,,,21no-dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,185,2025-12-02T16:04:59.615593
30488179.0,grade 3/4 AKI,dose-adjusted cycles,0,,n,,,,,,14,children ,,,,33 dose-adjusted cycles,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,186,2025-12-02T16:04:59.615593
32612964.0,cycles with delayed MTX elimination,,69,,n,,,,,,123,children,,,,MTX dose 2 g/m2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,187,2025-12-02T16:04:59.615593
32612964.0,cycles with delayed MTX elimination,,28,,n,,,,,,13,children,,,,MTX dose 5 g/m2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,188,2025-12-02T16:04:59.615593
33037681.0,toxicity (VCR-related),No,63,,n,,,,,,64,children,,,,"B-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,189,2025-12-02T16:04:59.615593
33037681.0,toxicity (VCR-related),Yes,1,,n,,,,,,64,children,,,,"B-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,190,2025-12-02T16:04:59.615593
33037681.0,toxicity (VCR-related),No,48,,n,,,,,,51,children,,,,"B-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,191,2025-12-02T16:04:59.615593
33037681.0,toxicity (VCR-related),Yes,3,,n,,,,,,51,children,,,,"B-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,192,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,Good,53,,n,,,,,,64,children,,,,"B-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,193,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,Poor,5,,n,,,,,,64,children,,,,"B-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,194,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,,6,,n,,,,,,64,children,,,,"B-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,195,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,Good,39,,n,,,,,,51,children,,,,"B-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,196,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,Poor,10,,n,,,,,,51,children,,,,"B-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,197,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,,2,,n,,,,,,51,children,,,,"B-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,198,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,SR,33,,n,,,,,,64,children,,,,"B-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,199,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,IR,21,,n,,,,,,64,children,,,,"B-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,200,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,HR,10,,n,,,,,,64,children,,,,"B-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,201,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,SR,24,,n,,,,,,51,children,,,,"B-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,202,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,IR,23,,n,,,,,,51,children,,,,"B-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,203,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,HR,4,,n,,,,,,51,children,,,,"B-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,204,2025-12-02T16:04:59.615593
33037681.0,toxicity (VCR-related),No,10,,n,,,,,,10,children,,,,"T-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,205,2025-12-02T16:04:59.615593
33037681.0,toxicity (VCR-related),Yes,0,,n,,,,,,10,children,,,0.21,"T-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,206,2025-12-02T16:04:59.615593
33037681.0,toxicity (VCR-related),No,9,,n,,,,,,10,children,,,,"T-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,207,2025-12-02T16:04:59.615593
33037681.0,toxicity (VCR-related),Yes,1,,n,,,,,,10,children,,,> 0.999,"T-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,208,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,Good,8,,n,,,,,,10,children,,,,"T-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,209,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,Poor,2,,n,,,,,,10,children,,,,"T-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,210,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,,0,,n,,,,,,10,children,,,0.08,"T-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,211,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,Good,5,,n,,,,,,10,children,,,,"T-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,212,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,Poor,5,,n,,,,,,10,children,,,,"T-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,213,2025-12-02T16:04:59.615593
33037681.0,Day 8 PB response,,0,,n,,,,,,10,children,,,0.16,"T-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,214,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,SR,1,,n,,,,,,10,children,,,,"T-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,215,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,IR,6,,n,,,,,,10,children,,,,"T-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,216,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,HR,3,,n,,,,,,10,children,,,0.27,"T-lineage, 15 min infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,217,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,SR,2,,n,,,,,,10,children,,,,"T-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,218,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,IR,4,,n,,,,,,10,children,,,,"T-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,219,2025-12-02T16:04:59.615593
33037681.0,D33 MRD,HR,4,,n,,,,,,10,children,,,0.88,"T-lineage, 3-h infusion",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,220,2025-12-02T16:04:59.615593
35303169.0,clinical outcome (CGI-I),(Very) much better,20,,n,,,,,,60,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,221,2025-12-02T16:04:59.615593
35303169.0,clinical outcome (CGI-I),Moderately better,23,,n,,,,,,60,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,222,2025-12-02T16:04:59.615593
35303169.0,clinical outcome (CGI-I),Unchanged/slightly worse,12,,n,,,,,,60,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,223,2025-12-02T16:04:59.615593
35303169.0,clinical outcome (CGI-I),Much worse,4,,n,,,,,,60,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,224,2025-12-02T16:04:59.615593
35303169.0,clinical outcome (CGI-I),Not assessable,1,,n,,,,,,60,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,225,2025-12-02T16:04:59.615593
35303169.0,"""Responder""",,43,,n,,,,,,60,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,226,2025-12-02T16:04:59.615593
35303169.0,Adverse Drug reactions (UKU),Documented side effects,40,,n,,,,,,63,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,227,2025-12-02T16:04:59.615593
35303169.0,Severity of ADRs (UKU),Mild,23,,n,,,,,,40,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,228,2025-12-02T16:04:59.615593
35303169.0,Severity of ADRs (UKU),Moderate,17,,n,,,,,,40,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,229,2025-12-02T16:04:59.615593
35303169.0,Severity of ADRs (UKU),Severe,0,,n,,,,,,40,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,230,2025-12-02T16:04:59.615593
32997183.0,Improvement,Very much better,11,,n,,,,,,130,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,231,2025-12-02T16:04:59.615593
32997183.0,Improvement,Much better,46,,n,,,,,,130,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,232,2025-12-02T16:04:59.615593
32997183.0,Improvement,Moderately better,44,,n,,,,,,130,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,233,2025-12-02T16:04:59.615593
32997183.0,Improvement,Unchanged,11,,n,,,,,,130,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,234,2025-12-02T16:04:59.615593
32997183.0,Improvement,Minimally worse,5,,n,,,,,,130,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,235,2025-12-02T16:04:59.615593
32997183.0,Improvement,Much worse,0,,n,,,,,,130,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,236,2025-12-02T16:04:59.615593
32997183.0,Improvement,Not assessed/ assessable,3/10,,n,,,,,,130,Children and Adolescents,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,237,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,unchanged or worse,3,,n,,,,,,78,children and adolescents,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,251,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,minimal,25,,n,,,,,,78,children and adolescents,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,252,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,moderate,41,,n,,,,,,78,children and adolescents,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,253,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,marked,9,,n,,,,,,78,children and adolescents,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,254,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,unchanged or worse,1,,n,,,,,,21,children and adolescents,,,,OCD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,255,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,minimal,6,,n,,,,,,21,children and adolescents,,,,OCD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,256,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,moderate,12,,n,,,,,,21,children and adolescents,,,,OCD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,257,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,marked,2,,n,,,,,,21,children and adolescents,,,,OCD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,258,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,unchanged or worse,1,,n,,,,,,36,children and adolescents,,,,Depression,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,259,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,minimal,13,,n,,,,,,36,children and adolescents,,,,Depression,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,260,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,moderate,19,,n,,,,,,36,children and adolescents,,,,Depression,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,261,2025-12-02T16:04:59.615593
35248877.0,CGI therapeutic effects,marked,3,,n,,,,,,36,children and adolescents,,,,Depression,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,262,2025-12-02T16:04:59.615593
35248877.0,CGI side effects,none,47,,n,,,,,,78,children and adolescents,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,263,2025-12-02T16:04:59.615593
35248877.0,CGI side effects,not severe,28,,n,,,,,,78,children and adolescents,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,264,2025-12-02T16:04:59.615593
35248877.0,CGI side effects,severe,3,,n,,,,,,78,children and adolescents,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,265,2025-12-02T16:04:59.615593
35248877.0,CGI side effects,none,12,,n,,,,,,21,children and adolescents,,,,OCD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,266,2025-12-02T16:04:59.615593
35248877.0,CGI side effects,not severe,7,,n,,,,,,21,children and adolescents,,,,OCD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,267,2025-12-02T16:04:59.615593
35248877.0,CGI side effects,severe,2,,n,,,,,,21,children and adolescents,,,,OCD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,268,2025-12-02T16:04:59.615593
35248877.0,CGI side effects,none,22,,n,,,,,,36,children and adolescents,,,,Depression,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,269,2025-12-02T16:04:59.615593
35248877.0,CGI side effects,not severe,13,,n,,,,,,36,children and adolescents,,,,Depression,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,270,2025-12-02T16:04:59.615593
35248877.0,CGI side effects,severe,1,,n,,,,,,36,children and adolescents,,,,Depression,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,271,2025-12-02T16:04:59.615593
31950485.0,Apgar score,at 1 min,9,,median,,,minmax,2,10,76,neonate,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,272,2025-12-02T16:04:59.615593
31950485.0,Apgar score,at 5 min,9,,median,,,minmax,6,10,76,neonate,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,273,2025-12-02T16:04:59.615593
31950485.0,pain intensity in NRS 0-10,before the first oxycodone administration,7,,median,,,minmax,4,10,73,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,274,2025-12-02T16:04:59.615593
31950485.0,pain intensity in NRS 0-10,at 30 miniutes after the first dose,5,,median,,,minmax,0,9,50,maternal,labor,,<0.001,compared to the pain scores before the first oxycodone administration,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,275,2025-12-02T16:04:59.615593
31950485.0,pain intensity in NRS 0-10,at 60 minutes after the first dose,5,,median,,,minmax,0,10,52,maternal,labor,,<0.001,compared to the pain scores before the first oxycodone administration,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,276,2025-12-02T16:04:59.615593
31950485.0,pain intensity in NRS 0-10,at 120 minutes after the first dose,6,,median,,,minmax,0,10,51,maternal,labor,,0.012,compared to the pain scores before the first oxycodone administration,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,277,2025-12-02T16:04:59.615593
31950485.0,%maxTOTPAR,,0.45,,median,,,minmax,-0.25,1,59,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,278,2025-12-02T16:04:59.615593
31950485.0,pain relief in NRS,,5,,median,,,minmax,0,10,61,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,279,2025-12-02T16:04:59.615593
31950485.0,pain relief in NRS at 60 minutes after the first dose in VRS,complete,9,,n,,,,,,46,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,280,2025-12-02T16:04:59.615593
31950485.0,pain relief in NRS at 60 minutes after the first dose in VRS,good,14,,n,,,,,,46,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,281,2025-12-02T16:04:59.615593
31950485.0,pain relief in NRS at 60 minutes after the first dose in VRS,moderate,14,,n,,,,,,46,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,282,2025-12-02T16:04:59.615593
31950485.0,pain relief in NRS at 60 minutes after the first dose in VRS,slight,9,,n,,,,,,46,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,283,2025-12-02T16:04:59.615593
31950485.0,adverse effects,sedation,27,,n,,,,,,29,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,284,2025-12-02T16:04:59.615593
31950485.0,adverse effects,decreased contraction frequency,2,,n,,,,,,29,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,285,2025-12-02T16:04:59.615593
31950485.0,adverse effects,vomiting,1,,n,,,,,,29,maternal,labor,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,286,2025-12-02T16:04:59.615593
31950485.0,time from the last dose to the delivery,,11:38,h:min,median,,,minmax,03:24:00,40:4,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1284,2025-12-02T16:04:59.615593
31950485.0,pain intensity in NRS 0-10 ,at 30 minutes after the first oxycodone administration ,5,,median,,,minmax,0,9,50,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1285,2025-12-02T16:04:59.615593
31950485.0,pain intensity in NRS 0-10 ,at 60 minutes after the first oxycodone administration ,5,,median,,,minmax,0,10,52,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1286,2025-12-02T16:04:59.615593
31950485.0,pain intensity in NRS 0-10 ,at 120 minutes after the first oxycodone administration ,6,,median,,,minmax,0,10,51,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1287,2025-12-02T16:04:59.615593
31950485.0,%maxTOTPAR,,0.45,,median,,,minmax,-0.25,1,59,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1288,2025-12-02T16:04:59.615593
31950485.0,pain relief in NRS,,5,,median,,,minmax,0,19,61,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1289,2025-12-02T16:04:59.615593
31950485.0,Pain relief in VRS at 60 min after the first oxycodone administration ,complete,9,,,,,,,,46,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1290,2025-12-02T16:04:59.615593
31950485.0,Pain relief in VRS at 60 min after the first oxycodone administration ,good,14,,,,,,,,46,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1291,2025-12-02T16:04:59.615593
31950485.0,Pain relief in VRS at 60 min after the first oxycodone administration ,moderate,14,,,,,,,,46,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1292,2025-12-02T16:04:59.615593
31950485.0,Pain relief in VRS at 60 min after the first oxycodone administration ,slight,9,,,,,,,,46,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1293,2025-12-02T16:04:59.615593
31950485.0,Additional analgesia as labour progressed in to the active phase,epidural analgesia ,67,,,,,,,,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1294,2025-12-02T16:04:59.615593
31950485.0,Additional analgesia as labour progressed in to the active phase,inhaled nitrous oxide ,62,,,,,,,,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1295,2025-12-02T16:04:59.615593
31950485.0,Additional analgesia as labour progressed in to the active phase,pudendal or paracervical block ,22,,,,,,,,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1296,2025-12-02T16:04:59.615593
31950485.0,Additional analgesia as labour progressed in to the active phase,spinal analgesia ,3,,,,,,,,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1297,2025-12-02T16:04:59.615593
31950485.0,Additional analgesia as labour progressed in to the active phase,acetaminophen (paracetamol) ,1,,,,,,,,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1298,2025-12-02T16:04:59.615593
31950485.0,Number of patients had adverse events ,,29,,N,,,,,,76,,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1299,2025-12-02T16:04:59.615593
31950485.0,total number mild adverse effects,,30,,N,,,,,,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1300,2025-12-02T16:04:59.615593
31950485.0,type of adverse effects,sadation,27,,N,,,,,,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1301,2025-12-02T16:04:59.615593
31950485.0,type of adverse effects,decreased contraction frequency,2,,N,,,,,,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1302,2025-12-02T16:04:59.615593
31950485.0,type of adverse effects,vomiting,1,,N,,,,,,76,maternal,labour,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1303,2025-12-02T16:04:59.615593
31950485.0,Apgar score,at 1 min,9,,median,,,minmax,2,10,76,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1304,2025-12-02T16:04:59.615593
31950485.0,Apgar score,at 5 min,9,,median,,,minmax,6,10,76,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1305,2025-12-02T16:04:59.615593
31950485.0,NACS score,,38,,median,,,minmax,31,39,76,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1306,2025-12-02T16:04:59.615593
31950485.0,Requirement of follow-up and treatment in the neonatal intensive care unit,,5,,N,,,,,,76,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1307,2025-12-02T16:04:59.615593
31950485.0,Reason for follow-up and treatment in the neonatal intensive care unit,infection,2,,,,,,,,76,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1308,2025-12-02T16:04:59.615593
31950485.0,Reason for follow-up and treatment in the neonatal intensive care unit,premature birth,1,,,,,,,,76,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1309,2025-12-02T16:04:59.615593
31950485.0,Reason for follow-up and treatment in the neonatal intensive care unit,hypoglycaemia,1,,,,,,,,76,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1310,2025-12-02T16:04:59.615593
31950485.0,Reason for follow-up and treatment in the neonatal intensive care unit,breathing difficulty,1,,,,,,,,76,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1311,2025-12-02T16:04:59.615593
33180318.0,death,Apnoeic group,1,,n,,,,,,64,preterm neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,287,2025-12-02T16:04:59.615593
33180318.0,death,Apnoeic-free  group,0,,n,,,,,,48,preterm neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,288,2025-12-02T16:04:59.615593
33180318.0,BPD,Apnoeic group,23,,n,,,,,,64,preterm neonates,,,0.005,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,289,2025-12-02T16:04:59.615593
33180318.0,BPD,Apnoeic-free  group,6,,n,,,,,,48,preterm neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,290,2025-12-02T16:04:59.615593
33180318.0,Severe neurological injury,Apnoeic group,16,,n,,,,,,64,preterm neonates,,,0.099,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,291,2025-12-02T16:04:59.615593
33180318.0,Severe neurological injury,Apnoeic-free  group,6,,n,,,,,,48,preterm neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,292,2025-12-02T16:04:59.615593
33180318.0,Necrotizing enterocolitis,Apnoeic group,19,,n,,,,,,64,preterm neonates,,,0.111,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,293,2025-12-02T16:04:59.615593
33180318.0,Necrotizing enterocolitis,Apnoeic-free  group,8,,n,,,,,,48,preterm neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,294,2025-12-02T16:04:59.615593
33180318.0,retinopathy of prematurity,Apnoeic group,10,,n,,,,,,64,preterm neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,295,2025-12-02T16:04:59.615593
33180318.0,retinopathy of prematurity,Apnoeic-free  group,7,,,,,,,,48,preterm neonates,,,0.879,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,296,2025-12-02T16:04:59.615593
31101409.0,death,Site 1,0,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,297,2025-12-02T16:04:59.615593
31101409.0,BPD,Site 1,0.49,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,298,2025-12-02T16:04:59.615593
31101409.0,Medical NEC,Site 1,0.01,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,299,2025-12-02T16:04:59.615593
31101409.0,Surgical NEC,Site 1,0.04,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,300,2025-12-02T16:04:59.615593
31101409.0,SIP,Site 1,0.05,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,301,2025-12-02T16:04:59.615593
31101409.0,Grade II IVH,Site 1,0.07,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,302,2025-12-02T16:04:59.615593
31101409.0,Grade III or IV IVH,Site 1,0.17,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,303,2025-12-02T16:04:59.615593
31101409.0,PDA ligation,Site 1,0.14,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,304,2025-12-02T16:04:59.615593
31101409.0,Seizures,Site 1,0.02,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,305,2025-12-02T16:04:59.615593
31101409.0,Arrhythmia,Site 1,0,,,,,,,,100,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,306,2025-12-02T16:04:59.615593
31101409.0,death,Site 2,0.02,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,307,2025-12-02T16:04:59.615593
31101409.0,BPD,Site 2,0.27,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,308,2025-12-02T16:04:59.615593
31101409.0,Medical NEC,Site 2,0.08,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,309,2025-12-02T16:04:59.615593
31101409.0,Surgical NEC,Site 2,0.03,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,310,2025-12-02T16:04:59.615593
31101409.0,SIP,Site 2,0.07,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,311,2025-12-02T16:04:59.615593
31101409.0,Grade II IVH,Site 2,0.07,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,312,2025-12-02T16:04:59.615593
31101409.0,Grade III or IV IVH,Site 2,0.09,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,313,2025-12-02T16:04:59.615593
31101409.0,PDA ligation,Site 2,0.19,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,314,2025-12-02T16:04:59.615593
31101409.0,Seizures,Site 2,0.08,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,315,2025-12-02T16:04:59.615593
31101409.0,Arrhythmia,Site 2,0,,,,,,,,108,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,316,2025-12-02T16:04:59.615593
31101409.0,death,Site 3,0.04,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,317,2025-12-02T16:04:59.615593
31101409.0,BPD,Site 3,0.29,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,318,2025-12-02T16:04:59.615593
31101409.0,Medical NEC,Site 3,0.04,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,319,2025-12-02T16:04:59.615593
31101409.0,Surgical NEC,Site 3,0.08,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,320,2025-12-02T16:04:59.615593
31101409.0,SIP,Site 3,0.05,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,321,2025-12-02T16:04:59.615593
31101409.0,Grade II IVH,Site 3,0.08,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,322,2025-12-02T16:04:59.615593
31101409.0,Grade III or IV IVH,Site 3,0.14,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,323,2025-12-02T16:04:59.615593
31101409.0,PDA ligation,Site 3,0.08,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,324,2025-12-02T16:04:59.615593
31101409.0,Seizures,Site 3,0.02,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,325,2025-12-02T16:04:59.615593
31101409.0,Arrhythmia,Site 3,0,,,,,,,,107,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,326,2025-12-02T16:04:59.615593
31101409.0,death,Site 4,0.03,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,327,2025-12-02T16:04:59.615593
31101409.0,BPD,Site 4,0.4,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,328,2025-12-02T16:04:59.615593
31101409.0,Medical NEC,Site 4,0.05,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,329,2025-12-02T16:04:59.615593
31101409.0,Surgical NEC,Site 4,0.03,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,330,2025-12-02T16:04:59.615593
31101409.0,SIP,Site 4,0.02,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,331,2025-12-02T16:04:59.615593
31101409.0,Grade II IVH,Site 4,0.07,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,332,2025-12-02T16:04:59.615593
31101409.0,Grade III or IV IVH,Site 4,0.11,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,333,2025-12-02T16:04:59.615593
31101409.0,PDA ligation,Site 4,0.06,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,334,2025-12-02T16:04:59.615593
31101409.0,Seizures,Site 4,0,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,335,2025-12-02T16:04:59.615593
31101409.0,Arrhythmia,Site 4,0,,,,,,,,95,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,336,2025-12-02T16:04:59.615593
31101409.0,death,Total,0.02,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,337,2025-12-02T16:04:59.615593
31101409.0,BPD,Total,0.37,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,338,2025-12-02T16:04:59.615593
31101409.0,Medical NEC,Total,0.05,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,339,2025-12-02T16:04:59.615593
31101409.0,Surgical NEC,Total,0.04,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,340,2025-12-02T16:04:59.615593
31101409.0,SIP,Total,0.05,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,341,2025-12-02T16:04:59.615593
31101409.0,Grade II IVH,Total,0.07,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,342,2025-12-02T16:04:59.615593
31101409.0,Grade III or IV IVH,Total,0.13,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,343,2025-12-02T16:04:59.615593
31101409.0,PDA ligation,Total,0.12,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,344,2025-12-02T16:04:59.615593
31101409.0,Seizures,Total,0.03,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,345,2025-12-02T16:04:59.615593
31101409.0,Arrhythmia,Total,0,,,,,,,,410,premature infants,,,,on a day of caffeine exposure ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,346,2025-12-02T16:04:59.615593
35489632.0,LOS,Extended infusion,25,days,median,,,IQR,12,46,54,pediatric,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,347,2025-12-02T16:04:59.615593
35489632.0,LOS,Intermittent bolus,29,days,median,,,IQR,10,56,18,pediatric,,,0.94,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,348,2025-12-02T16:04:59.615593
35489632.0,30-day mortality rate,Extended infusion,2,,N,,,,,,54,pediatric,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,349,2025-12-02T16:04:59.615593
35489632.0,30-day mortality rate,Intermittent bolus,3,,N,,,,,,18,pediatric,,,0.1,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,350,2025-12-02T16:04:59.615593
33248975.0,Any adverse events,,9,,N,,,,,,10,maternal,delivery,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,351,2025-12-02T16:04:59.615593
33248975.0,Nuasea or vomiting,,8,,N,,,,,,10,maternal,delivery,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,352,2025-12-02T16:04:59.615593
33248975.0,Diarrhea,,0,,N,,,,,,10,maternal,delivery,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,353,2025-12-02T16:04:59.615593
33248975.0,Seizure,,0,,N,,,,,,10,maternal,delivery,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,354,2025-12-02T16:04:59.615593
33248975.0,Allergic reaction,,0,,N,,,,,,10,maternal,delivery,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,355,2025-12-02T16:04:59.615593
33248975.0,Maternal thrombosis,,0,,N,,,,,,10,maternal,delivery,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,356,2025-12-02T16:04:59.615593
33248975.0,Facial rash,,1,,N,,,,,,10,maternal,delivery,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,357,2025-12-02T16:04:59.615593
33248975.0,Itching,,0,,N,,,,,,10,maternal,delivery,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,358,2025-12-02T16:04:59.615593
33248975.0,Bradycardia,,0,,N,,,,,,10,maternal,delivery,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,359,2025-12-02T16:04:59.615593
33248975.0,Blood in neonate's stool,,0,,N,,,,,,10,neonates,,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,360,2025-12-02T16:04:59.615593
33248975.0,Neonatal thrombosis,,0,,N,,,,,,10,neonates,,,,Cohort 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,361,2025-12-02T16:04:59.615593
33248975.0,Any adverse events,,8,,N,,,,,,10,maternal,delivery,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,362,2025-12-02T16:04:59.615593
33248975.0,Nuasea or vomiting,,6,,N,,,,,,10,maternal,delivery,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,363,2025-12-02T16:04:59.615593
33248975.0,Diarrhea,,0,,N,,,,,,10,maternal,delivery,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,364,2025-12-02T16:04:59.615593
33248975.0,Seizure,,0,,N,,,,,,10,maternal,delivery,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,365,2025-12-02T16:04:59.615593
33248975.0,Allergic reaction,,0,,N,,,,,,10,maternal,delivery,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,366,2025-12-02T16:04:59.615593
33248975.0,Maternal thrombosis,,0,,N,,,,,,10,maternal,delivery,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,367,2025-12-02T16:04:59.615593
33248975.0,Facial rash,,0,,N,,,,,,10,maternal,delivery,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,368,2025-12-02T16:04:59.615593
33248975.0,Itching,,1,,N,,,,,,10,maternal,delivery,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,369,2025-12-02T16:04:59.615593
33248975.0,Bradycardia,,1,,N,,,,,,10,maternal,delivery,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,370,2025-12-02T16:04:59.615593
33248975.0,Blood in neonate's stool,,0,,N,,,,,,10,neonates,,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,371,2025-12-02T16:04:59.615593
33248975.0,Neonatal thrombosis,,0,,N,,,,,,10,neonates,,,,Cohort 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,372,2025-12-02T16:04:59.615593
33248975.0,Any adverse events,,6,,N,,,,,,10,maternal,delivery,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,373,2025-12-02T16:04:59.615593
33248975.0,Nuasea or vomiting,,4,,N,,,,,,10,maternal,delivery,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,374,2025-12-02T16:04:59.615593
33248975.0,Diarrhea,,0,,N,,,,,,10,maternal,delivery,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,375,2025-12-02T16:04:59.615593
33248975.0,Seizure,,0,,N,,,,,,10,maternal,delivery,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,376,2025-12-02T16:04:59.615593
33248975.0,Allergic reaction,,0,,N,,,,,,10,maternal,delivery,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,377,2025-12-02T16:04:59.615593
33248975.0,Maternal thrombosis,,0,,N,,,,,,10,maternal,delivery,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,378,2025-12-02T16:04:59.615593
33248975.0,Facial rash,,0,,N,,,,,,10,maternal,delivery,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,379,2025-12-02T16:04:59.615593
33248975.0,Itching,,0,,N,,,,,,10,maternal,delivery,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,380,2025-12-02T16:04:59.615593
33248975.0,Bradycardia,,0,,N,,,,,,10,maternal,delivery,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,381,2025-12-02T16:04:59.615593
33248975.0,Blood in neonate's stool,,1,,N,,,,,,10,neonates,,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,382,2025-12-02T16:04:59.615593
33248975.0,Neonatal thrombosis,,1,,N,,,,,,10,neonates,,,,Cohort 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,383,2025-12-02T16:04:59.615593
32620262.0,Blood loss,intraoperative,39.4,ml/kg,mean,SD,4.4,,,,34,children,,,0.909,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,384,2025-12-02T16:04:59.615593
32620262.0,Blood loss,postoperative surgical drain loss,16.5,ml/kg,mean,SD,1.4,,,,34,children,,,0.672,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,385,2025-12-02T16:04:59.615593
32620262.0,Blood loss,intraoperative,40.3,ml/kg,mean,SD,6.2,,,,32,children,,,0.909,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,386,2025-12-02T16:04:59.615593
32620262.0,Blood loss,postoperative surgical drain loss,15.6,ml/kg,mean,SD,1.6,,,,32,children,,,0.672,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,387,2025-12-02T16:04:59.615593
32620262.0,RBCs transfused,Intraoperative use of RBC,30,,N,,,,,,34,children,,,0.753,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,388,2025-12-02T16:04:59.615593
32620262.0,RBCs transfused,Intraoperative RBC transfused,21.3,ml/kg,mean,SD,1.6,,,,34,children,,,0.306,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,389,2025-12-02T16:04:59.615593
32620262.0,RBCs transfused,Total RBC transfused,23.3,ml/kg,mean,SD,1.9,,,,34,children,,,0.06,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,390,2025-12-02T16:04:59.615593
32620262.0,RBCs transfused,Intraoperative use of RBC,29,,N,,,,,,32,children,,,0.753,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,391,2025-12-02T16:04:59.615593
32620262.0,RBCs transfused,Intraoperative RBC transfused,23.6,ml/kg,mean,SD,1.5,,,,32,children,,,0.306,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,392,2025-12-02T16:04:59.615593
32620262.0,RBCs transfused,Total RBC transfused,29.9,ml/kg,mean,SD,2.9,,,,32,children,,,0.06,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,393,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Total cryopercipitate,0.1,ml/kg,mean,SD,0.1,,,,34,children,,,0.319,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,394,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Use of cryoprecipitate (no. of patients),1,,N,,,,,,34,children,,,0.608,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,395,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Total frsh frozen plasma,0.7,ml/kg,mean,SD,0.5,,,,34,children,,,0.859,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,396,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Use of fresh frozen plasma (no. of patients),2,,N,,,,,,34,children,,,0.591,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,397,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Total use of platelets,0,,N,,,,,,32,children,,,0.999,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,398,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Total cryopercipitate,0.6,ml/kg,mean,SD,0.5,,,,32,children,,,0.319,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,399,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Use of cryoprecipitate (no. of patients),2,,N,,,,,,32,children,,,0.608,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,400,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Total frsh frozen plasma,0.9,ml/kg,mean,SD,0.8,,,,32,children,,,0.859,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,401,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Use of fresh frozen plasma (no. of patients),1,,N,,,,,,32,children,,,0.591,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,402,2025-12-02T16:04:59.615593
32620262.0,Yellow blood products transfused,Total use of platelets,3,,N,,,,,,32,children,,,0.999,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,403,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Total crystalloid,44.1,mg/kg,mean,SD,4.9,,,,34,children,,,0.796,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,404,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Total albumin 5%,15.4,mg/kg,mean,SD,2.5,,,,34,children,,,0.29,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,405,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Use of albumin,15,,N,,,,,,34,children,,,0.027,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,406,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Use of albumin (BCH),13,,N,,,,,,34,children,,,0.48,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,407,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Use of albumin (GCH),9,,N,,,,,,34,children,,,0.176,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,408,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Total crystalloid,45.7,mg/kg,mean,SD,3.2,,,,32,children,,,0.796,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,409,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Total albumin 5%,19.7,mg/kg,mean,SD,3.1,,,,32,children,,,0.29,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,410,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Use of albumin,23,,N,,,,,,32,children,,,0.027,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,411,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Use of albumin (BCH),11,,N,,,,,,32,children,,,0.48,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,412,2025-12-02T16:04:59.615593
32620262.0,Intrauperative fluids,Use of albumin (GCH),4,,N,,,,,,32,children,,,0.176,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,413,2025-12-02T16:04:59.615593
32620262.0,Length of stay,ICU,1.9,days,median,,,IQR,1,3.1,34,children,,,0.928,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,414,2025-12-02T16:04:59.615593
32620262.0,Length of stay,In hospital,8,days,median,,,IQR,4,13,34,children,,,0.205,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,415,2025-12-02T16:04:59.615593
32620262.0,Length of stay,ICU,1.4,days,median,,,IQR,1,3.4,32,children,,,0.928,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,416,2025-12-02T16:04:59.615593
32620262.0,Length of stay,In hospital,10,days,median,,,IQR,5,15,32,children,,,0.205,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,417,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,Haemoglobin,10.4,%,mean,SD,0.3,,,,34,children,,,0.238,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,418,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,Haematocrit,32.2,,mean,SD,0.7,,,,34,children,,,0.168,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,419,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,Platelets,367,10^3 cell/ug/L,mean,SD,49.0,,,,34,children,,,0.537,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,420,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,PT (s): BCH,13.3,s,mean,SD,0.3,,,,34,children,,,0.937,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,421,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,PT (s): GCH,78.1,s,mean,SD,3.1,,,,34,children,,,0.659,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,422,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,PTT,30.5,s,mean,SD,0.5,,,,34,children,,,0.359,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,423,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,INR,1.1,,mean,SD,0.02,,,,34,children,,,0.879,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,424,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,Fibrinogen,184.8,,mean,SD,7.7,,,,34,children,,,0.131,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,425,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,Haemoglobin,10,%,mean,SD,0.2,,,,32,children,,,0.238,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,426,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,Haematocrit,31,,mean,SD,0.5,,,,32,children,,,0.168,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,427,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,Platelets,415,10^3 cell/ug/L,mean,SD,46.0,,,,32,children,,,0.537,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,428,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,PT (s): BCH,13.3,s,mean,SD,0.4,,,,32,children,,,0.937,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,429,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,PT (s): GCH,76.6,s,mean,SD,1.8,,,,32,children,,,0.659,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,430,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,PTT,32.3,s,mean,SD,1.9,,,,32,children,,,0.359,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,431,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,INR,1.1,,mean,SD,0.02,,,,32,children,,,0.879,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,432,2025-12-02T16:04:59.615593
32620262.0,Intraoperative,Fibrinogen,202.7,,mean,SD,8.7,,,,32,children,,,0.131,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,433,2025-12-02T16:04:59.615593
32620262.0,POD 1,Haemoglobin,10.8,%,mean,SD,0.4,,,,34,children,,,0.218,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,434,2025-12-02T16:04:59.615593
32620262.0,POD 1,Haematocrit,31.3,,mean,SD,1.1,,,,34,children,,,0.185,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,435,2025-12-02T16:04:59.615593
32620262.0,POD 1,Platelets,241,10^3 cell/ug/L,mean,SD,20.0,,,,34,children,,,0.526,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,436,2025-12-02T16:04:59.615593
32620262.0,POD 1,PT (s): BCH,15.1,s,mean,SD,0.4,,,,34,children,,,0.833,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,437,2025-12-02T16:04:59.615593
32620262.0,POD 1,PT (s): GCH,69.5,s,mean,SD,4.1,,,,34,children,,,0.578,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,438,2025-12-02T16:04:59.615593
32620262.0,POD 1,PTT,29.6,s,mean,SD,1.3,,,,34,children,,,0.328,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,439,2025-12-02T16:04:59.615593
32620262.0,POD 1,INR,1.2,,mean,SD,0.04,,,,34,children,,,0.216,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,440,2025-12-02T16:04:59.615593
32620262.0,POD 1,Fibrinogen,297.3,,mean,SD,23.7,,,,34,children,,,0.081,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,441,2025-12-02T16:04:59.615593
32620262.0,POD 1,Haemoglobin,10.1,%,mean,SD,0.3,,,,32,children,,,0.218,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,442,2025-12-02T16:04:59.615593
32620262.0,POD 1,Haematocrit,29.4,,mean,SD,0.9,,,,32,children,,,0.185,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,443,2025-12-02T16:04:59.615593
32620262.0,POD 1,Platelets,224,10^3 cell/ug/L,mean,SD,17.0,,,,32,children,,,0.526,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,444,2025-12-02T16:04:59.615593
32620262.0,POD 1,PT (s): BCH,15.3,s,mean,SD,0.5,,,,32,children,,,0.833,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,445,2025-12-02T16:04:59.615593
32620262.0,POD 1,PT (s): GCH,66.8,s,mean,SD,2.4,,,,32,children,,,0.578,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,446,2025-12-02T16:04:59.615593
32620262.0,POD 1,PTT,36.2,s,mean,SD,5.8,,,,32,children,,,0.328,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,447,2025-12-02T16:04:59.615593
32620262.0,POD 1,INR,1.3,,mean,SD,0.03,,,,32,children,,,0.216,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,448,2025-12-02T16:04:59.615593
32620262.0,POD 1,Fibrinogen,249.1,,mean,SD,13.9,,,,32,children,,,0.081,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,449,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),Haemoglobin,-1.3,%,mean,SD,0.5,,,,34,children,,,0.281,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,450,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),Haematocrit,-4.4,,mean,SD,1.4,,,,34,children,,,0.481,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,451,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),Platelets,-157,10^3 cell/ug/L,mean,SD,23.0,,,,34,children,,,0.897,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,452,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),PT (s): BCH,2.4,s,mean,SD,0.2,,,,34,children,,,0.889,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,453,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),PT (s): GCH,-19.3,s,mean,SD,3.4,,,,34,children,,,0.63,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,454,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),PTT,0.7,s,mean,SD,1.2,,,,34,children,,,0.377,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,455,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),INR,0.18,,mean,SD,0.04,,,,34,children,,,0.639,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,456,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),Fibrinogen,98.2,,mean,SD,30.5,,,,34,children,,,0.027,Low-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,457,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),Haemoglobin,-4.2,%,mean,SD,2.6,,,,32,children,,,0.281,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,458,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),Haematocrit,-5.6,,mean,SD,0.9,,,,32,children,,,0.481,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,459,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),Platelets,-153,10^3 cell/ug/L,mean,SD,16.0,,,,32,children,,,0.897,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,460,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),PT (s): BCH,2.4,s,mean,SD,0.3,,,,32,children,,,0.889,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,461,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),PT (s): GCH,-22.1,s,mean,SD,4.8,,,,32,children,,,0.63,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,462,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),PTT,6.7,s,mean,SD,6.0,,,,32,children,,,0.377,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,463,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),INR,0.21,,mean,SD,0.04,,,,32,children,,,0.639,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,464,2025-12-02T16:04:59.615593
32620262.0,Delta (preoperative to POD 1),Fibrinogen,46.7,,mean,SD,24.8,,,,32,children,,,0.027,High-dose scheme,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,465,2025-12-02T16:04:59.615593
35679896.0,EBL or QBL,,1500,ml,median,,,IQR,898.5,2076,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,466,2025-12-02T16:04:59.615593
35679896.0,Change in hemoglobin,,2.45,g/dL,median,,,IQR,1.4,3.5,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,467,2025-12-02T16:04:59.615593
35679896.0,Hysterectomy,,11,,N,,,,,,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,468,2025-12-02T16:04:59.615593
35679896.0,Crystalloid volume infused,,2100,mL,median,,,IQR,1500,2500,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,469,2025-12-02T16:04:59.615593
35679896.0,Blood transfusion,,9,,N,,,,,,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,470,2025-12-02T16:04:59.615593
35679896.0,Blood Transfused > 2 units,,4,,N,,,,,,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,471,2025-12-02T16:04:59.615593
35679896.0,Arterial line placed,,12,,N,,,,,,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,472,2025-12-02T16:04:59.615593
35679896.0,Anesthesia type,CSE,12,,N,,,,,,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,473,2025-12-02T16:04:59.615593
35679896.0,Anesthesia type,Epidural,3,,N,,,,,,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,474,2025-12-02T16:04:59.615593
35679896.0,Anesthesia type,Spinal,5,,N,,,,,,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,475,2025-12-02T16:04:59.615593
35679896.0,Anesthesia type,GA conversion,2,,N,,,,,,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,476,2025-12-02T16:04:59.615593
35679896.0,Serious adverse events,,0,,N,,,,,,20,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,477,2025-12-02T16:04:59.615593
31623213.0,Hb,,8.1,g/dL,mean,SD,0.7,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,478,2025-12-02T16:04:59.615593
31623213.0,Hb,,7.8,g/dL,median,,,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,479,2025-12-02T16:04:59.615593
31623213.0,MCV,post-HU,90.2,fL,mean,SD,12.5,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,480,2025-12-02T16:04:59.615593
31623213.0,MCV,post-HU,94.9,fL,median,,,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,481,2025-12-02T16:04:59.615593
31623213.0,Retic,,224.3,G/L,mean,SD,61.5,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,482,2025-12-02T16:04:59.615593
31623213.0,Retic,,192.7,G/L,median,,,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,483,2025-12-02T16:04:59.615593
31623213.0,PNN,,7.5,G/L,mean,SD,3.6,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,484,2025-12-02T16:04:59.615593
31623213.0,PNN,,6,G/L,median,,,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,485,2025-12-02T16:04:59.615593
31623213.0,Platelets,,354,G/L,mean,SD,163.0,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,486,2025-12-02T16:04:59.615593
31623213.0,Platelets,,290,G/L,median,,,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,487,2025-12-02T16:04:59.615593
31623213.0,HbF,post-HU,10.1,%,mean,SD,7.8,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,488,2025-12-02T16:04:59.615593
31623213.0,HbF,post-HU,7.4,%,median,,,,,,9,children,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,489,2025-12-02T16:04:59.615593
33029796.0,platelet count,,554,K/uL,median,,,IQR,530,615,11,pediatric,,,0.001,PK1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,490,2025-12-02T16:04:59.615593
33029796.0,platelet count,,669,K/uL,median,,,IQR,609,941,9,pediatric,,,0.001,PK2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,491,2025-12-02T16:04:59.615593
33029796.0,GFR,,143,ml/min/1.73m2,median,,,IQR,121,173,11,pediatric,,,0.99,PK1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,492,2025-12-02T16:04:59.615593
33029796.0,GFR,,145,ml/min/1.73m2,median,,,IQR,135,163,9,pediatric,,,0.99,PK2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,493,2025-12-02T16:04:59.615593
33029796.0,AST,,73,U/L,median,,,IQR,42,109,11,pediatric,,,0.31,PK1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,494,2025-12-02T16:04:59.615593
33029796.0,AST,,30,U/L,median,,,IQR,24,41,9,pediatric,,,0.31,PK2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,495,2025-12-02T16:04:59.615593
33029796.0,ALT,,53,U/L,median,,,IQR,38,90,11,pediatric,,,0.03,PK1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,496,2025-12-02T16:04:59.615593
33029796.0,ALT,,26,U/L,median,,,IQR,24,45,9,pediatric,,,0.03,PK2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,497,2025-12-02T16:04:59.615593
33029796.0,ALP,,125,U/L,median,,,IQR,84,154,11,pediatric,,,0.06,PK1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,498,2025-12-02T16:04:59.615593
33029796.0,ALP,,145,U/L,median,,,IQR,91,239,9,pediatric,,,0.06,PK2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,499,2025-12-02T16:04:59.615593
33029796.0,Total bilirubin,,0.4,g/dL,median,,,IQR,0.3,0.5,11,pediatric,,,0.5,PK1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,500,2025-12-02T16:04:59.615593
33029796.0,Total bilirubin,,0.35,g/dL,median,,,IQR,0.2,0.6,9,pediatric,,,0.5,PK2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,501,2025-12-02T16:04:59.615593
32006953.0,RSS ,24 h after first dose,2.7,,mean,SD,1.5,,,,8,infants,,,p = 0.03 vs. predosing.,0.025 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,502,2025-12-02T16:04:59.615593
32006953.0,RSS ,48 h after first dose,3.1,,mean,SD,2.1,,,,8,infants,,,,0.025 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,503,2025-12-02T16:04:59.615593
32006953.0,RSS ,24 h after first dose,3.6,,mean,SD,1.4,,,,8,infants,,,,0.05 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,504,2025-12-02T16:04:59.615593
32006953.0,RSS ,48 h after first dose,3,,mean,SD,1.9,,,,8,infants,,,,0.05 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,505,2025-12-02T16:04:59.615593
32006953.0,RSS ,24 h after first dose,2.5,,mean,SD,1.4,,,,8,infants,,,,0.1 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,506,2025-12-02T16:04:59.615593
32006953.0,RSS ,48 h after first dose,2.7,,mean,SD,1.4,,,,8,infants,,,,0.1 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,507,2025-12-02T16:04:59.615593
32006953.0,RSS ,24 h after first dose,2.9,,mean,SD,1.5,,,,24,infants,,,p = 0.006 vs. predosing.,All SASSIE patients,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,508,2025-12-02T16:04:59.615593
32006953.0,RSS ,48 h after first dose,2.9,,mean,SD,1.8,,,,24,infants,,,,All SASSIE patients,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,509,2025-12-02T16:04:59.615593
32006953.0,Death at <28 days,,0,,N,,,,,,8,infants,,,,0.025 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,510,2025-12-02T16:04:59.615593
32006953.0,Death at <28 days,,0,,N,,,,,,8,infants,,,,0.05 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,511,2025-12-02T16:04:59.615593
32006953.0,Death at <28 days,,3,,N,,,,,,8,infants,,,,0.1 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,512,2025-12-02T16:04:59.615593
32006953.0,Death at <28 days,,3,,N,,,,,,24,infants,,,,All SASSIE patients,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,513,2025-12-02T16:04:59.615593
32006953.0,Respiratory support at 28 days,,100,%,N,,,,,,8,infants,,,,0.025 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,514,2025-12-02T16:04:59.615593
32006953.0,Respiratory support at 28 days,,100,%,N,,,,,,8,infants,,,,0.05 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,515,2025-12-02T16:04:59.615593
32006953.0,Respiratory support at 28 days,,100,%,N,,,,,,8,infants,,,,0.1 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,516,2025-12-02T16:04:59.615593
32006953.0,Respiratory support at 28 days,,100,%,N,,,,,,24,infants,,,,All SASSIE patients,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,517,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 36 weeks,,38,%,N,,,,,,8,infants,,,,0.025 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,518,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 36 weeks,,0,%,N,,,,,,8,infants,,,,0.05 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,519,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 36 weeks,,13,%,N,,,,,,8,infants,,,,0.1 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,520,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 36 weeks,,17,%,N,,,,,,24,infants,,,,Alll SASSIE patients,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,521,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 40 weeks,,63,%,N,,,,,,8,infants,,,,0.025 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,522,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 40 weeks,,13,%,N,,,,,,8,infants,,,,0.05 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,523,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 40 weeks,,13,%,N,,,,,,8,infants,,,,0.1 mg/kg group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,524,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 40 weeks,,29,%,N,,,,,,24,infants,,,,All SASSIE patients,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,525,2025-12-02T16:04:59.615593
32006953.0,RSS ,24 h after first dose,3.8,,mean,SD,1.8,,,,48,infants,,,,TOLSURF controls,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,526,2025-12-02T16:04:59.615593
32006953.0,Death at <28 days,,2,,N,,,,,,48,infants,,,,TOLSURF controls,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,527,2025-12-02T16:04:59.615593
32006953.0,Respiratory support at 28 days,,100,%,N,,,,,,48,infants,,,,TOLSURF controls,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,528,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 36 weeks,,31,%,N,,,,,,48,infants,,,,TOLSURF controls,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,529,2025-12-02T16:04:59.615593
32006953.0,Survival without BPD at 40 weeks,,60,%,N,,,,,,48,infants,,,,TOLSURF controls,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,530,2025-12-02T16:04:59.615593
31561960.0,Total adverse events,,87,,N,,,,,,34,children,,,,all dose levels,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,531,2025-12-02T16:04:59.615593
31561960.0,Total adverse events,,11,,N,,,,,,6,children,,,,Dose 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,532,2025-12-02T16:04:59.615593
31561960.0,Total adverse events,,14,,N,,,,,,7,children,,,,Dose 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,533,2025-12-02T16:04:59.615593
31561960.0,Total adverse events,,6,,N,,,,,,3,children,,,,Dose 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,534,2025-12-02T16:04:59.615593
31561960.0,Total adverse events,,56,,N,,,,,,18,children,,,,Dose 4,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,535,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 1 adverse event,24,,N,,,,,,34,children,,,0.754,all dose levels,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,536,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 1 adverse event,4,,N,,,,,,6,children,,,0.754,Dose 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,537,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 1 adverse event,4,,N,,,,,,7,children,,,0.754,Dose 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,538,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 1 adverse event,2,,N,,,,,,3,children,,,0.754,Dose 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,539,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 1 adverse event,14,,N,,,,,,18,children,,,0.754,Dose 4,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,540,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 2 adverse event,20,,N,,,,,,34,children,,,0.263,all dose levels,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,541,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 2 adverse event,2,,N,,,,,,6,children,,,0.263,Dose 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,542,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 2 adverse event,3,,N,,,,,,7,children,,,0.263,Dose 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,543,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 2 adverse event,2,,N,,,,,,3,children,,,0.263,Dose 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,544,2025-12-02T16:04:59.615593
31561960.0,Subjects who experienced,>= 2 adverse event,13,,N,,,,,,18,children,,,0.263,Dose 4,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,545,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,probably related to study drug,3,,N,,,,,,34,children,,,>0.99,all dose levels,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,546,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,probably related to study drug,0,,N,,,,,,6,children,,,>0.99,Dose 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,547,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,probably related to study drug,1,,N,,,,,,7,children,,,>0.99,Dose 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,548,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,probably related to study drug,0,,N,,,,,,3,children,,,>0.99,Dose 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,549,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,probably related to study drug,2,,N,,,,,,18,children,,,>0.99,Dose 4,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,550,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,possibly related to study drug,6,,N,,,,,,34,children,,,0.16,all dose levels,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,551,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,possibly related to study drug,0,,N,,,,,,6,children,,,0.16,Dose 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,552,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,possibly related to study drug,0,,N,,,,,,7,children,,,0.16,Dose 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,553,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,possibly related to study drug,0,,N,,,,,,3,children,,,0.16,Dose 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,554,2025-12-02T16:04:59.615593
31561960.0,AE study drug relationship,possibly related to study drug,6,,N,,,,,,18,children,,,0.16,Dose 4,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,555,2025-12-02T16:04:59.615593
31561960.0,Serious adverse events,,4,,N,,,,,,34,children,,,,all dose levels,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,556,2025-12-02T16:04:59.615593
31561960.0,Serious adverse events,,0,,N,,,,,,6,children,,,,Dose 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,557,2025-12-02T16:04:59.615593
31561960.0,Serious adverse events,,0,,N,,,,,,7,children,,,,Dose 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,558,2025-12-02T16:04:59.615593
31561960.0,Serious adverse events,,1,,N,,,,,,3,children,,,,Dose 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,559,2025-12-02T16:04:59.615593
31561960.0,Serious adverse events,,3,,N,,,,,,18,children,,,,Dose 4,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,560,2025-12-02T16:04:59.615593
31561960.0,Number of subjects who experienced SAE,,4,,N,,,,,,34,children,,,0.369,all dose levels,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,561,2025-12-02T16:04:59.615593
31561960.0,Number of subjects who experienced SAE,,0,,N,,,,,,6,children,,,0.369,Dose 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,562,2025-12-02T16:04:59.615593
31561960.0,Number of subjects who experienced SAE,,0,,N,,,,,,7,children,,,0.369,Dose 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,563,2025-12-02T16:04:59.615593
31561960.0,Number of subjects who experienced SAE,,1,,N,,,,,,3,children,,,0.369,Dose 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,564,2025-12-02T16:04:59.615593
31561960.0,Number of subjects who experienced SAE,,3,,N,,,,,,18,children,,,0.369,Dose 4,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,565,2025-12-02T16:04:59.615593
31561960.0,Recrudescent fever,,2,,N,,,,,,34,children,,,,all dose levels,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,566,2025-12-02T16:04:59.615593
31561960.0,Recrudescent fever,,0,,N,,,,,,6,children,,,,Dose 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,567,2025-12-02T16:04:59.615593
31561960.0,Recrudescent fever,,0,,N,,,,,,7,children,,,,Dose 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,568,2025-12-02T16:04:59.615593
31561960.0,Recrudescent fever,,1,,N,,,,,,3,children,,,,Dose 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,569,2025-12-02T16:04:59.615593
31561960.0,Recrudescent fever,,1,,N,,,,,,18,children,,,,Dose 4,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,570,2025-12-02T16:04:59.615593
31561960.0,Worsening CAA,,2,,N,,,,,,34,children,,,,all dose levels,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,571,2025-12-02T16:04:59.615593
31561960.0,Worsening CAA,,0,,N,,,,,,6,children,,,,Dose 1,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,572,2025-12-02T16:04:59.615593
31561960.0,Worsening CAA,,0,,N,,,,,,7,children,,,,Dose 2,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,573,2025-12-02T16:04:59.615593
31561960.0,Worsening CAA,,0,,N,,,,,,3,children,,,,Dose 3,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,574,2025-12-02T16:04:59.615593
31561960.0,Worsening CAA,,2,,N,,,,,,18,children,,,,Dose 4,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,575,2025-12-02T16:04:59.615593
34033812.0,Developed preeclampsia,,0.5,,,,,,,,10,maternal,,,,in the placebo group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,576,2025-12-02T16:04:59.615593
34033812.0,Developed preeclampsia,,0.2,,,,,,,,10,maternal,,,,pravastation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,577,2025-12-02T16:04:59.615593
34033812.0,preterm deliveries,,0.6,,,,,,,,10,maternal,,,,in the placebo group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,578,2025-12-02T16:04:59.615593
34033812.0,preterm deliveries,,0.3,,,,,,,,10,maternal,,,,pravastation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,579,2025-12-02T16:04:59.615593
34029707.0,rates of antibiotic escalation,,9/45,,,,,,,,45,children,,,0.79,Extended infusion ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,580,2025-12-02T16:04:59.615593
34029707.0,rates of antibiotic escalation,,8/45,,,,,,,,45,children,,,0.79,Intermittent bolus  ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,581,2025-12-02T16:04:59.615593
34029707.0,addition of aminoglycosides,,1/9,,,,,,,,45,children,,,,Extended infusion ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,582,2025-12-02T16:04:59.615593
34029707.0,addition of aminoglycosides,,0/8,,,,,,,,45,children,,,,Intermittent bolus  ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,583,2025-12-02T16:04:59.615593
34029707.0,bbeing switched to carbapenem,,8/9,,,,,,,,45,children,,,,Extended infusion ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,584,2025-12-02T16:04:59.615593
34029707.0,bbeing switched to carbapenem,,8/8,,,,,,,,45,children,,,,Intermittent bolus  ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,585,2025-12-02T16:04:59.615593
34029707.0,Lack of clinical improvement,,7/9,,,,,,,,45,children,,,,Extended infusion ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,586,2025-12-02T16:04:59.615593
34029707.0,Lack of clinical improvement,,7/8,,,,,,,,45,children,,,,Intermittent bolus  ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,587,2025-12-02T16:04:59.615593
34029707.0,LOS,,11,days,median,,,IQR,6,27,45,children,,,,Extended infusion ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,588,2025-12-02T16:04:59.615593
34029707.0,LOS,,13,days,median,,,IQR,7,25,45,children,,,,Intermittent bolus  ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,589,2025-12-02T16:04:59.615593
34029707.0,Thirty-day status,discharged,35,,,,,,,,45,children,,,0.6,Extended infusion ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,590,2025-12-02T16:04:59.615593
34029707.0,Thirty-day status,discharged,37,,,,,,,,45,children,,,0.6,Intermittent bolus  ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,591,2025-12-02T16:04:59.615593
34029707.0,Thirty-day status,Ongoing admission,10,,,,,,,,45,children,,,0.6,Extended infusion ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,592,2025-12-02T16:04:59.615593
34029707.0,Thirty-day status,Ongoing admission,8,,,,,,,,45,children,,,0.6,Intermittent bolus  ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,593,2025-12-02T16:04:59.615593
34029707.0,LOS of patients diagnosed with sepsis or febrile neutropenis,,9,days,median,,,IQR,5,22,45,children,,,0.12,Extended infusion ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,594,2025-12-02T16:04:59.615593
34029707.0,LOS of patients diagnosed with sepsis or febrile neutropenis,,19,days,median,,,IQR,10,25,45,children,,,0.12,Intermittent bolus  ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,595,2025-12-02T16:04:59.615593
34029707.0,LOS of patients diagnosed with pneumonia,,25,days,median,,,IQR,7,30,45,children,,,0.09,Extended infusion ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,596,2025-12-02T16:04:59.615593
34029707.0,LOS of patients diagnosed with pneumonia,,11,days,median,,,IQR,7,21,45,children,,,0.09,Intermittent bolus  ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,597,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,2,,N,,,,,,85,adolescents,,,,placebo,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,598,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,7,,N,,,,,,85,adolescents,,,,placebo,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,599,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-23.6,,LS mean,SD,5.5,,,,85,adolescents,,,,placebo,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,600,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-19,,LS mean,SD,4.1,,,,85,adolescents,,,,placebo,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,601,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,21,,N,,,,,,85,adolescents,,,,placebo,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,602,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),17,,N,,,,,,85,adolescents,,,,placebo,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,603,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,4,,N,,,,,,85,adolescents,,,,placebo,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,604,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,3,,N,,,,,,85,adolescents,,,,placebo,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,605,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,7,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,606,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,18,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,607,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-68.5,,LS mean,SD,6.5,,,,42,adolescents,,,,Dupilumab 300 mg q4w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,608,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-47.7,,LS mean,SD,5.2,,,,42,adolescents,,,,Dupilumab 300 mg q4w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,609,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,7,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,610,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),5,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,611,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,7,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,612,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,3,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,613,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,13,,N,,,,,,43,adolescents,,,,Dupilumab 200 mg q2w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,614,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,20,,N,,,,,,43,adolescents,,,,Dupilumab 200 mg q2w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,615,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-67.8,,LS mean,SD,6.0,,,,43,adolescents,,,,Dupilumab 200 mg q2w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,616,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-48,,LS mean,SD,4.9,,,,43,adolescents,,,,Dupilumab 200 mg q2w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,617,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,10,,N,,,,,,43,adolescents,,,,Dupilumab 200 mg q2w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,618,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),7,,N,,,,,,43,adolescents,,,,Dupilumab 200 mg q2w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,619,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,5,,N,,,,,,43,adolescents,,,,Dupilumab 200 mg q2w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,620,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,3,,N,,,,,,43,adolescents,,,,Dupilumab 200 mg q2w (< 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,621,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,7,,N,,,,,,39,adolescents,,,,Dupilumab 200 mg q2w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,622,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,14,,N,,,,,,39,adolescents,,,,Dupilumab 200 mg q2w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,623,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-63.7,,LS mean,SD,5.4,,,,39,adolescents,,,,Dupilumab 200 mg q2w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,624,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-48,,LS mean,SD,4.8,,,,39,adolescents,,,,Dupilumab 200 mg q2w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,625,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,5,,N,,,,,,39,adolescents,,,,Dupilumab 200 mg q2w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,626,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),2,,N,,,,,,39,adolescents,,,,Dupilumab 200 mg q2w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,627,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,3,,N,,,,,,39,adolescents,,,,Dupilumab 200 mg q2w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,628,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,4,,N,,,,,,39,adolescents,,,,Dupilumab 200 mg q2w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,629,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,8,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,630,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,14,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,631,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-60.6,,LS mean,SD,6.0,,,,42,adolescents,,,,Dupilumab 300 mg q4w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,632,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-43.5,,LS mean,SD,5.1,,,,42,adolescents,,,,Dupilumab 300 mg q4w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,633,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,8,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,634,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),6,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,635,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,3,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,636,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,2,,N,,,,,,42,adolescents,,,,Dupilumab 300 mg q4w (>= 60 kg),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,637,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,14,,N,,,,,,123,children ,,,,Placebo + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,638,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,33,,N,,,,,,123,children ,,,,Placebo + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,639,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-48.6,,LS mean,SD,2.5,,,,123,children ,,,,Placebo + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,640,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-25.9,,LS mean,SD,2.9,,,,123,children ,,,,Placebo + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,641,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,17,,N,,,,,,123,children ,,,,Placebo + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,642,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),16,,N,,,,,,123,children ,,,,Placebo + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,643,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,5,,N,,,,,,123,children ,,,,Placebo + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,644,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,7,,N,,,,,,123,children ,,,,Placebo + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,645,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,13,,N,,,,,,63,children ,,,,Dupilumab 100 mg q2w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,646,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,38,,N,,,,,,63,children ,,,,Dupilumab 100 mg q2w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,647,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-76.7,,LS mean,SD,3.04,,,,63,children ,,,,Dupilumab 100 mg q2w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,648,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-56.1,,LS mean,SD,3.1,,,,63,children ,,,,Dupilumab 100 mg q2w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,649,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,8,,N,,,,,,63,children ,,,,Dupilumab 100 mg q2w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,650,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),5,,N,,,,,,63,children ,,,,Dupilumab 100 mg q2w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,651,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,13,,N,,,,,,63,children ,,,,Dupilumab 100 mg q2w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,652,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,5,,N,,,,,,63,children ,,,,Dupilumab 100 mg q2w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,653,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,18,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,654,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,46,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,655,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-84.3,,LS mean,SD,3.08,,,,61,children ,,,,Dupilumab 300 mg q4w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,656,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-55.1,,LS mean,SD,3.9,,,,61,children ,,,,Dupilumab 300 mg q4w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,657,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,4,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,658,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),4,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,659,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,4,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,660,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,6,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (< 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,661,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,23,,N,,,,,,59,children ,,,,Dupilumab 200 mg q2w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,662,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,44,,N,,,,,,59,children ,,,,Dupilumab 200 mg q2w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,663,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-80.4,,LS mean,SD,3.6,,,,59,children ,,,,Dupilumab 200 mg q2w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,664,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-58.2,,LS mean,SD,4.0,,,,59,children ,,,,Dupilumab 200 mg q2w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,665,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,2,,N,,,,,,59,children ,,,,Dupilumab 200 mg q2w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,666,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),5,,N,,,,,,59,children ,,,,Dupilumab 200 mg q2w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,667,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,5,,N,,,,,,59,children ,,,,Dupilumab 200 mg q2w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,668,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,8,,N,,,,,,59,children ,,,,Dupilumab 200 mg q2w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,669,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,proportion of patients with IGA 0 or 1 at week 16,22,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,670,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,Proportion of patients with EASI-75 at week 16,39,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,671,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in EASI,-79.9,,LS mean,SD,3.6,,,,61,children ,,,,Dupilumab 300 mg q4w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,672,2025-12-02T16:04:59.615593
34270797.0,Efficacy outcomes,LS mean percentage change from baseline to week 16 in Peak Pruritus NRS,-54.3,,LS mean,SD,4.2,,,,61,children ,,,,Dupilumab 300 mg q4w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,673,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Dermatitis atopic,4,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,674,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Skin infections (adjusted),3,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,675,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Conjunctivitis,4,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,676,2025-12-02T16:04:59.615593
34270797.0,Safety outcomes,Injection-site reactions,6,,N,,,,,,61,children ,,,,Dupilumab 300 mg q4w (>= 30 kg) + TCS,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,677,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs,18,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,678,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs,23,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,679,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs,47,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,680,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs,47,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,681,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs,136,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,682,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs,139,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,683,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs,353,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,684,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs,458,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,685,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,686,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,687,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs,3,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,688,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,689,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs,2,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,690,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs,5,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,691,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs,5,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,692,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs,16,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,693,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs related to treatment,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,694,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs related to treatment,1,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,695,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs related to treatment,4,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,696,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs related to treatment,4,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,697,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs related to treatment,14,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,698,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs related to treatment,2,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,699,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs related to treatment,36,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,700,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs related to treatment,7,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,701,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs related to treatment,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,702,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs related to treatment,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,703,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs related to treatment,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,704,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs related to treatment,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,705,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs related to treatment,0,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,706,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs related to treatment,0,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,707,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs related to treatment,0,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,708,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total serious TEAEs related to treatment,0,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,709,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs resulting in permanent study drug discontinuation,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,710,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs resulting in permanent study drug discontinuation,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,711,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs resulting in permanent study drug discontinuation,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,712,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs resulting in permanent study drug discontinuation,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,713,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs resulting in permanent study drug discontinuation,0,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,714,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs resulting in permanent study drug discontinuation,0,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,715,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs resulting in permanent study drug discontinuation,0,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,716,2025-12-02T16:04:59.615593
32969489.0,Number of TEAEs,Total TEAEs resulting in permanent study drug discontinuation,0,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,717,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE,9,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,718,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE,10,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,719,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE,16,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,720,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE,17,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,721,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE,16,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,722,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE,16,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,723,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE,266,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,724,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE,471,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,725,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any serious TEAE,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,726,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any serious TEAE,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,727,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any serious TEAE,2,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,728,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any serious TEAE,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,729,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any serious TEAE,2,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,730,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any serious TEAE,3,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,731,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any serious TEAE,6,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,732,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any serious TEAE,11,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,733,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,AnyTEAE related to treatment,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,734,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,AnyTEAE related to treatment,1,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,735,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,AnyTEAE related to treatment,3,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,736,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,AnyTEAE related to treatment,3,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,737,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,AnyTEAE related to treatment,4,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,738,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,AnyTEAE related to treatment,2,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,739,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,AnyTEAE related to treatment,13,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,740,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,AnyTEAE related to treatment,7,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,741,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE leading to treatment discontinuation,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,742,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE leading to treatment discontinuation,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,743,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE leading to treatment discontinuation,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,744,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE leading to treatment discontinuation,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,745,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE leading to treatment discontinuation,0,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,746,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE leading to treatment discontinuation,0,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,747,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE leading to treatment discontinuation,0,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,748,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Any TEAE leading to treatment discontinuation,0,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,749,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Patients with TEAE resulting in death,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,750,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Patients with TEAE resulting in death,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,751,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Patients with TEAE resulting in death,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,752,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Patients with TEAE resulting in death,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,753,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Patients with TEAE resulting in death,0,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,754,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Patients with TEAE resulting in death,0,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,755,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Patients with TEAE resulting in death,0,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,756,2025-12-02T16:04:59.615593
32969489.0,Patients with TEAEs,Patients with TEAE resulting in death,0,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,757,2025-12-02T16:04:59.615593
32969489.0,Any infection,,6,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,758,2025-12-02T16:04:59.615593
32969489.0,Any infection,,8,,,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,759,2025-12-02T16:04:59.615593
32969489.0,Any infection,,10,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,760,2025-12-02T16:04:59.615593
32969489.0,Any infection,,12,,,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,761,2025-12-02T16:04:59.615593
32969489.0,Any infection,,12,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,762,2025-12-02T16:04:59.615593
32969489.0,Any infection,,15,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,763,2025-12-02T16:04:59.615593
32969489.0,Any infection,,98,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,764,2025-12-02T16:04:59.615593
32969489.0,Any infection,,209,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,765,2025-12-02T16:04:59.615593
32969489.0,Any infection,Skin infection,1,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,766,2025-12-02T16:04:59.615593
32969489.0,Any infection,Skin infection,1,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,767,2025-12-02T16:04:59.615593
32969489.0,Any infection,Skin infection,7,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,768,2025-12-02T16:04:59.615593
32969489.0,Any infection,Skin infection,5,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,769,2025-12-02T16:04:59.615593
32969489.0,Any infection,Skin infection,5,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,770,2025-12-02T16:04:59.615593
32969489.0,Any infection,Skin infection,6,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,771,2025-12-02T16:04:59.615593
32969489.0,Any infection,Skin infection,17,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,772,2025-12-02T16:04:59.615593
32969489.0,Any infection,Skin infection,25,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,773,2025-12-02T16:04:59.615593
32969489.0,Any infection,Nonherpetic skin infections (adjudicated),1,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,774,2025-12-02T16:04:59.615593
32969489.0,Any infection,Nonherpetic skin infections (adjudicated),1,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,775,2025-12-02T16:04:59.615593
32969489.0,Any infection,Nonherpetic skin infections (adjudicated),6,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,776,2025-12-02T16:04:59.615593
32969489.0,Any infection,Nonherpetic skin infections (adjudicated),5,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,777,2025-12-02T16:04:59.615593
32969489.0,Any infection,Nonherpetic skin infections (adjudicated),4,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,778,2025-12-02T16:04:59.615593
32969489.0,Any infection,Nonherpetic skin infections (adjudicated),3,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,779,2025-12-02T16:04:59.615593
32969489.0,Any infection,Nonherpetic skin infections (adjudicated),12,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,780,2025-12-02T16:04:59.615593
32969489.0,Any infection,Nonherpetic skin infections (adjudicated),11,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,781,2025-12-02T16:04:59.615593
32969489.0,Any infection,Herpes viral infections,1,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,782,2025-12-02T16:04:59.615593
32969489.0,Any infection,Herpes viral infections,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,783,2025-12-02T16:04:59.615593
32969489.0,Any infection,Herpes viral infections,1,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,784,2025-12-02T16:04:59.615593
32969489.0,Any infection,Herpes viral infections,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,785,2025-12-02T16:04:59.615593
32969489.0,Any infection,Herpes viral infections,2,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,786,2025-12-02T16:04:59.615593
32969489.0,Any infection,Herpes viral infections,4,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,787,2025-12-02T16:04:59.615593
32969489.0,Any infection,Herpes viral infections,6,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,788,2025-12-02T16:04:59.615593
32969489.0,Any infection,Herpes viral infections,15,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,789,2025-12-02T16:04:59.615593
32969489.0,Injection-site reaction,,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,790,2025-12-02T16:04:59.615593
32969489.0,Injection-site reaction,,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,791,2025-12-02T16:04:59.615593
32969489.0,Injection-site reaction,,1,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,792,2025-12-02T16:04:59.615593
32969489.0,Injection-site reaction,,1,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,793,2025-12-02T16:04:59.615593
32969489.0,Injection-site reaction,,2,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,794,2025-12-02T16:04:59.615593
32969489.0,Injection-site reaction,,1,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,795,2025-12-02T16:04:59.615593
32969489.0,Injection-site reaction,,5,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,796,2025-12-02T16:04:59.615593
32969489.0,Injection-site reaction,,3,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,797,2025-12-02T16:04:59.615593
32969489.0,Conjunctivitis,,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,798,2025-12-02T16:04:59.615593
32969489.0,Conjunctivitis,,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,799,2025-12-02T16:04:59.615593
32969489.0,Conjunctivitis,,1,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,800,2025-12-02T16:04:59.615593
32969489.0,Conjunctivitis,,2,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,801,2025-12-02T16:04:59.615593
32969489.0,Conjunctivitis,,2,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,802,2025-12-02T16:04:59.615593
32969489.0,Conjunctivitis,,5,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,803,2025-12-02T16:04:59.615593
32969489.0,Conjunctivitis,,5,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,804,2025-12-02T16:04:59.615593
32969489.0,Conjunctivitis,,21,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,805,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Nasopharyngitis,3,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,806,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Nasopharyngitis,4,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,807,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Nasopharyngitis,6,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,808,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Nasopharyngitis,4,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,809,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Nasopharyngitis,8,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,810,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Nasopharyngitis,9,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,811,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Nasopharyngitis,35,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,812,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Nasopharyngitis,37,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,813,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis atopic,4,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,814,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis atopic,4,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,815,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis atopic,5,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,816,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis atopic,3,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,817,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis atopic,5,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,818,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis atopic,2,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,819,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis atopic,16,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,820,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis atopic,7,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,821,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Cough,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,822,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Cough,1,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,823,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Cough,5,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,824,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Cough,3,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,825,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Cough,2,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,826,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Cough,5,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,827,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Cough,6,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,828,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Cough,20,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,829,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis infected,1,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,830,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis infected,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,831,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis infected,3,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,832,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis infected,2,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,833,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis infected,2,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,834,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis infected,0,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,835,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis infected,5,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,836,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Dermatitis infected,0,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,837,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Headache,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,838,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Headache,1,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,839,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Headache,2,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,840,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Headache,1,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,841,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Headache,4,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,842,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Headache,2,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,843,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Headache,13,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,844,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Headache,7,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,845,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Upper respiratory tract infection,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,846,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Upper respiratory tract infection,1,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,847,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Upper respiratory tract infection,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,848,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Upper respiratory tract infection,1,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,849,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Upper respiratory tract infection,2,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,850,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Upper respiratory tract infection,4,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,851,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Upper respiratory tract infection,6,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,852,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Upper respiratory tract infection,16,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,853,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Herpes simplex,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part A,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,854,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Herpes simplex,0,,N,,,,,,18,children ,,,,"Phase IIa study, Part B,  2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,855,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Herpes simplex,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part A, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,856,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Herpes simplex,0,,N,,,,,,19,children ,,,,"Phase IIa study, Part B, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,857,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Herpes simplex,0,,N,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,858,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Herpes simplex,4,,N,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,859,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Herpes simplex,0,,number of events  per 100 PYs,,,,,,17,children ,,,,"Phase III OLE study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,860,2025-12-02T16:04:59.615593
32969489.0,Most common TEAEs,Herpes simplex,15,,number of events  per 100 PYs,,,,,,16,children ,,,,"Phase III OLE study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,861,2025-12-02T16:04:59.615593
32969489.0,EASI,,23,,mean,SD,18.0,,,,18,children ,,,,"Week 2, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,862,2025-12-02T16:04:59.615593
32969489.0,EASI,,9,,mean,SD,13.0,,,,18,children ,,,,"Week 12, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,863,2025-12-02T16:04:59.615593
32969489.0,EASI,,21,,mean,SD,18.0,,,,17,children ,,,,"Week 0, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,864,2025-12-02T16:04:59.615593
32969489.0,EASI,,9,,mean,SD,14.0,,,,17,children ,,,,"Week 16, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,865,2025-12-02T16:04:59.615593
32969489.0,EASI,,2,,mean,SD,3.0,,,,17,children ,,,,"Week 52, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,866,2025-12-02T16:04:59.615593
32969489.0,EASI,,26,,mean,SD,16.0,,,,19,children ,,,,"Week 2, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,867,2025-12-02T16:04:59.615593
32969489.0,EASI,,16,,mean,SD,15.0,,,,19,children ,,,,"Week 12, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,868,2025-12-02T16:04:59.615593
32969489.0,EASI,,32,,mean,SD,20.0,,,,16,children ,,,,"Week 0, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,869,2025-12-02T16:04:59.615593
32969489.0,EASI,,7,,mean,SD,8.0,,,,16,children ,,,,"Week 16, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,870,2025-12-02T16:04:59.615593
32969489.0,EASI,,15,,mean,SD,5.0,,,,16,children ,,,,"Week 52, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,871,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-37,,mean,SD,34.0,,,,18,children ,,,,"Week 2, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,872,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-76,,mean,SD,25.0,,,,18,children ,,,,"Week 12, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,873,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-37,,mean,SD,37.0,,,,17,children ,,,,"Week 0, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,874,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-73,,mean,SD,42.0,,,,17,children ,,,,"Week 16, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,875,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-92,,mean,SD,14.0,,,,17,children ,,,,"Week 52, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,876,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-33,,mean,SD,28.0,,,,19,children ,,,,"Week 2, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,877,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-63,,mean,SD,25.0,,,,19,children ,,,,"Week 12, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,878,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-20,,mean,SD,32.0,,,,16,children ,,,,"Week 0, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,879,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-84,,mean,SD,4.0,,,,16,children ,,,,"Week 16, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,880,2025-12-02T16:04:59.615593
32969489.0,Percentage change in EASI from baseline of phase IIa study,,-84,,mean,SD,17.0,,,,16,children ,,,,"Week 52, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,881,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,7/18,,n/N,,,,,,18,children ,,,,"Week 2, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,882,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,14/18,,n/N,,,,,,18,children ,,,,"Week 12, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,883,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,7/17,,n/N,,,,,,17,children ,,,,"Week 0, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,884,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,16/17,,n/N,,,,,,17,children ,,,,"Week 16, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,885,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,16/17,,n/N,,,,,,17,children ,,,,"Week 52, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,886,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,5/19,,n/N,,,,,,19,children ,,,,"Week 2, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,887,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,11/19,,n/N,,,,,,19,children ,,,,"Week 12, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,888,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,3/16,,n/N,,,,,,16,children ,,,,"Week 0, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,889,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,14/15,,n/N,,,,,,16,children ,,,,"Week 16, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,890,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EAST 50 from baseline of phase IIa study,,15/16,,n/N,,,,,,16,children ,,,,"Week 52, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,891,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,3/18,,n/N,,,,,,18,children ,,,,"Week 2, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,892,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,10/18,,n/N,,,,,,18,children ,,,,"Week 12, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,893,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,4/17,,n/N,,,,,,17,children ,,,,"Week 0, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,894,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,10/17,,n/N,,,,,,17,children ,,,,"Week 16, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,895,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,16/17,,n/N,,,,,,17,children ,,,,"Week 52, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,896,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,2/19,,n/N,,,,,,19,children ,,,,"Week 2, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,897,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,9/19,,n/N,,,,,,19,children ,,,,"Week 12, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,898,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,1/16,,n/N,,,,,,16,children ,,,,"Week 0, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,899,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,11/15,,n/N,,,,,,16,children ,,,,"Week 16, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,900,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 75 from baseline of phase IIa study,,12/16,,n/N,,,,,,16,children ,,,,"Week 52, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,901,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,1/18,,n/N,,,,,,18,children ,,,,"Week 2, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,902,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,6/18,,n/N,,,,,,18,children ,,,,"Week 12, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,903,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,0/17,,n/N,,,,,,17,children ,,,,"Week 0, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,904,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,7/17,,n/N,,,,,,17,children ,,,,"Week 16, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,905,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,12/17,,n/N,,,,,,17,children ,,,,"Week 52, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,906,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,0/19,,n/N,,,,,,19,children ,,,,"Week 2, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,907,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,5/19,,n/N,,,,,,19,children ,,,,"Week 12, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,908,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,0/16,,n/N,,,,,,16,children ,,,,"Week 0, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,909,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,5/15,,n/N,,,,,,16,children ,,,,"Week 16, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,910,2025-12-02T16:04:59.615593
32969489.0,Patients achieving EASI 90 from baseline of phase IIa study,,7/16,,n/N,,,,,,16,children ,,,,"Week 52, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,911,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,1/18,,n/N,,,,,,18,children ,,,,"Week 2, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,912,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,3/18,,n/N,,,,,,18,children ,,,,"Week 12, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,913,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,1/17,,n/N,,,,,,17,children ,,,,"Week 0, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,914,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,6/17,,n/N,,,,,,17,children ,,,,"Week 16, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,915,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,13/17,,n/N,,,,,,17,children ,,,,"Week 52, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,916,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,0/19,,n/N,,,,,,19,children ,,,,"Week 2, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,917,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,4/19,,n/N,,,,,,19,children ,,,,"Week 12, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,918,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,0/16,,n/N,,,,,,16,children ,,,,"Week 0, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,919,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,6/15,,n/N,,,,,,16,children ,,,,"Week 16, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,920,2025-12-02T16:04:59.615593
32969489.0,Patients achieving IGA score 0 or 1,,4/16,,n/N,,,,,,16,children ,,,,"Week 52, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,921,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,5,,mean,SD,3.0,,,,18,children ,,,,"Week 2, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,922,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,3,,mean,SD,2.0,,,,18,children ,,,,"Week 12, Phase IIa study, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,923,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,6,,mean,SD,3.0,,,,17,children ,,,,"Week 0, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,924,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,3,,mean,SD,2.0,,,,17,children ,,,,"Week 16, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,925,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,2,,mean,SD,2.0,,,,17,children ,,,,"Week 52, Phase III OLE, 2 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,926,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,5,,mean,SD,3.0,,,,19,children ,,,,"Week 2, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,927,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,4,,mean,SD,2.0,,,,19,children ,,,,"Week 12, Phase IIa study, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,928,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,6,,mean,SD,2.0,,,,16,children ,,,,"Week 0, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,929,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,3,,mean,SD,2.0,,,,16,children ,,,,"Week 16, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,930,2025-12-02T16:04:59.615593
32969489.0,Peak pruritus NRS,,3,,mean,SD,2.0,,,,16,children ,,,,"Week 52, Phase III OLE, 4 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,931,2025-12-02T16:04:59.615593
32893393.0,EASI score,Baselline,35.2,,mean,SD,9.21,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,932,2025-12-02T16:04:59.615593
32893393.0,EASI score,Week 3,20.9,,mean,SD,17.31,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,933,2025-12-02T16:04:59.615593
32893393.0,EASI score,Week 4,26.2,,mean,SD,18.44,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,934,2025-12-02T16:04:59.615593
32893393.0,EASI score,Baselline,40.2,,mean,SD,11.81,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,935,2025-12-02T16:04:59.615593
32893393.0,EASI score,Week 3,20.1,,mean,SD,12.25,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,936,2025-12-02T16:04:59.615593
32893393.0,EASI score,Week 4,20.9,,mean,SD,12.87,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,937,2025-12-02T16:04:59.615593
32893393.0,EASI score,Baselline,34.4,,mean,SD,14.25,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,938,2025-12-02T16:04:59.615593
32893393.0,EASI score,Week 3,22.4,,mean,SD,19.7,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,939,2025-12-02T16:04:59.615593
32893393.0,EASI score,Week 4,27,,mean,SD,15.75,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,940,2025-12-02T16:04:59.615593
32893393.0,EASI score,Baselline,36.1,,mean,SD,12.94,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,941,2025-12-02T16:04:59.615593
32893393.0,EASI score,Week 3,22.4,,mean,SD,12.23,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,942,2025-12-02T16:04:59.615593
32893393.0,EASI score,Week 4,21.2,,mean,SD,17.44,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,943,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,944,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Week 3,-44.6,,mean,SD,36.77,95% CI,-70.9,-18.3,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,945,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Week 4,-26.6,,mean,SD,47.37,95% CI,-60.5,7.3,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,946,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,947,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Week 3,-49.7,,mean,SD,29.05,95% CI,-70.5,-29,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,948,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Week 4,-48.7,,mean,SD,28.89,95% CI,-69.3,-28,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,949,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,950,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Week 3,-42.7,,mean,SD,33.13,95% CI,-66.4,-19,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,951,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Week 4,-22.4,,mean,SD,42.52,95% CI,-52.9,8,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,952,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,953,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Week 3,-38.8,,mean,SD,24.98,95% CI,-56.7,-20.9,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,954,2025-12-02T16:04:59.615593
32893393.0,EASI score % change from baseline,Week 4,-43.2,,mean,SD,35.55,95% CI,-68.6,-17.8,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,955,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Baselline,73.5,,mean,SD,10.2,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,956,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Week 3,50.1,,mean,SD,26.88,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,957,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Week 4,60.1,,mean,SD,22.02,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,958,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Baselline,75.1,,mean,SD,8.08,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,959,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Week 3,49.5,,mean,SD,19.26,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,960,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Week 4,51.6,,mean,SD,15.79,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,961,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Baselline,69.8,,mean,SD,13.1,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,962,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Week 3,48.7,,mean,SD,23.21,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,963,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Week 4,55.2,,mean,SD,21.34,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,964,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Baselline,75.9,,mean,SD,11.74,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,965,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Week 3,56.2,,mean,SD,13.84,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,966,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD score,Week 4,54.9,,mean,SD,24.5,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,967,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,968,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Week 3,-33,,mean,SD,32.09,95% CI,-55.9,-10,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,969,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Week 4,-18.6,,mean,SD,26.18,95% CI,-37.4,0.1,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,970,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,971,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Week 3,-34.7,,mean,SD,23.18,95% CI,-51.3,-18.1,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,972,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Week 4,-31.9,,mean,SD,17.45,95% CI,-44.4,-19.4,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,973,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,974,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Week 3,-32.9,,mean,SD,23.76,95% CI,-49.9,-15.9,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,975,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Week 4,-22.4,,mean,SD,26.44,95% CI,-41.3,-3.5,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,976,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,977,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Week 3,-25.2,,mean,SD,17.18,95% CI,-37.5,-12.9,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,978,2025-12-02T16:04:59.615593
32893393.0,Total SCORAD % change from baseline,Week 4,-28.1,,mean,SD,27.84,95% CI,-48.1,-8.2,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,979,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Baselline,6.3,,mean,SD,2.54,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,980,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Week 3,5.5,,mean,SD,3.87,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,981,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Week 4,5.1,,mean,SD,3.76,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,982,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Baselline,6.3,,mean,SD,2.82,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,983,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Week 3,3.2,,mean,SD,2.39,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,984,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Week 4,4,,mean,SD,3.01,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,985,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Baselline,6,,mean,SD,2.83,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,986,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Week 3,4.2,,mean,SD,2.96,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,987,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Week 4,4.3,,mean,SD,3.0,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,988,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Baselline,7.8,,mean,SD,1.9,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,989,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Week 3,4.8,,mean,SD,2.52,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,990,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score,Week 4,6,,mean,SD,3.49,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,991,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,992,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Week 3,-2.8,,mean,SD,92.32,95% CI,-68.9,63.2,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,993,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Week 4,11.8,,mean,SD,136.08,95% CI,-85.5,109.2,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,994,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,995,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Week 3,-44.1,,mean,SD,48.42,95% CI,-78.8,-9.5,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,996,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Week 4,-37.9,,mean,SD,35.08,95% CI,-63,-12.8,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,997,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,998,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Week 3,-32.8,,mean,SD,39.83,95% CI,-61.3,-4.3,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,999,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Week 4,-25.2,,mean,SD,53.14,95% CI,-63.2,12.9,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1000,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1001,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Week 3,-34.5,,mean,SD,39.75,95% CI,-62.9,-6.1,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1002,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS sleep score % change from baseline,Week 4,-24.3,,mean,SD,46.68,95% CI,-57.7,9.1,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1003,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Baselline,8.4,,mean,SD,1.18,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1004,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Week 3,6,,mean,SD,3.29,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1005,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Week 4,7.2,,mean,SD,2.81,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1006,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Baselline,7.6,,mean,SD,1.78,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1007,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Week 3,4.2,,mean,SD,1.92,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1008,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Week 4,5.2,,mean,SD,1.84,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1009,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Baselline,7.5,,mean,SD,2.4,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1010,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Week 3,5.1,,mean,SD,2.31,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1011,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Week 4,5.9,,mean,SD,2.57,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1012,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Baselline,8.2,,mean,SD,1.42,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1013,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Week 3,6.3,,mean,SD,2.77,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1014,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score,Week 4,6.4,,mean,SD,3.2,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1015,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1016,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Week 3,-30,,mean,SD,34.68,95% CI,-54.8,-5.2,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1017,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Week 4,-14.1,,mean,SD,30.22,95% CI,-35.7,7.5,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1018,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1019,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Week 3,-44.5,,mean,SD,26.04,95% CI,-63.1,-25.8,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1020,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Week 4,-27.1,,mean,SD,35.17,95% CI,-52.2,-1.9,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1021,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1022,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Week 3,-27,,mean,SD,33.73,95% CI,-51.1,-2.9,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1023,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Week 4,-11.7,,mean,SD,48.44,95% CI,-46.4,22.9,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1024,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1025,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Week 3,-19.2,,mean,SD,43.49,95% CI,-50.4,11.9,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1026,2025-12-02T16:04:59.615593
32893393.0,SCORAD VAS itch score % change from baseline,Week 4,-24.7,,mean,SD,31.09,95% CI,-47,-2.5,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1027,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Baselline,,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1028,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Week 3,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1029,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Week 4,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1030,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Baselline,,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1031,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Week 3,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1032,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Week 4,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1033,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Baselline,,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1034,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Week 3,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1035,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Week 4,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1036,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Baselline,,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1037,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Week 3,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1038,2025-12-02T16:04:59.615593
32893393.0,Patients with IGA 0 or 1,Week 4,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1039,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Baselline,,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1040,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Week 3,5,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1041,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Week 4,3,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1042,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Baselline,,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1043,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Week 3,5,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1044,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Week 4,4,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1045,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Baselline,,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1046,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Week 3,5,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1047,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Week 4,2,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1048,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Baselline,,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1049,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Week 3,4,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1050,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-50,Week 4,4,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1051,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Baselline,,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1052,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Week 3,3,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1053,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Week 4,2,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1054,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Baselline,,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1055,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Week 3,2,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1056,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Week 4,3,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1057,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Baselline,,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1058,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Week 3,2,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1059,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Week 4,2,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1060,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Baselline,,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1061,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Week 3,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1062,2025-12-02T16:04:59.615593
32893393.0,Patients with EASI-75,Week 4,3,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1063,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Baselline,8.4,,mean,SD,1.2,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1064,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Week 3,6.7,,mean,SD,2.8,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1065,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Week 4,7.1,,mean,SD,3.1,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1066,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Baselline,8.1,,mean,SD,1.4,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1067,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Week 3,4.5,,mean,SD,1.6,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1068,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Week 4,6.1,,mean,SD,2.3,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1069,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Baselline,7.6,,mean,SD,2.5,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1070,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Week 3,5.8,,mean,SD,2.2,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1071,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Week 4,6.5,,mean,SD,2.1,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1072,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Baselline,8.5,,mean,SD,0.7,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1073,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Week 3,7,,mean,SD,2.4,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1074,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score,Week 4,6.3,,mean,SD,3.2,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1075,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Baselline,,,mean,SD,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1076,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Week 3,-22.9,,mean,SD,29.9,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1077,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Week 4,-16.7,,mean,SD,32.5,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1078,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Baselline,,,mean,SD,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1079,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Week 3,-44.7,,mean,SD,17.5,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1080,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Week 4,-22,,mean,SD,34.5,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1081,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Baselline,,,mean,SD,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1082,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Week 3,-11.1,,mean,SD,57.5,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1083,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Week 4,4.1,,mean,SD,84.2,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1084,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Baselline,,,mean,SD,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1085,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Week 3,-18.2,,mean,SD,26.4,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1086,2025-12-02T16:04:59.615593
32893393.0,Caregiver-reported Peak Pruritus NRS score % change from baseline,Week 4,-26.7,,mean,SD,35.5,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1087,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Baselline,58.1,,mean,SD,11.09,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1088,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Week 3,38.1,,mean,SD,20.74,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1089,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Week 4,42.2,,mean,SD,20.95,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1090,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Baselline,67.5,,mean,SD,16.05,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1091,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Week 3,39.5,,mean,SD,17.46,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1092,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Week 4,37.2,,mean,SD,22.03,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1093,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Baselline,55.3,,mean,SD,25.66,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1094,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Week 3,46.2,,mean,SD,30.41,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1095,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Week 4,50.1,,mean,SD,29.54,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1096,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Baselline,57.9,,mean,SD,21.37,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1097,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Week 3,35,,mean,SD,18.79,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1098,2025-12-02T16:04:59.615593
32893393.0,% BSA affected,Week 4,33,,mean,SD,24.7,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1099,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1100,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Week 3,-34.5,,mean,SD,33.66,95% CI,-58.6,-10.4,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1101,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Week 4,-23.8,,mean,SD,41.82,95% CI,-53.8,6.1,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1102,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1103,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Week 3,-40.8,,mean,SD,25.72,95% CI,-59.2,-22.4,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1104,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Week 4,-43.6,,mean,SD,29.56,95% CI,-64.7,-22.4,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1105,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1106,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Week 3,-22.1,,mean,SD,31.57,95% CI,-44.6,0.5,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1107,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Week 4,-12.3,,mean,SD,38.38,95% CI,-39.8,15.1,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1108,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Baselline,,,mean,SD,,95% CI,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1109,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Week 3,-40.3,,mean,SD,21.21,95% CI,-55.4,-25.1,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1110,2025-12-02T16:04:59.615593
32893393.0,"% BSA affected, % change from baseline",Week 4,-44.8,,mean,SD,31.75,95% CI,-67.5,-22,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1111,2025-12-02T16:04:59.615593
32893393.0,Total number of TEAEs,,5,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1112,2025-12-02T16:04:59.615593
32893393.0,Total number of TEAEs,,3,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1113,2025-12-02T16:04:59.615593
32893393.0,Total number of TEAEs,,11,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1114,2025-12-02T16:04:59.615593
32893393.0,Total number of TEAEs,,11,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1115,2025-12-02T16:04:59.615593
32893393.0,Total number of serious TEAEs,,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1116,2025-12-02T16:04:59.615593
32893393.0,Total number of serious TEAEs,,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1117,2025-12-02T16:04:59.615593
32893393.0,Total number of serious TEAEs,,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1118,2025-12-02T16:04:59.615593
32893393.0,Total number of serious TEAEs,,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1119,2025-12-02T16:04:59.615593
32893393.0,Total number of TEAEs related to treatment,,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1120,2025-12-02T16:04:59.615593
32893393.0,Total number of TEAEs related to treatment,,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1121,2025-12-02T16:04:59.615593
32893393.0,Total number of TEAEs related to treatment,,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1122,2025-12-02T16:04:59.615593
32893393.0,Total number of TEAEs related to treatment,,2,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1123,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 TEAE,3,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1124,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 TEAE,2,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1125,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 TEAE,7,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1126,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 TEAE,7,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1127,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 serious TEAE,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1128,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 serious TEAE,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1129,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 serious TEAE,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1130,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 serious TEAE,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1131,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 severe TEAE,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1132,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 severe TEAE,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1133,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 severe TEAE,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1134,2025-12-02T16:04:59.615593
32893393.0,Patients with TEAEs,>=1 severe TEAE,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1135,2025-12-02T16:04:59.615593
32893393.0,Any infection,Total,2,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1136,2025-12-02T16:04:59.615593
32893393.0,Any infection,Total,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1137,2025-12-02T16:04:59.615593
32893393.0,Any infection,Total,3,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1138,2025-12-02T16:04:59.615593
32893393.0,Any infection,Total,4,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1139,2025-12-02T16:04:59.615593
32893393.0,Any infection,skin infection,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1140,2025-12-02T16:04:59.615593
32893393.0,Any infection,skin infection,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1141,2025-12-02T16:04:59.615593
32893393.0,Any infection,skin infection,2,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1142,2025-12-02T16:04:59.615593
32893393.0,Any infection,skin infection,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1143,2025-12-02T16:04:59.615593
32893393.0,Any infection,Non-herpetic skin infection,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1144,2025-12-02T16:04:59.615593
32893393.0,Any infection,Non-herpetic skin infection,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1145,2025-12-02T16:04:59.615593
32893393.0,Any infection,Non-herpetic skin infection,2,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1146,2025-12-02T16:04:59.615593
32893393.0,Any infection,Non-herpetic skin infection,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1147,2025-12-02T16:04:59.615593
32893393.0,Any infection,Impetigo,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1148,2025-12-02T16:04:59.615593
32893393.0,Any infection,Impetigo,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1149,2025-12-02T16:04:59.615593
32893393.0,Any infection,Impetigo,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1150,2025-12-02T16:04:59.615593
32893393.0,Any infection,Impetigo,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1151,2025-12-02T16:04:59.615593
32893393.0,Any infection,Folliculitis,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1152,2025-12-02T16:04:59.615593
32893393.0,Any infection,Folliculitis,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1153,2025-12-02T16:04:59.615593
32893393.0,Any infection,Folliculitis,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1154,2025-12-02T16:04:59.615593
32893393.0,Any infection,Folliculitis,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1155,2025-12-02T16:04:59.615593
32893393.0,Any infection,Herpes viral infections,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1156,2025-12-02T16:04:59.615593
32893393.0,Any infection,Herpes viral infections,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1157,2025-12-02T16:04:59.615593
32893393.0,Any infection,Herpes viral infections,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1158,2025-12-02T16:04:59.615593
32893393.0,Any infection,Herpes viral infections,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1159,2025-12-02T16:04:59.615593
32893393.0,Injection-site reactions,Total,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1160,2025-12-02T16:04:59.615593
32893393.0,Injection-site reactions,Total,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1161,2025-12-02T16:04:59.615593
32893393.0,Injection-site reactions,Total,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1162,2025-12-02T16:04:59.615593
32893393.0,Injection-site reactions,Total,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1163,2025-12-02T16:04:59.615593
32893393.0,Injection-site reactions,Injection-site erythema,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1164,2025-12-02T16:04:59.615593
32893393.0,Injection-site reactions,Injection-site erythema,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1165,2025-12-02T16:04:59.615593
32893393.0,Injection-site reactions,Injection-site erythema,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1166,2025-12-02T16:04:59.615593
32893393.0,Injection-site reactions,Injection-site erythema,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1167,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Nasopharyngitis,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1168,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Nasopharyngitis,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1169,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Nasopharyngitis,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1170,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Nasopharyngitis,2,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1171,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Diarrhea,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1172,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Diarrhea,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1173,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Diarrhea,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1174,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Diarrhea,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1175,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Upper respiratory tract infection,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1176,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Upper respiratory tract infection,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1177,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Upper respiratory tract infection,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1178,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Upper respiratory tract infection,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1179,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Urticaria,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1180,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Urticaria,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1181,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Urticaria,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1182,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Urticaria,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1183,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Dermatitis atopic,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1184,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Dermatitis atopic,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1185,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Dermatitis atopic,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1186,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Dermatitis atopic,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1187,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Cough,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1188,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Cough,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1189,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Cough,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1190,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Cough,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1191,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Pyrexia,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1192,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Pyrexia,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1193,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Pyrexia,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1194,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Pyrexia,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1195,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Anaphylactic reaction,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1196,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Anaphylactic reaction,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1197,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Anaphylactic reaction,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1198,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Anaphylactic reaction,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1199,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Constipation,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1200,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Constipation,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1201,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Constipation,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1202,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Constipation,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1203,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Folliculitis,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1204,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Folliculitis,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1205,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Folliculitis,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1206,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Folliculitis,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1207,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Joint swelling,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1208,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Joint swelling,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1209,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Joint swelling,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1210,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Joint swelling,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1211,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Lacrimation increased,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1212,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Lacrimation increased,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1213,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Lacrimation increased,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1214,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Lacrimation increased,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1215,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Skin abrasion,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1216,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Skin abrasion,1,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1217,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Skin abrasion,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1218,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Skin abrasion,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1219,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Teething,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1220,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Teething,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1221,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Teething,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1222,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Teething,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1223,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Thrmbocytosis,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1224,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Thrmbocytosis,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1225,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Thrmbocytosis,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1226,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Thrmbocytosis,1,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1227,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Conjunctivitis,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1228,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Conjunctivitis,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1229,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Conjunctivitis,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1230,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Conjunctivitis,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1231,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Herpes simplex,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1232,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Herpes simplex,0,,N,,,,,,10,children ,,,,">=2 to <6 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1233,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Herpes simplex,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 3 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1234,2025-12-02T16:04:59.615593
32893393.0,TEAEs (PT),Herpes simplex,0,,N,,,,,,10,children ,,,,">=6 months to <2 years of age, 6 mg/kg",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1235,2025-12-02T16:04:59.615593
30539740.0,CRE,,0.72,,mean,SD,0.54,,,,20,neonates,,,,before treatment,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1236,2025-12-02T16:04:59.615593
30539740.0,CRE,,0.76,,mean,SD,0.7,,,,20,neonates,,,,after treatment completion,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1237,2025-12-02T16:04:59.615593
30539740.0,Ototoxicity,trough >=10 ug/ml,3,,N,,,,,,20,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1238,2025-12-02T16:04:59.615593
30539740.0,Ototoxicity,trough <10 ug/ml,1,,N,,,,,,20,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1239,2025-12-02T16:04:59.615593
34035682.0,AKI,,10,,N,,,,,,54,neonates,,,0.16,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1240,2025-12-02T16:04:59.615593
34035682.0,AKI,,5,,N,,,,,,54,neonates,,,0.16,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1241,2025-12-02T16:04:59.615593
34035682.0,Concomitant nephrotoxins,0,20,,N,,,,,,54,neonates,,,<0.001,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1242,2025-12-02T16:04:59.615593
34035682.0,Concomitant nephrotoxins,1,17,,N,,,,,,54,neonates,,,<0.001,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1243,2025-12-02T16:04:59.615593
34035682.0,Concomitant nephrotoxins,2,15,,N,,,,,,54,neonates,,,<0.001,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1244,2025-12-02T16:04:59.615593
34035682.0,Concomitant nephrotoxins,3,2,,N,,,,,,54,neonates,,,<0.001,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1245,2025-12-02T16:04:59.615593
34035682.0,Concomitant nephrotoxins,0,36,,N,,,,,,54,neonates,,,<0.001,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1246,2025-12-02T16:04:59.615593
34035682.0,Concomitant nephrotoxins,1,16,,N,,,,,,54,neonates,,,<0.001,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1247,2025-12-02T16:04:59.615593
34035682.0,Concomitant nephrotoxins,2,2,,N,,,,,,54,neonates,,,<0.001,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1248,2025-12-02T16:04:59.615593
34035682.0,Concomitant nephrotoxins,3,0,,N,,,,,,54,neonates,,,<0.001,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1249,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Ibuprofen/indomethacin ,3,,N,,,,,,54,neonates,,,1,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1250,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Ibuprofen/indomethacin ,4,,N,,,,,,54,neonates,,,1,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1251,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Acyclovir ,2,,N,,,,,,54,neonates,,,1,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1252,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Acyclovir ,2,,N,,,,,,54,neonates,,,1,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1253,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Vancomycin ,23,,N,,,,,,54,neonates,,,0.001,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1254,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Vancomycin ,8,,N,,,,,,54,neonates,,,0.001,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1255,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Furosemide,24,,N,,,,,,54,neonates,,,<0.001,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1256,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Furosemide,5,,N,,,,,,54,neonates,,,<0.001,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1257,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Contrast ,1,,N,,,,,,54,neonates,,,1,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1258,2025-12-02T16:04:59.615593
34035682.0,Type of nephrotoxin,Contrast ,1,,N,,,,,,54,neonates,,,1,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1259,2025-12-02T16:04:59.615593
34035682.0,Vasopressors or Inotropes ,,19,,N,,,,,,54,neonates,,,0.015,CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1260,2025-12-02T16:04:59.615593
34035682.0,Vasopressors or Inotropes ,,8,,N,,,,,,54,neonates,,,0.015,Non-CHD,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1261,2025-12-02T16:04:59.615593
30721546.0,Effect of procedure (value at peak pain),BIIP score,3,,median,,,minmax,0,8,19,infants,,,,0.5 ug/kg,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1262,2025-12-02T16:04:59.615593
30721546.0,Effect of procedure (value at peak pain),PIPP score,7.5,,median,,,minmax,0,13,19,infants,,,,0.5 ug/kg,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1263,2025-12-02T16:04:59.615593
30721546.0,Effect of procedure (value at peak pain),Mean arterial blood pressure change,0,,median,,,minmax,-9,9,19,infants,,,,0.5 ug/kg,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1264,2025-12-02T16:04:59.615593
30721546.0,Effect of procedure (value at peak pain),Heart rate change,-2,,median,,,minmax,-12,8,19,infants,,,,0.5 ug/kg,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1265,2025-12-02T16:04:59.615593
30721546.0,Effect of procedure (value at peak pain),Peripheral oxygenation change,1,,median,,,minmax,-11,9,19,infants,,,,0.5 ug/kg,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1266,2025-12-02T16:04:59.615593
30721546.0,Effect of procedure (value at peak pain),Need for change in fraction of inspired oxygen (FiO2),0,,median,,,minmax,0,7,19,infants,,,,0.5 ug/kg,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1267,2025-12-02T16:04:59.615593
35842213.0,Number of patients had adverse events possibly related to levofloxacin,,1,,N,,,,,,5,children ,,,,WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1268,2025-12-02T16:04:59.615593
35842213.0,Number of patients had adverse events possibly related to levofloxacin,,4,,N,,,,,,5,children ,,,,Higher-than-WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1269,2025-12-02T16:04:59.615593
35842213.0,Grade 3 and 4 adverse events,,0,,N,,,,,,10,children ,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1270,2025-12-02T16:04:59.615593
35842213.0,QTcF,at baseline,388,msec,median,,,IQR,363,388,5,children ,,,,WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1271,2025-12-02T16:04:59.615593
35842213.0,QTcF,at the PK study day,403,msec,median,,,IQR,350,413,5,children ,,,,WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1272,2025-12-02T16:04:59.615593
35842213.0,QTcF,at 4 weeks after treatment,400,msec,median,,,IQR,397,413,5,children ,,,,WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1273,2025-12-02T16:04:59.615593
35842213.0,QTcF,at baseline,388,msec,median,,,IQR,372,388,5,children ,,,,Higher-than-WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1274,2025-12-02T16:04:59.615593
35842213.0,QTcF,at the PK study day,384,msec,median,,,IQR,343,395,5,children ,,,,Higher-than-WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1275,2025-12-02T16:04:59.615593
35842213.0,QTcF,at 4 weeks after treatment,390,msec,median,,,IQR,387,411,5,children ,,,,Higher-than-WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1276,2025-12-02T16:04:59.615593
35842213.0,Alanine aminotransferase at PK study day,,10,U/I,median,,,IQR,8,13,5,children ,,,,WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1277,2025-12-02T16:04:59.615593
35842213.0,Alanine aminotransferase at PK study day,,12,U/I,median,,,IQR,12,14,5,children ,,,,Higher-than-WHO dosage group (15-20 mg/kg/day),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1278,2025-12-02T16:04:59.615593
35842213.0,Discontinuation because of drug-related adverse events,,0,,N,,,,,,10,children ,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1279,2025-12-02T16:04:59.615593
34213821.0,Adverse effect,,0,,N,,,,,,50,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1280,2025-12-02T16:04:59.615593
34213821.0,Signs of Severe LA toxicity ,,0,,N,,,,,,50,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1281,2025-12-02T16:04:59.615593
34213821.0,Fluid bolus ,,7,,N,,,,,,50,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1282,2025-12-02T16:04:59.615593
34213821.0,Second cannula removed ,,45,,N,,,,,,50,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1283,2025-12-02T16:04:59.615593
31910460.0,Number of patients had >=3 Treatment-emergent AEs,,3,,N,,,,,,13,neonates and young infants,,,,all,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1312,2025-12-02T16:04:59.615593
29742643.0,Presence of AKI,,4,,N,,,,,,43,pediactric,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1313,2025-12-02T16:04:59.615593
29742643.0,time from vancomycin initiation to AKI onset,,4,days,median,,,minmax,2,5,4,pediactric,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1314,2025-12-02T16:04:59.615593
31935538.0,Adverse drug reactions,Red man syndrome,2,,N,,,,,,14,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1315,2025-12-02T16:04:59.615593
31935538.0,Adverse drug reactions,Nephrotoxicity,0,,N,,,,,,14,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1316,2025-12-02T16:04:59.615593
31935538.0,Adverse drug reactions,Length of hospitalization stay,49,days,median,,,IQR,35,73,14,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1317,2025-12-02T16:04:59.615593
31935538.0,Adverse drug reactions,Death,0,,N,,,,,,14,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1318,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,clinical cure,38,,N,,,,,,60,children ,,,"0.11, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1319,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,clinical cure,24,,N,,,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1320,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,clinical cure,48,,N,,,,,,60,children ,,,"1, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1321,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,Death,4,,N,,,,,,60,children ,,,"0.29, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1322,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,Death,4,,N,,,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1323,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,Death,7,,N,,,,,,60,children ,,,"0.82, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1324,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,Final CRP,2.7,mg/dL,mean,SD,6.2,,,,60,children ,,,"0.85, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1325,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,Final CRP,3,mg/dL,mean,SD,3.6,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1326,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,Final CRP,2.9,mg/dL,mean,SD,5.7,,,,60,children ,,,"0.93, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1327,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,>=30 days,21,,N,,,,,,60,children ,,,"0.01, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1328,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,>=30 days,3,,N,,,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1329,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,>=30 days,10,,N,,,,,,60,children ,,,"0.4, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1330,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,Length of hospitalization stay,72.6,days,mean,SD,96.5,,,,60,children ,,,"0.98, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1331,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,Length of hospitalization stay,72,days,mean,SD,140.5,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1332,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,Length of hospitalization stay,54,days,mean,SD,70.0,,,,60,children ,,,"0.42, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1333,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,"Retreatment within 30 days, n/survivors",18/56,,,,,,,,56,children ,,,"0.02, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1334,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,"Retreatment within 30 days, n/survivors",2/26,,,,,,,,26,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1335,2025-12-02T16:04:59.615593
32636687.0,Clinical outcome,"Retreatment within 30 days, n/survivors",5/53,,,,,,,,53,children ,,,"0.8, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1336,2025-12-02T16:04:59.615593
32636687.0,Microbiological outcome,"Resistant Gram + isolates identified while on therapy or within 30 days after vancomycin discontinuation, n/survivors",4/56,,,,,,,,56,children ,,,"0.93, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1337,2025-12-02T16:04:59.615593
32636687.0,Microbiological outcome,"Resistant Gram + isolates identified while on therapy or within 30 days after vancomycin discontinuation, n/survivors",2/26,,,,,,,,26,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1338,2025-12-02T16:04:59.615593
32636687.0,Microbiological outcome,"Resistant Gram + isolates identified while on therapy or within 30 days after vancomycin discontinuation, n/survivors",4/53,,,,,,,,53,children ,,,"0.98, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1339,2025-12-02T16:04:59.615593
32636687.0,Number of patients with daily dose >=60 mg/kg/day,,10,,N,,,,,,60,children ,,,"0.02, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1340,2025-12-02T16:04:59.615593
32636687.0,Number of patients with daily dose >=60 mg/kg/day,,12,,N,,,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1341,2025-12-02T16:04:59.615593
32636687.0,Number of patients with daily dose >=60 mg/kg/day,,12,,N,,,,,,60,children ,,,"0.05, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1342,2025-12-02T16:04:59.615593
32636687.0,Number of patients requiring dose adjustment,,45,,N,,,,,,60,children ,,,"<0.001, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1343,2025-12-02T16:04:59.615593
32636687.0,Number of patients requiring dose adjustment,,10,,N,,,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1344,2025-12-02T16:04:59.615593
32636687.0,Number of patients requiring dose adjustment,,15,,N,,,,,,60,children ,,,"0.41, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1345,2025-12-02T16:04:59.615593
32636687.0,Number of dose adjustments per patients,,1.9,,mean,SD,1.8,,,,60,children ,,,"<0.001, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1346,2025-12-02T16:04:59.615593
32636687.0,Number of dose adjustments per patients,,0.6,,mean,SD,1.2,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1347,2025-12-02T16:04:59.615593
32636687.0,Number of dose adjustments per patients,,0.5,,mean,SD,1.3,,,,60,children ,,,"0.69, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1348,2025-12-02T16:04:59.615593
32636687.0,Renal function outcome,Final SCr,0.4,mg/dL,mean,SD,0.1,,,,60,children ,,,"0.06, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1349,2025-12-02T16:04:59.615593
32636687.0,Renal function outcome,Final SCr,0.6,mg/dL,mean,SD,1.1,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1350,2025-12-02T16:04:59.615593
32636687.0,Renal function outcome,Final SCr,0.5,mg/dL,mean,SD,0.5,,,,60,children ,,,"0.35, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1351,2025-12-02T16:04:59.615593
32636687.0,Renal function outcome,GFR,112.4,ml/min,mean,SD,42.9,,,,60,children ,,,"0.17, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1352,2025-12-02T16:04:59.615593
32636687.0,Renal function outcome,GFR,95.8,ml/min,mean,SD,52.3,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1353,2025-12-02T16:04:59.615593
32636687.0,Renal function outcome,GFR,108.3,ml/min,mean,SD,54.6,,,,60,children ,,,"0.36, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1354,2025-12-02T16:04:59.615593
32636687.0,Renal function outcome,Renal event,2,,N,,,,,,60,children ,,,"0.19, Lower-Trough vs
High-Trough",Lower-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1355,2025-12-02T16:04:59.615593
32636687.0,Renal function outcome,Renal event,3,,N,,,,,,30,children ,,,,High-Trough cohort (reference),PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1356,2025-12-02T16:04:59.615593
32636687.0,Renal function outcome,Renal event,3,,N,,,,,,60,children ,,,"0.37, Low-Trough vs
High-Trough",Low-Trough cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1357,2025-12-02T16:04:59.615593
32641912.0,Elevated EOT creatinine,,6.1,%,mean,,,,,,77,children ,,,0.4073,Standard dose cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1358,2025-12-02T16:04:59.615593
32641912.0,Elevated EOT creatinine,,2.7,%,mean,,,,,,74,children ,,,0.4073,Loading dose cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1359,2025-12-02T16:04:59.615593
32641912.0,Oliguria at EOT,,2.4,%,mean,,,,,,77,children ,,,0.3584,Standard dose cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1360,2025-12-02T16:04:59.615593
32641912.0,Oliguria at EOT,,5.5,%,mean,,,,,,74,children ,,,0.3584,Loading dose cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1361,2025-12-02T16:04:59.615593
32641912.0,Length of hospital stay,,22.3,days,mean,,,,,,77,children ,,,0.3292,Standard dose cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1362,2025-12-02T16:04:59.615593
32641912.0,Length of hospital stay,,25.5,days,mean,,,,,,74,children ,,,0.3292,Loading dose cohort,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1363,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC,,254.73,mg h/L,median,,,interquartile range,165.89,508.06,8,Neonates,,,0.12,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1364,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC,,452.09,mg h/L,median,,,interquartile range,366.85,674.27,12,Infants,,,0.12,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1365,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC,,433.18,mg h/L,median,,,interquartile range,421.82,737.08,9,children ,,<10 years,0.12,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1366,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC,,590.49,mg h/L,median,,,interquartile range,535.02,745.03,11,children ,,>=10 years,0.12,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1367,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC <400 mg h/L,,5,,N,,,,,,8,Neonates,,,0.07,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1368,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC <400 mg h/L,,3,,N,,,,,,12,Infants,,,0.07,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1369,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC <400 mg h/L,,2,,N,,,,,,9,children ,,<10 years,0.07,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1370,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC <400 mg h/L,,1,,N,,,,,,11,children ,,>=10 years,0.07,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1371,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC >=400 mg h/L,,3,,N,,,,,,8,Neonates,,,0.02,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1372,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC >=400 mg h/L,,9,,N,,,,,,12,Infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1373,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC >=400 mg h/L,,7,,N,,,,,,9,children ,,<10 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1374,2025-12-02T16:04:59.615593
33789546.0,AUCintra/MIC >=400 mg h/L,,10,,N,,,,,,11,children ,,>=10 years,0.02,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1375,2025-12-02T16:04:59.615593
33793589.0,initial AUC/MIC,,336.4,,median,,,interquartile range,271.4,422.6,73,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1376,2025-12-02T16:04:59.615593
33830468.0,outcome,discharge,46,,N,,,,,,65,pediactric,,,0.23,"Pre-protocl, 2016",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1377,2025-12-02T16:04:59.615593
33830468.0,outcome,death,19,,N,,,,,,66,pediactric,,,0.23,"Pre-protocl, 2016",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1378,2025-12-02T16:04:59.615593
33830468.0,outcome,hospital transfer,0,,N,,,,,,67,pediactric,,,0.23,"Pre-protocl, 2016",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1379,2025-12-02T16:04:59.615593
33830468.0,outcome,discharge,52,,N,,,,,,68,pediactric,,,0.23,"Post-protocl, 2018",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1380,2025-12-02T16:04:59.615593
33830468.0,outcome,death,12,,N,,,,,,69,pediactric,,,0.23,"Post-protocl, 2018",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1381,2025-12-02T16:04:59.615593
33830468.0,outcome,hospital transfer,1,,N,,,,,,70,pediactric,,,0.23,"Post-protocl, 2018",PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1382,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,<400,4,,N,,,,,,10,pediactric,,<1 month,,daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1383,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,<400,185,,N,,,,,,267,pediactric,,>=1 month,,daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1384,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,<400,61,,N,,,,,,119,pediactric,,>=1 month,,daily dose of vancomycin 60 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1385,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,=400-600,3,,N,,,,,,10,pediactric,,<1 month,,daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1386,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,=400-600,57,,N,,,,,,267,pediactric,,>=1 month,,daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1387,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,=400-600,44,,N,,,,,,119,pediactric,,>=1 month,,daily dose of vancomycin 60 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1388,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,>600,3,,N,,,,,,10,pediactric,,<1 month,,daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1389,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,>600,25,,N,,,,,,267,pediactric,,>=1 month,,daily dose of vancomycin 40 mg/kg/d ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1390,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,>600,14,,N,,,,,,119,pediactric,,>=1 month,,daily dose of vancomycin 60 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1391,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,<400,114,,N,,,,,,180,pediactric,,,,eGFR 50-130 ml/min with daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1392,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,<400,70,,N,,,,,,80,pediactric,,,,eGFR >130 ml/min with daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1393,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,<400,36,,N,,,,,,86,pediactric,,,,eGFR 50-130 ml/min with daily dose of vancomycin 60 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1394,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,<400,23,,N,,,,,,29,pediactric,,,,eGFR >130 ml/min with daily dose of vancomycin 60 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1395,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,=400-600,46,,N,,,,,,180,pediactric,,,,eGFR 50-130 ml/min with daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1396,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,=400-600,10,,N,,,,,,80,pediactric,,,,eGFR >130 ml/min with daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1397,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,=400-600,38,,N,,,,,,86,pediactric,,,,eGFR 50-130 ml/min with daily dose of vancomycin 60 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1398,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,=400-600,6,,N,,,,,,29,pediactric,,,,eGFR >130 ml/min with daily dose of vancomycin 60 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1399,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,>600,20,,N,,,,,,180,pediactric,,,,eGFR 50-130 ml/min with daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1400,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,>600,0,,N,,,,,,80,pediactric,,,,eGFR >130 ml/min with daily dose of vancomycin 40 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1401,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,>600,12,,N,,,,,,86,pediactric,,,,eGFR 50-130 ml/min with daily dose of vancomycin 60 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1402,2025-12-02T16:04:59.615593
34664790.0,AUC24/MIC,>600,0,,N,,,,,,29,pediactric,,,,eGFR >130 ml/min with daily dose of vancomycin 60 mg/kg/d,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1403,2025-12-02T16:04:59.615593
35465728.0,Initial average concentration/MIC ratio,<8,10,,N,,,,,,22,neonates,,,,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1404,2025-12-02T16:04:59.615593
35465728.0,Initial average concentration/MIC ratio,<8,2,,N,,,,,,17,neonates,,,,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1405,2025-12-02T16:04:59.615593
35465728.0,Initial average concentration/MIC ratio,>=8,12,,N,,,,,,22,neonates,,,,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1406,2025-12-02T16:04:59.615593
35465728.0,Initial average concentration/MIC ratio,>=8,15,,N,,,,,,17,neonates,,,,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1407,2025-12-02T16:04:59.615593
35465728.0,Initial average concentration/MIC ratio,,8.8,,median,,,25th-75th percentiles,6.2,11.5,22,neonates,,,0.004,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1408,2025-12-02T16:04:59.615593
35465728.0,Initial average concentration/MIC ratio,,12.8,,median,,,25th-75th percentiles,10.9,20.9,17,neonates,,,0.004,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1409,2025-12-02T16:04:59.615593
35465728.0,Initial AUC/MIC ratio,<400,20,,N,,,,,,22,neonates,,,,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1410,2025-12-02T16:04:59.615593
35465728.0,Initial AUC/MIC ratio,<400,10,,N,,,,,,17,neonates,,,,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1411,2025-12-02T16:04:59.615593
35465728.0,Initial AUC/MIC ratio,>=400,2,,N,,,,,,22,neonates,,,,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1412,2025-12-02T16:04:59.615593
35465728.0,Initial AUC/MIC ratio,>=400,7,,N,,,,,,17,neonates,,,,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1413,2025-12-02T16:04:59.615593
35465728.0,Initial AUC/MIC ratio,,211,,median,,,25th-75th percentiles,149,275,22,neonates,,,0.006,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1414,2025-12-02T16:04:59.615593
35465728.0,Initial AUC/MIC ratio,,307,,median,,,25th-75th percentiles,262,502,17,neonates,,,0.006,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1415,2025-12-02T16:04:59.615593
35465728.0,Antibiotic switch,,9/31,,N,,,,,,60,neonates,,,0.025,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1416,2025-12-02T16:04:59.615593
35465728.0,Antibiotic switch,,1/22,,N,,,,,,58,neonates,,,0.025,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1417,2025-12-02T16:04:59.615593
35465728.0,Biological parameters,Nephrotoxicity,1,,N,,,,,,59,neonates,,,0.54,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1418,2025-12-02T16:04:59.615593
35465728.0,Biological parameters,Nephrotoxicity,2,,N,,,,,,57,neonates,,,0.54,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1419,2025-12-02T16:04:59.615593
35465728.0,Biological parameters,Time to blood culture negativation,54.6,h,median,,,25th-75th percentiles,48.9,107,31,neonates,,,<0.001,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1420,2025-12-02T16:04:59.615593
35465728.0,Biological parameters,Time to blood culture negativation,37.5,h,median,,,25th-75th percentiles,28.1,53.6,22,neonates,,,<0.001,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1421,2025-12-02T16:04:59.615593
35465728.0,Biological parameters,relapse,3,,N,,,,,,31,neonates,,,0.13,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1422,2025-12-02T16:04:59.615593
35465728.0,Biological parameters,relapse,0,,N,,,,,,22,neonates,,,0.13,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1423,2025-12-02T16:04:59.615593
35465728.0,Biological parameters,decrease of inflammatory syndrome,4,,N,,,,,,23,neonates,,,0.12,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1424,2025-12-02T16:04:59.615593
35465728.0,Biological parameters,decrease of inflammatory syndrome,8,,N,,,,,,21,neonates,,,0.12,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1425,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Increased respiratory support,26,,N,,,,,,60,neonates,,,0.15,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1426,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Increased respiratory support,18,,N,,,,,,59,neonates,,,0.15,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1427,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Duration of vasoactive drugs use,3.5,days,median,,,25th-75th percentiles,1,9,18,neonates,,,0.18,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1428,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Duration of vasoactive drugs use,1.5,days,median,,,25th-75th percentiles,1,5,10,neonates,,,0.18,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1429,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Duration of parenteral nutrition,16,days,median,,,25th-75th percentiles,9,25,53,neonates,,,0.87,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1430,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Duration of parenteral nutrition,17,days,median,,,25th-75th percentiles,9,29,49,neonates,,,0.87,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1431,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Duration of insulin therapy,5,days,median,,,25th-75th percentiles,3,7,9,neonates,,,0.81,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1432,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Duration of insulin therapy,4,days,median,,,25th-75th percentiles,2,7.5,15,neonates,,,0.81,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1433,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Catheter removal,12,,N,,,,,,31,neonates,,,0.62,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1434,2025-12-02T16:04:59.615593
35465728.0,Immediate clinical outcomes,Catheter removal,10,,N,,,,,,22,neonates,,,0.62,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1435,2025-12-02T16:04:59.615593
35465728.0,Consequences on morbidities,Severe bronchopulmonary dysplasia,10,,N,,,,,,29,neonates,,,0.066,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1436,2025-12-02T16:04:59.615593
35465728.0,Consequences on morbidities,Severe bronchopulmonary dysplasia,5,,N,,,,,,34,neonates,,,0.066,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1437,2025-12-02T16:04:59.615593
35465728.0,Consequences on morbidities,Periventricular leukomalacia,7,,N,,,,,,31,neonates,,,0.021,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1438,2025-12-02T16:04:59.615593
35465728.0,Consequences on morbidities,Periventricular leukomalacia,1,,N,,,,,,35,neonates,,,0.021,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1439,2025-12-02T16:04:59.615593
35465728.0,Consequences on morbidities,Total duration of hospitalization,86.5,days,median,,,25th-75th percentiles,46.3,107,36,neonates,,,0.75,before-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1440,2025-12-02T16:04:59.615593
35465728.0,Consequences on morbidities,Total duration of hospitalization,86.5,days,median,,,25th-75th percentiles,55,123,46,neonates,,,0.75,after-implementation group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1441,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level before dose adjustment,Not achieved,18,,N,,,,,,48,children ,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1442,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level before dose adjustment,Not achieved,11,,N,,,,,,36,children ,,,,non-SCD patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1443,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level before dose adjustment,Not achieved,7,,N,,,,,,12,children ,,,,sickle cell disease patients with  acute chest syndrome ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1444,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level before dose adjustment,Achieved,30,,N,,,,,,48,children ,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1445,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level before dose adjustment,Achieved,25,,N,,,,,,36,children ,,,,non-SCD patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1446,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level before dose adjustment,Achieved,15,,N,,,,,,12,children ,,,,sickle cell disease patients with  acute chest syndrome ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1447,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level post dose adjustment,Not achieved,12,,N,,,,,,48,children ,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1448,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level post dose adjustment,Not achieved,5,,N,,,,,,36,children ,,,,non-SCD patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1449,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level post dose adjustment,Not achieved,7,,N,,,,,,12,children ,,,,sickle cell disease patients with  acute chest syndrome ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1450,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level post dose adjustment,Achieved,36,,N,,,,,,48,children ,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1451,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level post dose adjustment,Achieved,31,,N,,,,,,36,children ,,,,non-SCD patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1452,2025-12-02T16:04:59.615593
35688759.0,achievement of therapeutic trough level post dose adjustment,Achieved,5,,N,,,,,,12,children ,,,,sickle cell disease patients with  acute chest syndrome ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1453,2025-12-02T16:04:59.615593
35688759.0,achievement of target AUC (400-600 mg h/L),Not achieved,27,,N,,,,,,48,children ,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1454,2025-12-02T16:04:59.615593
35688759.0,achievement of target AUC (400-600 mg h/L),Not achieved,17,,N,,,,,,36,children ,,,,non-SCD patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1455,2025-12-02T16:04:59.615593
35688759.0,achievement of target AUC (400-600 mg h/L),Not achieved,10,,N,,,,,,12,children ,,,,sickle cell disease patients with  acute chest syndrome ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1456,2025-12-02T16:04:59.615593
35688759.0,achievement of target AUC (400-600 mg h/L),Achieved,21,,N,,,,,,48,children ,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1457,2025-12-02T16:04:59.615593
35688759.0,achievement of target AUC (400-600 mg h/L),Achieved,19,,N,,,,,,36,children ,,,,non-SCD patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1458,2025-12-02T16:04:59.615593
35688759.0,achievement of target AUC (400-600 mg h/L),Achieved,2,,N,,,,,,12,children ,,,,sickle cell disease patients with  acute chest syndrome ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1459,2025-12-02T16:04:59.615593
35688759.0,Days until achievement of therapeutic trough level,,2,days,median,,,IQR,3,,48,children ,,,0.009,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1460,2025-12-02T16:04:59.615593
35688759.0,Days until achievement of therapeutic trough level,,2024-01-22 00:00:00,days,median,,,IQR,1.625,,36,children ,,,0.009,non-SCD patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1461,2025-12-02T16:04:59.615593
35688759.0,Days until achievement of therapeutic trough level,,4.75,days,median,,,IQR,6.375,,12,children ,,,0.009,sickle cell disease patients with  acute chest syndrome ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1462,2025-12-02T16:04:59.615593
35844752.0,Treatment outcome,Good outcome,84,,N,,,,,,110,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1463,2025-12-02T16:04:59.615593
35844752.0,Treatment outcome,Poor outcome,26,,N,,,,,,110,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1464,2025-12-02T16:04:59.615593
35844752.0,Clinical efficacy of vancomycin,Effective,76,,N,,,,,,110,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1465,2025-12-02T16:04:59.615593
35844752.0,Clinical efficacy of vancomycin,Ineffective,34,,N,,,,,,110,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1466,2025-12-02T16:04:59.615593
35844752.0,Adverse reactions,Nephrotoxicity,15,,N,,,,,,110,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1467,2025-12-02T16:04:59.615593
35844752.0,Adverse reactions,Rash,7,,N,,,,,,110,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1468,2025-12-02T16:04:59.615593
35844752.0,APACHE II Score,,30,,mean,SD,7.0,,,,76,children ,,,0.676,effective group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1469,2025-12-02T16:04:59.615593
35844752.0,APACHE II Score,,29,,mean,SD,8.0,,,,34,children ,,,0.676,ineffective group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1470,2025-12-02T16:04:59.615593
35844752.0,LOS of hospital,,29,days,median,,,IQR,20,47,76,children ,,,0.11,effective group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1471,2025-12-02T16:04:59.615593
35844752.0,LOS of hospital,,27,days,median,,,IQR,16,38,34,children ,,,0.11,ineffective group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1472,2025-12-02T16:04:59.615593
35844752.0,LOC of ICU,,11,days,median,,,IQR,7,18,76,children ,,,0.935,effective group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1473,2025-12-02T16:04:59.615593
35844752.0,LOC of ICU,,12,days,median,,,IQR,8,19,34,children ,,,0.935,ineffective group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1474,2025-12-02T16:04:59.615593
35844752.0,Mechanical ventilation time,,169,hours,median,,,IQR,90,314,76,children ,,,0.992,effective group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1475,2025-12-02T16:04:59.615593
35844752.0,Mechanical ventilation time,,172,hours,median,,,IQR,84,478,34,children ,,,0.992,ineffective group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1476,2025-12-02T16:04:59.615593
35844752.0,APACHE II Score,,29,,mean,SD,5.0,,,,49,children ,,,0.735,Pathogen-cleared group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1477,2025-12-02T16:04:59.615593
35844752.0,APACHE II Score,,29,,mean,SD,5.0,,,,17,children ,,,0.735,Pathogen-uncleared group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1478,2025-12-02T16:04:59.615593
35844752.0,AUC02-4/MIC,,833.02,mg h/L,median,,,IQR,562.65,1058.96,49,children ,,,0.288,Pathogen-cleared group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1479,2025-12-02T16:04:59.615593
35844752.0,AUC02-4/MIC,,622.47,mg h/L,median,,,IQR,433.71,1032.42,17,children ,,,0.288,Pathogen-uncleared group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1480,2025-12-02T16:04:59.615593
35844752.0,APACHE II Score,,29,,mean,SD,7.0,,,,95,children ,,,0.001,Non-nephrotoxic group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1481,2025-12-02T16:04:59.615593
35844752.0,APACHE II Score,,36,,mean,SD,7.0,,,,15,children ,,,0.001,Nephrotoxic group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1482,2025-12-02T16:04:59.615593
35844752.0,AUC02-4/MIC,,478.8,mg h/L,median,,,IQR,374.34,579.55,95,children ,,,0.001,Non-nephrotoxic group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1483,2025-12-02T16:04:59.615593
35844752.0,AUC02-4/MIC,,763.24,mg h/L,median,,,IQR,464.81,1297.89,15,children ,,,0.001,Nephrotoxic group,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1484,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event,,40,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1485,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Upper respiratory tract infection ,12,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1486,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Diarrhoea,5,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1487,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Headache,4,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1488,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Cough,3,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1489,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Influenza,6,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1490,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Nasopharyngitis,3,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1491,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Respiratory tract infection ,3,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1492,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Vomiting,2,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1493,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Allergic rhinitis,5,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1494,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Abdominal pain,3,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1495,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Streptococcal pharyngitis ,0,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1496,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Tonsillitis,2,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1497,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Urinary tract infection ,5,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1498,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Viral upper respiratory tract infection,4,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1499,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Decreased appetite,2,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1500,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event,,41,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1501,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Upper respiratory tract infection ,14,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1502,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Diarrhoea,6,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1503,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Headache,5,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1504,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Cough,6,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1505,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Influenza,2,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1506,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Nasopharyngitis,3,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1507,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Respiratory tract infection ,3,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1508,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Vomiting,4,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1509,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Allergic rhinitis,1,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1510,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Abdominal pain,2,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1511,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Streptococcal pharyngitis ,5,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1512,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Tonsillitis,3,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1513,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Urinary tract infection ,0,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1514,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Viral upper respiratory tract infection,1,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1515,2025-12-02T16:04:59.615593
34302760.0,Any grade adverse event (≥5% in all participants) ,Decreased appetite,3,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1516,2025-12-02T16:04:59.615593
34302760.0,Grade 3 or 4 adverse event,,3,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1517,2025-12-02T16:04:59.615593
34302760.0,Grade 3 or 4 adverse event,,0,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1518,2025-12-02T16:04:59.615593
34302760.0,Adverse event attributed to study drug,,3,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1519,2025-12-02T16:04:59.615593
34302760.0,Adverse event attributed to study drug,,8,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1520,2025-12-02T16:04:59.615593
34302760.0,Serious adverse event,,3,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1521,2025-12-02T16:04:59.615593
34302760.0,Serious adverse event,,0,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1522,2025-12-02T16:04:59.615593
34302760.0,Adverse evnet leading to study drug discontinuation,,0,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1523,2025-12-02T16:04:59.615593
34302760.0,Adverse evnet leading to study drug discontinuation,,1,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1524,2025-12-02T16:04:59.615593
34302760.0,Death,,0,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1525,2025-12-02T16:04:59.615593
34302760.0,Death,,0,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1526,2025-12-02T16:04:59.615593
34302760.0,Virological suppression (HIV-1 RNA <50 copies per mL) ,at weeks 24,50,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1527,2025-12-02T16:04:59.615593
34302760.0,Virological suppression (HIV-1 RNA <50 copies per mL) ,at weeks 48,49,,N,,,,,,50,adolescents ,,aged 12 to <18 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1528,2025-12-02T16:04:59.615593
34302760.0,Virological suppression (HIV-1 RNA <50 copies per mL) ,at weeks 24,50,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1529,2025-12-02T16:04:59.615593
34302760.0,Virological suppression (HIV-1 RNA <50 copies per mL) ,at weeks 48,49,,N,,,,,,50,children,,aged 6 to <12 years ,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1530,2025-12-02T16:04:59.615593
34302760.0,Virological suppression (HIV-1 RNA <50 copies per mL) ,at weeks 24,100,,N,,,,,,100,adolescents and children,,overall,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1531,2025-12-02T16:04:59.615593
34302760.0,Virological suppression (HIV-1 RNA <50 copies per mL) ,at weeks 48,98,,N,,,,,,100,adolescents and children,,overall,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1532,2025-12-02T16:04:59.615593
30358179.0,infnat infection status,confirmed uninfected,11,,N,,,,,,17,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1533,2025-12-02T16:04:59.615593
30358179.0,infnat infection status,Indeterminate,4,,N,,,,,,17,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1534,2025-12-02T16:04:59.615593
30358179.0,infnat infection status,Uninfected by best available data,3,,N,,,,,,17,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1535,2025-12-02T16:04:59.615593
30358179.0,Gestational age at delivery,,39.1,weeks,median,,,IQR,38,40.4,17,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1536,2025-12-02T16:04:59.615593
30358179.0,birth weight,,3165,g,median,,,IQR,2910,3515,17,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1537,2025-12-02T16:04:59.615593
30358179.0,length,,49,cm,median,,,IQR,48.3,51,17,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1538,2025-12-02T16:04:59.615593
32015036.0,birth weight,,3237.5,g,median,,,IQR,2935,3477.9,29,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1539,2025-12-02T16:04:59.615593
32015036.0,No. of infants with infection status,uninfected,26,,N,,,,,,29,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1540,2025-12-02T16:04:59.615593
32015036.0,No. of infants with infection status,indeterminate,2,,N,,,,,,29,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1541,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 adverse events ,,11,,N,,,95% CI,23.4,63.1,26,children ,,,,all treated,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1543,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 drug-related adverse events ,,3,,N,,,95% CI,2.4,30.2,26,children ,,,,all treated,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1544,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 adverse events ,,5,,N,,,95% CI,11,58.7,16,children ,,1 to<6 years,,Participants started on final weight-band based dose ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1545,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 drug-related adverse events ,,2,,N,,,95% CI,1.6,38.3,16,children ,,1 to<6 years,,Participants started on final weight-band based dose ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1546,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 adverse events through week 48,,4,,N,,,95% CI,10.9,69.2,11,children ,,1 to<6 years,,Participants receiving final weight band based dose through week 48 ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1547,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 drug-related adverse events through week 48,,2,,N,,,95% CI,2.3,51.8,11,children ,,1 to<6 years,,Participants receiving final weight band based dose through week 48 ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1548,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 adverse events ,,5,,N,,,95% CI,35.9,99.6,6,children ,,0 to <2 years,,Participants started on final weight-band based dose ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1549,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 drug-related adverse events ,,0,,N,,,95% CI,0,45.9,6,children ,,0 to <2 years,,Participants started on final weight-band based dose ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1550,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 adverse events through week 48,,4,,N,,,95% CI,39.8,100,4,children ,,0 to <2 years,,Participants receiving final weight band based dose through week 48 ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1551,2025-12-02T16:04:59.615593
33831904.0,With grade >=3 drug-related adverse events through week 48,,0,,N,,,95% CI,0,60.2,4,children ,,0 to <2 years,,Participants receiving final weight band based dose through week 48 ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1552,2025-12-02T16:04:59.615593
33831904.0,Number with virologic failures by week 48,,8,,N,,,95% CI,14.3,51.8,26,children ,,,,all treated,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1553,2025-12-02T16:04:59.615593
33831904.0,Number with virologic failures by week 48,,5,,N,,,95% CI,7.3,52.4,16,children ,,1 to<6 years,,Participants started on final weight-band based dose ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1554,2025-12-02T16:04:59.615593
33831904.0,Number with virologic failures by week 48,,3,,N,,,95% CI,6,61,11,children ,,1 to<6 years,,Participants receiving final weight band based dose through week 48 ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1555,2025-12-02T16:04:59.615593
33831904.0,Number with virologic failures by week 48,,4,,N,,,95% CI,22.3,95.7,6,children ,,0 to <2 years,,Participants started on final weight-band based dose ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1556,2025-12-02T16:04:59.615593
33831904.0,Number with virologic failures by week 48,,3,,N,,,95% CI,19.4,99.4,4,children ,,0 to <2 years,,Participants receiving final weight band based dose through week 49,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1557,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater events through week 48,,10,,N,,,95% CI,20.2,59.4,26,children ,,>=2 years to <6 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1558,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater clinical events through week 48,,5,,N,,,95% CI,6.6,39.4,26,children ,,>=2 years to <6 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1559,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater laboratory events through week 48,,6,,N,,,95% CI,9,43.7,26,children ,,>=2 years to <6 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1560,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related events through week 48,,0,,N,,,95% CI,0,13.2,26,children ,,>=2 years to <6 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1561,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related clinical events through week 48,,0,,N,,,95% CI,0,13.2,26,children ,,>=2 years to <6 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1562,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related laboratory events through week 48,,0,,N,,,95% CI,0,13.2,26,children ,,>=2 years to <6 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1563,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater events through week 48,,12,,N,,,95% CI,32.2,75.6,22,infants and children,,>=6 months to <2 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1564,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater clinical events through week 48,,4,,N,,,95% CI,5.2,40.3,22,infants and children,,>=6 months to <2 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1565,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater laboratory events through week 48,,9,,N,,,95% CI,20.7,63.7,22,infants and children,,>=6 months to <2 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1566,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related events through week 48,,0,,N,,,95% CI,0,15.4,22,infants and children,,>=6 months to <2 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1567,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related clinical events through week 48,,0,,N,,,95% CI,0,15.4,22,infants and children,,>=6 months to <2 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1568,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related laboratory events through week 48,,0,,N,,,95% CI,0,15.4,22,infants and children,,>=6 months to <2 years,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1569,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater events through week 48,,16,,N,,,95% CI,42.5,82,25,infants,,>=4 weeks to <6 months,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1570,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater clinical events through week 48,,3,,N,,,95% CI,2.6,31.2,25,infants,,>=4 weeks to <6 months,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1571,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater laboratory events through week 48,,14,,N,,,95% CI,34.9,75.6,25,infants,,>=4 weeks to <6 months,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1572,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related events through week 48,,0,,N,,,95% CI,0,13.7,25,infants,,>=4 weeks to <6 months,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1573,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related clinical events through week 48,,0,,N,,,95% CI,0,13.7,25,infants,,>=4 weeks to <6 months,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1574,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related laboratory events through week 48,,0,,N,,,95% CI,0,13.7,25,infants,,>=4 weeks to <6 months,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1575,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater events through week 48,,38,,N,,,95% CI,40,63.9,73,infants and children,,,,total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1576,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater clinical events through week 48,,12,,N,,,95% CI,8.8,27,73,infants and children,,,,total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1577,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater laboratory events through week 48,,29,,N,,,95% CI,28.5,51.9,73,infants and children,,,,total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1578,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related events through week 48,,0,,N,,,95% CI,0,4.9,73,infants and children,,,,total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1579,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related clinical events through week 48,,0,,N,,,95% CI,0,4.9,73,infants and children,,,,total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1580,2025-12-02T16:04:59.615593
35489377.0,With Grade 3 or greater drug related laboratory events through week 48,,0,,N,,,95% CI,0,4.9,73,infants and children,,,,total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1581,2025-12-02T16:04:59.615593
35868341.0,Safety follow-up,,31,weeks,median,,,IQR,28,34,17,children,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1582,2025-12-02T16:04:59.615593
35868341.0,Safety follow-up,,,,,,,minmax,8,44,17,children,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1583,2025-12-02T16:04:59.615593
35868341.0,Safety follow-up,,37,weeks,median,,,IQR,30,43,20,children,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1584,2025-12-02T16:04:59.615593
35868341.0,Safety follow-up,,,,,,,minmax,26,147,20,children,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1585,2025-12-02T16:04:59.615593
35868341.0,Safety follow-up,,31,weeks,median,,,IQR,30,40,37,children,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1586,2025-12-02T16:04:59.615593
35868341.0,Safety follow-up,,,,,,,minmax,8,147,37,children,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1587,2025-12-02T16:04:59.615593
35868341.0,Number of safety follow-up periods,1,15,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1588,2025-12-02T16:04:59.615593
35868341.0,Number of safety follow-up periods,2,2,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1589,2025-12-02T16:04:59.615593
35868341.0,Number of safety follow-up periods,3,0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1590,2025-12-02T16:04:59.615593
35868341.0,Number of safety follow-up periods,1,18,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1591,2025-12-02T16:04:59.615593
35868341.0,Number of safety follow-up periods,2,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1592,2025-12-02T16:04:59.615593
35868341.0,Number of safety follow-up periods,3,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1593,2025-12-02T16:04:59.615593
35868341.0,Number of safety follow-up periods,1,33,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1594,2025-12-02T16:04:59.615593
35868341.0,Number of safety follow-up periods,2,3,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1595,2025-12-02T16:04:59.615593
35868341.0,Number of safety follow-up periods,3,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1596,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Total,5,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1597,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Cardiovascular: deep vein thrombosis,0,,,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1598,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Hepatic: drug-induced liver injury,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1599,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,"Nervous system: epilepsy, fits, and convulsions",0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1600,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Renal: renal failure chronic,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1601,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,injury: trauma,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1602,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Skin: rash maculopapular and upper respiratory infection,0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1603,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Systemic: kwashiorkor,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1604,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,"Infectious disease: Acute febrile episode, undiagnosed",0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1605,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,"Infectious disease: TB, disseminated or miliary",1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1606,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Total,5,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1607,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Cardiovascular: deep vein thrombosis,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1608,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Hepatic: drug-induced liver injury,0,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1609,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,"Nervous system: epilepsy, fits, and convulsions",1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1610,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Injruty: trauma,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1611,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Renal: renal failure chronic,0,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1612,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Skin: rash maculopapular and upper respiratory infection,0,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1613,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Systemic: kwashiorkor,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1614,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,"Infectious disease: Acute febrile episode, undiagnosed",0,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1615,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,"Infectious disease: TB, disseminated or miliary",1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1616,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Total,10,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1617,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Cardiovascular: deep vein thrombosis,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1618,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Hepatic: drug-induced liver injury,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1619,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,"Nervous system: epilepsy, fits, and convulsions",1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1620,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,injury: trauma,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1621,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Renal: renal failure chronic,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1622,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Skin: rash maculopapular and upper respiratory infection,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1623,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,Systemic: kwashiorkor,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1624,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,"Infectious disease: Acute febrile episode, undiagnosed",1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1625,2025-12-02T16:04:59.615593
35868341.0,Number of serious adverse events ,"Infectious disease: TB, disseminated or miliary",2,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1626,2025-12-02T16:04:59.615593
35868341.0,Person-years of follow-up,,9.1,,,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1627,2025-12-02T16:04:59.615593
35868341.0,Person-years of follow-up,,16.4,,,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1628,2025-12-02T16:04:59.615593
35868341.0,Person-years of follow-up,,25.5,,,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1629,2025-12-02T16:04:59.615593
35868341.0,Grade>=3 adverse event rate per 100 person-years,,66,,,,,95% CI,24,143,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1630,2025-12-02T16:04:59.615593
35868341.0,Grade>=3 adverse event rate per 100 person-years,,55,,,,,95% CI,25,104,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1631,2025-12-02T16:04:59.615593
35868341.0,Grade>=3 adverse event rate per 100 person-years,,59,,,,,95% CI,33,97,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1632,2025-12-02T16:04:59.615593
35868341.0,Incidence rate ratio,,1,,,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1633,2025-12-02T16:04:59.615593
35868341.0,Incidence rate ratio,,0.83,,,,,,,,20,children ,0.26,2.84,0.72,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1634,2025-12-02T16:04:59.615593
35868341.0,Person-years of follow-up on currently licensed dolutegravir dose,,6.3,,,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1635,2025-12-02T16:04:59.615593
35868341.0,Person-years of follow-up on currently licensed dolutegravir dose,,8.7,,,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1636,2025-12-02T16:04:59.615593
35868341.0,Person-years of follow-up on currently licensed dolutegravir dose,,14.9,,,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1637,2025-12-02T16:04:59.615593
35868341.0,Grade>=3 adverse event rate per 100 person-years on currently liscensed dolutegravir doses,,48,,,,,95% CI,10,140,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1638,2025-12-02T16:04:59.615593
35868341.0,Grade>=3 adverse event rate per 100 person-years on currently liscensed dolutegravir doses,,46,,,,,95% CI,13,118,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1639,2025-12-02T16:04:59.615593
35868341.0,Grade>=3 adverse event rate per 100 person-years on currently liscensed dolutegravir doses,,47,,,,,95% CI,19,97,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1640,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Total,6,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1641,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Cardiovascular: deep vein thrombosis,0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1642,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Hepatic: drug-induced liver injury,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1643,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,"Nervous system: epilepsy, fits, and convulsions",0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1644,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,injury: trauma,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1645,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Renal: renal failure chronic,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1646,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Systemic: kwashiorkor,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1647,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1648,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological: Anaemia with clinical symptoms,0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1649,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological: Anaemia with no clinical symptoms,0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1650,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological: Neutropenia,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1651,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Infectious disease,1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1652,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,"Infectious disease: Acute febrile episode, undiagnosed",0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1653,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Infectious disease: Hepatitis A virus,0,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1654,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,"Infectious disease: TB, disseminated or miliary",1,,N,,,,,,17,children ,,,,Not enrolled in pharmacolinetic substudy,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1655,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Total,9,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1656,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Cardiovascular: deep vein thrombosis,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1657,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Hepatic: drug-induced liver injury,0,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1658,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,"Nervous system: epilepsy, fits, and convulsions",1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1659,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,injury: trauma,0,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1660,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Renal: renal failure chronic,0,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1661,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Systemic: kwashiorkor,0,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1662,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological,3,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1663,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological: Anaemia with clinical symptoms,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1664,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological: Anaemia with no clinical symptoms,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1665,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological: Neutropenia,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1666,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Infectious disease,4,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1667,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,"Infectious disease: Acute febrile episode, undiagnosed",1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1668,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Infectious disease: Hepatitis A virus,1,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1669,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,"Infectious disease: TB, disseminated or miliary",2,,N,,,,,,20,children ,,,,Pharmacokinetic substudy participants,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1670,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Total,15,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1671,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Cardiovascular: deep vein thrombosis,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1672,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Hepatic: drug-induced liver injury,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1673,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,"Nervous system: epilepsy, fits, and convulsions",1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1674,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,injury: trauma,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1675,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Renal: renal failure chronic,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1676,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Systemic: kwashiorkor,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1677,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological,4,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1678,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological: Anaemia with clinical symptoms,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1679,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological: Anaemia with no clinical symptoms,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1680,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Haematological: Neutropenia,2,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1681,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Infectious disease,5,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1682,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,"Infectious disease: Acute febrile episode, undiagnosed",1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1683,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,Infectious disease: Hepatitis A virus,1,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1684,2025-12-02T16:04:59.615593
35868341.0,Number of >=3 adverse events ,"Infectious disease: TB, disseminated or miliary",3,,N,,,,,,37,children ,,,,Total safety population,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1685,2025-12-02T16:04:59.615593
36111542.0,AE resulted in dolutegravir discontinuation ,nocturnal nose bleeds combined with loss of concentra- tion ,1,,N,,,,,,20,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1686,2025-12-02T16:04:59.615593
36111542.0,severe AE,increased lipid and amylase levels ,1,,N,,,,,,20,children ,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1687,2025-12-02T16:04:59.615593
32103260.0,birth weight,,3145,g,median,,,minmax,2120,4040,16,maternal,pregnancy,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1688,2025-12-02T16:04:59.615593
32103260.0,low birth weight (<2500 g),,2,,N,,,,,,15,maternal,pregnancy,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1689,2025-12-02T16:04:59.615593
32103260.0,Small for gestational age,,1,,N,,,,,,15,maternal,pregnancy,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1690,2025-12-02T16:04:59.615593
32103260.0,HIV RNA polymerase chain reaction test negative ,,14,,N,,,,,,14,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1691,2025-12-02T16:04:59.615593
32661003.0,moderate premature,,2,,N,,,,,,41,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1692,2025-12-02T16:04:59.615593
32661003.0,birth weight,,3210,g,median,,,IQR,2840,3450,41,neonates,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1693,2025-12-02T16:04:59.615593
32661003.0,Infant HIV DNA and/RNA PCR test negative,,41,,N,,,,,,41,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1694,2025-12-02T16:04:59.615593
31923087.0,gastational age,,39,weeks,median,,,IQR,38.1,39.6,24,newborns,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1695,2025-12-02T16:04:59.615593
31923087.0,birth weight,,3118,g,median,,,IQR,2770,3405,24,newborns,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1696,2025-12-02T16:04:59.615593
31923087.0,Infection status,uninfected,20,,N,,,,,,24,newborns,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1697,2025-12-02T16:04:59.615593
31923087.0,Infection status,indeterminate,4,,N,,,,,,24,newborns,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1698,2025-12-02T16:04:59.615593
30873741.0,Any AE,,5,,N,,,,,,7,maternal,pregnancy,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1699,2025-12-02T16:04:59.615593
30873741.0,Any AE leading to discontinuation,,0,,N,,,,,,7,maternal,pregnancy,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1700,2025-12-02T16:04:59.615593
30873741.0,Any AE considered at least possibly related to study medication,,0,,N,,,,,,7,maternal,pregnancy,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1701,2025-12-02T16:04:59.615593
30873741.0,Any SAE,,1,,N,,,,,,7,maternal,pregnancy,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1702,2025-12-02T16:04:59.615593
30873741.0,Any grade 3 AE,,1,,N,,,,,,7,maternal,pregnancy,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1703,2025-12-02T16:04:59.615593
30873741.0,Most common AE (occurring in >1 woman),Vulvovaginal mycotic infection,2,,N,,,,,,7,maternal,pregnancy,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1704,2025-12-02T16:04:59.615593
30728322.0,plasma viral load <50 copies/ml,,1,,N,,,,,,1,maternal,T1,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1705,2025-12-02T16:04:59.615593
30728322.0,plasma viral load <50 copies/ml,,11,,N,,,,,,14,maternal,T2,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1706,2025-12-02T16:04:59.615593
30728322.0,plasma viral load <50 copies/ml,,23,,N,,,,,,32,maternal,T3,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1707,2025-12-02T16:04:59.615593
30728322.0,plasma viral load <50 copies/ml,,24,,N,,,,,,29,maternal,postpartum,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1708,2025-12-02T16:04:59.615593
30728322.0,CD4 T-cell count,,346,cells/ul,,,,,,,1,maternal,T1,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1709,2025-12-02T16:04:59.615593
30728322.0,CD4 T-cell count,,453,cells/ul,geometric mean,,,minmax,209,723,14,maternal,T2,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1710,2025-12-02T16:04:59.615593
30728322.0,CD4 T-cell count,,462,cells/ul,geometric mean,,,minmax,62,330,31,maternal,T3,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1711,2025-12-02T16:04:59.615593
30728322.0,CD4 T-cell count,,562,cells/ul,geometric mean,,,minmax,111,697,29,maternal,postpartum,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1712,2025-12-02T16:04:59.615593
30728322.0,weight,,115,kg,,,,,,,1,maternal,T1,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1713,2025-12-02T16:04:59.615593
30728322.0,weight,,73.8,kg,geometric mean,,,minmax,65,118,14,maternal,T2,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1714,2025-12-02T16:04:59.615593
30728322.0,weight,,74.3,kg,geometric mean,,,minmax,53.4,124,30,maternal,T3,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1715,2025-12-02T16:04:59.615593
30728322.0,weight,,70.1,kg,geometric mean,,,minmax,43.6,119,29,maternal,postpartum,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1716,2025-12-02T16:04:59.615593
34732682.0,gestational age,,37.3,weeks,median,,,minmax,28.4,40,11,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1717,2025-12-02T16:04:59.615593
34732682.0,birth weight,,2990,g,median,,,minmax,960,4445,11,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1718,2025-12-02T16:04:59.615593
34732682.0,HIV Status,uninfected,8,,N,,,,,,11,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1719,2025-12-02T16:04:59.615593
34732682.0,HIV Status,Negative based upon best available data,3,,N,,,,,,11,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1720,2025-12-02T16:04:59.615593
34732682.0,HIV-1 RNA<=50 copies/mL,,6,,N,,,,,,6,maternal,2T,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1721,2025-12-02T16:04:59.615593
34732682.0,HIV-1 RNA<=50 copies/mL,,9,,N,,,,,,9,maternal,3T,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1722,2025-12-02T16:04:59.615593
34732682.0,HIV-1 RNA<=50 copies/mL,,11,,N,,,,,,11,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1723,2025-12-02T16:04:59.615593
34732682.0,HIV-1 RNA<=50 copies/mL,,7,,N,,,,,,9,maternal,postpartum,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1724,2025-12-02T16:04:59.615593
34855626.0,Heart rate,,143,beats/min,median,,,IQR,120,150,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1725,2025-12-02T16:04:59.615593
34855626.0,Heart rate,,129,beats/min,median,,,IQR,120,140,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1726,2025-12-02T16:04:59.615593
34855626.0,Heart rate,,132,beats/min,median,,,IQR,120,150,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1727,2025-12-02T16:04:59.615593
34855626.0,QT interval,,280,msec,median,,,IQR,240,280,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1728,2025-12-02T16:04:59.615593
34855626.0,QT interval,,280,msec,median,,,IQR,248,300,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1729,2025-12-02T16:04:59.615593
34855626.0,QT interval,,280,msec,median,,,IQR,248,288,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1730,2025-12-02T16:04:59.615593
34855626.0,QTcF1,,346,msec,median,,,IQR,331,363,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1731,2025-12-02T16:04:59.615593
34855626.0,QTcF1,,364,msec,median,,,IQR,340,378,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1732,2025-12-02T16:04:59.615593
34855626.0,QTcF1,,356,msec,median,,,IQR,331,365,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1733,2025-12-02T16:04:59.615593
34855626.0,HIV-1 NAT,Negative,9,,N,,,,,,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1734,2025-12-02T16:04:59.615593
34855626.0,HIV-1 NAT,Negative,9,,N,,,,,,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1735,2025-12-02T16:04:59.615593
34855626.0,HIV-1 NAT,Negative,18,,N,,,,,,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1736,2025-12-02T16:04:59.615593
34855626.0,Hemoglobin,,17.6,g/dl,median,,,IQR,16.2,18.2,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1737,2025-12-02T16:04:59.615593
34855626.0,Hemoglobin,,17.3,g/dl,median,,,IQR,17.1,19,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1738,2025-12-02T16:04:59.615593
34855626.0,Hemoglobin,,17.5,g/dl,median,,,IQR,16.3,18.4,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1739,2025-12-02T16:04:59.615593
34855626.0,Sodium,,143,mmol/L,median,,,IQR,139,144,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1740,2025-12-02T16:04:59.615593
34855626.0,Sodium,,140,mmol/L,median,,,IQR,138,142,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1741,2025-12-02T16:04:59.615593
34855626.0,Sodium,,142,mmol/L,median,,,IQR,139,144,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1742,2025-12-02T16:04:59.615593
34855626.0,Potassium,,5.2,mmol/L,median,,,IQR,4.7,5.3,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1743,2025-12-02T16:04:59.615593
34855626.0,Potassium,,5.1,mmol/L,median,,,IQR,5,5.4,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1744,2025-12-02T16:04:59.615593
34855626.0,Potassium,,5.2,mmol/L,median,,,IQR,4.8,5.4,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1745,2025-12-02T16:04:59.615593
34855626.0,Creatinine,,51,umol/L,median,,,IQR,49,63,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1746,2025-12-02T16:04:59.615593
34855626.0,Creatinine,,68,umol/L,median,,,IQR,57,69,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1747,2025-12-02T16:04:59.615593
34855626.0,Creatinine,,58,umol/L,median,,,IQR,51,69,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1748,2025-12-02T16:04:59.615593
34855626.0,ALT,,11,U/L,median,,,IQR,8,14,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1749,2025-12-02T16:04:59.615593
34855626.0,ALT,,10,U/L,median,,,IQR,8,11,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1750,2025-12-02T16:04:59.615593
34855626.0,ALT,,11,U/L,median,,,IQR,8,13,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1751,2025-12-02T16:04:59.615593
34855626.0,AST,,54,U/L,median,,,IQR,31,59,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1752,2025-12-02T16:04:59.615593
34855626.0,AST,,53,U/L,median,,,IQR,50,58,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1753,2025-12-02T16:04:59.615593
34855626.0,AST,,54,U/L,median,,,IQR,46,59,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1754,2025-12-02T16:04:59.615593
34855626.0,Total bilirubin,,72,umol/L,median,,,IQR,30,106,9,neonates,,>=14 days and <21days ,,Cohort 1A,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1755,2025-12-02T16:04:59.615593
34855626.0,Total bilirubin,,61,umol/L,median,,,IQR,29,72,9,neonates,,>=3 days and <14 days ,,Cohort 1B,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1756,2025-12-02T16:04:59.615593
34855626.0,Total bilirubin,,69,umol/L,median,,,IQR,29,79,18,neonates,,,,Total,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1757,2025-12-02T16:04:59.615593
33464021.0,viral load <=400 copies/ml at baseline,,0.08,,mean,,,95% CI,0.01,0.26,25,children,,,>0.999,Severe malnutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1758,2025-12-02T16:04:59.615593
33464021.0,viral load <=400 copies/ml at baseline,,0.074,,mean,,,95% CI,0.009,0.243,27,children,,,>0.999,Mid malnutrition/Normal mutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1759,2025-12-02T16:04:59.615593
33464021.0,viral load <=400 copies/ml at week 12,,0.348,,mean,,,95% CI,0.164,0.573,25,children,,,0.15,Severe malnutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1760,2025-12-02T16:04:59.615593
33464021.0,viral load <=400 copies/ml at week 12,,0.583,,mean,,,95% CI,0.366,0.779,27,children,,,0.15,Mid malnutrition/Normal mutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1761,2025-12-02T16:04:59.615593
33464021.0,viral load <=400 copies/ml at week 24 and 48,,0.5,,mean,,,95% CI,0.282,0.718,25,children,,,0.065,Severe malnutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1762,2025-12-02T16:04:59.615593
33464021.0,viral load <=400 copies/ml at week 24 and 48,,0.783,,mean,,,95% CI,0.563,0.925,27,children,,,0.065,Mid malnutrition/Normal mutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1763,2025-12-02T16:04:59.615593
33464021.0,CD4 cell percent at baseline,,0.155,,mean,,,95% CI,0.11900000000000001,0.192,25,children,,,,Severe malnutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1764,2025-12-02T16:04:59.615593
33464021.0,CD4 cell percent at baseline,,0.245,,mean,,,95% CI,0.2,0.29,27,children,,,,Mid malnutrition/Normal mutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1765,2025-12-02T16:04:59.615593
33464021.0,CD4 cell percent change at week 48,,0.127,,mean,,,95% CI,0.083,0.171,25,children,,,0.018,Severe malnutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1766,2025-12-02T16:04:59.615593
33464021.0,CD4 cell percent change at week 48,,0.067,,mean,,,95% CI,0.042,0.091,27,children,,,0.018,Mid malnutrition/Normal mutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1767,2025-12-02T16:04:59.615593
33464021.0,CD4 cell percent at week 48,,0.289,,mean,,,95% CI,0.23199999999999998,0.34700000000000003,25,children,,,,Severe malnutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1768,2025-12-02T16:04:59.615593
33464021.0,CD4 cell percent at week 48,,0.29,,mean,,,95% CI,0.253,0.32799999999999996,27,children,,,,Mid malnutrition/Normal mutrition,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1769,2025-12-02T16:04:59.615593
32960984.0,gestational age at delivery,,0.39,weeks,median,,,IQR,38,40,59,maternal,delivery,,,HIV Infected Patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1770,2025-12-02T16:04:59.615593
32960984.0,gestational age at delivery,,0.39,weeks,median,,,IQR,38,40,137,maternal,delivery,,,HBV-Infected Patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1771,2025-12-02T16:04:59.615593
32960984.0,Birth weight,,3160,g,median,,,IQR,2750,3520,59,infants,,,,HIV Infected Patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1772,2025-12-02T16:04:59.615593
32960984.0,Birth weight,,3050,g,median,,,IQR,2766,3310,137,infants,,,,HBV-Infected Patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1773,2025-12-02T16:04:59.615593
32960984.0,VL HIV RNA load undetectable,,52,,N,,,,,,59,infants,,,,HIV Infected Patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1774,2025-12-02T16:04:59.615593
32960984.0,VL HIV RNA load undetectable,unknown,7,,N,,,,,,59,infants,,,,HIV Infected Patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1775,2025-12-02T16:04:59.615593
32960984.0,VL HIV RNA load undetectable,,,,N,,,,,,137,infants,,,,HBV-Infected Patients ,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1776,2025-12-02T16:04:59.615593
30530925.0,gestational age at delivery,,38.9,weeks,median,,,minmax,32,41,33,maternal,delivery,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1777,2025-12-02T16:04:59.615593
30530925.0,infant birth weight,,3162,g,median,,,minmax,1875,4365,40,infants,,,,,PK Curation_BPCA_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1778,2025-12-02T16:04:59.615593
8329296.0,Thromboxane B2 concentration, in maternal serum,136,ng/ml,mean,SD,81,,,,9,maternal,delivery,,,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,2,2025-12-02T16:05:09.863062
8329296.0,Thromboxane B2 concentration, in cord serum,151,ng/ml,mean,SD,111,,,,9,maternal,delivery,,,controls,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,3,2025-12-02T16:05:09.863062
8329296.0,Thromboxane B2 concentration, in maternal serum,14.9,ng/ml,mean,SD,9.9,,,,12,maternal,delivery,,<0.001 vs. controls,taking aspirin,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,4,2025-12-02T16:05:09.863062
8329296.0,Thromboxane B2 concentration, in cord serum,14.3,ng/ml,mean,SD,15.7,,,,12,maternal,delivery,,<0.001 vs. controls,taking aspirin,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,5,2025-12-02T16:05:09.863062
8329296.0,Thromboxane B2 concentration, in maternal serum,136,ng/ml,mean,SD,81,,,,9,maternal,delivery,,,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,2,2025-12-02T16:05:12.251790
8329296.0,Thromboxane B2 concentration, in cord serum,151,ng/ml,mean,SD,111,,,,9,maternal,delivery,,,controls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,3,2025-12-02T16:05:12.251790
8329296.0,Thromboxane B2 concentration, in maternal serum,14.9,ng/ml,mean,SD,9.9,,,,12,maternal,delivery,,<0.001 vs. controls,taking aspirin,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,4,2025-12-02T16:05:12.251790
8329296.0,Thromboxane B2 concentration, in cord serum,14.3,ng/ml,mean,SD,15.7,,,,12,maternal,delivery,,<0.001 vs. controls,taking aspirin,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,5,2025-12-02T16:05:12.251790
8329296.0,Thromboxane B2 concentration, in maternal serum,136,ng/ml,mean,SD,81,,,,9,maternal,delivery,,,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,2,2025-12-02T16:05:16.158507
8329296.0,Thromboxane B2 concentration, in cord serum,151,ng/ml,mean,SD,111,,,,9,maternal,delivery,,,controls,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,3,2025-12-02T16:05:16.158507
8329296.0,Thromboxane B2 concentration, in maternal serum,14.9,ng/ml,mean,SD,9.9,,,,12,maternal,delivery,,<0.001 vs. controls,taking aspirin,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,4,2025-12-02T16:05:16.158507
8329296.0,Thromboxane B2 concentration, in cord serum,14.3,ng/ml,mean,SD,15.7,,,,12,maternal,delivery,,<0.001 vs. controls,taking aspirin,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,5,2025-12-02T16:05:16.158507
8329296.0,Thromboxane B2 concentration, in maternal serum,136,ng/ml,mean,SD,81,,,,9,maternal,delivery,,,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,2,2025-12-02T16:05:22.595023
8329296.0,Thromboxane B2 concentration, in cord serum,151,ng/ml,mean,SD,111,,,,9,maternal,delivery,,,controls,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,3,2025-12-02T16:05:22.595023
8329296.0,Thromboxane B2 concentration, in maternal serum,14.9,ng/ml,mean,SD,9.9,,,,12,maternal,delivery,,<0.001 vs. controls,taking aspirin,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,4,2025-12-02T16:05:22.595023
8329296.0,Thromboxane B2 concentration, in cord serum,14.3,ng/ml,mean,SD,15.7,,,,12,maternal,delivery,,<0.001 vs. controls,taking aspirin,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,5,2025-12-02T16:05:22.595023
16390902.0,Duration of exposure,,33.5,weeks,mean,SD,5.4,,,,4,maternal,delivery,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,6,2025-12-02T16:05:09.863062
16390902.0,estimated gestational age,,36.1,weeks,mean,SD,0.2,,,,4,maternal,delivery,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,7,2025-12-02T16:05:09.863062
16390902.0,Apgar score at 1 min,,7.4,,mean,SD,1.7,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,8,2025-12-02T16:05:09.863062
16390902.0,Apgar score at 5 min,,8.8,,mean,SD,0.4,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,9,2025-12-02T16:05:09.863062
16390902.0,borth weight,,2.69,kg,mean,SD,0.33,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,10,2025-12-02T16:05:09.863062
16390902.0,Duration of exposure,,33.5,weeks,mean,SD,5.4,,,,4,maternal,delivery,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,6,2025-12-02T16:05:12.251790
16390902.0,estimated gestational age,,36.1,weeks,mean,SD,0.2,,,,4,maternal,delivery,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,7,2025-12-02T16:05:12.251790
16390902.0,Apgar score at 1 min,,7.4,,mean,SD,1.7,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,8,2025-12-02T16:05:12.251790
16390902.0,Apgar score at 5 min,,8.8,,mean,SD,0.4,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,9,2025-12-02T16:05:12.251790
16390902.0,borth weight,,2.69,kg,mean,SD,0.33,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,10,2025-12-02T16:05:12.251790
16390902.0,Duration of exposure,,33.5,weeks,mean,SD,5.4,,,,4,maternal,delivery,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,6,2025-12-02T16:05:16.158507
16390902.0,estimated gestational age,,36.1,weeks,mean,SD,0.2,,,,4,maternal,delivery,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,7,2025-12-02T16:05:16.158507
16390902.0,Apgar score at 1 min,,7.4,,mean,SD,1.7,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,8,2025-12-02T16:05:16.158507
16390902.0,Apgar score at 5 min,,8.8,,mean,SD,0.4,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,9,2025-12-02T16:05:16.158507
16390902.0,borth weight,,2.69,kg,mean,SD,0.33,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,10,2025-12-02T16:05:16.158507
16390902.0,Duration of exposure,,33.5,weeks,mean,SD,5.4,,,,4,maternal,delivery,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,6,2025-12-02T16:05:22.595023
16390902.0,estimated gestational age,,36.1,weeks,mean,SD,0.2,,,,4,maternal,delivery,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,7,2025-12-02T16:05:22.595023
16390902.0,Apgar score at 1 min,,7.4,,mean,SD,1.7,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,8,2025-12-02T16:05:22.595023
16390902.0,Apgar score at 5 min,,8.8,,mean,SD,0.4,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,9,2025-12-02T16:05:22.595023
16390902.0,borth weight,,2.69,kg,mean,SD,0.33,,,,5,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,10,2025-12-02T16:05:22.595023
19455083.0,hospital stay ,,3,days,median,,,minmax,2.0,11.0,6,pediatric,,neonate,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,27,2025-12-02T16:05:09.863062
19455083.0,hospital stay ,,3,days,median,,,minmax,2.0,11.0,6,pediatric,,neonate,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,27,2025-12-02T16:05:12.251790
19455083.0,hospital stay ,,3,days,median,,,minmax,2.0,11.0,6,pediatric,,neonate,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,27,2025-12-02T16:05:16.158507
19455083.0,hospital stay ,,3,days,median,,,minmax,2.0,11.0,6,pediatric,,neonate,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,27,2025-12-02T16:05:22.595023
31371035.0,reporteing odds ratio for the association between venlafaxine and postpartum bleeding,,2.92,,ROR,,,95% CI,1.56,5.45,10,maternal,postpartum,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,28,2025-12-02T16:05:09.863062
31371035.0,reporteing odds ratio for the association between sertraline and postpartum bleeding,,3.25,,ROR,,,95% CI,1.84,5.76,12,maternal,postpartum,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,29,2025-12-02T16:05:09.863062
31371035.0,reporteing odds ratio for the association between citalopram and postpartum bleeding,,2.77,,ROR,,,95% CI,1.32,5.83,7,maternal,postpartum,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,30,2025-12-02T16:05:09.863062
31371035.0,reporteing odds ratio for the association between fluoxetine and postpartum bleeding,,6.42,,ROR,,,95% CI,3.05,13.53,7,maternal,postpartum,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,31,2025-12-02T16:05:09.863062
31371035.0,reporteing odds ratio for the association between paroxetine and postpartum bleeding,,,,ROR,,,95% CI,,,2,maternal,postpartum,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,32,2025-12-02T16:05:09.863062
31371035.0,reporteing odds ratio for the association between venlafaxine and postpartum bleeding,,2.92,,ROR,,,95% CI,1.56,5.45,10,maternal,postpartum,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,28,2025-12-02T16:05:12.251790
31371035.0,reporteing odds ratio for the association between sertraline and postpartum bleeding,,3.25,,ROR,,,95% CI,1.84,5.76,12,maternal,postpartum,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,29,2025-12-02T16:05:12.251790
31371035.0,reporteing odds ratio for the association between citalopram and postpartum bleeding,,2.77,,ROR,,,95% CI,1.32,5.83,7,maternal,postpartum,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,30,2025-12-02T16:05:12.251790
31371035.0,reporteing odds ratio for the association between fluoxetine and postpartum bleeding,,6.42,,ROR,,,95% CI,3.05,13.53,7,maternal,postpartum,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,31,2025-12-02T16:05:12.251790
31371035.0,reporteing odds ratio for the association between paroxetine and postpartum bleeding,,,,ROR,,,95% CI,,,2,maternal,postpartum,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,32,2025-12-02T16:05:12.251790
31371035.0,reporteing odds ratio for the association between venlafaxine and postpartum bleeding,,2.92,,ROR,,,95% CI,1.56,5.45,10,maternal,postpartum,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,28,2025-12-02T16:05:16.158507
31371035.0,reporteing odds ratio for the association between sertraline and postpartum bleeding,,3.25,,ROR,,,95% CI,1.84,5.76,12,maternal,postpartum,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,29,2025-12-02T16:05:16.158507
31371035.0,reporteing odds ratio for the association between citalopram and postpartum bleeding,,2.77,,ROR,,,95% CI,1.32,5.83,7,maternal,postpartum,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,30,2025-12-02T16:05:16.158507
31371035.0,reporteing odds ratio for the association between fluoxetine and postpartum bleeding,,6.42,,ROR,,,95% CI,3.05,13.53,7,maternal,postpartum,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,31,2025-12-02T16:05:16.158507
31371035.0,reporteing odds ratio for the association between paroxetine and postpartum bleeding,,,,ROR,,,95% CI,,,2,maternal,postpartum,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,32,2025-12-02T16:05:16.158507
31371035.0,reporteing odds ratio for the association between venlafaxine and postpartum bleeding,,2.92,,ROR,,,95% CI,1.56,5.45,10,maternal,postpartum,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,28,2025-12-02T16:05:22.595023
31371035.0,reporteing odds ratio for the association between sertraline and postpartum bleeding,,3.25,,ROR,,,95% CI,1.84,5.76,12,maternal,postpartum,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,29,2025-12-02T16:05:22.595023
31371035.0,reporteing odds ratio for the association between citalopram and postpartum bleeding,,2.77,,ROR,,,95% CI,1.32,5.83,7,maternal,postpartum,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,30,2025-12-02T16:05:22.595023
31371035.0,reporteing odds ratio for the association between fluoxetine and postpartum bleeding,,6.42,,ROR,,,95% CI,3.05,13.53,7,maternal,postpartum,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,31,2025-12-02T16:05:22.595023
31371035.0,reporteing odds ratio for the association between paroxetine and postpartum bleeding,,,,ROR,,,95% CI,,,2,maternal,postpartum,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,32,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 4,remitted,15,,N,%,27,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,33,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 4,responded,25,,N,%,46,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,34,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 4,nonresponse,19,,N,%,35,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,35,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 4,no follow-up data available,11,,N,%,20,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,36,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 4,remitted,16,,N,%,30,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,37,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 4,responded,30,,N,%,56,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,38,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 4,nonresponse,21,,N,%,39,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,39,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 4,no follow-up data available,3,,N,%,6,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,40,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 8,remitted,25,,N,%,46,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,41,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 8,responded,31,,N,%,56,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,42,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 8,nonresponse,13,,N,%,24,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,43,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 8,no follow-up data available,11,,N,%,20,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,44,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 8,remitted,26,,N,%,48,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,45,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 8,responded,37,,N,%,69,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,46,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 8,nonresponse,14,,N,%,26,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,47,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 8,no follow-up data available,3,,N,%,6,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,48,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,response,29,,N,%,80,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,49,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,remission,24,,N,%,67,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,50,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,time to response,2,weeks,median,,,95% CI,1.3,2.8,36,maternal,postpartum,,0.21,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,51,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,time to remission,5,weeks,median,,,95% CI,3.4,6.6,36,maternal,postpartum,,0.82,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,52,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,HRSD,7.5,,mean,SD,5.8,,,,36,maternal,postpartum,,0.89,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,53,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,response,36,,N,%,77,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,54,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,remission,26,,N,%,55,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,55,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,time to response,3,weeks,median,,,95% CI,2.6,3.4,47,maternal,postpartum,,0.21,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,56,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,time to remission,5,weeks,median,,,95% CI,4.1,5.9,47,maternal,postpartum,,0.82,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,57,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 8 weeks,HRSD,7.3,,mean,SD,5.9,,,,47,maternal,postpartum,,0.89,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,58,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 8weeks,0-1,32,,N,%,94,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,59,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 8weeks,2-3,1,,N,%,3,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,60,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 8weeks,>-4,1,,N,%,3,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,61,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 8weeks,0-1,44,,N,%,94,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,62,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 8weeks,2-3,1,,N,%,2,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,63,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 8weeks,>-4,2,,N,%,4,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,64,2025-12-02T16:05:09.863062
16855451.0,Functioning at 8 weeks,GAS,74.8,,mean,SD,12.6,,,,36,maternal,postpartum,,0.87,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,65,2025-12-02T16:05:09.863062
16855451.0,Functioning at 8 weeks,Percent with any social problems,16,,N,%,70,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,66,2025-12-02T16:05:09.863062
16855451.0,Functioning at 8 weeks,GAS,74.1,,mean,SD,12,,,,47,maternal,postpartum,,0.87,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,67,2025-12-02T16:05:09.863062
16855451.0,Functioning at 8 weeks,Percent with any social problems,23,,N,%,66,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,68,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,response,14,,N,%,93,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,69,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,remission,11,,N,%,73,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,70,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,time to response,2,weeks,median,,,95% CI,1.3,2.8,15,maternal,postpartum,,0.21,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,71,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,time to remission,5,weeks,median,,,95% CI,3.4,6.6,15,maternal,postpartum,,0.83,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,72,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,HRSD,5.4,,mean,SD,6.2,,,,15,maternal,postpartum,,0.58,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,73,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,response,14,,N,%,100,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,74,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,remission,11,,N,%,79,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,75,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,time to response,3,weeks,median,,,95% CI,2.6,3.4,14,maternal,postpartum,,0.21,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,76,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,time to remission,5,weeks,median,,,95% CI,4.1,5.9,14,maternal,postpartum,,0.83,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,77,2025-12-02T16:05:09.863062
16855451.0,Symptoms at 20-24 weeks,HRSD,4.3,,mean,SD,4.4,,,,14,maternal,postpartum,,0.58,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,78,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 20-24 weeks,0-1,14,,N,%,93,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,79,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 20-24 weeks,2-3,1,,N,%,7,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,80,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 20-24 weeks,>-4,0,,N,%,,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,81,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 20-24 weeks,0-1,14,,N,%,100,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,82,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 20-24 weeks,2-3,0,,N,%,,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,83,2025-12-02T16:05:09.863062
16855451.0,CGI/S categories at 20-24 weeks,>-4,0,,N,%,,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,84,2025-12-02T16:05:09.863062
16855451.0,Functioning at 20-24 weeks,GAS,81.7,,mean,SD,7.9,,,,15,maternal,postpartum,,0.93,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,85,2025-12-02T16:05:09.863062
16855451.0,Functioning at 20-24 weeks,Percent with any social problems,4,,N,%,58,,,,15,maternal,postpartum,,0.65,SERT,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,86,2025-12-02T16:05:09.863062
16855451.0,Functioning at 20-24 weeks,GAS,81.4,,mean,SD,9.5,,,,14,maternal,postpartum,,0.93,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,87,2025-12-02T16:05:09.863062
16855451.0,Functioning at 20-24 weeks,Percent with any social problems,4,,N,%,58,,,,14,maternal,postpartum,,0.65,NTP,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,88,2025-12-02T16:05:09.863062
16855451.0,Primary symptom outcomes at week 4,remitted,15,,N,%,27,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,33,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 4,responded,25,,N,%,46,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,34,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 4,nonresponse,19,,N,%,35,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,35,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 4,no follow-up data available,11,,N,%,20,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,36,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 4,remitted,16,,N,%,30,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,37,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 4,responded,30,,N,%,56,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,38,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 4,nonresponse,21,,N,%,39,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,39,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 4,no follow-up data available,3,,N,%,6,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,40,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 8,remitted,25,,N,%,46,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,41,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 8,responded,31,,N,%,56,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,42,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 8,nonresponse,13,,N,%,24,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,43,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 8,no follow-up data available,11,,N,%,20,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,44,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 8,remitted,26,,N,%,48,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,45,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 8,responded,37,,N,%,69,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,46,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 8,nonresponse,14,,N,%,26,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,47,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 8,no follow-up data available,3,,N,%,6,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,48,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,response,29,,N,%,80,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,49,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,remission,24,,N,%,67,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,50,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,time to response,2,weeks,median,,,95% CI,1.3,2.8,36,maternal,postpartum,,0.21,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,51,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,time to remission,5,weeks,median,,,95% CI,3.4,6.6,36,maternal,postpartum,,0.82,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,52,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,HRSD,7.5,,mean,SD,5.8,,,,36,maternal,postpartum,,0.89,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,53,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,response,36,,N,%,77,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,54,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,remission,26,,N,%,55,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,55,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,time to response,3,weeks,median,,,95% CI,2.6,3.4,47,maternal,postpartum,,0.21,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,56,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,time to remission,5,weeks,median,,,95% CI,4.1,5.9,47,maternal,postpartum,,0.82,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,57,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 8 weeks,HRSD,7.3,,mean,SD,5.9,,,,47,maternal,postpartum,,0.89,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,58,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 8weeks,0-1,32,,N,%,94,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,59,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 8weeks,2-3,1,,N,%,3,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,60,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 8weeks,>-4,1,,N,%,3,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,61,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 8weeks,0-1,44,,N,%,94,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,62,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 8weeks,2-3,1,,N,%,2,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,63,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 8weeks,>-4,2,,N,%,4,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,64,2025-12-02T16:05:12.251790
16855451.0,Functioning at 8 weeks,GAS,74.8,,mean,SD,12.6,,,,36,maternal,postpartum,,0.87,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,65,2025-12-02T16:05:12.251790
16855451.0,Functioning at 8 weeks,Percent with any social problems,16,,N,%,70,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,66,2025-12-02T16:05:12.251790
16855451.0,Functioning at 8 weeks,GAS,74.1,,mean,SD,12,,,,47,maternal,postpartum,,0.87,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,67,2025-12-02T16:05:12.251790
16855451.0,Functioning at 8 weeks,Percent with any social problems,23,,N,%,66,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,68,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,response,14,,N,%,93,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,69,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,remission,11,,N,%,73,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,70,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,time to response,2,weeks,median,,,95% CI,1.3,2.8,15,maternal,postpartum,,0.21,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,71,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,time to remission,5,weeks,median,,,95% CI,3.4,6.6,15,maternal,postpartum,,0.83,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,72,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,HRSD,5.4,,mean,SD,6.2,,,,15,maternal,postpartum,,0.58,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,73,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,response,14,,N,%,100,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,74,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,remission,11,,N,%,79,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,75,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,time to response,3,weeks,median,,,95% CI,2.6,3.4,14,maternal,postpartum,,0.21,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,76,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,time to remission,5,weeks,median,,,95% CI,4.1,5.9,14,maternal,postpartum,,0.83,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,77,2025-12-02T16:05:12.251790
16855451.0,Symptoms at 20-24 weeks,HRSD,4.3,,mean,SD,4.4,,,,14,maternal,postpartum,,0.58,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,78,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 20-24 weeks,0-1,14,,N,%,93,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,79,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 20-24 weeks,2-3,1,,N,%,7,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,80,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 20-24 weeks,>-4,0,,N,%,,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,81,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 20-24 weeks,0-1,14,,N,%,100,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,82,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 20-24 weeks,2-3,0,,N,%,,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,83,2025-12-02T16:05:12.251790
16855451.0,CGI/S categories at 20-24 weeks,>-4,0,,N,%,,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,84,2025-12-02T16:05:12.251790
16855451.0,Functioning at 20-24 weeks,GAS,81.7,,mean,SD,7.9,,,,15,maternal,postpartum,,0.93,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,85,2025-12-02T16:05:12.251790
16855451.0,Functioning at 20-24 weeks,Percent with any social problems,4,,N,%,58,,,,15,maternal,postpartum,,0.65,SERT,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,86,2025-12-02T16:05:12.251790
16855451.0,Functioning at 20-24 weeks,GAS,81.4,,mean,SD,9.5,,,,14,maternal,postpartum,,0.93,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,87,2025-12-02T16:05:12.251790
16855451.0,Functioning at 20-24 weeks,Percent with any social problems,4,,N,%,58,,,,14,maternal,postpartum,,0.65,NTP,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,88,2025-12-02T16:05:12.251790
16855451.0,Primary symptom outcomes at week 4,remitted,15,,N,%,27,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,33,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 4,responded,25,,N,%,46,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,34,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 4,nonresponse,19,,N,%,35,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,35,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 4,no follow-up data available,11,,N,%,20,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,36,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 4,remitted,16,,N,%,30,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,37,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 4,responded,30,,N,%,56,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,38,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 4,nonresponse,21,,N,%,39,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,39,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 4,no follow-up data available,3,,N,%,6,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,40,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 8,remitted,25,,N,%,46,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,41,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 8,responded,31,,N,%,56,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,42,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 8,nonresponse,13,,N,%,24,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,43,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 8,no follow-up data available,11,,N,%,20,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,44,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 8,remitted,26,,N,%,48,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,45,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 8,responded,37,,N,%,69,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,46,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 8,nonresponse,14,,N,%,26,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,47,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 8,no follow-up data available,3,,N,%,6,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,48,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,response,29,,N,%,80,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,49,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,remission,24,,N,%,67,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,50,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,time to response,2,weeks,median,,,95% CI,1.3,2.8,36,maternal,postpartum,,0.21,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,51,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,time to remission,5,weeks,median,,,95% CI,3.4,6.6,36,maternal,postpartum,,0.82,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,52,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,HRSD,7.5,,mean,SD,5.8,,,,36,maternal,postpartum,,0.89,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,53,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,response,36,,N,%,77,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,54,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,remission,26,,N,%,55,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,55,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,time to response,3,weeks,median,,,95% CI,2.6,3.4,47,maternal,postpartum,,0.21,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,56,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,time to remission,5,weeks,median,,,95% CI,4.1,5.9,47,maternal,postpartum,,0.82,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,57,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 8 weeks,HRSD,7.3,,mean,SD,5.9,,,,47,maternal,postpartum,,0.89,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,58,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 8weeks,0-1,32,,N,%,94,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,59,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 8weeks,2-3,1,,N,%,3,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,60,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 8weeks,>-4,1,,N,%,3,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,61,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 8weeks,0-1,44,,N,%,94,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,62,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 8weeks,2-3,1,,N,%,2,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,63,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 8weeks,>-4,2,,N,%,4,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,64,2025-12-02T16:05:16.158507
16855451.0,Functioning at 8 weeks,GAS,74.8,,mean,SD,12.6,,,,36,maternal,postpartum,,0.87,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,65,2025-12-02T16:05:16.158507
16855451.0,Functioning at 8 weeks,Percent with any social problems,16,,N,%,70,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,66,2025-12-02T16:05:16.158507
16855451.0,Functioning at 8 weeks,GAS,74.1,,mean,SD,12,,,,47,maternal,postpartum,,0.87,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,67,2025-12-02T16:05:16.158507
16855451.0,Functioning at 8 weeks,Percent with any social problems,23,,N,%,66,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,68,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,response,14,,N,%,93,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,69,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,remission,11,,N,%,73,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,70,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,time to response,2,weeks,median,,,95% CI,1.3,2.8,15,maternal,postpartum,,0.21,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,71,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,time to remission,5,weeks,median,,,95% CI,3.4,6.6,15,maternal,postpartum,,0.83,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,72,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,HRSD,5.4,,mean,SD,6.2,,,,15,maternal,postpartum,,0.58,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,73,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,response,14,,N,%,100,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,74,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,remission,11,,N,%,79,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,75,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,time to response,3,weeks,median,,,95% CI,2.6,3.4,14,maternal,postpartum,,0.21,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,76,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,time to remission,5,weeks,median,,,95% CI,4.1,5.9,14,maternal,postpartum,,0.83,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,77,2025-12-02T16:05:16.158507
16855451.0,Symptoms at 20-24 weeks,HRSD,4.3,,mean,SD,4.4,,,,14,maternal,postpartum,,0.58,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,78,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 20-24 weeks,0-1,14,,N,%,93,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,79,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 20-24 weeks,2-3,1,,N,%,7,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,80,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 20-24 weeks,>-4,0,,N,%,,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,81,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 20-24 weeks,0-1,14,,N,%,100,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,82,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 20-24 weeks,2-3,0,,N,%,,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,83,2025-12-02T16:05:16.158507
16855451.0,CGI/S categories at 20-24 weeks,>-4,0,,N,%,,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,84,2025-12-02T16:05:16.158507
16855451.0,Functioning at 20-24 weeks,GAS,81.7,,mean,SD,7.9,,,,15,maternal,postpartum,,0.93,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,85,2025-12-02T16:05:16.158507
16855451.0,Functioning at 20-24 weeks,Percent with any social problems,4,,N,%,58,,,,15,maternal,postpartum,,0.65,SERT,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,86,2025-12-02T16:05:16.158507
16855451.0,Functioning at 20-24 weeks,GAS,81.4,,mean,SD,9.5,,,,14,maternal,postpartum,,0.93,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,87,2025-12-02T16:05:16.158507
16855451.0,Functioning at 20-24 weeks,Percent with any social problems,4,,N,%,58,,,,14,maternal,postpartum,,0.65,NTP,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,88,2025-12-02T16:05:16.158507
16855451.0,Primary symptom outcomes at week 4,remitted,15,,N,%,27,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,33,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 4,responded,25,,N,%,46,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,34,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 4,nonresponse,19,,N,%,35,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,35,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 4,no follow-up data available,11,,N,%,20,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,36,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 4,remitted,16,,N,%,30,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,37,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 4,responded,30,,N,%,56,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,38,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 4,nonresponse,21,,N,%,39,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,39,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 4,no follow-up data available,3,,N,%,6,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,40,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 8,remitted,25,,N,%,46,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,41,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 8,responded,31,,N,%,56,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,42,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 8,nonresponse,13,,N,%,24,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,43,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 8,no follow-up data available,11,,N,%,20,,,,55,maternal,postpartum,,,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,44,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 8,remitted,26,,N,%,48,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,45,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 8,responded,37,,N,%,69,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,46,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 8,nonresponse,14,,N,%,26,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,47,2025-12-02T16:05:22.595023
16855451.0,Primary symptom outcomes at week 8,no follow-up data available,3,,N,%,6,,,,54,maternal,postpartum,,,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,48,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,response,29,,N,%,80,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,49,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,remission,24,,N,%,67,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,50,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,time to response,2,weeks,median,,,95% CI,1.3,2.8,36,maternal,postpartum,,0.21,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,51,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,time to remission,5,weeks,median,,,95% CI,3.4,6.6,36,maternal,postpartum,,0.82,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,52,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,HRSD,7.5,,mean,SD,5.8,,,,36,maternal,postpartum,,0.89,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,53,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,response,36,,N,%,77,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,54,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,remission,26,,N,%,55,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,55,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,time to response,3,weeks,median,,,95% CI,2.6,3.4,47,maternal,postpartum,,0.21,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,56,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,time to remission,5,weeks,median,,,95% CI,4.1,5.9,47,maternal,postpartum,,0.82,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,57,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 8 weeks,HRSD,7.3,,mean,SD,5.9,,,,47,maternal,postpartum,,0.89,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,58,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 8weeks,0-1,32,,N,%,94,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,59,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 8weeks,2-3,1,,N,%,3,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,60,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 8weeks,>-4,1,,N,%,3,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,61,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 8weeks,0-1,44,,N,%,94,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,62,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 8weeks,2-3,1,,N,%,2,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,63,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 8weeks,>-4,2,,N,%,4,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,64,2025-12-02T16:05:22.595023
16855451.0,Functioning at 8 weeks,GAS,74.8,,mean,SD,12.6,,,,36,maternal,postpartum,,0.87,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,65,2025-12-02T16:05:22.595023
16855451.0,Functioning at 8 weeks,Percent with any social problems,16,,N,%,70,,,,36,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,66,2025-12-02T16:05:22.595023
16855451.0,Functioning at 8 weeks,GAS,74.1,,mean,SD,12,,,,47,maternal,postpartum,,0.87,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,67,2025-12-02T16:05:22.595023
16855451.0,Functioning at 8 weeks,Percent with any social problems,23,,N,%,66,,,,47,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,68,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,response,14,,N,%,93,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,69,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,remission,11,,N,%,73,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,70,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,time to response,2,weeks,median,,,95% CI,1.3,2.8,15,maternal,postpartum,,0.21,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,71,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,time to remission,5,weeks,median,,,95% CI,3.4,6.6,15,maternal,postpartum,,0.83,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,72,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,HRSD,5.4,,mean,SD,6.2,,,,15,maternal,postpartum,,0.58,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,73,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,response,14,,N,%,100,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,74,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,remission,11,,N,%,79,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,75,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,time to response,3,weeks,median,,,95% CI,2.6,3.4,14,maternal,postpartum,,0.21,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,76,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,time to remission,5,weeks,median,,,95% CI,4.1,5.9,14,maternal,postpartum,,0.83,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,77,2025-12-02T16:05:22.595023
16855451.0,Symptoms at 20-24 weeks,HRSD,4.3,,mean,SD,4.4,,,,14,maternal,postpartum,,0.58,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,78,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 20-24 weeks,0-1,14,,N,%,93,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,79,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 20-24 weeks,2-3,1,,N,%,7,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,80,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 20-24 weeks,>-4,0,,N,%,,,,,15,maternal,postpartum,,1,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,81,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 20-24 weeks,0-1,14,,N,%,100,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,82,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 20-24 weeks,2-3,0,,N,%,,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,83,2025-12-02T16:05:22.595023
16855451.0,CGI/S categories at 20-24 weeks,>-4,0,,N,%,,,,,14,maternal,postpartum,,1,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,84,2025-12-02T16:05:22.595023
16855451.0,Functioning at 20-24 weeks,GAS,81.7,,mean,SD,7.9,,,,15,maternal,postpartum,,0.93,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,85,2025-12-02T16:05:22.595023
16855451.0,Functioning at 20-24 weeks,Percent with any social problems,4,,N,%,58,,,,15,maternal,postpartum,,0.65,SERT,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,86,2025-12-02T16:05:22.595023
16855451.0,Functioning at 20-24 weeks,GAS,81.4,,mean,SD,9.5,,,,14,maternal,postpartum,,0.93,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,87,2025-12-02T16:05:22.595023
16855451.0,Functioning at 20-24 weeks,Percent with any social problems,4,,N,%,58,,,,14,maternal,postpartum,,0.65,NTP,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,88,2025-12-02T16:05:22.595023
23834232.0,Spontaneous abortion,,5,,N,%,12,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,89,2025-12-02T16:05:09.863062
23834232.0,Therapeutic abortion,,2,,N,%,5,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,90,2025-12-02T16:05:09.863062
23834232.0,Live births,,34,,N,%,83,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,91,2025-12-02T16:05:09.863062
23834232.0,Preterm births,,6,,N,%,18,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,92,2025-12-02T16:05:09.863062
23834232.0,Caesarean section,,21,,N,%,62,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,93,2025-12-02T16:05:09.863062
23834232.0,birth weight,,3145,g,median,,,minmax,2400.0,4450.0,34,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,94,2025-12-02T16:05:09.863062
23834232.0,low birth weight,,1,,N,%,3,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,95,2025-12-02T16:05:09.863062
23834232.0,gestational age at birth,,39,,median,,,minmax,34.0,42.0,34,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,96,2025-12-02T16:05:09.863062
23834232.0,congenital malformations,,1,,N,,,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,97,2025-12-02T16:05:09.863062
23834232.0,perinatal complications,,4,,N,,,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,98,2025-12-02T16:05:09.863062
23834232.0,disease activity,Activity,10,,N,%,24,,,,41,maternal,conception,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,99,2025-12-02T16:05:09.863062
23834232.0,disease activity,Remission,31,,N,%,76,,,,41,maternal,conception,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,100,2025-12-02T16:05:09.863062
23834232.0,disease activity,Activity,11,,N,%,27,,,,41,maternal,first trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,101,2025-12-02T16:05:09.863062
23834232.0,disease activity,Remission,30,,N,%,73,,,,41,maternal,first trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,102,2025-12-02T16:05:09.863062
23834232.0,disease activity,Activity,6,,N,%,17,,,,36,maternal,second trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,103,2025-12-02T16:05:09.863062
23834232.0,disease activity,Remission,30,,N,%,83,,,,36,maternal,second trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,104,2025-12-02T16:05:09.863062
23834232.0,disease activity,Activity,5,,N,%,15,,,,34,maternal,third trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,105,2025-12-02T16:05:09.863062
23834232.0,disease activity,Remission,29,,N,%,85,,,,34,maternal,third trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,106,2025-12-02T16:05:09.863062
23834232.0,Spontaneous abortion,,5,,N,%,12,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,89,2025-12-02T16:05:12.251790
23834232.0,Therapeutic abortion,,2,,N,%,5,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,90,2025-12-02T16:05:12.251790
23834232.0,Live births,,34,,N,%,83,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,91,2025-12-02T16:05:12.251790
23834232.0,Preterm births,,6,,N,%,18,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,92,2025-12-02T16:05:12.251790
23834232.0,Caesarean section,,21,,N,%,62,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,93,2025-12-02T16:05:12.251790
23834232.0,birth weight,,3145,g,median,,,minmax,2400.0,4450.0,34,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,94,2025-12-02T16:05:12.251790
23834232.0,low birth weight,,1,,N,%,3,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,95,2025-12-02T16:05:12.251790
23834232.0,gestational age at birth,,39,,median,,,minmax,34.0,42.0,34,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,96,2025-12-02T16:05:12.251790
23834232.0,congenital malformations,,1,,N,,,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,97,2025-12-02T16:05:12.251790
23834232.0,perinatal complications,,4,,N,,,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,98,2025-12-02T16:05:12.251790
23834232.0,disease activity,Activity,10,,N,%,24,,,,41,maternal,conception,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,99,2025-12-02T16:05:12.251790
23834232.0,disease activity,Remission,31,,N,%,76,,,,41,maternal,conception,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,100,2025-12-02T16:05:12.251790
23834232.0,disease activity,Activity,11,,N,%,27,,,,41,maternal,first trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,101,2025-12-02T16:05:12.251790
23834232.0,disease activity,Remission,30,,N,%,73,,,,41,maternal,first trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,102,2025-12-02T16:05:12.251790
23834232.0,disease activity,Activity,6,,N,%,17,,,,36,maternal,second trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,103,2025-12-02T16:05:12.251790
23834232.0,disease activity,Remission,30,,N,%,83,,,,36,maternal,second trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,104,2025-12-02T16:05:12.251790
23834232.0,disease activity,Activity,5,,N,%,15,,,,34,maternal,third trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,105,2025-12-02T16:05:12.251790
23834232.0,disease activity,Remission,29,,N,%,85,,,,34,maternal,third trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,106,2025-12-02T16:05:12.251790
23834232.0,Spontaneous abortion,,5,,N,%,12,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,89,2025-12-02T16:05:16.158507
23834232.0,Therapeutic abortion,,2,,N,%,5,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,90,2025-12-02T16:05:16.158507
23834232.0,Live births,,34,,N,%,83,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,91,2025-12-02T16:05:16.158507
23834232.0,Preterm births,,6,,N,%,18,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,92,2025-12-02T16:05:16.158507
23834232.0,Caesarean section,,21,,N,%,62,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,93,2025-12-02T16:05:16.158507
23834232.0,birth weight,,3145,g,median,,,minmax,2400.0,4450.0,34,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,94,2025-12-02T16:05:16.158507
23834232.0,low birth weight,,1,,N,%,3,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,95,2025-12-02T16:05:16.158507
23834232.0,gestational age at birth,,39,,median,,,minmax,34.0,42.0,34,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,96,2025-12-02T16:05:16.158507
23834232.0,congenital malformations,,1,,N,,,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,97,2025-12-02T16:05:16.158507
23834232.0,perinatal complications,,4,,N,,,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,98,2025-12-02T16:05:16.158507
23834232.0,disease activity,Activity,10,,N,%,24,,,,41,maternal,conception,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,99,2025-12-02T16:05:16.158507
23834232.0,disease activity,Remission,31,,N,%,76,,,,41,maternal,conception,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,100,2025-12-02T16:05:16.158507
23834232.0,disease activity,Activity,11,,N,%,27,,,,41,maternal,first trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,101,2025-12-02T16:05:16.158507
23834232.0,disease activity,Remission,30,,N,%,73,,,,41,maternal,first trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,102,2025-12-02T16:05:16.158507
23834232.0,disease activity,Activity,6,,N,%,17,,,,36,maternal,second trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,103,2025-12-02T16:05:16.158507
23834232.0,disease activity,Remission,30,,N,%,83,,,,36,maternal,second trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,104,2025-12-02T16:05:16.158507
23834232.0,disease activity,Activity,5,,N,%,15,,,,34,maternal,third trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,105,2025-12-02T16:05:16.158507
23834232.0,disease activity,Remission,29,,N,%,85,,,,34,maternal,third trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,106,2025-12-02T16:05:16.158507
23834232.0,Spontaneous abortion,,5,,N,%,12,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,89,2025-12-02T16:05:22.595023
23834232.0,Therapeutic abortion,,2,,N,%,5,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,90,2025-12-02T16:05:22.595023
23834232.0,Live births,,34,,N,%,83,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,91,2025-12-02T16:05:22.595023
23834232.0,Preterm births,,6,,N,%,18,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,92,2025-12-02T16:05:22.595023
23834232.0,Caesarean section,,21,,N,%,62,,,,41,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,93,2025-12-02T16:05:22.595023
23834232.0,birth weight,,3145,g,median,,,minmax,2400.0,4450.0,34,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,94,2025-12-02T16:05:22.595023
23834232.0,low birth weight,,1,,N,%,3,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,95,2025-12-02T16:05:22.595023
23834232.0,gestational age at birth,,39,,median,,,minmax,34.0,42.0,34,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,96,2025-12-02T16:05:22.595023
23834232.0,congenital malformations,,1,,N,,,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,97,2025-12-02T16:05:22.595023
23834232.0,perinatal complications,,4,,N,,,,,,34,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,98,2025-12-02T16:05:22.595023
23834232.0,disease activity,Activity,10,,N,%,24,,,,41,maternal,conception,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,99,2025-12-02T16:05:22.595023
23834232.0,disease activity,Remission,31,,N,%,76,,,,41,maternal,conception,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,100,2025-12-02T16:05:22.595023
23834232.0,disease activity,Activity,11,,N,%,27,,,,41,maternal,first trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,101,2025-12-02T16:05:22.595023
23834232.0,disease activity,Remission,30,,N,%,73,,,,41,maternal,first trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,102,2025-12-02T16:05:22.595023
23834232.0,disease activity,Activity,6,,N,%,17,,,,36,maternal,second trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,103,2025-12-02T16:05:22.595023
23834232.0,disease activity,Remission,30,,N,%,83,,,,36,maternal,second trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,104,2025-12-02T16:05:22.595023
23834232.0,disease activity,Activity,5,,N,%,15,,,,34,maternal,third trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,105,2025-12-02T16:05:22.595023
23834232.0,disease activity,Remission,29,,N,%,85,,,,34,maternal,third trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,106,2025-12-02T16:05:22.595023
23103819.0,spontaneous miscarriages,,1,,N,,,,,,17,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,107,2025-12-02T16:05:09.863062
23103819.0,spontaneous miscarriages,,1,,N,,,,,,17,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,107,2025-12-02T16:05:12.251790
23103819.0,spontaneous miscarriages,,1,,N,,,,,,17,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,107,2025-12-02T16:05:16.158507
23103819.0,spontaneous miscarriages,,1,,N,,,,,,17,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,107,2025-12-02T16:05:22.595023
29771301.0,weight gain ,,12,kg,median,,,IQR,10.0,18.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,108,2025-12-02T16:05:09.863062
29771301.0,anti-TNF stopped during pregnancy <week 25,,37,,N,%,52,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,109,2025-12-02T16:05:09.863062
29771301.0,anti-TNF stop week during pregnancy,,23,,median,,,IQR,21.0,32.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,110,2025-12-02T16:05:09.863062
29771301.0,total disease activity during pregnancy,,19,,N,%,26,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,111,2025-12-02T16:05:09.863062
29771301.0,activity ongoing from conception,,7,,N,%,10,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,112,2025-12-02T16:05:09.863062
29771301.0,new relapse during pregnancy,,12,,N,%,16,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,113,2025-12-02T16:05:09.863062
29771301.0,successful relapse treatment before delivery,,14,,N,%,78,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,114,2025-12-02T16:05:09.863062
29771301.0,anti-TNF restart week postpartum,,3,,median,,,IQR,1.0,4.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,115,2025-12-02T16:05:09.863062
29771301.0,allergic reaction at restart anti-TNF,,2,,N,%,3,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,116,2025-12-02T16:05:09.863062
29771301.0,Loss of response after restart anti-TNF,,1,,N,%,1,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,117,2025-12-02T16:05:09.863062
29771301.0,disease relapse within 3 months postpartum,,7,,N,%,12,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,118,2025-12-02T16:05:09.863062
29771301.0,birthweight ,,3.3,kg,median,,,IQR,3.0,3.7,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,119,2025-12-02T16:05:09.863062
29771301.0,Low birth weight,,6,,N,%,9,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,120,2025-12-02T16:05:09.863062
29771301.0,gestational age,,39,weeks,median,,,IQR,38.0,40.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,121,2025-12-02T16:05:09.863062
29771301.0,preterm birth,,7,,N,%,10,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,122,2025-12-02T16:05:09.863062
29771301.0,small for gestational age,,3,,N,%,4,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,123,2025-12-02T16:05:09.863062
29771301.0,major congenital abnormalities,,3,,N,%,4.7,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,124,2025-12-02T16:05:09.863062
29771301.0,breastfeeding >2 weeks,,18,,N,%,30,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,125,2025-12-02T16:05:09.863062
29771301.0,mode of delivery,vaginal delivery,32,,N,%,48,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,126,2025-12-02T16:05:09.863062
29771301.0,mode of delivery,caesarean section,35,,N,%,52,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,127,2025-12-02T16:05:09.863062
29771301.0,weight gain ,,12,kg,median,,,IQR,10.0,18.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,108,2025-12-02T16:05:12.251790
29771301.0,anti-TNF stopped during pregnancy <week 25,,37,,N,%,52,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,109,2025-12-02T16:05:12.251790
29771301.0,anti-TNF stop week during pregnancy,,23,,median,,,IQR,21.0,32.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,110,2025-12-02T16:05:12.251790
29771301.0,total disease activity during pregnancy,,19,,N,%,26,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,111,2025-12-02T16:05:12.251790
29771301.0,activity ongoing from conception,,7,,N,%,10,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,112,2025-12-02T16:05:12.251790
29771301.0,new relapse during pregnancy,,12,,N,%,16,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,113,2025-12-02T16:05:12.251790
29771301.0,successful relapse treatment before delivery,,14,,N,%,78,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,114,2025-12-02T16:05:12.251790
29771301.0,anti-TNF restart week postpartum,,3,,median,,,IQR,1.0,4.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,115,2025-12-02T16:05:12.251790
29771301.0,allergic reaction at restart anti-TNF,,2,,N,%,3,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,116,2025-12-02T16:05:12.251790
29771301.0,Loss of response after restart anti-TNF,,1,,N,%,1,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,117,2025-12-02T16:05:12.251790
29771301.0,disease relapse within 3 months postpartum,,7,,N,%,12,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,118,2025-12-02T16:05:12.251790
29771301.0,birthweight ,,3.3,kg,median,,,IQR,3.0,3.7,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,119,2025-12-02T16:05:12.251790
29771301.0,Low birth weight,,6,,N,%,9,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,120,2025-12-02T16:05:12.251790
29771301.0,gestational age,,39,weeks,median,,,IQR,38.0,40.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,121,2025-12-02T16:05:12.251790
29771301.0,preterm birth,,7,,N,%,10,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,122,2025-12-02T16:05:12.251790
29771301.0,small for gestational age,,3,,N,%,4,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,123,2025-12-02T16:05:12.251790
29771301.0,major congenital abnormalities,,3,,N,%,4.7,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,124,2025-12-02T16:05:12.251790
29771301.0,breastfeeding >2 weeks,,18,,N,%,30,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,125,2025-12-02T16:05:12.251790
29771301.0,mode of delivery,vaginal delivery,32,,N,%,48,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,126,2025-12-02T16:05:12.251790
29771301.0,mode of delivery,caesarean section,35,,N,%,52,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,127,2025-12-02T16:05:12.251790
29771301.0,weight gain ,,12,kg,median,,,IQR,10.0,18.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,108,2025-12-02T16:05:16.158507
29771301.0,anti-TNF stopped during pregnancy <week 25,,37,,N,%,52,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,109,2025-12-02T16:05:16.158507
29771301.0,anti-TNF stop week during pregnancy,,23,,median,,,IQR,21.0,32.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,110,2025-12-02T16:05:16.158507
29771301.0,total disease activity during pregnancy,,19,,N,%,26,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,111,2025-12-02T16:05:16.158507
29771301.0,activity ongoing from conception,,7,,N,%,10,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,112,2025-12-02T16:05:16.158507
29771301.0,new relapse during pregnancy,,12,,N,%,16,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,113,2025-12-02T16:05:16.158507
29771301.0,successful relapse treatment before delivery,,14,,N,%,78,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,114,2025-12-02T16:05:16.158507
29771301.0,anti-TNF restart week postpartum,,3,,median,,,IQR,1.0,4.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,115,2025-12-02T16:05:16.158507
29771301.0,allergic reaction at restart anti-TNF,,2,,N,%,3,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,116,2025-12-02T16:05:16.158507
29771301.0,Loss of response after restart anti-TNF,,1,,N,%,1,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,117,2025-12-02T16:05:16.158507
29771301.0,disease relapse within 3 months postpartum,,7,,N,%,12,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,118,2025-12-02T16:05:16.158507
29771301.0,birthweight ,,3.3,kg,median,,,IQR,3.0,3.7,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,119,2025-12-02T16:05:16.158507
29771301.0,Low birth weight,,6,,N,%,9,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,120,2025-12-02T16:05:16.158507
29771301.0,gestational age,,39,weeks,median,,,IQR,38.0,40.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,121,2025-12-02T16:05:16.158507
29771301.0,preterm birth,,7,,N,%,10,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,122,2025-12-02T16:05:16.158507
29771301.0,small for gestational age,,3,,N,%,4,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,123,2025-12-02T16:05:16.158507
29771301.0,major congenital abnormalities,,3,,N,%,4.7,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,124,2025-12-02T16:05:16.158507
29771301.0,breastfeeding >2 weeks,,18,,N,%,30,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,125,2025-12-02T16:05:16.158507
29771301.0,mode of delivery,vaginal delivery,32,,N,%,48,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,126,2025-12-02T16:05:16.158507
29771301.0,mode of delivery,caesarean section,35,,N,%,52,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,127,2025-12-02T16:05:16.158507
29771301.0,weight gain ,,12,kg,median,,,IQR,10.0,18.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,108,2025-12-02T16:05:22.595023
29771301.0,anti-TNF stopped during pregnancy <week 25,,37,,N,%,52,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,109,2025-12-02T16:05:22.595023
29771301.0,anti-TNF stop week during pregnancy,,23,,median,,,IQR,21.0,32.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,110,2025-12-02T16:05:22.595023
29771301.0,total disease activity during pregnancy,,19,,N,%,26,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,111,2025-12-02T16:05:22.595023
29771301.0,activity ongoing from conception,,7,,N,%,10,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,112,2025-12-02T16:05:22.595023
29771301.0,new relapse during pregnancy,,12,,N,%,16,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,113,2025-12-02T16:05:22.595023
29771301.0,successful relapse treatment before delivery,,14,,N,%,78,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,114,2025-12-02T16:05:22.595023
29771301.0,anti-TNF restart week postpartum,,3,,median,,,IQR,1.0,4.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,115,2025-12-02T16:05:22.595023
29771301.0,allergic reaction at restart anti-TNF,,2,,N,%,3,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,116,2025-12-02T16:05:22.595023
29771301.0,Loss of response after restart anti-TNF,,1,,N,%,1,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,117,2025-12-02T16:05:22.595023
29771301.0,disease relapse within 3 months postpartum,,7,,N,%,12,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,118,2025-12-02T16:05:22.595023
29771301.0,birthweight ,,3.3,kg,median,,,IQR,3.0,3.7,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,119,2025-12-02T16:05:22.595023
29771301.0,Low birth weight,,6,,N,%,9,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,120,2025-12-02T16:05:22.595023
29771301.0,gestational age,,39,weeks,median,,,IQR,38.0,40.0,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,121,2025-12-02T16:05:22.595023
29771301.0,preterm birth,,7,,N,%,10,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,122,2025-12-02T16:05:22.595023
29771301.0,small for gestational age,,3,,N,%,4,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,123,2025-12-02T16:05:22.595023
29771301.0,major congenital abnormalities,,3,,N,%,4.7,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,124,2025-12-02T16:05:22.595023
29771301.0,breastfeeding >2 weeks,,18,,N,%,30,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,125,2025-12-02T16:05:22.595023
29771301.0,mode of delivery,vaginal delivery,32,,N,%,48,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,126,2025-12-02T16:05:22.595023
29771301.0,mode of delivery,caesarean section,35,,N,%,52,,,,73,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,127,2025-12-02T16:05:22.595023
29857090.0,NICU stay (0-12 mo),No,728,,N,%,88,,,,824,pediatric,,infants,0.3141,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,128,2025-12-02T16:05:09.863062
29857090.0,NICU stay (0-12 mo),Yes,96,,N,%,12,,,,824,pediatric,,infants,0.3141,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,129,2025-12-02T16:05:09.863062
29857090.0,NICU stay (0-12 mo),No,552,,N,%,89,,,,620,pediatric,,infants,0.3141,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,130,2025-12-02T16:05:09.863062
29857090.0,NICU stay (0-12 mo),Yes,68,,N,%,11,,,,620,pediatric,,infants,0.3141,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,131,2025-12-02T16:05:09.863062
29857090.0,NICU stay (0-12 mo),No,176,,N,%,86,,,,204,pediatric,,infants,0.3141,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,132,2025-12-02T16:05:09.863062
29857090.0,NICU stay (0-12 mo),Yes,28,,N,%,14,,,,204,pediatric,,infants,0.3141,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,133,2025-12-02T16:05:09.863062
29857090.0,milestone scores (12 mo),,87,,mean,SD,10,,,,824,pediatric,,infants,0.9992,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,134,2025-12-02T16:05:09.863062
29857090.0,milestone scores (12 mo),,87,,mean,SD,9.7,,,,620,pediatric,,infants,0.9992,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,135,2025-12-02T16:05:09.863062
29857090.0,milestone scores (12 mo),,86,,mean,SD,11,,,,204,pediatric,,infants,0.9992,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,136,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (4 mo)",No,705,,N,%,86,,,,824,pediatric,,infants,0.4869,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,137,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (4 mo)",Yes,116,,N,%,14,,,,824,pediatric,,infants,0.4869,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,138,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (4 mo)",No,533,,N,%,86,,,,620,pediatric,,infants,0.4869,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,139,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (4 mo)",Yes,84,,N,%,14,,,,620,pediatric,,infants,0.4869,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,140,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (4 mo)",No,172,,N,%,84,,,,204,pediatric,,infants,0.4869,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,141,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (4 mo)",Yes,32,,N,%,16,,,,204,pediatric,,infants,0.4869,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,142,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (9 mo)",No,512,,N,%,68,,,,824,pediatric,,infants,0.8555,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,143,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (9 mo)",Yes,236,,N,%,32,,,,824,pediatric,,infants,0.8555,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,144,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (9 mo)",No,384,,N,%,68,,,,620,pediatric,,infants,0.8555,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,145,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (9 mo)",Yes,179,,N,%,32,,,,620,pediatric,,infants,0.8555,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,146,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (9 mo)",No,128,,N,%,69,,,,204,pediatric,,infants,0.8555,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,147,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (9 mo)",Yes,57,,N,%,31,,,,204,pediatric,,infants,0.8555,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,148,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (12mo)",No,500,,N,%,61,,,,824,pediatric,,infants,>0.99,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,149,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (12mo)",Yes,324,,N,%,39,,,,824,pediatric,,infants,>0.99,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,150,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (12mo)",No,376,,N,%,61,,,,620,pediatric,,infants,>0.99,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,151,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (12mo)",Yes,244,,N,%,39,,,,620,pediatric,,infants,>0.99,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,152,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (12mo)",No,124,,N,%,61,,,,204,pediatric,,infants,>0.99,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,153,2025-12-02T16:05:09.863062
29857090.0,"Infection, any (12mo)",Yes,80,,N,%,39,,,,204,pediatric,,infants,>0.99,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,154,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (4 mo)",No,755,,N,%,92,,,,824,pediatric,,infants,0.6564,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,155,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (4 mo)",Yes,66,,N,%,8,,,,824,pediatric,,infants,0.6564,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,156,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (4 mo)",No,569,,N,%,92,,,,620,pediatric,,infants,0.6564,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,157,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (4 mo)",Yes,48,,N,%,8,,,,620,pediatric,,infants,0.6564,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,158,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (4 mo)",No,186,,N,%,91,,,,204,pediatric,,infants,0.6564,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,159,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (4 mo)",Yes,18,,N,%,9,,,,204,pediatric,,infants,0.6564,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,160,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (9 mo)",No,643,,N,%,86,,,,824,pediatric,,infants,0.4654,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,161,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (9 mo)",Yes,105,,N,%,14,,,,824,pediatric,,infants,0.4654,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,162,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (9 mo)",No,487,,N,%,87,,,,620,pediatric,,infants,0.4654,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,163,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (9 mo)",Yes,76,,N,%,13,,,,620,pediatric,,infants,0.4654,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,164,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (9 mo)",No,156,,N,%,84,,,,204,pediatric,,infants,0.4654,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,165,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (9 mo)",Yes,29,,N,%,16,,,,204,pediatric,,infants,0.4654,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,166,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (12 mo)",No,659,,N,%,80,,,,824,pediatric,,infants,0.9198,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,167,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (12 mo)",Yes,165,,N,%,20,,,,824,pediatric,,infants,0.9198,Overall PIANO,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,168,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (12 mo)",No,495,,N,%,80,,,,620,pediatric,,infants,0.9198,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,169,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (12 mo)",Yes,125,,N,%,20,,,,620,pediatric,,infants,0.9198,breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,170,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (12 mo)",No,164,,N,%,80,,,,204,pediatric,,infants,0.9198,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,171,2025-12-02T16:05:09.863062
29857090.0,"Infection, no OM, (12 mo)",Yes,40,,N,%,20,,,,204,pediatric,,infants,0.9198,no breastfed,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,172,2025-12-02T16:05:09.863062
29857090.0,NICU stay (0-12 mo),No,728,,N,%,88,,,,824,pediatric,,infants,0.3141,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,128,2025-12-02T16:05:12.251790
29857090.0,NICU stay (0-12 mo),Yes,96,,N,%,12,,,,824,pediatric,,infants,0.3141,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,129,2025-12-02T16:05:12.251790
29857090.0,NICU stay (0-12 mo),No,552,,N,%,89,,,,620,pediatric,,infants,0.3141,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,130,2025-12-02T16:05:12.251790
29857090.0,NICU stay (0-12 mo),Yes,68,,N,%,11,,,,620,pediatric,,infants,0.3141,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,131,2025-12-02T16:05:12.251790
29857090.0,NICU stay (0-12 mo),No,176,,N,%,86,,,,204,pediatric,,infants,0.3141,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,132,2025-12-02T16:05:12.251790
29857090.0,NICU stay (0-12 mo),Yes,28,,N,%,14,,,,204,pediatric,,infants,0.3141,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,133,2025-12-02T16:05:12.251790
29857090.0,milestone scores (12 mo),,87,,mean,SD,10,,,,824,pediatric,,infants,0.9992,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,134,2025-12-02T16:05:12.251790
29857090.0,milestone scores (12 mo),,87,,mean,SD,9.7,,,,620,pediatric,,infants,0.9992,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,135,2025-12-02T16:05:12.251790
29857090.0,milestone scores (12 mo),,86,,mean,SD,11,,,,204,pediatric,,infants,0.9992,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,136,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (4 mo)",No,705,,N,%,86,,,,824,pediatric,,infants,0.4869,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,137,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (4 mo)",Yes,116,,N,%,14,,,,824,pediatric,,infants,0.4869,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,138,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (4 mo)",No,533,,N,%,86,,,,620,pediatric,,infants,0.4869,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,139,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (4 mo)",Yes,84,,N,%,14,,,,620,pediatric,,infants,0.4869,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,140,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (4 mo)",No,172,,N,%,84,,,,204,pediatric,,infants,0.4869,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,141,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (4 mo)",Yes,32,,N,%,16,,,,204,pediatric,,infants,0.4869,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,142,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (9 mo)",No,512,,N,%,68,,,,824,pediatric,,infants,0.8555,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,143,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (9 mo)",Yes,236,,N,%,32,,,,824,pediatric,,infants,0.8555,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,144,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (9 mo)",No,384,,N,%,68,,,,620,pediatric,,infants,0.8555,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,145,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (9 mo)",Yes,179,,N,%,32,,,,620,pediatric,,infants,0.8555,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,146,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (9 mo)",No,128,,N,%,69,,,,204,pediatric,,infants,0.8555,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,147,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (9 mo)",Yes,57,,N,%,31,,,,204,pediatric,,infants,0.8555,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,148,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (12mo)",No,500,,N,%,61,,,,824,pediatric,,infants,>0.99,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,149,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (12mo)",Yes,324,,N,%,39,,,,824,pediatric,,infants,>0.99,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,150,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (12mo)",No,376,,N,%,61,,,,620,pediatric,,infants,>0.99,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,151,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (12mo)",Yes,244,,N,%,39,,,,620,pediatric,,infants,>0.99,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,152,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (12mo)",No,124,,N,%,61,,,,204,pediatric,,infants,>0.99,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,153,2025-12-02T16:05:12.251790
29857090.0,"Infection, any (12mo)",Yes,80,,N,%,39,,,,204,pediatric,,infants,>0.99,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,154,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (4 mo)",No,755,,N,%,92,,,,824,pediatric,,infants,0.6564,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,155,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (4 mo)",Yes,66,,N,%,8,,,,824,pediatric,,infants,0.6564,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,156,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (4 mo)",No,569,,N,%,92,,,,620,pediatric,,infants,0.6564,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,157,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (4 mo)",Yes,48,,N,%,8,,,,620,pediatric,,infants,0.6564,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,158,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (4 mo)",No,186,,N,%,91,,,,204,pediatric,,infants,0.6564,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,159,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (4 mo)",Yes,18,,N,%,9,,,,204,pediatric,,infants,0.6564,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,160,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (9 mo)",No,643,,N,%,86,,,,824,pediatric,,infants,0.4654,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,161,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (9 mo)",Yes,105,,N,%,14,,,,824,pediatric,,infants,0.4654,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,162,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (9 mo)",No,487,,N,%,87,,,,620,pediatric,,infants,0.4654,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,163,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (9 mo)",Yes,76,,N,%,13,,,,620,pediatric,,infants,0.4654,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,164,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (9 mo)",No,156,,N,%,84,,,,204,pediatric,,infants,0.4654,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,165,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (9 mo)",Yes,29,,N,%,16,,,,204,pediatric,,infants,0.4654,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,166,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (12 mo)",No,659,,N,%,80,,,,824,pediatric,,infants,0.9198,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,167,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (12 mo)",Yes,165,,N,%,20,,,,824,pediatric,,infants,0.9198,Overall PIANO,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,168,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (12 mo)",No,495,,N,%,80,,,,620,pediatric,,infants,0.9198,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,169,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (12 mo)",Yes,125,,N,%,20,,,,620,pediatric,,infants,0.9198,breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,170,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (12 mo)",No,164,,N,%,80,,,,204,pediatric,,infants,0.9198,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,171,2025-12-02T16:05:12.251790
29857090.0,"Infection, no OM, (12 mo)",Yes,40,,N,%,20,,,,204,pediatric,,infants,0.9198,no breastfed,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,172,2025-12-02T16:05:12.251790
29857090.0,NICU stay (0-12 mo),No,728,,N,%,88,,,,824,pediatric,,infants,0.3141,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,128,2025-12-02T16:05:16.158507
29857090.0,NICU stay (0-12 mo),Yes,96,,N,%,12,,,,824,pediatric,,infants,0.3141,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,129,2025-12-02T16:05:16.158507
29857090.0,NICU stay (0-12 mo),No,552,,N,%,89,,,,620,pediatric,,infants,0.3141,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,130,2025-12-02T16:05:16.158507
29857090.0,NICU stay (0-12 mo),Yes,68,,N,%,11,,,,620,pediatric,,infants,0.3141,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,131,2025-12-02T16:05:16.158507
29857090.0,NICU stay (0-12 mo),No,176,,N,%,86,,,,204,pediatric,,infants,0.3141,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,132,2025-12-02T16:05:16.158507
29857090.0,NICU stay (0-12 mo),Yes,28,,N,%,14,,,,204,pediatric,,infants,0.3141,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,133,2025-12-02T16:05:16.158507
29857090.0,milestone scores (12 mo),,87,,mean,SD,10,,,,824,pediatric,,infants,0.9992,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,134,2025-12-02T16:05:16.158507
29857090.0,milestone scores (12 mo),,87,,mean,SD,9.7,,,,620,pediatric,,infants,0.9992,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,135,2025-12-02T16:05:16.158507
29857090.0,milestone scores (12 mo),,86,,mean,SD,11,,,,204,pediatric,,infants,0.9992,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,136,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (4 mo)",No,705,,N,%,86,,,,824,pediatric,,infants,0.4869,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,137,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (4 mo)",Yes,116,,N,%,14,,,,824,pediatric,,infants,0.4869,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,138,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (4 mo)",No,533,,N,%,86,,,,620,pediatric,,infants,0.4869,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,139,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (4 mo)",Yes,84,,N,%,14,,,,620,pediatric,,infants,0.4869,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,140,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (4 mo)",No,172,,N,%,84,,,,204,pediatric,,infants,0.4869,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,141,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (4 mo)",Yes,32,,N,%,16,,,,204,pediatric,,infants,0.4869,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,142,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (9 mo)",No,512,,N,%,68,,,,824,pediatric,,infants,0.8555,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,143,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (9 mo)",Yes,236,,N,%,32,,,,824,pediatric,,infants,0.8555,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,144,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (9 mo)",No,384,,N,%,68,,,,620,pediatric,,infants,0.8555,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,145,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (9 mo)",Yes,179,,N,%,32,,,,620,pediatric,,infants,0.8555,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,146,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (9 mo)",No,128,,N,%,69,,,,204,pediatric,,infants,0.8555,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,147,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (9 mo)",Yes,57,,N,%,31,,,,204,pediatric,,infants,0.8555,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,148,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (12mo)",No,500,,N,%,61,,,,824,pediatric,,infants,>0.99,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,149,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (12mo)",Yes,324,,N,%,39,,,,824,pediatric,,infants,>0.99,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,150,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (12mo)",No,376,,N,%,61,,,,620,pediatric,,infants,>0.99,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,151,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (12mo)",Yes,244,,N,%,39,,,,620,pediatric,,infants,>0.99,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,152,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (12mo)",No,124,,N,%,61,,,,204,pediatric,,infants,>0.99,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,153,2025-12-02T16:05:16.158507
29857090.0,"Infection, any (12mo)",Yes,80,,N,%,39,,,,204,pediatric,,infants,>0.99,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,154,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (4 mo)",No,755,,N,%,92,,,,824,pediatric,,infants,0.6564,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,155,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (4 mo)",Yes,66,,N,%,8,,,,824,pediatric,,infants,0.6564,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,156,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (4 mo)",No,569,,N,%,92,,,,620,pediatric,,infants,0.6564,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,157,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (4 mo)",Yes,48,,N,%,8,,,,620,pediatric,,infants,0.6564,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,158,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (4 mo)",No,186,,N,%,91,,,,204,pediatric,,infants,0.6564,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,159,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (4 mo)",Yes,18,,N,%,9,,,,204,pediatric,,infants,0.6564,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,160,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (9 mo)",No,643,,N,%,86,,,,824,pediatric,,infants,0.4654,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,161,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (9 mo)",Yes,105,,N,%,14,,,,824,pediatric,,infants,0.4654,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,162,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (9 mo)",No,487,,N,%,87,,,,620,pediatric,,infants,0.4654,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,163,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (9 mo)",Yes,76,,N,%,13,,,,620,pediatric,,infants,0.4654,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,164,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (9 mo)",No,156,,N,%,84,,,,204,pediatric,,infants,0.4654,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,165,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (9 mo)",Yes,29,,N,%,16,,,,204,pediatric,,infants,0.4654,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,166,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (12 mo)",No,659,,N,%,80,,,,824,pediatric,,infants,0.9198,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,167,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (12 mo)",Yes,165,,N,%,20,,,,824,pediatric,,infants,0.9198,Overall PIANO,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,168,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (12 mo)",No,495,,N,%,80,,,,620,pediatric,,infants,0.9198,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,169,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (12 mo)",Yes,125,,N,%,20,,,,620,pediatric,,infants,0.9198,breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,170,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (12 mo)",No,164,,N,%,80,,,,204,pediatric,,infants,0.9198,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,171,2025-12-02T16:05:16.158507
29857090.0,"Infection, no OM, (12 mo)",Yes,40,,N,%,20,,,,204,pediatric,,infants,0.9198,no breastfed,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,172,2025-12-02T16:05:16.158507
29857090.0,NICU stay (0-12 mo),No,728,,N,%,88,,,,824,pediatric,,infants,0.3141,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,128,2025-12-02T16:05:22.595023
29857090.0,NICU stay (0-12 mo),Yes,96,,N,%,12,,,,824,pediatric,,infants,0.3141,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,129,2025-12-02T16:05:22.595023
29857090.0,NICU stay (0-12 mo),No,552,,N,%,89,,,,620,pediatric,,infants,0.3141,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,130,2025-12-02T16:05:22.595023
29857090.0,NICU stay (0-12 mo),Yes,68,,N,%,11,,,,620,pediatric,,infants,0.3141,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,131,2025-12-02T16:05:22.595023
29857090.0,NICU stay (0-12 mo),No,176,,N,%,86,,,,204,pediatric,,infants,0.3141,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,132,2025-12-02T16:05:22.595023
29857090.0,NICU stay (0-12 mo),Yes,28,,N,%,14,,,,204,pediatric,,infants,0.3141,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,133,2025-12-02T16:05:22.595023
29857090.0,milestone scores (12 mo),,87,,mean,SD,10,,,,824,pediatric,,infants,0.9992,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,134,2025-12-02T16:05:22.595023
29857090.0,milestone scores (12 mo),,87,,mean,SD,9.7,,,,620,pediatric,,infants,0.9992,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,135,2025-12-02T16:05:22.595023
29857090.0,milestone scores (12 mo),,86,,mean,SD,11,,,,204,pediatric,,infants,0.9992,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,136,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (4 mo)",No,705,,N,%,86,,,,824,pediatric,,infants,0.4869,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,137,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (4 mo)",Yes,116,,N,%,14,,,,824,pediatric,,infants,0.4869,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,138,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (4 mo)",No,533,,N,%,86,,,,620,pediatric,,infants,0.4869,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,139,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (4 mo)",Yes,84,,N,%,14,,,,620,pediatric,,infants,0.4869,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,140,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (4 mo)",No,172,,N,%,84,,,,204,pediatric,,infants,0.4869,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,141,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (4 mo)",Yes,32,,N,%,16,,,,204,pediatric,,infants,0.4869,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,142,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (9 mo)",No,512,,N,%,68,,,,824,pediatric,,infants,0.8555,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,143,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (9 mo)",Yes,236,,N,%,32,,,,824,pediatric,,infants,0.8555,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,144,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (9 mo)",No,384,,N,%,68,,,,620,pediatric,,infants,0.8555,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,145,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (9 mo)",Yes,179,,N,%,32,,,,620,pediatric,,infants,0.8555,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,146,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (9 mo)",No,128,,N,%,69,,,,204,pediatric,,infants,0.8555,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,147,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (9 mo)",Yes,57,,N,%,31,,,,204,pediatric,,infants,0.8555,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,148,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (12mo)",No,500,,N,%,61,,,,824,pediatric,,infants,>0.99,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,149,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (12mo)",Yes,324,,N,%,39,,,,824,pediatric,,infants,>0.99,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,150,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (12mo)",No,376,,N,%,61,,,,620,pediatric,,infants,>0.99,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,151,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (12mo)",Yes,244,,N,%,39,,,,620,pediatric,,infants,>0.99,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,152,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (12mo)",No,124,,N,%,61,,,,204,pediatric,,infants,>0.99,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,153,2025-12-02T16:05:22.595023
29857090.0,"Infection, any (12mo)",Yes,80,,N,%,39,,,,204,pediatric,,infants,>0.99,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,154,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (4 mo)",No,755,,N,%,92,,,,824,pediatric,,infants,0.6564,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,155,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (4 mo)",Yes,66,,N,%,8,,,,824,pediatric,,infants,0.6564,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,156,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (4 mo)",No,569,,N,%,92,,,,620,pediatric,,infants,0.6564,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,157,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (4 mo)",Yes,48,,N,%,8,,,,620,pediatric,,infants,0.6564,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,158,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (4 mo)",No,186,,N,%,91,,,,204,pediatric,,infants,0.6564,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,159,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (4 mo)",Yes,18,,N,%,9,,,,204,pediatric,,infants,0.6564,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,160,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (9 mo)",No,643,,N,%,86,,,,824,pediatric,,infants,0.4654,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,161,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (9 mo)",Yes,105,,N,%,14,,,,824,pediatric,,infants,0.4654,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,162,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (9 mo)",No,487,,N,%,87,,,,620,pediatric,,infants,0.4654,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,163,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (9 mo)",Yes,76,,N,%,13,,,,620,pediatric,,infants,0.4654,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,164,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (9 mo)",No,156,,N,%,84,,,,204,pediatric,,infants,0.4654,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,165,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (9 mo)",Yes,29,,N,%,16,,,,204,pediatric,,infants,0.4654,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,166,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (12 mo)",No,659,,N,%,80,,,,824,pediatric,,infants,0.9198,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,167,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (12 mo)",Yes,165,,N,%,20,,,,824,pediatric,,infants,0.9198,Overall PIANO,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,168,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (12 mo)",No,495,,N,%,80,,,,620,pediatric,,infants,0.9198,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,169,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (12 mo)",Yes,125,,N,%,20,,,,620,pediatric,,infants,0.9198,breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,170,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (12 mo)",No,164,,N,%,80,,,,204,pediatric,,infants,0.9198,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,171,2025-12-02T16:05:22.595023
29857090.0,"Infection, no OM, (12 mo)",Yes,40,,N,%,20,,,,204,pediatric,,infants,0.9198,no breastfed,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,172,2025-12-02T16:05:22.595023
25966992.0,time off anti-TNF,,21,weeks,median,,,IQR,18.7,23.8,27,maternal,pregnancy,,0.0001,Anti-TNF stop group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,173,2025-12-02T16:05:09.863062
25966992.0,time off anti-TNF,,3.5,weeks,median,,,IQR,0.0,9.4,21,maternal,pregnancy,,0.0001,Anti-TNF continue group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,174,2025-12-02T16:05:09.863062
25966992.0,number of infusions/injections skipped,,3,,,,,IQR,2.4,3.5,27,maternal,pregnancy,,0.0001,Anti-TNF stop group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,175,2025-12-02T16:05:09.863062
25966992.0,number of infusions/injections skipped,,0.7,,,,,IQR,0.0,1.2,21,maternal,pregnancy,,0.0001,Anti-TNF continue group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,176,2025-12-02T16:05:09.863062
25966992.0,time off anti-TNF,,21,weeks,median,,,IQR,18.7,23.8,27,maternal,pregnancy,,0.0001,Anti-TNF stop group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,173,2025-12-02T16:05:12.251790
25966992.0,time off anti-TNF,,3.5,weeks,median,,,IQR,0.0,9.4,21,maternal,pregnancy,,0.0001,Anti-TNF continue group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,174,2025-12-02T16:05:12.251790
25966992.0,number of infusions/injections skipped,,3,,,,,IQR,2.4,3.5,27,maternal,pregnancy,,0.0001,Anti-TNF stop group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,175,2025-12-02T16:05:12.251790
25966992.0,number of infusions/injections skipped,,0.7,,,,,IQR,0.0,1.2,21,maternal,pregnancy,,0.0001,Anti-TNF continue group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,176,2025-12-02T16:05:12.251790
25966992.0,time off anti-TNF,,21,weeks,median,,,IQR,18.7,23.8,27,maternal,pregnancy,,0.0001,Anti-TNF stop group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,173,2025-12-02T16:05:16.158507
25966992.0,time off anti-TNF,,3.5,weeks,median,,,IQR,0.0,9.4,21,maternal,pregnancy,,0.0001,Anti-TNF continue group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,174,2025-12-02T16:05:16.158507
25966992.0,number of infusions/injections skipped,,3,,,,,IQR,2.4,3.5,27,maternal,pregnancy,,0.0001,Anti-TNF stop group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,175,2025-12-02T16:05:16.158507
25966992.0,number of infusions/injections skipped,,0.7,,,,,IQR,0.0,1.2,21,maternal,pregnancy,,0.0001,Anti-TNF continue group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,176,2025-12-02T16:05:16.158507
25966992.0,time off anti-TNF,,21,weeks,median,,,IQR,18.7,23.8,27,maternal,pregnancy,,0.0001,Anti-TNF stop group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,173,2025-12-02T16:05:22.595023
25966992.0,time off anti-TNF,,3.5,weeks,median,,,IQR,0.0,9.4,21,maternal,pregnancy,,0.0001,Anti-TNF continue group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,174,2025-12-02T16:05:22.595023
25966992.0,number of infusions/injections skipped,,3,,,,,IQR,2.4,3.5,27,maternal,pregnancy,,0.0001,Anti-TNF stop group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,175,2025-12-02T16:05:22.595023
25966992.0,number of infusions/injections skipped,,0.7,,,,,IQR,0.0,1.2,21,maternal,pregnancy,,0.0001,Anti-TNF continue group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,176,2025-12-02T16:05:22.595023
27063728.0,Caesarean section,planned,38,,N,%,47.5,,,,45,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,177,2025-12-02T16:05:09.863062
27063728.0,Caesarean section,emergency,7,,N,%,8.8,,,,45,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,178,2025-12-02T16:05:09.863062
27063728.0,Preterm,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,179,2025-12-02T16:05:09.863062
27063728.0,small for gestational age,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,180,2025-12-02T16:05:09.863062
27063728.0,Low birth weight (<2500g),,6,,N,%,7.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,181,2025-12-02T16:05:09.863062
27063728.0,congenital malformations,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,182,2025-12-02T16:05:09.863062
27063728.0,Stillbirth,,0,,N,%,0,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,183,2025-12-02T16:05:09.863062
27063728.0,Apgar score <7,1 minute after birth,6,,N,%,7.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,184,2025-12-02T16:05:09.863062
27063728.0,Apgar score <7,5 minutes after birth,1,,N,%,1.3,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,185,2025-12-02T16:05:09.863062
27063728.0,Sex,girl,38,,N,%,47.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,186,2025-12-02T16:05:09.863062
27063728.0,Sex,boy,42,,N,%,52.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,187,2025-12-02T16:05:09.863062
27063728.0,weight ,,3318,g,median,,,minmax,2105.0,5070.0,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,188,2025-12-02T16:05:09.863062
27063728.0,length,,51,cm,median,,,minmax,41.0,56.0,80,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,189,2025-12-02T16:05:09.863062
27063728.0,Caesarean section,planned,38,,N,%,47.5,,,,45,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,177,2025-12-02T16:05:12.251790
27063728.0,Caesarean section,emergency,7,,N,%,8.8,,,,45,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,178,2025-12-02T16:05:12.251790
27063728.0,Preterm,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,179,2025-12-02T16:05:12.251790
27063728.0,small for gestational age,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,180,2025-12-02T16:05:12.251790
27063728.0,Low birth weight (<2500g),,6,,N,%,7.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,181,2025-12-02T16:05:12.251790
27063728.0,congenital malformations,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,182,2025-12-02T16:05:12.251790
27063728.0,Stillbirth,,0,,N,%,0,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,183,2025-12-02T16:05:12.251790
27063728.0,Apgar score <7,1 minute after birth,6,,N,%,7.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,184,2025-12-02T16:05:12.251790
27063728.0,Apgar score <7,5 minutes after birth,1,,N,%,1.3,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,185,2025-12-02T16:05:12.251790
27063728.0,Sex,girl,38,,N,%,47.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,186,2025-12-02T16:05:12.251790
27063728.0,Sex,boy,42,,N,%,52.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,187,2025-12-02T16:05:12.251790
27063728.0,weight ,,3318,g,median,,,minmax,2105.0,5070.0,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,188,2025-12-02T16:05:12.251790
27063728.0,length,,51,cm,median,,,minmax,41.0,56.0,80,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,189,2025-12-02T16:05:12.251790
27063728.0,Caesarean section,planned,38,,N,%,47.5,,,,45,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,177,2025-12-02T16:05:16.158507
27063728.0,Caesarean section,emergency,7,,N,%,8.8,,,,45,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,178,2025-12-02T16:05:16.158507
27063728.0,Preterm,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,179,2025-12-02T16:05:16.158507
27063728.0,small for gestational age,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,180,2025-12-02T16:05:16.158507
27063728.0,Low birth weight (<2500g),,6,,N,%,7.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,181,2025-12-02T16:05:16.158507
27063728.0,congenital malformations,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,182,2025-12-02T16:05:16.158507
27063728.0,Stillbirth,,0,,N,%,0,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,183,2025-12-02T16:05:16.158507
27063728.0,Apgar score <7,1 minute after birth,6,,N,%,7.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,184,2025-12-02T16:05:16.158507
27063728.0,Apgar score <7,5 minutes after birth,1,,N,%,1.3,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,185,2025-12-02T16:05:16.158507
27063728.0,Sex,girl,38,,N,%,47.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,186,2025-12-02T16:05:16.158507
27063728.0,Sex,boy,42,,N,%,52.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,187,2025-12-02T16:05:16.158507
27063728.0,weight ,,3318,g,median,,,minmax,2105.0,5070.0,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,188,2025-12-02T16:05:16.158507
27063728.0,length,,51,cm,median,,,minmax,41.0,56.0,80,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,189,2025-12-02T16:05:16.158507
27063728.0,Caesarean section,planned,38,,N,%,47.5,,,,45,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,177,2025-12-02T16:05:22.595023
27063728.0,Caesarean section,emergency,7,,N,%,8.8,,,,45,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,178,2025-12-02T16:05:22.595023
27063728.0,Preterm,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,179,2025-12-02T16:05:22.595023
27063728.0,small for gestational age,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,180,2025-12-02T16:05:22.595023
27063728.0,Low birth weight (<2500g),,6,,N,%,7.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,181,2025-12-02T16:05:22.595023
27063728.0,congenital malformations,,3,,N,%,3.8,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,182,2025-12-02T16:05:22.595023
27063728.0,Stillbirth,,0,,N,%,0,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,183,2025-12-02T16:05:22.595023
27063728.0,Apgar score <7,1 minute after birth,6,,N,%,7.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,184,2025-12-02T16:05:22.595023
27063728.0,Apgar score <7,5 minutes after birth,1,,N,%,1.3,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,185,2025-12-02T16:05:22.595023
27063728.0,Sex,girl,38,,N,%,47.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,186,2025-12-02T16:05:22.595023
27063728.0,Sex,boy,42,,N,%,52.5,,,,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,187,2025-12-02T16:05:22.595023
27063728.0,weight ,,3318,g,median,,,minmax,2105.0,5070.0,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,188,2025-12-02T16:05:22.595023
27063728.0,length,,51,cm,median,,,minmax,41.0,56.0,80,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,189,2025-12-02T16:05:22.595023
28318043.0,term births,,13,,N,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,190,2025-12-02T16:05:09.863062
28318043.0,pre-terms births,,2,,N,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,191,2025-12-02T16:05:09.863062
28318043.0,gestational age at birth,term,34.6,weeks,,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,192,2025-12-02T16:05:09.863062
28318043.0,gestational age at birth,pre-term,36.2,weeks,,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,193,2025-12-02T16:05:09.863062
28318043.0,inactive disease with HBI scores,,0,,,,,,,,2,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,194,2025-12-02T16:05:09.863062
28318043.0,term births,,13,,N,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,190,2025-12-02T16:05:12.251790
28318043.0,pre-terms births,,2,,N,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,191,2025-12-02T16:05:12.251790
28318043.0,gestational age at birth,term,34.6,weeks,,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,192,2025-12-02T16:05:12.251790
28318043.0,gestational age at birth,pre-term,36.2,weeks,,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,193,2025-12-02T16:05:12.251790
28318043.0,inactive disease with HBI scores,,0,,,,,,,,2,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,194,2025-12-02T16:05:12.251790
28318043.0,term births,,13,,N,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,190,2025-12-02T16:05:16.158507
28318043.0,pre-terms births,,2,,N,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,191,2025-12-02T16:05:16.158507
28318043.0,gestational age at birth,term,34.6,weeks,,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,192,2025-12-02T16:05:16.158507
28318043.0,gestational age at birth,pre-term,36.2,weeks,,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,193,2025-12-02T16:05:16.158507
28318043.0,inactive disease with HBI scores,,0,,,,,,,,2,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,194,2025-12-02T16:05:16.158507
28318043.0,term births,,13,,N,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,190,2025-12-02T16:05:22.595023
28318043.0,pre-terms births,,2,,N,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,191,2025-12-02T16:05:22.595023
28318043.0,gestational age at birth,term,34.6,weeks,,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,192,2025-12-02T16:05:22.595023
28318043.0,gestational age at birth,pre-term,36.2,weeks,,,,,,,15,pediatric,,infants,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,193,2025-12-02T16:05:22.595023
28318043.0,inactive disease with HBI scores,,0,,,,,,,,2,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,194,2025-12-02T16:05:22.595023
21366638.0,birth weight,,3235,g,median,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,195,2025-12-02T16:05:09.863062
21366638.0,birth height,,49,cm,median,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,196,2025-12-02T16:05:09.863062
21366638.0,Apgar score at 1 min,<7,0,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,197,2025-12-02T16:05:09.863062
21366638.0,Apgar score at 5 min,10,6,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,198,2025-12-02T16:05:09.863062
21366638.0,Apgar score at 5 min,9,2,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,199,2025-12-02T16:05:09.863062
21366638.0,birth weight,,3235,g,median,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,195,2025-12-02T16:05:12.251790
21366638.0,birth height,,49,cm,median,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,196,2025-12-02T16:05:12.251790
21366638.0,Apgar score at 1 min,<7,0,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,197,2025-12-02T16:05:12.251790
21366638.0,Apgar score at 5 min,10,6,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,198,2025-12-02T16:05:12.251790
21366638.0,Apgar score at 5 min,9,2,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,199,2025-12-02T16:05:12.251790
21366638.0,birth weight,,3235,g,median,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,195,2025-12-02T16:05:16.158507
21366638.0,birth height,,49,cm,median,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,196,2025-12-02T16:05:16.158507
21366638.0,Apgar score at 1 min,<7,0,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,197,2025-12-02T16:05:16.158507
21366638.0,Apgar score at 5 min,10,6,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,198,2025-12-02T16:05:16.158507
21366638.0,Apgar score at 5 min,9,2,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,199,2025-12-02T16:05:16.158507
21366638.0,birth weight,,3235,g,median,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,195,2025-12-02T16:05:22.595023
21366638.0,birth height,,49,cm,median,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,196,2025-12-02T16:05:22.595023
21366638.0,Apgar score at 1 min,<7,0,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,197,2025-12-02T16:05:22.595023
21366638.0,Apgar score at 5 min,10,6,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,198,2025-12-02T16:05:22.595023
21366638.0,Apgar score at 5 min,9,2,,N,,,,,,8,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,199,2025-12-02T16:05:22.595023
23018469.0,birth weight,,3235,g,median,,,,,,8,pediatric,,newborn,,PCOS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,200,2025-12-02T16:05:09.863062
23018469.0,birth weight,,3590,g,median,,,,,,9,pediatric,,newborn,,T2DM,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,201,2025-12-02T16:05:09.863062
23018469.0,birth length,,49,cm,median,,,,,,8,pediatric,,newborn,,PCOS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,202,2025-12-02T16:05:09.863062
23018469.0,birth length,,50,,median,,,,,,9,pediatric,,newborn,,T2DM,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,203,2025-12-02T16:05:09.863062
23018469.0,caesarean section ,,6,,N,,,,,,8,maternal,delivery,,,PCOS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,204,2025-12-02T16:05:09.863062
23018469.0,caesarean section ,,7,,N,,,,,,9,maternal,delivery,,,T2DM,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,205,2025-12-02T16:05:09.863062
23018469.0,birth weight,,3235,g,median,,,,,,8,pediatric,,newborn,,PCOS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,200,2025-12-02T16:05:12.251790
23018469.0,birth weight,,3590,g,median,,,,,,9,pediatric,,newborn,,T2DM,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,201,2025-12-02T16:05:12.251790
23018469.0,birth length,,49,cm,median,,,,,,8,pediatric,,newborn,,PCOS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,202,2025-12-02T16:05:12.251790
23018469.0,birth length,,50,,median,,,,,,9,pediatric,,newborn,,T2DM,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,203,2025-12-02T16:05:12.251790
23018469.0,caesarean section ,,6,,N,,,,,,8,maternal,delivery,,,PCOS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,204,2025-12-02T16:05:12.251790
23018469.0,caesarean section ,,7,,N,,,,,,9,maternal,delivery,,,T2DM,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,205,2025-12-02T16:05:12.251790
23018469.0,birth weight,,3235,g,median,,,,,,8,pediatric,,newborn,,PCOS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,200,2025-12-02T16:05:16.158507
23018469.0,birth weight,,3590,g,median,,,,,,9,pediatric,,newborn,,T2DM,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,201,2025-12-02T16:05:16.158507
23018469.0,birth length,,49,cm,median,,,,,,8,pediatric,,newborn,,PCOS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,202,2025-12-02T16:05:16.158507
23018469.0,birth length,,50,,median,,,,,,9,pediatric,,newborn,,T2DM,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,203,2025-12-02T16:05:16.158507
23018469.0,caesarean section ,,6,,N,,,,,,8,maternal,delivery,,,PCOS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,204,2025-12-02T16:05:16.158507
23018469.0,caesarean section ,,7,,N,,,,,,9,maternal,delivery,,,T2DM,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,205,2025-12-02T16:05:16.158507
23018469.0,birth weight,,3235,g,median,,,,,,8,pediatric,,newborn,,PCOS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,200,2025-12-02T16:05:22.595023
23018469.0,birth weight,,3590,g,median,,,,,,9,pediatric,,newborn,,T2DM,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,201,2025-12-02T16:05:22.595023
23018469.0,birth length,,49,cm,median,,,,,,8,pediatric,,newborn,,PCOS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,202,2025-12-02T16:05:22.595023
23018469.0,birth length,,50,,median,,,,,,9,pediatric,,newborn,,T2DM,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,203,2025-12-02T16:05:22.595023
23018469.0,caesarean section ,,6,,N,,,,,,8,maternal,delivery,,,PCOS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,204,2025-12-02T16:05:22.595023
23018469.0,caesarean section ,,7,,N,,,,,,9,maternal,delivery,,,T2DM,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,205,2025-12-02T16:05:22.595023
24633859.0,HbA1c,,5.56,%,mean,SD,0.31,minmax,4.9,6.1,37,maternal,pregnancy,36 GW,0.25,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,206,2025-12-02T16:05:09.863062
24633859.0,HbA1c,,5.56,%,mean,SD,0.25,minmax,5.2,5.9,12,maternal,pregnancy,36 GW,0.25,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,207,2025-12-02T16:05:09.863062
24633859.0,HbA1c,,5.44,%,mean,SD,0.27,minmax,4.9,5.8,12,maternal,pregnancy,36 GW,0.25,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,208,2025-12-02T16:05:09.863062
24633859.0,HbA1c,,5.65,%,mean,SD,0.38,minmax,4.9,6.1,13,maternal,pregnancy,36 GW,0.25,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,209,2025-12-02T16:05:09.863062
24633859.0,HbA1c,,37.4,mmol/mol,mean,SD,3.4,minmax,30.0,43.0,37,maternal,pregnancy,36 GW,,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,210,2025-12-02T16:05:09.863062
24633859.0,HbA1c,,37.4,mmol/mol,mean,SD,2.8,minmax,33.0,41.0,12,maternal,pregnancy,36 GW,,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,211,2025-12-02T16:05:09.863062
24633859.0,HbA1c,,36.1,mmol/mol,mean,SD,3.1,minmax,30.0,40.0,12,maternal,pregnancy,36 GW,,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,212,2025-12-02T16:05:09.863062
24633859.0,HbA1c,,38.4,mmol/mol,mean,SD,4.1,minmax,30.0,43.0,13,maternal,pregnancy,36 GW,,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,213,2025-12-02T16:05:09.863062
24633859.0,Fructosamine,,205,umol/I,mean,SD,17,minmax,170.0,259.0,37,maternal,pregnancy,36 GW,0.098,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,214,2025-12-02T16:05:09.863062
24633859.0,Fructosamine,,198,umol/I,mean,SD,12,minmax,181.0,216.0,12,maternal,pregnancy,36 GW,0.098,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,215,2025-12-02T16:05:09.863062
24633859.0,Fructosamine,,212,umol/I,mean,SD,17,minmax,186.0,259.0,12,maternal,pregnancy,36 GW,0.098,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,216,2025-12-02T16:05:09.863062
24633859.0,Fructosamine,,204,umol/I,mean,SD,18,minmax,170.0,229.0,13,maternal,pregnancy,36 GW,0.098,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,217,2025-12-02T16:05:09.863062
24633859.0,weight gain ,,264,g/week,mean,SD,300,minmax,-380.0,1130.0,37,maternal,pregnancy,36 GW,0.119,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,218,2025-12-02T16:05:09.863062
24633859.0,weight gain ,,414,g/week,mean,SD,341,minmax,-230.0,1130.0,12,maternal,pregnancy,36 GW,0.119,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,219,2025-12-02T16:05:09.863062
24633859.0,weight gain ,,198,g/week,mean,SD,313,minmax,-380.0,910.0,12,maternal,pregnancy,36 GW,0.119,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,220,2025-12-02T16:05:09.863062
24633859.0,weight gain ,,185,g/week,mean,SD,200,minmax,-140.0,570.0,13,maternal,pregnancy,36 GW,0.119,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,221,2025-12-02T16:05:09.863062
24633859.0,birth weight,,3596,ng/ml,mean,SD,430,minmax,2525.0,4410.0,37,pediatric,,neonates,0.93,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,222,2025-12-02T16:05:09.863062
24633859.0,birth weight,,3584,ng/ml,mean,SD,461,minmax,2750.0,4330.0,12,pediatric,,neonates,0.93,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,223,2025-12-02T16:05:09.863062
24633859.0,birth weight,,3663,ng/ml,mean,SD,378,minmax,2956.0,4410.0,12,pediatric,,neonates,0.93,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,224,2025-12-02T16:05:09.863062
24633859.0,birth weight,,3545,ng/ml,mean,SD,471,minmax,2525.0,4190.0,13,pediatric,,neonates,0.93,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,225,2025-12-02T16:05:09.863062
24633859.0,birth weight,,3.588,ng/ml,mean,SD,447,minmax,1650.0,4430.0,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,226,2025-12-02T16:05:09.863062
24633859.0,birth weight,,0.09,SD units,mean,SD,0.82,minmax,-2.2,2.2,37,pediatric,,neonates,0.49,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,227,2025-12-02T16:05:09.863062
24633859.0,birth weight,,-0.01,SD units,mean,SD,0.86,minmax,-1.6,1.0,12,pediatric,,neonates,0.49,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,228,2025-12-02T16:05:09.863062
24633859.0,birth weight,,0.43,SD units,mean,SD,0.71,minmax,-0.5,2.2,12,pediatric,,neonates,0.49,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,229,2025-12-02T16:05:09.863062
24633859.0,birth weight,,-0.12,SD units,mean,SD,0.85,minmax,-2.2,0.9,13,pediatric,,neonates,0.49,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,230,2025-12-02T16:05:09.863062
24633859.0,birth weight,,0.15,SD units,mean,SD,0.96,minmax,-1.9,3.0,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,231,2025-12-02T16:05:09.863062
24633859.0,gestational weeks at birth,,39.6,weeks,mean,SD,1.3,minmax,37.3,42.3,37,pediatric,,neonates,0.71,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,232,2025-12-02T16:05:09.863062
24633859.0,gestational weeks at birth,,39.7,weeks,mean,SD,1.4,minmax,37.4,41.9,12,pediatric,,neonates,0.71,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,233,2025-12-02T16:05:09.863062
24633859.0,gestational weeks at birth,,39.2,weeks,mean,SD,1.3,minmax,37.3,41.4,12,pediatric,,neonates,0.71,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,234,2025-12-02T16:05:09.863062
24633859.0,gestational weeks at birth,,39.9,weeks,mean,SD,1.2,minmax,38.3,42.3,13,pediatric,,neonates,0.71,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,235,2025-12-02T16:05:09.863062
24633859.0,gestational weeks at birth,,39.5,weeks,mean,SD,1.8,minmax,31.7,42.1,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,236,2025-12-02T16:05:09.863062
24633859.0,Umbilical artery pH,,7.27,,mean,SD,0.09,minmax,7.08,7.43,58,maternal,delivery,,0.78,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,237,2025-12-02T16:05:09.863062
24633859.0,Umbilical artery pH,,7.27,,mean,SD,0.07,minmax,7.1,7.39,19,maternal,delivery,,0.78,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,238,2025-12-02T16:05:09.863062
24633859.0,Umbilical artery pH,,7.26,,mean,SD,0.1,minmax,7.08,7.43,19,maternal,delivery,,0.78,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,239,2025-12-02T16:05:09.863062
24633859.0,Umbilical artery pH,,7.28,,mean,SD,0.08,minmax,7.09,7.41,20,maternal,delivery,,0.78,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,240,2025-12-02T16:05:09.863062
24633859.0,Umbilical artery pH,,7.28,,mean,SD,0.08,minmax,7.11,7.45,107,maternal,delivery,,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,241,2025-12-02T16:05:09.863062
24633859.0,Neonatal Hypolycemia,,8,,N,%,13.8,,,,58,pediatric,,neonates,0.92,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,242,2025-12-02T16:05:09.863062
24633859.0,Neonatal Hypolycemia,,2,,N,%,10.5,,,,19,pediatric,,neonates,0.92,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,243,2025-12-02T16:05:09.863062
24633859.0,Neonatal Hypolycemia,,3,,N,%,15.8,,,,19,pediatric,,neonates,0.92,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,244,2025-12-02T16:05:09.863062
24633859.0,Neonatal Hypolycemia,,3,,N,%,15,,,,20,pediatric,,neonates,0.92,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,245,2025-12-02T16:05:09.863062
24633859.0,Neonatal Hypolycemia,,18,,N,%,16.8,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,246,2025-12-02T16:05:09.863062
24633859.0,Neonatal admission to NICU,,15,,N,%,25.9,,,,58,pediatric,,neonates,0.36,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,247,2025-12-02T16:05:09.863062
24633859.0,Neonatal admission to NICU,,6,,N,%,31.6,,,,19,pediatric,,neonates,0.36,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,248,2025-12-02T16:05:09.863062
24633859.0,Neonatal admission to NICU,,3,,N,%,15.8,,,,19,pediatric,,neonates,0.36,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,249,2025-12-02T16:05:09.863062
24633859.0,Neonatal admission to NICU,,6,,N,%,30,,,,20,pediatric,,neonates,0.36,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,250,2025-12-02T16:05:09.863062
24633859.0,Neonatal admission to NICU,,39,,N,%,36.4,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,251,2025-12-02T16:05:09.863062
24633859.0,Neonatal hyperbilirubinemia,,3,,N,%,5.2,,,,58,pediatric,,neonates,0.58,All,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,252,2025-12-02T16:05:09.863062
24633859.0,Neonatal hyperbilirubinemia,,1,,N,%,5.3,,,,19,pediatric,,neonates,0.58,Lowest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,253,2025-12-02T16:05:09.863062
24633859.0,Neonatal hyperbilirubinemia,,0,,N,%,0,,,,19,pediatric,,neonates,0.58,Middle tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,254,2025-12-02T16:05:09.863062
24633859.0,Neonatal hyperbilirubinemia,,2,,N,%,10,,,,20,pediatric,,neonates,0.58,Highest tertile,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,255,2025-12-02T16:05:09.863062
24633859.0,Neonatal hyperbilirubinemia,,10,,N,%,9.3,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,256,2025-12-02T16:05:09.863062
24633859.0,HbA1c,,5.56,%,mean,SD,0.31,minmax,4.9,6.1,37,maternal,pregnancy,36 GW,0.25,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,206,2025-12-02T16:05:12.251790
24633859.0,HbA1c,,5.56,%,mean,SD,0.25,minmax,5.2,5.9,12,maternal,pregnancy,36 GW,0.25,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,207,2025-12-02T16:05:12.251790
24633859.0,HbA1c,,5.44,%,mean,SD,0.27,minmax,4.9,5.8,12,maternal,pregnancy,36 GW,0.25,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,208,2025-12-02T16:05:12.251790
24633859.0,HbA1c,,5.65,%,mean,SD,0.38,minmax,4.9,6.1,13,maternal,pregnancy,36 GW,0.25,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,209,2025-12-02T16:05:12.251790
24633859.0,HbA1c,,37.4,mmol/mol,mean,SD,3.4,minmax,30.0,43.0,37,maternal,pregnancy,36 GW,,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,210,2025-12-02T16:05:12.251790
24633859.0,HbA1c,,37.4,mmol/mol,mean,SD,2.8,minmax,33.0,41.0,12,maternal,pregnancy,36 GW,,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,211,2025-12-02T16:05:12.251790
24633859.0,HbA1c,,36.1,mmol/mol,mean,SD,3.1,minmax,30.0,40.0,12,maternal,pregnancy,36 GW,,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,212,2025-12-02T16:05:12.251790
24633859.0,HbA1c,,38.4,mmol/mol,mean,SD,4.1,minmax,30.0,43.0,13,maternal,pregnancy,36 GW,,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,213,2025-12-02T16:05:12.251790
24633859.0,Fructosamine,,205,umol/I,mean,SD,17,minmax,170.0,259.0,37,maternal,pregnancy,36 GW,0.098,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,214,2025-12-02T16:05:12.251790
24633859.0,Fructosamine,,198,umol/I,mean,SD,12,minmax,181.0,216.0,12,maternal,pregnancy,36 GW,0.098,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,215,2025-12-02T16:05:12.251790
24633859.0,Fructosamine,,212,umol/I,mean,SD,17,minmax,186.0,259.0,12,maternal,pregnancy,36 GW,0.098,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,216,2025-12-02T16:05:12.251790
24633859.0,Fructosamine,,204,umol/I,mean,SD,18,minmax,170.0,229.0,13,maternal,pregnancy,36 GW,0.098,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,217,2025-12-02T16:05:12.251790
24633859.0,weight gain ,,264,g/week,mean,SD,300,minmax,-380.0,1130.0,37,maternal,pregnancy,36 GW,0.119,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,218,2025-12-02T16:05:12.251790
24633859.0,weight gain ,,414,g/week,mean,SD,341,minmax,-230.0,1130.0,12,maternal,pregnancy,36 GW,0.119,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,219,2025-12-02T16:05:12.251790
24633859.0,weight gain ,,198,g/week,mean,SD,313,minmax,-380.0,910.0,12,maternal,pregnancy,36 GW,0.119,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,220,2025-12-02T16:05:12.251790
24633859.0,weight gain ,,185,g/week,mean,SD,200,minmax,-140.0,570.0,13,maternal,pregnancy,36 GW,0.119,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,221,2025-12-02T16:05:12.251790
24633859.0,birth weight,,3596,ng/ml,mean,SD,430,minmax,2525.0,4410.0,37,pediatric,,neonates,0.93,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,222,2025-12-02T16:05:12.251790
24633859.0,birth weight,,3584,ng/ml,mean,SD,461,minmax,2750.0,4330.0,12,pediatric,,neonates,0.93,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,223,2025-12-02T16:05:12.251790
24633859.0,birth weight,,3663,ng/ml,mean,SD,378,minmax,2956.0,4410.0,12,pediatric,,neonates,0.93,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,224,2025-12-02T16:05:12.251790
24633859.0,birth weight,,3545,ng/ml,mean,SD,471,minmax,2525.0,4190.0,13,pediatric,,neonates,0.93,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,225,2025-12-02T16:05:12.251790
24633859.0,birth weight,,3.588,ng/ml,mean,SD,447,minmax,1650.0,4430.0,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,226,2025-12-02T16:05:12.251790
24633859.0,birth weight,,0.09,SD units,mean,SD,0.82,minmax,-2.2,2.2,37,pediatric,,neonates,0.49,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,227,2025-12-02T16:05:12.251790
24633859.0,birth weight,,-0.01,SD units,mean,SD,0.86,minmax,-1.6,1.0,12,pediatric,,neonates,0.49,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,228,2025-12-02T16:05:12.251790
24633859.0,birth weight,,0.43,SD units,mean,SD,0.71,minmax,-0.5,2.2,12,pediatric,,neonates,0.49,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,229,2025-12-02T16:05:12.251790
24633859.0,birth weight,,-0.12,SD units,mean,SD,0.85,minmax,-2.2,0.9,13,pediatric,,neonates,0.49,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,230,2025-12-02T16:05:12.251790
24633859.0,birth weight,,0.15,SD units,mean,SD,0.96,minmax,-1.9,3.0,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,231,2025-12-02T16:05:12.251790
24633859.0,gestational weeks at birth,,39.6,weeks,mean,SD,1.3,minmax,37.3,42.3,37,pediatric,,neonates,0.71,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,232,2025-12-02T16:05:12.251790
24633859.0,gestational weeks at birth,,39.7,weeks,mean,SD,1.4,minmax,37.4,41.9,12,pediatric,,neonates,0.71,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,233,2025-12-02T16:05:12.251790
24633859.0,gestational weeks at birth,,39.2,weeks,mean,SD,1.3,minmax,37.3,41.4,12,pediatric,,neonates,0.71,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,234,2025-12-02T16:05:12.251790
24633859.0,gestational weeks at birth,,39.9,weeks,mean,SD,1.2,minmax,38.3,42.3,13,pediatric,,neonates,0.71,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,235,2025-12-02T16:05:12.251790
24633859.0,gestational weeks at birth,,39.5,weeks,mean,SD,1.8,minmax,31.7,42.1,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,236,2025-12-02T16:05:12.251790
24633859.0,Umbilical artery pH,,7.27,,mean,SD,0.09,minmax,7.08,7.43,58,maternal,delivery,,0.78,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,237,2025-12-02T16:05:12.251790
24633859.0,Umbilical artery pH,,7.27,,mean,SD,0.07,minmax,7.1,7.39,19,maternal,delivery,,0.78,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,238,2025-12-02T16:05:12.251790
24633859.0,Umbilical artery pH,,7.26,,mean,SD,0.1,minmax,7.08,7.43,19,maternal,delivery,,0.78,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,239,2025-12-02T16:05:12.251790
24633859.0,Umbilical artery pH,,7.28,,mean,SD,0.08,minmax,7.09,7.41,20,maternal,delivery,,0.78,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,240,2025-12-02T16:05:12.251790
24633859.0,Umbilical artery pH,,7.28,,mean,SD,0.08,minmax,7.11,7.45,107,maternal,delivery,,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,241,2025-12-02T16:05:12.251790
24633859.0,Neonatal Hypolycemia,,8,,N,%,13.8,,,,58,pediatric,,neonates,0.92,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,242,2025-12-02T16:05:12.251790
24633859.0,Neonatal Hypolycemia,,2,,N,%,10.5,,,,19,pediatric,,neonates,0.92,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,243,2025-12-02T16:05:12.251790
24633859.0,Neonatal Hypolycemia,,3,,N,%,15.8,,,,19,pediatric,,neonates,0.92,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,244,2025-12-02T16:05:12.251790
24633859.0,Neonatal Hypolycemia,,3,,N,%,15,,,,20,pediatric,,neonates,0.92,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,245,2025-12-02T16:05:12.251790
24633859.0,Neonatal Hypolycemia,,18,,N,%,16.8,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,246,2025-12-02T16:05:12.251790
24633859.0,Neonatal admission to NICU,,15,,N,%,25.9,,,,58,pediatric,,neonates,0.36,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,247,2025-12-02T16:05:12.251790
24633859.0,Neonatal admission to NICU,,6,,N,%,31.6,,,,19,pediatric,,neonates,0.36,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,248,2025-12-02T16:05:12.251790
24633859.0,Neonatal admission to NICU,,3,,N,%,15.8,,,,19,pediatric,,neonates,0.36,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,249,2025-12-02T16:05:12.251790
24633859.0,Neonatal admission to NICU,,6,,N,%,30,,,,20,pediatric,,neonates,0.36,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,250,2025-12-02T16:05:12.251790
24633859.0,Neonatal admission to NICU,,39,,N,%,36.4,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,251,2025-12-02T16:05:12.251790
24633859.0,Neonatal hyperbilirubinemia,,3,,N,%,5.2,,,,58,pediatric,,neonates,0.58,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,252,2025-12-02T16:05:12.251790
24633859.0,Neonatal hyperbilirubinemia,,1,,N,%,5.3,,,,19,pediatric,,neonates,0.58,Lowest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,253,2025-12-02T16:05:12.251790
24633859.0,Neonatal hyperbilirubinemia,,0,,N,%,0,,,,19,pediatric,,neonates,0.58,Middle tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,254,2025-12-02T16:05:12.251790
24633859.0,Neonatal hyperbilirubinemia,,2,,N,%,10,,,,20,pediatric,,neonates,0.58,Highest tertile,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,255,2025-12-02T16:05:12.251790
24633859.0,Neonatal hyperbilirubinemia,,10,,N,%,9.3,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,256,2025-12-02T16:05:12.251790
24633859.0,HbA1c,,5.56,%,mean,SD,0.31,minmax,4.9,6.1,37,maternal,pregnancy,36 GW,0.25,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,206,2025-12-02T16:05:16.158507
24633859.0,HbA1c,,5.56,%,mean,SD,0.25,minmax,5.2,5.9,12,maternal,pregnancy,36 GW,0.25,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,207,2025-12-02T16:05:16.158507
24633859.0,HbA1c,,5.44,%,mean,SD,0.27,minmax,4.9,5.8,12,maternal,pregnancy,36 GW,0.25,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,208,2025-12-02T16:05:16.158507
24633859.0,HbA1c,,5.65,%,mean,SD,0.38,minmax,4.9,6.1,13,maternal,pregnancy,36 GW,0.25,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,209,2025-12-02T16:05:16.158507
24633859.0,HbA1c,,37.4,mmol/mol,mean,SD,3.4,minmax,30.0,43.0,37,maternal,pregnancy,36 GW,,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,210,2025-12-02T16:05:16.158507
24633859.0,HbA1c,,37.4,mmol/mol,mean,SD,2.8,minmax,33.0,41.0,12,maternal,pregnancy,36 GW,,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,211,2025-12-02T16:05:16.158507
24633859.0,HbA1c,,36.1,mmol/mol,mean,SD,3.1,minmax,30.0,40.0,12,maternal,pregnancy,36 GW,,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,212,2025-12-02T16:05:16.158507
24633859.0,HbA1c,,38.4,mmol/mol,mean,SD,4.1,minmax,30.0,43.0,13,maternal,pregnancy,36 GW,,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,213,2025-12-02T16:05:16.158507
24633859.0,Fructosamine,,205,umol/I,mean,SD,17,minmax,170.0,259.0,37,maternal,pregnancy,36 GW,0.098,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,214,2025-12-02T16:05:16.158507
24633859.0,Fructosamine,,198,umol/I,mean,SD,12,minmax,181.0,216.0,12,maternal,pregnancy,36 GW,0.098,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,215,2025-12-02T16:05:16.158507
24633859.0,Fructosamine,,212,umol/I,mean,SD,17,minmax,186.0,259.0,12,maternal,pregnancy,36 GW,0.098,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,216,2025-12-02T16:05:16.158507
24633859.0,Fructosamine,,204,umol/I,mean,SD,18,minmax,170.0,229.0,13,maternal,pregnancy,36 GW,0.098,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,217,2025-12-02T16:05:16.158507
24633859.0,weight gain ,,264,g/week,mean,SD,300,minmax,-380.0,1130.0,37,maternal,pregnancy,36 GW,0.119,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,218,2025-12-02T16:05:16.158507
24633859.0,weight gain ,,414,g/week,mean,SD,341,minmax,-230.0,1130.0,12,maternal,pregnancy,36 GW,0.119,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,219,2025-12-02T16:05:16.158507
24633859.0,weight gain ,,198,g/week,mean,SD,313,minmax,-380.0,910.0,12,maternal,pregnancy,36 GW,0.119,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,220,2025-12-02T16:05:16.158507
24633859.0,weight gain ,,185,g/week,mean,SD,200,minmax,-140.0,570.0,13,maternal,pregnancy,36 GW,0.119,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,221,2025-12-02T16:05:16.158507
24633859.0,birth weight,,3596,ng/ml,mean,SD,430,minmax,2525.0,4410.0,37,pediatric,,neonates,0.93,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,222,2025-12-02T16:05:16.158507
24633859.0,birth weight,,3584,ng/ml,mean,SD,461,minmax,2750.0,4330.0,12,pediatric,,neonates,0.93,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,223,2025-12-02T16:05:16.158507
24633859.0,birth weight,,3663,ng/ml,mean,SD,378,minmax,2956.0,4410.0,12,pediatric,,neonates,0.93,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,224,2025-12-02T16:05:16.158507
24633859.0,birth weight,,3545,ng/ml,mean,SD,471,minmax,2525.0,4190.0,13,pediatric,,neonates,0.93,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,225,2025-12-02T16:05:16.158507
24633859.0,birth weight,,3.588,ng/ml,mean,SD,447,minmax,1650.0,4430.0,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,226,2025-12-02T16:05:16.158507
24633859.0,birth weight,,0.09,SD units,mean,SD,0.82,minmax,-2.2,2.2,37,pediatric,,neonates,0.49,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,227,2025-12-02T16:05:16.158507
24633859.0,birth weight,,-0.01,SD units,mean,SD,0.86,minmax,-1.6,1.0,12,pediatric,,neonates,0.49,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,228,2025-12-02T16:05:16.158507
24633859.0,birth weight,,0.43,SD units,mean,SD,0.71,minmax,-0.5,2.2,12,pediatric,,neonates,0.49,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,229,2025-12-02T16:05:16.158507
24633859.0,birth weight,,-0.12,SD units,mean,SD,0.85,minmax,-2.2,0.9,13,pediatric,,neonates,0.49,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,230,2025-12-02T16:05:16.158507
24633859.0,birth weight,,0.15,SD units,mean,SD,0.96,minmax,-1.9,3.0,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,231,2025-12-02T16:05:16.158507
24633859.0,gestational weeks at birth,,39.6,weeks,mean,SD,1.3,minmax,37.3,42.3,37,pediatric,,neonates,0.71,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,232,2025-12-02T16:05:16.158507
24633859.0,gestational weeks at birth,,39.7,weeks,mean,SD,1.4,minmax,37.4,41.9,12,pediatric,,neonates,0.71,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,233,2025-12-02T16:05:16.158507
24633859.0,gestational weeks at birth,,39.2,weeks,mean,SD,1.3,minmax,37.3,41.4,12,pediatric,,neonates,0.71,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,234,2025-12-02T16:05:16.158507
24633859.0,gestational weeks at birth,,39.9,weeks,mean,SD,1.2,minmax,38.3,42.3,13,pediatric,,neonates,0.71,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,235,2025-12-02T16:05:16.158507
24633859.0,gestational weeks at birth,,39.5,weeks,mean,SD,1.8,minmax,31.7,42.1,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,236,2025-12-02T16:05:16.158507
24633859.0,Umbilical artery pH,,7.27,,mean,SD,0.09,minmax,7.08,7.43,58,maternal,delivery,,0.78,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,237,2025-12-02T16:05:16.158507
24633859.0,Umbilical artery pH,,7.27,,mean,SD,0.07,minmax,7.1,7.39,19,maternal,delivery,,0.78,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,238,2025-12-02T16:05:16.158507
24633859.0,Umbilical artery pH,,7.26,,mean,SD,0.1,minmax,7.08,7.43,19,maternal,delivery,,0.78,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,239,2025-12-02T16:05:16.158507
24633859.0,Umbilical artery pH,,7.28,,mean,SD,0.08,minmax,7.09,7.41,20,maternal,delivery,,0.78,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,240,2025-12-02T16:05:16.158507
24633859.0,Umbilical artery pH,,7.28,,mean,SD,0.08,minmax,7.11,7.45,107,maternal,delivery,,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,241,2025-12-02T16:05:16.158507
24633859.0,Neonatal Hypolycemia,,8,,N,%,13.8,,,,58,pediatric,,neonates,0.92,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,242,2025-12-02T16:05:16.158507
24633859.0,Neonatal Hypolycemia,,2,,N,%,10.5,,,,19,pediatric,,neonates,0.92,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,243,2025-12-02T16:05:16.158507
24633859.0,Neonatal Hypolycemia,,3,,N,%,15.8,,,,19,pediatric,,neonates,0.92,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,244,2025-12-02T16:05:16.158507
24633859.0,Neonatal Hypolycemia,,3,,N,%,15,,,,20,pediatric,,neonates,0.92,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,245,2025-12-02T16:05:16.158507
24633859.0,Neonatal Hypolycemia,,18,,N,%,16.8,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,246,2025-12-02T16:05:16.158507
24633859.0,Neonatal admission to NICU,,15,,N,%,25.9,,,,58,pediatric,,neonates,0.36,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,247,2025-12-02T16:05:16.158507
24633859.0,Neonatal admission to NICU,,6,,N,%,31.6,,,,19,pediatric,,neonates,0.36,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,248,2025-12-02T16:05:16.158507
24633859.0,Neonatal admission to NICU,,3,,N,%,15.8,,,,19,pediatric,,neonates,0.36,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,249,2025-12-02T16:05:16.158507
24633859.0,Neonatal admission to NICU,,6,,N,%,30,,,,20,pediatric,,neonates,0.36,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,250,2025-12-02T16:05:16.158507
24633859.0,Neonatal admission to NICU,,39,,N,%,36.4,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,251,2025-12-02T16:05:16.158507
24633859.0,Neonatal hyperbilirubinemia,,3,,N,%,5.2,,,,58,pediatric,,neonates,0.58,All,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,252,2025-12-02T16:05:16.158507
24633859.0,Neonatal hyperbilirubinemia,,1,,N,%,5.3,,,,19,pediatric,,neonates,0.58,Lowest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,253,2025-12-02T16:05:16.158507
24633859.0,Neonatal hyperbilirubinemia,,0,,N,%,0,,,,19,pediatric,,neonates,0.58,Middle tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,254,2025-12-02T16:05:16.158507
24633859.0,Neonatal hyperbilirubinemia,,2,,N,%,10,,,,20,pediatric,,neonates,0.58,Highest tertile,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,255,2025-12-02T16:05:16.158507
24633859.0,Neonatal hyperbilirubinemia,,10,,N,%,9.3,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,256,2025-12-02T16:05:16.158507
24633859.0,HbA1c,,5.56,%,mean,SD,0.31,minmax,4.9,6.1,37,maternal,pregnancy,36 GW,0.25,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,206,2025-12-02T16:05:22.595023
24633859.0,HbA1c,,5.56,%,mean,SD,0.25,minmax,5.2,5.9,12,maternal,pregnancy,36 GW,0.25,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,207,2025-12-02T16:05:22.595023
24633859.0,HbA1c,,5.44,%,mean,SD,0.27,minmax,4.9,5.8,12,maternal,pregnancy,36 GW,0.25,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,208,2025-12-02T16:05:22.595023
24633859.0,HbA1c,,5.65,%,mean,SD,0.38,minmax,4.9,6.1,13,maternal,pregnancy,36 GW,0.25,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,209,2025-12-02T16:05:22.595023
24633859.0,HbA1c,,37.4,mmol/mol,mean,SD,3.4,minmax,30.0,43.0,37,maternal,pregnancy,36 GW,,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,210,2025-12-02T16:05:22.595023
24633859.0,HbA1c,,37.4,mmol/mol,mean,SD,2.8,minmax,33.0,41.0,12,maternal,pregnancy,36 GW,,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,211,2025-12-02T16:05:22.595023
24633859.0,HbA1c,,36.1,mmol/mol,mean,SD,3.1,minmax,30.0,40.0,12,maternal,pregnancy,36 GW,,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,212,2025-12-02T16:05:22.595023
24633859.0,HbA1c,,38.4,mmol/mol,mean,SD,4.1,minmax,30.0,43.0,13,maternal,pregnancy,36 GW,,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,213,2025-12-02T16:05:22.595023
24633859.0,Fructosamine,,205,umol/I,mean,SD,17,minmax,170.0,259.0,37,maternal,pregnancy,36 GW,0.098,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,214,2025-12-02T16:05:22.595023
24633859.0,Fructosamine,,198,umol/I,mean,SD,12,minmax,181.0,216.0,12,maternal,pregnancy,36 GW,0.098,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,215,2025-12-02T16:05:22.595023
24633859.0,Fructosamine,,212,umol/I,mean,SD,17,minmax,186.0,259.0,12,maternal,pregnancy,36 GW,0.098,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,216,2025-12-02T16:05:22.595023
24633859.0,Fructosamine,,204,umol/I,mean,SD,18,minmax,170.0,229.0,13,maternal,pregnancy,36 GW,0.098,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,217,2025-12-02T16:05:22.595023
24633859.0,weight gain ,,264,g/week,mean,SD,300,minmax,-380.0,1130.0,37,maternal,pregnancy,36 GW,0.119,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,218,2025-12-02T16:05:22.595023
24633859.0,weight gain ,,414,g/week,mean,SD,341,minmax,-230.0,1130.0,12,maternal,pregnancy,36 GW,0.119,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,219,2025-12-02T16:05:22.595023
24633859.0,weight gain ,,198,g/week,mean,SD,313,minmax,-380.0,910.0,12,maternal,pregnancy,36 GW,0.119,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,220,2025-12-02T16:05:22.595023
24633859.0,weight gain ,,185,g/week,mean,SD,200,minmax,-140.0,570.0,13,maternal,pregnancy,36 GW,0.119,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,221,2025-12-02T16:05:22.595023
24633859.0,birth weight,,3596,ng/ml,mean,SD,430,minmax,2525.0,4410.0,37,pediatric,,neonates,0.93,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,222,2025-12-02T16:05:22.595023
24633859.0,birth weight,,3584,ng/ml,mean,SD,461,minmax,2750.0,4330.0,12,pediatric,,neonates,0.93,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,223,2025-12-02T16:05:22.595023
24633859.0,birth weight,,3663,ng/ml,mean,SD,378,minmax,2956.0,4410.0,12,pediatric,,neonates,0.93,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,224,2025-12-02T16:05:22.595023
24633859.0,birth weight,,3545,ng/ml,mean,SD,471,minmax,2525.0,4190.0,13,pediatric,,neonates,0.93,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,225,2025-12-02T16:05:22.595023
24633859.0,birth weight,,3.588,ng/ml,mean,SD,447,minmax,1650.0,4430.0,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,226,2025-12-02T16:05:22.595023
24633859.0,birth weight,,0.09,SD units,mean,SD,0.82,minmax,-2.2,2.2,37,pediatric,,neonates,0.49,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,227,2025-12-02T16:05:22.595023
24633859.0,birth weight,,-0.01,SD units,mean,SD,0.86,minmax,-1.6,1.0,12,pediatric,,neonates,0.49,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,228,2025-12-02T16:05:22.595023
24633859.0,birth weight,,0.43,SD units,mean,SD,0.71,minmax,-0.5,2.2,12,pediatric,,neonates,0.49,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,229,2025-12-02T16:05:22.595023
24633859.0,birth weight,,-0.12,SD units,mean,SD,0.85,minmax,-2.2,0.9,13,pediatric,,neonates,0.49,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,230,2025-12-02T16:05:22.595023
24633859.0,birth weight,,0.15,SD units,mean,SD,0.96,minmax,-1.9,3.0,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,231,2025-12-02T16:05:22.595023
24633859.0,gestational weeks at birth,,39.6,weeks,mean,SD,1.3,minmax,37.3,42.3,37,pediatric,,neonates,0.71,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,232,2025-12-02T16:05:22.595023
24633859.0,gestational weeks at birth,,39.7,weeks,mean,SD,1.4,minmax,37.4,41.9,12,pediatric,,neonates,0.71,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,233,2025-12-02T16:05:22.595023
24633859.0,gestational weeks at birth,,39.2,weeks,mean,SD,1.3,minmax,37.3,41.4,12,pediatric,,neonates,0.71,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,234,2025-12-02T16:05:22.595023
24633859.0,gestational weeks at birth,,39.9,weeks,mean,SD,1.2,minmax,38.3,42.3,13,pediatric,,neonates,0.71,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,235,2025-12-02T16:05:22.595023
24633859.0,gestational weeks at birth,,39.5,weeks,mean,SD,1.8,minmax,31.7,42.1,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,236,2025-12-02T16:05:22.595023
24633859.0,Umbilical artery pH,,7.27,,mean,SD,0.09,minmax,7.08,7.43,58,maternal,delivery,,0.78,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,237,2025-12-02T16:05:22.595023
24633859.0,Umbilical artery pH,,7.27,,mean,SD,0.07,minmax,7.1,7.39,19,maternal,delivery,,0.78,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,238,2025-12-02T16:05:22.595023
24633859.0,Umbilical artery pH,,7.26,,mean,SD,0.1,minmax,7.08,7.43,19,maternal,delivery,,0.78,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,239,2025-12-02T16:05:22.595023
24633859.0,Umbilical artery pH,,7.28,,mean,SD,0.08,minmax,7.09,7.41,20,maternal,delivery,,0.78,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,240,2025-12-02T16:05:22.595023
24633859.0,Umbilical artery pH,,7.28,,mean,SD,0.08,minmax,7.11,7.45,107,maternal,delivery,,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,241,2025-12-02T16:05:22.595023
24633859.0,Neonatal Hypolycemia,,8,,N,%,13.8,,,,58,pediatric,,neonates,0.92,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,242,2025-12-02T16:05:22.595023
24633859.0,Neonatal Hypolycemia,,2,,N,%,10.5,,,,19,pediatric,,neonates,0.92,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,243,2025-12-02T16:05:22.595023
24633859.0,Neonatal Hypolycemia,,3,,N,%,15.8,,,,19,pediatric,,neonates,0.92,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,244,2025-12-02T16:05:22.595023
24633859.0,Neonatal Hypolycemia,,3,,N,%,15,,,,20,pediatric,,neonates,0.92,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,245,2025-12-02T16:05:22.595023
24633859.0,Neonatal Hypolycemia,,18,,N,%,16.8,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,246,2025-12-02T16:05:22.595023
24633859.0,Neonatal admission to NICU,,15,,N,%,25.9,,,,58,pediatric,,neonates,0.36,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,247,2025-12-02T16:05:22.595023
24633859.0,Neonatal admission to NICU,,6,,N,%,31.6,,,,19,pediatric,,neonates,0.36,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,248,2025-12-02T16:05:22.595023
24633859.0,Neonatal admission to NICU,,3,,N,%,15.8,,,,19,pediatric,,neonates,0.36,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,249,2025-12-02T16:05:22.595023
24633859.0,Neonatal admission to NICU,,6,,N,%,30,,,,20,pediatric,,neonates,0.36,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,250,2025-12-02T16:05:22.595023
24633859.0,Neonatal admission to NICU,,39,,N,%,36.4,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,251,2025-12-02T16:05:22.595023
24633859.0,Neonatal hyperbilirubinemia,,3,,N,%,5.2,,,,58,pediatric,,neonates,0.58,All,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,252,2025-12-02T16:05:22.595023
24633859.0,Neonatal hyperbilirubinemia,,1,,N,%,5.3,,,,19,pediatric,,neonates,0.58,Lowest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,253,2025-12-02T16:05:22.595023
24633859.0,Neonatal hyperbilirubinemia,,0,,N,%,0,,,,19,pediatric,,neonates,0.58,Middle tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,254,2025-12-02T16:05:22.595023
24633859.0,Neonatal hyperbilirubinemia,,2,,N,%,10,,,,20,pediatric,,neonates,0.58,Highest tertile,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,255,2025-12-02T16:05:22.595023
24633859.0,Neonatal hyperbilirubinemia,,10,,N,%,9.3,,,,107,pediatric,,neonates,,"Reference group, insulin-treated GDM patients",PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,256,2025-12-02T16:05:22.595023
17464806.0,Side effects,headaches,8,,N,%,33,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,257,2025-12-02T16:05:09.863062
17464806.0,Side effects,nausea,2,,N,%,8.3,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,258,2025-12-02T16:05:09.863062
17464806.0,Side effects,skin rash,1,,N,%,4.1,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,259,2025-12-02T16:05:09.863062
17464806.0,Side effects,headaches,8,,N,%,33,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,257,2025-12-02T16:05:12.251790
17464806.0,Side effects,nausea,2,,N,%,8.3,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,258,2025-12-02T16:05:12.251790
17464806.0,Side effects,skin rash,1,,N,%,4.1,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,259,2025-12-02T16:05:12.251790
17464806.0,Side effects,headaches,8,,N,%,33,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,257,2025-12-02T16:05:16.158507
17464806.0,Side effects,nausea,2,,N,%,8.3,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,258,2025-12-02T16:05:16.158507
17464806.0,Side effects,skin rash,1,,N,%,4.1,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,259,2025-12-02T16:05:16.158507
17464806.0,Side effects,headaches,8,,N,%,33,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,257,2025-12-02T16:05:22.595023
17464806.0,Side effects,nausea,2,,N,%,8.3,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,258,2025-12-02T16:05:22.595023
17464806.0,Side effects,skin rash,1,,N,%,4.1,,,,24,maternal,pregnant,22-34 GW,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,259,2025-12-02T16:05:22.595023
17667209.0,Side effects,temporary headache,2,,N,,,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,260,2025-12-02T16:05:09.863062
17667209.0,heart rate after starting tocolysis,,92,beats per minutes,mean,SD,8,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,261,2025-12-02T16:05:09.863062
17667209.0,systolic blood pressure during the first 4 hours after starting initial tocolysis,,117,mm Hg,mean,SD,2.6,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,262,2025-12-02T16:05:09.863062
17667209.0,diastolic blood pressure during the first 4 hours after starting initial tocolysis,,77,mm Hg,mean,SD,2.1,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,263,2025-12-02T16:05:09.863062
17667209.0,Side effects,temporary headache,2,,N,,,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,260,2025-12-02T16:05:12.251790
17667209.0,heart rate after starting tocolysis,,92,beats per minutes,mean,SD,8,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,261,2025-12-02T16:05:12.251790
17667209.0,systolic blood pressure during the first 4 hours after starting initial tocolysis,,117,mm Hg,mean,SD,2.6,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,262,2025-12-02T16:05:12.251790
17667209.0,diastolic blood pressure during the first 4 hours after starting initial tocolysis,,77,mm Hg,mean,SD,2.1,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,263,2025-12-02T16:05:12.251790
17667209.0,Side effects,temporary headache,2,,N,,,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,260,2025-12-02T16:05:16.158507
17667209.0,heart rate after starting tocolysis,,92,beats per minutes,mean,SD,8,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,261,2025-12-02T16:05:16.158507
17667209.0,systolic blood pressure during the first 4 hours after starting initial tocolysis,,117,mm Hg,mean,SD,2.6,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,262,2025-12-02T16:05:16.158507
17667209.0,diastolic blood pressure during the first 4 hours after starting initial tocolysis,,77,mm Hg,mean,SD,2.1,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,263,2025-12-02T16:05:16.158507
17667209.0,Side effects,temporary headache,2,,N,,,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,260,2025-12-02T16:05:22.595023
17667209.0,heart rate after starting tocolysis,,92,beats per minutes,mean,SD,8,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,261,2025-12-02T16:05:22.595023
17667209.0,systolic blood pressure during the first 4 hours after starting initial tocolysis,,117,mm Hg,mean,SD,2.6,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,262,2025-12-02T16:05:22.595023
17667209.0,diastolic blood pressure during the first 4 hours after starting initial tocolysis,,77,mm Hg,mean,SD,2.1,,,,5,maternal,3rd trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,263,2025-12-02T16:05:22.595023
18394772.0,gestational weeks at birth,,38,weeks,median,,,minmax,30.43,41.43,14,maternal,3rd trimester,,,all,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,264,2025-12-02T16:05:09.863062
18394772.0,birth percentile <5,,0,,N,,,,,,14,pediatric,,neonates,,all,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,265,2025-12-02T16:05:09.863062
18394772.0,Apgar at 1 min <7,,0,,N,,,,,,14,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,266,2025-12-02T16:05:09.863062
18394772.0,preterm birth,,0,,N,,,,,,7,pediatric,,neonates,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,267,2025-12-02T16:05:09.863062
18394772.0,preterm birth,,1,,N,,,,,,7,pediatric,,neonates,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,268,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 0.5h,-12,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,269,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 0.5h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,270,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 1h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,271,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 1h,-13,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,272,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 5h,0.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,273,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 5h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,274,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 7h,-10.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,275,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 7h,-11,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,276,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 10h,-15,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,277,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 10h,-6.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,278,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 24h,-17,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,279,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 24h,3,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,280,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 48h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,281,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 48h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,282,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 72h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,283,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 72h,-15,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,284,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 96h,1.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,285,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 96h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,286,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 120h,-8,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,287,2025-12-02T16:05:09.863062
18394772.0,Changes of Systolic blood pressure,at 120h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,288,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 0.5h,2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,289,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 0.5h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,290,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 1h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,291,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 1h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,292,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 5h,-8,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,293,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 5h,-7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,294,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 7h,-1.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,295,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 7h,-7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,296,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 10h,-5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,297,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 10h,-5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,298,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 24h,7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,299,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 24h,-3,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,300,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 48h,1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,301,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 48h,1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,302,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 72h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,303,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 72h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,304,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 96h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,305,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 96h,6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,306,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 120h,3.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,307,2025-12-02T16:05:09.863062
18394772.0,Changes of diastolic blood pressure ,at 120h,6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,308,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 0.5h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,309,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 0.5h,10,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,310,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 1h,-2,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,311,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 1h,3,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,312,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 5h,0.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,313,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 5h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,314,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 7h,-1.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,315,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 7h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,316,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 10h,-9,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,317,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 10h,4.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,318,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 24h,8,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,319,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 24h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,320,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 48h,4,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,321,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 48h,6,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,322,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 72h,-5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,323,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 72h,-3,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,324,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 96h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,325,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 96h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,326,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 120h,6.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,327,2025-12-02T16:05:09.863062
18394772.0,Changes of heart rate,at 120h,10,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,328,2025-12-02T16:05:09.863062
18394772.0,gestational weeks at birth,,38,weeks,median,,,minmax,30.43,41.43,14,maternal,3rd trimester,,,all,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,264,2025-12-02T16:05:12.251790
18394772.0,birth percentile <5,,0,,N,,,,,,14,pediatric,,neonates,,all,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,265,2025-12-02T16:05:12.251790
18394772.0,Apgar at 1 min <7,,0,,N,,,,,,14,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,266,2025-12-02T16:05:12.251790
18394772.0,preterm birth,,0,,N,,,,,,7,pediatric,,neonates,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,267,2025-12-02T16:05:12.251790
18394772.0,preterm birth,,1,,N,,,,,,7,pediatric,,neonates,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,268,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 0.5h,-12,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,269,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 0.5h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,270,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 1h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,271,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 1h,-13,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,272,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 5h,0.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,273,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 5h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,274,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 7h,-10.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,275,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 7h,-11,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,276,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 10h,-15,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,277,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 10h,-6.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,278,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 24h,-17,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,279,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 24h,3,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,280,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 48h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,281,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 48h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,282,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 72h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,283,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 72h,-15,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,284,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 96h,1.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,285,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 96h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,286,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 120h,-8,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,287,2025-12-02T16:05:12.251790
18394772.0,Changes of Systolic blood pressure,at 120h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,288,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 0.5h,2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,289,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 0.5h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,290,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 1h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,291,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 1h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,292,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 5h,-8,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,293,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 5h,-7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,294,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 7h,-1.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,295,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 7h,-7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,296,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 10h,-5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,297,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 10h,-5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,298,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 24h,7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,299,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 24h,-3,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,300,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 48h,1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,301,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 48h,1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,302,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 72h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,303,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 72h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,304,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 96h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,305,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 96h,6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,306,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 120h,3.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,307,2025-12-02T16:05:12.251790
18394772.0,Changes of diastolic blood pressure ,at 120h,6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,308,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 0.5h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,309,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 0.5h,10,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,310,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 1h,-2,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,311,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 1h,3,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,312,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 5h,0.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,313,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 5h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,314,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 7h,-1.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,315,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 7h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,316,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 10h,-9,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,317,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 10h,4.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,318,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 24h,8,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,319,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 24h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,320,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 48h,4,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,321,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 48h,6,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,322,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 72h,-5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,323,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 72h,-3,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,324,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 96h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,325,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 96h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,326,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 120h,6.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,327,2025-12-02T16:05:12.251790
18394772.0,Changes of heart rate,at 120h,10,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,328,2025-12-02T16:05:12.251790
18394772.0,gestational weeks at birth,,38,weeks,median,,,minmax,30.43,41.43,14,maternal,3rd trimester,,,all,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,264,2025-12-02T16:05:16.158507
18394772.0,birth percentile <5,,0,,N,,,,,,14,pediatric,,neonates,,all,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,265,2025-12-02T16:05:16.158507
18394772.0,Apgar at 1 min <7,,0,,N,,,,,,14,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,266,2025-12-02T16:05:16.158507
18394772.0,preterm birth,,0,,N,,,,,,7,pediatric,,neonates,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,267,2025-12-02T16:05:16.158507
18394772.0,preterm birth,,1,,N,,,,,,7,pediatric,,neonates,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,268,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 0.5h,-12,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,269,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 0.5h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,270,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 1h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,271,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 1h,-13,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,272,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 5h,0.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,273,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 5h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,274,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 7h,-10.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,275,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 7h,-11,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,276,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 10h,-15,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,277,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 10h,-6.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,278,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 24h,-17,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,279,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 24h,3,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,280,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 48h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,281,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 48h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,282,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 72h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,283,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 72h,-15,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,284,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 96h,1.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,285,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 96h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,286,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 120h,-8,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,287,2025-12-02T16:05:16.158507
18394772.0,Changes of Systolic blood pressure,at 120h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,288,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 0.5h,2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,289,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 0.5h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,290,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 1h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,291,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 1h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,292,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 5h,-8,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,293,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 5h,-7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,294,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 7h,-1.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,295,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 7h,-7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,296,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 10h,-5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,297,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 10h,-5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,298,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 24h,7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,299,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 24h,-3,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,300,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 48h,1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,301,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 48h,1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,302,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 72h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,303,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 72h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,304,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 96h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,305,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 96h,6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,306,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 120h,3.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,307,2025-12-02T16:05:16.158507
18394772.0,Changes of diastolic blood pressure ,at 120h,6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,308,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 0.5h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,309,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 0.5h,10,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,310,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 1h,-2,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,311,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 1h,3,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,312,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 5h,0.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,313,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 5h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,314,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 7h,-1.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,315,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 7h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,316,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 10h,-9,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,317,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 10h,4.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,318,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 24h,8,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,319,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 24h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,320,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 48h,4,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,321,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 48h,6,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,322,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 72h,-5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,323,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 72h,-3,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,324,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 96h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,325,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 96h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,326,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 120h,6.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,327,2025-12-02T16:05:16.158507
18394772.0,Changes of heart rate,at 120h,10,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,328,2025-12-02T16:05:16.158507
18394772.0,gestational weeks at birth,,38,weeks,median,,,minmax,30.43,41.43,14,maternal,3rd trimester,,,all,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,264,2025-12-02T16:05:22.595023
18394772.0,birth percentile <5,,0,,N,,,,,,14,pediatric,,neonates,,all,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,265,2025-12-02T16:05:22.595023
18394772.0,Apgar at 1 min <7,,0,,N,,,,,,14,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,266,2025-12-02T16:05:22.595023
18394772.0,preterm birth,,0,,N,,,,,,7,pediatric,,neonates,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,267,2025-12-02T16:05:22.595023
18394772.0,preterm birth,,1,,N,,,,,,7,pediatric,,neonates,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,268,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 0.5h,-12,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,269,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 0.5h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,270,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 1h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,271,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 1h,-13,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,272,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 5h,0.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,273,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 5h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,274,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 7h,-10.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,275,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 7h,-11,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,276,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 10h,-15,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,277,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 10h,-6.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,278,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 24h,-17,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,279,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 24h,3,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,280,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 48h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,281,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 48h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,282,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 72h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,283,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 72h,-15,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,284,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 96h,1.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,285,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 96h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,286,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 120h,-8,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,287,2025-12-02T16:05:22.595023
18394772.0,Changes of Systolic blood pressure,at 120h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,288,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 0.5h,2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,289,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 0.5h,-1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,290,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 1h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,291,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 1h,-2,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,292,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 5h,-8,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,293,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 5h,-7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,294,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 7h,-1.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,295,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 7h,-7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,296,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 10h,-5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,297,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 10h,-5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,298,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 24h,7,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,299,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 24h,-3,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,300,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 48h,1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,301,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 48h,1,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,302,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 72h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,303,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 72h,-6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,304,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 96h,0,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,305,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 96h,6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,306,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 120h,3.5,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,307,2025-12-02T16:05:22.595023
18394772.0,Changes of diastolic blood pressure ,at 120h,6,mm Hg,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,308,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 0.5h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,309,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 0.5h,10,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,310,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 1h,-2,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,311,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 1h,3,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,312,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 5h,0.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,313,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 5h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,314,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 7h,-1.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,315,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 7h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,316,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 10h,-9,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,317,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 10h,4.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,318,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 24h,8,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,319,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 24h,5,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,320,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 48h,4,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,321,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 48h,6,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,322,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 72h,-5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,323,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 72h,-3,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,324,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 96h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,325,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 96h,2,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,326,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 120h,6.5,/min,median,,,,,,7,maternal,pregnancy,,,Group 1 nifedipine slow-release,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,327,2025-12-02T16:05:22.595023
18394772.0,Changes of heart rate,at 120h,10,/min,median,,,,,,7,maternal,pregnancy,,,Group 2 nifedipine GITS,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,328,2025-12-02T16:05:22.595023
21644845.0,gestational age at delivery,,34.7,weeks,mean,SD,3.9,,,,20,maternal,delivery,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,329,2025-12-02T16:05:09.863062
21644845.0,days from admission to delivery,,35.8,days,mean,SD,29.8,,,,20,maternal,delivery,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,330,2025-12-02T16:05:09.863062
21644845.0,gestational age at delivery,,34.7,weeks,mean,SD,3.9,,,,20,maternal,delivery,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,329,2025-12-02T16:05:12.251790
21644845.0,days from admission to delivery,,35.8,days,mean,SD,29.8,,,,20,maternal,delivery,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,330,2025-12-02T16:05:12.251790
21644845.0,gestational age at delivery,,34.7,weeks,mean,SD,3.9,,,,20,maternal,delivery,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,329,2025-12-02T16:05:16.158507
21644845.0,days from admission to delivery,,35.8,days,mean,SD,29.8,,,,20,maternal,delivery,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,330,2025-12-02T16:05:16.158507
21644845.0,gestational age at delivery,,34.7,weeks,mean,SD,3.9,,,,20,maternal,delivery,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,329,2025-12-02T16:05:22.595023
21644845.0,days from admission to delivery,,35.8,days,mean,SD,29.8,,,,20,maternal,delivery,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,330,2025-12-02T16:05:22.595023
2216229.0,heart rate at the time of the first Doppler measurement,,76,beats per minutes,mean,SD,4,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,331,2025-12-02T16:05:09.863062
2216229.0,systolic BP at the time of the first Doppler measurement,,125,mm Hg,mean,SD,6,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,332,2025-12-02T16:05:09.863062
2216229.0,diastolic BP at the time of the first Doppler measurement,,77,mm Hg,mean,SD,4,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,333,2025-12-02T16:05:09.863062
2216229.0,S/D ratio of the flow velocity waveforms in the uterine artery after nifedipine,,1.72,,mean,SD,0.21,,,,10,maternal,3rd trimester,,<0.01,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,334,2025-12-02T16:05:09.863062
2216229.0,S/D ratio of the flow velocity waveforms in the uterine artery before nifedipine,,1.64,,mean,SD,0.13,,,,10,maternal,3rd trimester,,<0.01,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,335,2025-12-02T16:05:09.863062
2216229.0,birth weight,,3386,g,mean,,,minmax,3020.0,3760.0,10,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,336,2025-12-02T16:05:09.863062
2216229.0,pH in the umbilical artery,,7.29,,mean,,0.03,,,,10,pediatric,,fetus,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,337,2025-12-02T16:05:09.863062
2216229.0,pH in the umbilical vein,,7.35,,mean,,0.03,,,,10,pediatric,,fetus,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,338,2025-12-02T16:05:09.863062
2216229.0,Mean Arterial Pressure before nifedipine,,96,mm Hg,mean,SD,4,,,,10,maternal,3rd trimester,,<0.02,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,339,2025-12-02T16:05:09.863062
2216229.0,Mean Arterial Pressure at the second Doppler measurement ,,86,mm Hg,mean,SD,6,,,,10,maternal,3rd trimester,,<0.02,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,340,2025-12-02T16:05:09.863062
2216229.0,heart rate at the time of the first Doppler measurement,,76,beats per minutes,mean,SD,4,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,331,2025-12-02T16:05:12.251790
2216229.0,systolic BP at the time of the first Doppler measurement,,125,mm Hg,mean,SD,6,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,332,2025-12-02T16:05:12.251790
2216229.0,diastolic BP at the time of the first Doppler measurement,,77,mm Hg,mean,SD,4,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,333,2025-12-02T16:05:12.251790
2216229.0,S/D ratio of the flow velocity waveforms in the uterine artery after nifedipine,,1.72,,mean,SD,0.21,,,,10,maternal,3rd trimester,,<0.01,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,334,2025-12-02T16:05:12.251790
2216229.0,S/D ratio of the flow velocity waveforms in the uterine artery before nifedipine,,1.64,,mean,SD,0.13,,,,10,maternal,3rd trimester,,<0.01,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,335,2025-12-02T16:05:12.251790
2216229.0,birth weight,,3386,g,mean,,,minmax,3020.0,3760.0,10,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,336,2025-12-02T16:05:12.251790
2216229.0,pH in the umbilical artery,,7.29,,mean,,0.03,,,,10,pediatric,,fetus,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,337,2025-12-02T16:05:12.251790
2216229.0,pH in the umbilical vein,,7.35,,mean,,0.03,,,,10,pediatric,,fetus,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,338,2025-12-02T16:05:12.251790
2216229.0,Mean Arterial Pressure before nifedipine,,96,mm Hg,mean,SD,4,,,,10,maternal,3rd trimester,,<0.02,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,339,2025-12-02T16:05:12.251790
2216229.0,Mean Arterial Pressure at the second Doppler measurement ,,86,mm Hg,mean,SD,6,,,,10,maternal,3rd trimester,,<0.02,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,340,2025-12-02T16:05:12.251790
2216229.0,heart rate at the time of the first Doppler measurement,,76,beats per minutes,mean,SD,4,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,331,2025-12-02T16:05:16.158507
2216229.0,systolic BP at the time of the first Doppler measurement,,125,mm Hg,mean,SD,6,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,332,2025-12-02T16:05:16.158507
2216229.0,diastolic BP at the time of the first Doppler measurement,,77,mm Hg,mean,SD,4,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,333,2025-12-02T16:05:16.158507
2216229.0,S/D ratio of the flow velocity waveforms in the uterine artery after nifedipine,,1.72,,mean,SD,0.21,,,,10,maternal,3rd trimester,,<0.01,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,334,2025-12-02T16:05:16.158507
2216229.0,S/D ratio of the flow velocity waveforms in the uterine artery before nifedipine,,1.64,,mean,SD,0.13,,,,10,maternal,3rd trimester,,<0.01,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,335,2025-12-02T16:05:16.158507
2216229.0,birth weight,,3386,g,mean,,,minmax,3020.0,3760.0,10,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,336,2025-12-02T16:05:16.158507
2216229.0,pH in the umbilical artery,,7.29,,mean,,0.03,,,,10,pediatric,,fetus,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,337,2025-12-02T16:05:16.158507
2216229.0,pH in the umbilical vein,,7.35,,mean,,0.03,,,,10,pediatric,,fetus,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,338,2025-12-02T16:05:16.158507
2216229.0,Mean Arterial Pressure before nifedipine,,96,mm Hg,mean,SD,4,,,,10,maternal,3rd trimester,,<0.02,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,339,2025-12-02T16:05:16.158507
2216229.0,Mean Arterial Pressure at the second Doppler measurement ,,86,mm Hg,mean,SD,6,,,,10,maternal,3rd trimester,,<0.02,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,340,2025-12-02T16:05:16.158507
2216229.0,heart rate at the time of the first Doppler measurement,,76,beats per minutes,mean,SD,4,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,331,2025-12-02T16:05:22.595023
2216229.0,systolic BP at the time of the first Doppler measurement,,125,mm Hg,mean,SD,6,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,332,2025-12-02T16:05:22.595023
2216229.0,diastolic BP at the time of the first Doppler measurement,,77,mm Hg,mean,SD,4,,,,10,maternal,3rd trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,333,2025-12-02T16:05:22.595023
2216229.0,S/D ratio of the flow velocity waveforms in the uterine artery after nifedipine,,1.72,,mean,SD,0.21,,,,10,maternal,3rd trimester,,<0.01,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,334,2025-12-02T16:05:22.595023
2216229.0,S/D ratio of the flow velocity waveforms in the uterine artery before nifedipine,,1.64,,mean,SD,0.13,,,,10,maternal,3rd trimester,,<0.01,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,335,2025-12-02T16:05:22.595023
2216229.0,birth weight,,3386,g,mean,,,minmax,3020.0,3760.0,10,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,336,2025-12-02T16:05:22.595023
2216229.0,pH in the umbilical artery,,7.29,,mean,,0.03,,,,10,pediatric,,fetus,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,337,2025-12-02T16:05:22.595023
2216229.0,pH in the umbilical vein,,7.35,,mean,,0.03,,,,10,pediatric,,fetus,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,338,2025-12-02T16:05:22.595023
2216229.0,Mean Arterial Pressure before nifedipine,,96,mm Hg,mean,SD,4,,,,10,maternal,3rd trimester,,<0.02,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,339,2025-12-02T16:05:22.595023
2216229.0,Mean Arterial Pressure at the second Doppler measurement ,,86,mm Hg,mean,SD,6,,,,10,maternal,3rd trimester,,<0.02,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,340,2025-12-02T16:05:22.595023
2256493.0,placental weight,,559,gm,mean,SD,154,minmax,260.0,965.0,20,maternal,pregnancy,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,341,2025-12-02T16:05:09.863062
2256493.0,birth weight,,2031,gm,mean,SD,743,minmax,613.0,3418.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,342,2025-12-02T16:05:09.863062
2256493.0,Apgar scores,1 min,7.1,,mean,SD,2,minmax,1.0,9.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,343,2025-12-02T16:05:09.863062
2256493.0,Apgar scores,No. with score <=4,3,,N,,,,,,20,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,344,2025-12-02T16:05:09.863062
2256493.0,Apgar scores,5 min,8.7,,mean,SD,0.5,minmax,8.0,9.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,345,2025-12-02T16:05:09.863062
2256493.0,Cord arterial pH,,7.28,,mean,SD,0.05,minmax,7.16,7.38,20,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,346,2025-12-02T16:05:09.863062
2256493.0,Cord arterial Pco2,,51.3,,mean,SD,3,minmax,47.0,60.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,347,2025-12-02T16:05:09.863062
2256493.0,Cord arterial Po2,,25.7,,mean,SD,9.8,minmax,13.0,40.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,348,2025-12-02T16:05:09.863062
2256493.0,Base excess,,-2.7,,mean,SD,2.7,minmax,0.5,7.1,20,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,349,2025-12-02T16:05:09.863062
2256493.0,placental weight,,559,gm,mean,SD,154,minmax,260.0,965.0,20,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,341,2025-12-02T16:05:12.251790
2256493.0,birth weight,,2031,gm,mean,SD,743,minmax,613.0,3418.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,342,2025-12-02T16:05:12.251790
2256493.0,Apgar scores,1 min,7.1,,mean,SD,2,minmax,1.0,9.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,343,2025-12-02T16:05:12.251790
2256493.0,Apgar scores,No. with score <=4,3,,N,,,,,,20,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,344,2025-12-02T16:05:12.251790
2256493.0,Apgar scores,5 min,8.7,,mean,SD,0.5,minmax,8.0,9.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,345,2025-12-02T16:05:12.251790
2256493.0,Cord arterial pH,,7.28,,mean,SD,0.05,minmax,7.16,7.38,20,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,346,2025-12-02T16:05:12.251790
2256493.0,Cord arterial Pco2,,51.3,,mean,SD,3,minmax,47.0,60.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,347,2025-12-02T16:05:12.251790
2256493.0,Cord arterial Po2,,25.7,,mean,SD,9.8,minmax,13.0,40.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,348,2025-12-02T16:05:12.251790
2256493.0,Base excess,,-2.7,,mean,SD,2.7,minmax,0.5,7.1,20,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,349,2025-12-02T16:05:12.251790
2256493.0,placental weight,,559,gm,mean,SD,154,minmax,260.0,965.0,20,maternal,pregnancy,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,341,2025-12-02T16:05:16.158507
2256493.0,birth weight,,2031,gm,mean,SD,743,minmax,613.0,3418.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,342,2025-12-02T16:05:16.158507
2256493.0,Apgar scores,1 min,7.1,,mean,SD,2,minmax,1.0,9.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,343,2025-12-02T16:05:16.158507
2256493.0,Apgar scores,No. with score <=4,3,,N,,,,,,20,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,344,2025-12-02T16:05:16.158507
2256493.0,Apgar scores,5 min,8.7,,mean,SD,0.5,minmax,8.0,9.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,345,2025-12-02T16:05:16.158507
2256493.0,Cord arterial pH,,7.28,,mean,SD,0.05,minmax,7.16,7.38,20,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,346,2025-12-02T16:05:16.158507
2256493.0,Cord arterial Pco2,,51.3,,mean,SD,3,minmax,47.0,60.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,347,2025-12-02T16:05:16.158507
2256493.0,Cord arterial Po2,,25.7,,mean,SD,9.8,minmax,13.0,40.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,348,2025-12-02T16:05:16.158507
2256493.0,Base excess,,-2.7,,mean,SD,2.7,minmax,0.5,7.1,20,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,349,2025-12-02T16:05:16.158507
2256493.0,placental weight,,559,gm,mean,SD,154,minmax,260.0,965.0,20,maternal,pregnancy,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,341,2025-12-02T16:05:22.595023
2256493.0,birth weight,,2031,gm,mean,SD,743,minmax,613.0,3418.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,342,2025-12-02T16:05:22.595023
2256493.0,Apgar scores,1 min,7.1,,mean,SD,2,minmax,1.0,9.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,343,2025-12-02T16:05:22.595023
2256493.0,Apgar scores,No. with score <=4,3,,N,,,,,,20,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,344,2025-12-02T16:05:22.595023
2256493.0,Apgar scores,5 min,8.7,,mean,SD,0.5,minmax,8.0,9.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,345,2025-12-02T16:05:22.595023
2256493.0,Cord arterial pH,,7.28,,mean,SD,0.05,minmax,7.16,7.38,20,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,346,2025-12-02T16:05:22.595023
2256493.0,Cord arterial Pco2,,51.3,,mean,SD,3,minmax,47.0,60.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,347,2025-12-02T16:05:22.595023
2256493.0,Cord arterial Po2,,25.7,,mean,SD,9.8,minmax,13.0,40.0,20,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,348,2025-12-02T16:05:22.595023
2256493.0,Base excess,,-2.7,,mean,SD,2.7,minmax,0.5,7.1,20,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,349,2025-12-02T16:05:22.595023
27861509.0,Location of delivery,Medical facility,130,,N,%,81.3,,,,168,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,350,2025-12-02T16:05:09.863062
27861509.0,Location of delivery,Home,27,,N,%,16.9,,,,168,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,351,2025-12-02T16:05:09.863062
27861509.0,Location of delivery,Other,3,,N,%,1.9,,,,168,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,352,2025-12-02T16:05:09.863062
27861509.0,Mode of delivery,Vaginal,145,,N,%,90.6,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,353,2025-12-02T16:05:09.863062
27861509.0,Mode of delivery,Cesarean section,15,,N,%,9.4,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,354,2025-12-02T16:05:09.863062
27861509.0,Delivery assisted by trained obstetric personnel,Yes,132,,N,%,82.5,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,355,2025-12-02T16:05:09.863062
27861509.0,Delivery assisted by trained obstetric personnel,No. with score <=4,27,,N,%,16.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,356,2025-12-02T16:05:09.863062
27861509.0,Labor induced?,Yes,3,,N,%,1.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,357,2025-12-02T16:05:09.863062
27861509.0,Labor induced?,No,155,,N,%,96.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,358,2025-12-02T16:05:09.863062
27861509.0,Complications during delivery?,Yes,42,,N,%,26.3,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,359,2025-12-02T16:05:09.863062
27861509.0,Complications during delivery?,No,117,,N,%,73.1,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,360,2025-12-02T16:05:09.863062
27861509.0,Outcome of birth,Full term live birth,151,,N,%,94.4,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,361,2025-12-02T16:05:09.863062
27861509.0,Outcome of birth,Premature birth,6,,N,%,3.8,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,362,2025-12-02T16:05:09.863062
27861509.0,Outcome of birth,Spontaneous abortion,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,363,2025-12-02T16:05:09.863062
27861509.0,Outcome of birth,Induced/elective abortion,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,364,2025-12-02T16:05:09.863062
27861509.0,Outcome of birth,Stillbirth,3,,N,%,1.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,365,2025-12-02T16:05:09.863062
27861509.0,Outcome of birth,Unknown,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,366,2025-12-02T16:05:09.863062
27861509.0,gender,female,66,,N,%,42,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,367,2025-12-02T16:05:09.863062
27861509.0,gender,male,91,,N,%,58,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,368,2025-12-02T16:05:09.863062
27861509.0,birth length,,46.3,cm,mean,SD,3.6,minmax,29.0,54.0,133,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,369,2025-12-02T16:05:09.863062
27861509.0,birth weight,,3022.3,g,mean,SD,494.5,minmax,1200.0,4900.0,137,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,370,2025-12-02T16:05:09.863062
27861509.0,head circumference,,34.3,cm,mean,SD,2.2,minmax,24.0,46.0,133,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,371,2025-12-02T16:05:09.863062
27861509.0,Apgar score at 5 min,,9.7,,mean,SD,1.2,minmax,1.0,10.0,126,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,372,2025-12-02T16:05:09.863062
27861509.0,Normal newborn,Yes,144,,N,%,91.7,,,,155,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,373,2025-12-02T16:05:09.863062
27861509.0,Normal newborn,No,11,,N,%,7,,,,155,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,374,2025-12-02T16:05:09.863062
27861509.0,Congenital malformation/anomaly,"Yes (1 hypospadia, 1 polydactyly)",2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,375,2025-12-02T16:05:09.863062
27861509.0,Congenital malformation/anomaly,No,153,,N,%,97.5,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,376,2025-12-02T16:05:09.863062
27861509.0,Congenital malformation/anomaly,Unknown,2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,377,2025-12-02T16:05:09.863062
27861509.0,Other neonatal problem/abnormality,Yes,9,,N,%,5.7,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,378,2025-12-02T16:05:09.863062
27861509.0,Other neonatal problem/abnormality,No,146,,N,%,93,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,379,2025-12-02T16:05:09.863062
27861509.0,Other neonatal problem/abnormality,Unknown,2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,380,2025-12-02T16:05:09.863062
27861509.0,Location of delivery,Medical facility,130,,N,%,81.3,,,,168,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,350,2025-12-02T16:05:12.251790
27861509.0,Location of delivery,Home,27,,N,%,16.9,,,,168,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,351,2025-12-02T16:05:12.251790
27861509.0,Location of delivery,Other,3,,N,%,1.9,,,,168,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,352,2025-12-02T16:05:12.251790
27861509.0,Mode of delivery,Vaginal,145,,N,%,90.6,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,353,2025-12-02T16:05:12.251790
27861509.0,Mode of delivery,Cesarean section,15,,N,%,9.4,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,354,2025-12-02T16:05:12.251790
27861509.0,Delivery assisted by trained obstetric personnel,Yes,132,,N,%,82.5,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,355,2025-12-02T16:05:12.251790
27861509.0,Delivery assisted by trained obstetric personnel,No. with score <=4,27,,N,%,16.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,356,2025-12-02T16:05:12.251790
27861509.0,Labor induced?,Yes,3,,N,%,1.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,357,2025-12-02T16:05:12.251790
27861509.0,Labor induced?,No,155,,N,%,96.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,358,2025-12-02T16:05:12.251790
27861509.0,Complications during delivery?,Yes,42,,N,%,26.3,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,359,2025-12-02T16:05:12.251790
27861509.0,Complications during delivery?,No,117,,N,%,73.1,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,360,2025-12-02T16:05:12.251790
27861509.0,Outcome of birth,Full term live birth,151,,N,%,94.4,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,361,2025-12-02T16:05:12.251790
27861509.0,Outcome of birth,Premature birth,6,,N,%,3.8,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,362,2025-12-02T16:05:12.251790
27861509.0,Outcome of birth,Spontaneous abortion,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,363,2025-12-02T16:05:12.251790
27861509.0,Outcome of birth,Induced/elective abortion,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,364,2025-12-02T16:05:12.251790
27861509.0,Outcome of birth,Stillbirth,3,,N,%,1.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,365,2025-12-02T16:05:12.251790
27861509.0,Outcome of birth,Unknown,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,366,2025-12-02T16:05:12.251790
27861509.0,gender,female,66,,N,%,42,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,367,2025-12-02T16:05:12.251790
27861509.0,gender,male,91,,N,%,58,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,368,2025-12-02T16:05:12.251790
27861509.0,birth length,,46.3,cm,mean,SD,3.6,minmax,29.0,54.0,133,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,369,2025-12-02T16:05:12.251790
27861509.0,birth weight,,3022.3,g,mean,SD,494.5,minmax,1200.0,4900.0,137,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,370,2025-12-02T16:05:12.251790
27861509.0,head circumference,,34.3,cm,mean,SD,2.2,minmax,24.0,46.0,133,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,371,2025-12-02T16:05:12.251790
27861509.0,Apgar score at 5 min,,9.7,,mean,SD,1.2,minmax,1.0,10.0,126,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,372,2025-12-02T16:05:12.251790
27861509.0,Normal newborn,Yes,144,,N,%,91.7,,,,155,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,373,2025-12-02T16:05:12.251790
27861509.0,Normal newborn,No,11,,N,%,7,,,,155,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,374,2025-12-02T16:05:12.251790
27861509.0,Congenital malformation/anomaly,"Yes (1 hypospadia, 1 polydactyly)",2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,375,2025-12-02T16:05:12.251790
27861509.0,Congenital malformation/anomaly,No,153,,N,%,97.5,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,376,2025-12-02T16:05:12.251790
27861509.0,Congenital malformation/anomaly,Unknown,2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,377,2025-12-02T16:05:12.251790
27861509.0,Other neonatal problem/abnormality,Yes,9,,N,%,5.7,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,378,2025-12-02T16:05:12.251790
27861509.0,Other neonatal problem/abnormality,No,146,,N,%,93,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,379,2025-12-02T16:05:12.251790
27861509.0,Other neonatal problem/abnormality,Unknown,2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,380,2025-12-02T16:05:12.251790
27861509.0,Location of delivery,Medical facility,130,,N,%,81.3,,,,168,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,350,2025-12-02T16:05:16.158507
27861509.0,Location of delivery,Home,27,,N,%,16.9,,,,168,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,351,2025-12-02T16:05:16.158507
27861509.0,Location of delivery,Other,3,,N,%,1.9,,,,168,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,352,2025-12-02T16:05:16.158507
27861509.0,Mode of delivery,Vaginal,145,,N,%,90.6,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,353,2025-12-02T16:05:16.158507
27861509.0,Mode of delivery,Cesarean section,15,,N,%,9.4,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,354,2025-12-02T16:05:16.158507
27861509.0,Delivery assisted by trained obstetric personnel,Yes,132,,N,%,82.5,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,355,2025-12-02T16:05:16.158507
27861509.0,Delivery assisted by trained obstetric personnel,No. with score <=4,27,,N,%,16.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,356,2025-12-02T16:05:16.158507
27861509.0,Labor induced?,Yes,3,,N,%,1.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,357,2025-12-02T16:05:16.158507
27861509.0,Labor induced?,No,155,,N,%,96.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,358,2025-12-02T16:05:16.158507
27861509.0,Complications during delivery?,Yes,42,,N,%,26.3,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,359,2025-12-02T16:05:16.158507
27861509.0,Complications during delivery?,No,117,,N,%,73.1,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,360,2025-12-02T16:05:16.158507
27861509.0,Outcome of birth,Full term live birth,151,,N,%,94.4,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,361,2025-12-02T16:05:16.158507
27861509.0,Outcome of birth,Premature birth,6,,N,%,3.8,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,362,2025-12-02T16:05:16.158507
27861509.0,Outcome of birth,Spontaneous abortion,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,363,2025-12-02T16:05:16.158507
27861509.0,Outcome of birth,Induced/elective abortion,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,364,2025-12-02T16:05:16.158507
27861509.0,Outcome of birth,Stillbirth,3,,N,%,1.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,365,2025-12-02T16:05:16.158507
27861509.0,Outcome of birth,Unknown,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,366,2025-12-02T16:05:16.158507
27861509.0,gender,female,66,,N,%,42,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,367,2025-12-02T16:05:16.158507
27861509.0,gender,male,91,,N,%,58,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,368,2025-12-02T16:05:16.158507
27861509.0,birth length,,46.3,cm,mean,SD,3.6,minmax,29.0,54.0,133,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,369,2025-12-02T16:05:16.158507
27861509.0,birth weight,,3022.3,g,mean,SD,494.5,minmax,1200.0,4900.0,137,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,370,2025-12-02T16:05:16.158507
27861509.0,head circumference,,34.3,cm,mean,SD,2.2,minmax,24.0,46.0,133,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,371,2025-12-02T16:05:16.158507
27861509.0,Apgar score at 5 min,,9.7,,mean,SD,1.2,minmax,1.0,10.0,126,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,372,2025-12-02T16:05:16.158507
27861509.0,Normal newborn,Yes,144,,N,%,91.7,,,,155,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,373,2025-12-02T16:05:16.158507
27861509.0,Normal newborn,No,11,,N,%,7,,,,155,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,374,2025-12-02T16:05:16.158507
27861509.0,Congenital malformation/anomaly,"Yes (1 hypospadia, 1 polydactyly)",2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,375,2025-12-02T16:05:16.158507
27861509.0,Congenital malformation/anomaly,No,153,,N,%,97.5,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,376,2025-12-02T16:05:16.158507
27861509.0,Congenital malformation/anomaly,Unknown,2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,377,2025-12-02T16:05:16.158507
27861509.0,Other neonatal problem/abnormality,Yes,9,,N,%,5.7,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,378,2025-12-02T16:05:16.158507
27861509.0,Other neonatal problem/abnormality,No,146,,N,%,93,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,379,2025-12-02T16:05:16.158507
27861509.0,Other neonatal problem/abnormality,Unknown,2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,380,2025-12-02T16:05:16.158507
27861509.0,Location of delivery,Medical facility,130,,N,%,81.3,,,,168,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,350,2025-12-02T16:05:22.595023
27861509.0,Location of delivery,Home,27,,N,%,16.9,,,,168,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,351,2025-12-02T16:05:22.595023
27861509.0,Location of delivery,Other,3,,N,%,1.9,,,,168,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,352,2025-12-02T16:05:22.595023
27861509.0,Mode of delivery,Vaginal,145,,N,%,90.6,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,353,2025-12-02T16:05:22.595023
27861509.0,Mode of delivery,Cesarean section,15,,N,%,9.4,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,354,2025-12-02T16:05:22.595023
27861509.0,Delivery assisted by trained obstetric personnel,Yes,132,,N,%,82.5,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,355,2025-12-02T16:05:22.595023
27861509.0,Delivery assisted by trained obstetric personnel,No. with score <=4,27,,N,%,16.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,356,2025-12-02T16:05:22.595023
27861509.0,Labor induced?,Yes,3,,N,%,1.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,357,2025-12-02T16:05:22.595023
27861509.0,Labor induced?,No,155,,N,%,96.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,358,2025-12-02T16:05:22.595023
27861509.0,Complications during delivery?,Yes,42,,N,%,26.3,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,359,2025-12-02T16:05:22.595023
27861509.0,Complications during delivery?,No,117,,N,%,73.1,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,360,2025-12-02T16:05:22.595023
27861509.0,Outcome of birth,Full term live birth,151,,N,%,94.4,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,361,2025-12-02T16:05:22.595023
27861509.0,Outcome of birth,Premature birth,6,,N,%,3.8,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,362,2025-12-02T16:05:22.595023
27861509.0,Outcome of birth,Spontaneous abortion,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,363,2025-12-02T16:05:22.595023
27861509.0,Outcome of birth,Induced/elective abortion,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,364,2025-12-02T16:05:22.595023
27861509.0,Outcome of birth,Stillbirth,3,,N,%,1.9,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,365,2025-12-02T16:05:22.595023
27861509.0,Outcome of birth,Unknown,0,,N,%,0,,,,160,maternal,labor,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,366,2025-12-02T16:05:22.595023
27861509.0,gender,female,66,,N,%,42,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,367,2025-12-02T16:05:22.595023
27861509.0,gender,male,91,,N,%,58,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,368,2025-12-02T16:05:22.595023
27861509.0,birth length,,46.3,cm,mean,SD,3.6,minmax,29.0,54.0,133,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,369,2025-12-02T16:05:22.595023
27861509.0,birth weight,,3022.3,g,mean,SD,494.5,minmax,1200.0,4900.0,137,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,370,2025-12-02T16:05:22.595023
27861509.0,head circumference,,34.3,cm,mean,SD,2.2,minmax,24.0,46.0,133,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,371,2025-12-02T16:05:22.595023
27861509.0,Apgar score at 5 min,,9.7,,mean,SD,1.2,minmax,1.0,10.0,126,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,372,2025-12-02T16:05:22.595023
27861509.0,Normal newborn,Yes,144,,N,%,91.7,,,,155,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,373,2025-12-02T16:05:22.595023
27861509.0,Normal newborn,No,11,,N,%,7,,,,155,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,374,2025-12-02T16:05:22.595023
27861509.0,Congenital malformation/anomaly,"Yes (1 hypospadia, 1 polydactyly)",2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,375,2025-12-02T16:05:22.595023
27861509.0,Congenital malformation/anomaly,No,153,,N,%,97.5,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,376,2025-12-02T16:05:22.595023
27861509.0,Congenital malformation/anomaly,Unknown,2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,377,2025-12-02T16:05:22.595023
27861509.0,Other neonatal problem/abnormality,Yes,9,,N,%,5.7,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,378,2025-12-02T16:05:22.595023
27861509.0,Other neonatal problem/abnormality,No,146,,N,%,93,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,379,2025-12-02T16:05:22.595023
27861509.0,Other neonatal problem/abnormality,Unknown,2,,N,%,1.3,,,,157,pediatric,,neonates,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,380,2025-12-02T16:05:22.595023
1814844.0,blood pressure on the fifth dya of treatment,,148/90,mmHg,mean,SD,4/2,,,,10,maternal,third trimester,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,381,2025-12-02T16:05:09.863062
1814844.0,Apgar score at 1 min,,6,,mean,,,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,382,2025-12-02T16:05:09.863062
1814844.0,Apgar score at 5 min,,8,,mean,,,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,383,2025-12-02T16:05:09.863062
1814844.0,birth weight,,2616,g,mean,SD,196,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,384,2025-12-02T16:05:09.863062
1814844.0,blood pressure on the fifth dya of treatment,,148/90,mmHg,mean,SD,4/2,,,,10,maternal,third trimester,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,381,2025-12-02T16:05:12.251790
1814844.0,Apgar score at 1 min,,6,,mean,,,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,382,2025-12-02T16:05:12.251790
1814844.0,Apgar score at 5 min,,8,,mean,,,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,383,2025-12-02T16:05:12.251790
1814844.0,birth weight,,2616,g,mean,SD,196,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,384,2025-12-02T16:05:12.251790
1814844.0,blood pressure on the fifth dya of treatment,,148/90,mmHg,mean,SD,4/2,,,,10,maternal,third trimester,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,381,2025-12-02T16:05:16.158507
1814844.0,Apgar score at 1 min,,6,,mean,,,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,382,2025-12-02T16:05:16.158507
1814844.0,Apgar score at 5 min,,8,,mean,,,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,383,2025-12-02T16:05:16.158507
1814844.0,birth weight,,2616,g,mean,SD,196,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,384,2025-12-02T16:05:16.158507
1814844.0,blood pressure on the fifth dya of treatment,,148/90,mmHg,mean,SD,4/2,,,,10,maternal,third trimester,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,381,2025-12-02T16:05:22.595023
1814844.0,Apgar score at 1 min,,6,,mean,,,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,382,2025-12-02T16:05:22.595023
1814844.0,Apgar score at 5 min,,8,,mean,,,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,383,2025-12-02T16:05:22.595023
1814844.0,birth weight,,2616,g,mean,SD,196,,,,11,pediatric,,newborn,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,384,2025-12-02T16:05:22.595023
14595087.0,5-HT preexposure concentration,,156.6,ng/ml,mean,SD,71.4,,,,11,maternal,lactation,,<0.0001,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,411,2025-12-02T16:05:09.863062
14595087.0,5-HT postexposure concentration,,22.9,ng/ml,mean,SD,12.5,,,,11,maternal,lactation,,<0.0001,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,412,2025-12-02T16:05:09.863062
14595087.0,5-HT post/preexposure concentration x 100,,14.5,%,mean,SD,6.5,,,,11,maternal,lactation,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,413,2025-12-02T16:05:09.863062
14595087.0,whole-blood 5-HT level preexposure,,217.1,ng/ml,mean,SD,66.5,,,,11,pediatric,,infants,0.82,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,414,2025-12-02T16:05:09.863062
14595087.0,whole-blood 5-HT level postexposure,,229.9,ng/ml,mean,SD,83.5,,,,11,pediatric,,infants,0.82,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,415,2025-12-02T16:05:09.863062
14595087.0,whole-blood 5-HT level post/preexposure x 100,,103.6,%,mean,SD,31.1,,,,11,pediatric,,infants,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,416,2025-12-02T16:05:09.863062
14595087.0,5-HT preexposure concentration,,156.6,ng/ml,mean,SD,71.4,,,,11,maternal,lactation,,<0.0001,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,411,2025-12-02T16:05:12.251790
14595087.0,5-HT postexposure concentration,,22.9,ng/ml,mean,SD,12.5,,,,11,maternal,lactation,,<0.0001,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,412,2025-12-02T16:05:12.251790
14595087.0,5-HT post/preexposure concentration x 100,,14.5,%,mean,SD,6.5,,,,11,maternal,lactation,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,413,2025-12-02T16:05:12.251790
14595087.0,whole-blood 5-HT level preexposure,,217.1,ng/ml,mean,SD,66.5,,,,11,pediatric,,infants,0.82,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,414,2025-12-02T16:05:12.251790
14595087.0,whole-blood 5-HT level postexposure,,229.9,ng/ml,mean,SD,83.5,,,,11,pediatric,,infants,0.82,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,415,2025-12-02T16:05:12.251790
14595087.0,whole-blood 5-HT level post/preexposure x 100,,103.6,%,mean,SD,31.1,,,,11,pediatric,,infants,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,416,2025-12-02T16:05:12.251790
14595087.0,5-HT preexposure concentration,,156.6,ng/ml,mean,SD,71.4,,,,11,maternal,lactation,,<0.0001,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,411,2025-12-02T16:05:16.158507
14595087.0,5-HT postexposure concentration,,22.9,ng/ml,mean,SD,12.5,,,,11,maternal,lactation,,<0.0001,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,412,2025-12-02T16:05:16.158507
14595087.0,5-HT post/preexposure concentration x 100,,14.5,%,mean,SD,6.5,,,,11,maternal,lactation,,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,413,2025-12-02T16:05:16.158507
14595087.0,whole-blood 5-HT level preexposure,,217.1,ng/ml,mean,SD,66.5,,,,11,pediatric,,infants,0.82,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,414,2025-12-02T16:05:16.158507
14595087.0,whole-blood 5-HT level postexposure,,229.9,ng/ml,mean,SD,83.5,,,,11,pediatric,,infants,0.82,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,415,2025-12-02T16:05:16.158507
14595087.0,whole-blood 5-HT level post/preexposure x 100,,103.6,%,mean,SD,31.1,,,,11,pediatric,,infants,,,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,416,2025-12-02T16:05:16.158507
14595087.0,5-HT preexposure concentration,,156.6,ng/ml,mean,SD,71.4,,,,11,maternal,lactation,,<0.0001,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,411,2025-12-02T16:05:22.595023
14595087.0,5-HT postexposure concentration,,22.9,ng/ml,mean,SD,12.5,,,,11,maternal,lactation,,<0.0001,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,412,2025-12-02T16:05:22.595023
14595087.0,5-HT post/preexposure concentration x 100,,14.5,%,mean,SD,6.5,,,,11,maternal,lactation,,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,413,2025-12-02T16:05:22.595023
14595087.0,whole-blood 5-HT level preexposure,,217.1,ng/ml,mean,SD,66.5,,,,11,pediatric,,infants,0.82,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,414,2025-12-02T16:05:22.595023
14595087.0,whole-blood 5-HT level postexposure,,229.9,ng/ml,mean,SD,83.5,,,,11,pediatric,,infants,0.82,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,415,2025-12-02T16:05:22.595023
14595087.0,whole-blood 5-HT level post/preexposure x 100,,103.6,%,mean,SD,31.1,,,,11,pediatric,,infants,,,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,416,2025-12-02T16:05:22.595023
21824458.0,gestational weeks at birth,,39,weeks,mean,,,minmax,37.0,41.0,11,pediatric,,infants,0.26,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,417,2025-12-02T16:05:09.863062
21824458.0,gestational weeks at birth,,40,weeks,mean,,,minmax,38.0,41.0,10,pediatric,,infants,0.26,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,418,2025-12-02T16:05:09.863062
21824458.0,Apgar score,1 min,8.8,,mean,,,minmax,7.0,10.0,11,pediatric,,infants,0.44,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,419,2025-12-02T16:05:09.863062
21824458.0,Apgar score,1 min,9,,mean,,,minmax,9.0,9.0,10,pediatric,,infants,0.44,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,420,2025-12-02T16:05:09.863062
21824458.0,Apgar score,5 min,9.1,,mean,,,minmax,8.0,10.0,11,pediatric,,infants,0.16,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,421,2025-12-02T16:05:09.863062
21824458.0,Apgar score,5 min,9.3,,mean,,,minmax,9.0,10.0,10,pediatric,,infants,0.16,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,422,2025-12-02T16:05:09.863062
21824458.0,Apgar score,15 min,9.4,,mean,,,minmax,9.0,10.0,11,pediatric,,infants,0.11,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,423,2025-12-02T16:05:09.863062
21824458.0,Apgar score,15 min,9.3,,mean,,,minmax,9.0,10.0,10,pediatric,,infants,0.11,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,424,2025-12-02T16:05:09.863062
21824458.0,Umbilical artery pH,,7.27,,mean,,,minmax,7.15,7.4,11,pediatric,,infants,0.22,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,425,2025-12-02T16:05:09.863062
21824458.0,Umbilical artery pH,,7.33,,mean,,,minmax,7.22,7.47,10,pediatric,,infants,0.22,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,426,2025-12-02T16:05:09.863062
21824458.0,body temperature at birth,,37,,mean,,,minmax,36.6,37.7,11,pediatric,,infants,0.82,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,427,2025-12-02T16:05:09.863062
21824458.0,body temperature at birth,,37,,mean,,,minmax,36.3,37.5,10,pediatric,,infants,0.82,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,428,2025-12-02T16:05:09.863062
21824458.0,sex,female,6,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,429,2025-12-02T16:05:09.863062
21824458.0,sex,male,5,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,430,2025-12-02T16:05:09.863062
21824458.0,sex,female,6,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,431,2025-12-02T16:05:09.863062
21824458.0,sex,male,4,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,432,2025-12-02T16:05:09.863062
21824458.0,Delivery mode,vaginal,10,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,433,2025-12-02T16:05:09.863062
21824458.0,Delivery mode,cesarean,1,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,434,2025-12-02T16:05:09.863062
21824458.0,Delivery mode,vaginal,9,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,435,2025-12-02T16:05:09.863062
21824458.0,Delivery mode,cesarean,1,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,436,2025-12-02T16:05:09.863062
21824458.0,malformations,,,,,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,437,2025-12-02T16:05:09.863062
21824458.0,malformations,,,,,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,438,2025-12-02T16:05:09.863062
21824458.0,weight ,at birth,3460,g,mean,,,minmax,2830.0,4380.0,11,pediatric,,infants,0.62,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,439,2025-12-02T16:05:09.863062
21824458.0,weight ,at birth,10560,g,mean,,,minmax,11810.0,9420.0,10,pediatric,,infants,0.62,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,440,2025-12-02T16:05:09.863062
21824458.0,weight ,12 mo,3560,g,mean,,,minmax,3220.0,4260.0,11,pediatric,,infants,0.14,Citalopram,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,441,2025-12-02T16:05:09.863062
21824458.0,weight ,12 mo,9810,g,mean,,,minmax,10860.0,8900.0,10,pediatric,,infants,0.14,Control,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,442,2025-12-02T16:05:09.863062
21824458.0,gestational weeks at birth,,39,weeks,mean,,,minmax,37.0,41.0,11,pediatric,,infants,0.26,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,417,2025-12-02T16:05:12.251790
21824458.0,gestational weeks at birth,,40,weeks,mean,,,minmax,38.0,41.0,10,pediatric,,infants,0.26,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,418,2025-12-02T16:05:12.251790
21824458.0,Apgar score,1 min,8.8,,mean,,,minmax,7.0,10.0,11,pediatric,,infants,0.44,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,419,2025-12-02T16:05:12.251790
21824458.0,Apgar score,1 min,9,,mean,,,minmax,9.0,9.0,10,pediatric,,infants,0.44,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,420,2025-12-02T16:05:12.251790
21824458.0,Apgar score,5 min,9.1,,mean,,,minmax,8.0,10.0,11,pediatric,,infants,0.16,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,421,2025-12-02T16:05:12.251790
21824458.0,Apgar score,5 min,9.3,,mean,,,minmax,9.0,10.0,10,pediatric,,infants,0.16,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,422,2025-12-02T16:05:12.251790
21824458.0,Apgar score,15 min,9.4,,mean,,,minmax,9.0,10.0,11,pediatric,,infants,0.11,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,423,2025-12-02T16:05:12.251790
21824458.0,Apgar score,15 min,9.3,,mean,,,minmax,9.0,10.0,10,pediatric,,infants,0.11,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,424,2025-12-02T16:05:12.251790
21824458.0,Umbilical artery pH,,7.27,,mean,,,minmax,7.15,7.4,11,pediatric,,infants,0.22,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,425,2025-12-02T16:05:12.251790
21824458.0,Umbilical artery pH,,7.33,,mean,,,minmax,7.22,7.47,10,pediatric,,infants,0.22,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,426,2025-12-02T16:05:12.251790
21824458.0,body temperature at birth,,37,,mean,,,minmax,36.6,37.7,11,pediatric,,infants,0.82,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,427,2025-12-02T16:05:12.251790
21824458.0,body temperature at birth,,37,,mean,,,minmax,36.3,37.5,10,pediatric,,infants,0.82,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,428,2025-12-02T16:05:12.251790
21824458.0,sex,female,6,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,429,2025-12-02T16:05:12.251790
21824458.0,sex,male,5,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,430,2025-12-02T16:05:12.251790
21824458.0,sex,female,6,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,431,2025-12-02T16:05:12.251790
21824458.0,sex,male,4,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,432,2025-12-02T16:05:12.251790
21824458.0,Delivery mode,vaginal,10,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,433,2025-12-02T16:05:12.251790
21824458.0,Delivery mode,cesarean,1,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,434,2025-12-02T16:05:12.251790
21824458.0,Delivery mode,vaginal,9,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,435,2025-12-02T16:05:12.251790
21824458.0,Delivery mode,cesarean,1,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,436,2025-12-02T16:05:12.251790
21824458.0,malformations,,,,,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,437,2025-12-02T16:05:12.251790
21824458.0,malformations,,,,,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,438,2025-12-02T16:05:12.251790
21824458.0,weight ,at birth,3460,g,mean,,,minmax,2830.0,4380.0,11,pediatric,,infants,0.62,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,439,2025-12-02T16:05:12.251790
21824458.0,weight ,at birth,10560,g,mean,,,minmax,11810.0,9420.0,10,pediatric,,infants,0.62,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,440,2025-12-02T16:05:12.251790
21824458.0,weight ,12 mo,3560,g,mean,,,minmax,3220.0,4260.0,11,pediatric,,infants,0.14,Citalopram,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,441,2025-12-02T16:05:12.251790
21824458.0,weight ,12 mo,9810,g,mean,,,minmax,10860.0,8900.0,10,pediatric,,infants,0.14,Control,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,442,2025-12-02T16:05:12.251790
21824458.0,gestational weeks at birth,,39,weeks,mean,,,minmax,37.0,41.0,11,pediatric,,infants,0.26,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,417,2025-12-02T16:05:16.158507
21824458.0,gestational weeks at birth,,40,weeks,mean,,,minmax,38.0,41.0,10,pediatric,,infants,0.26,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,418,2025-12-02T16:05:16.158507
21824458.0,Apgar score,1 min,8.8,,mean,,,minmax,7.0,10.0,11,pediatric,,infants,0.44,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,419,2025-12-02T16:05:16.158507
21824458.0,Apgar score,1 min,9,,mean,,,minmax,9.0,9.0,10,pediatric,,infants,0.44,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,420,2025-12-02T16:05:16.158507
21824458.0,Apgar score,5 min,9.1,,mean,,,minmax,8.0,10.0,11,pediatric,,infants,0.16,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,421,2025-12-02T16:05:16.158507
21824458.0,Apgar score,5 min,9.3,,mean,,,minmax,9.0,10.0,10,pediatric,,infants,0.16,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,422,2025-12-02T16:05:16.158507
21824458.0,Apgar score,15 min,9.4,,mean,,,minmax,9.0,10.0,11,pediatric,,infants,0.11,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,423,2025-12-02T16:05:16.158507
21824458.0,Apgar score,15 min,9.3,,mean,,,minmax,9.0,10.0,10,pediatric,,infants,0.11,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,424,2025-12-02T16:05:16.158507
21824458.0,Umbilical artery pH,,7.27,,mean,,,minmax,7.15,7.4,11,pediatric,,infants,0.22,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,425,2025-12-02T16:05:16.158507
21824458.0,Umbilical artery pH,,7.33,,mean,,,minmax,7.22,7.47,10,pediatric,,infants,0.22,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,426,2025-12-02T16:05:16.158507
21824458.0,body temperature at birth,,37,,mean,,,minmax,36.6,37.7,11,pediatric,,infants,0.82,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,427,2025-12-02T16:05:16.158507
21824458.0,body temperature at birth,,37,,mean,,,minmax,36.3,37.5,10,pediatric,,infants,0.82,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,428,2025-12-02T16:05:16.158507
21824458.0,sex,female,6,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,429,2025-12-02T16:05:16.158507
21824458.0,sex,male,5,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,430,2025-12-02T16:05:16.158507
21824458.0,sex,female,6,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,431,2025-12-02T16:05:16.158507
21824458.0,sex,male,4,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,432,2025-12-02T16:05:16.158507
21824458.0,Delivery mode,vaginal,10,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,433,2025-12-02T16:05:16.158507
21824458.0,Delivery mode,cesarean,1,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,434,2025-12-02T16:05:16.158507
21824458.0,Delivery mode,vaginal,9,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,435,2025-12-02T16:05:16.158507
21824458.0,Delivery mode,cesarean,1,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,436,2025-12-02T16:05:16.158507
21824458.0,malformations,,,,,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,437,2025-12-02T16:05:16.158507
21824458.0,malformations,,,,,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,438,2025-12-02T16:05:16.158507
21824458.0,weight ,at birth,3460,g,mean,,,minmax,2830.0,4380.0,11,pediatric,,infants,0.62,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,439,2025-12-02T16:05:16.158507
21824458.0,weight ,at birth,10560,g,mean,,,minmax,11810.0,9420.0,10,pediatric,,infants,0.62,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,440,2025-12-02T16:05:16.158507
21824458.0,weight ,12 mo,3560,g,mean,,,minmax,3220.0,4260.0,11,pediatric,,infants,0.14,Citalopram,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,441,2025-12-02T16:05:16.158507
21824458.0,weight ,12 mo,9810,g,mean,,,minmax,10860.0,8900.0,10,pediatric,,infants,0.14,Control,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,442,2025-12-02T16:05:16.158507
21824458.0,gestational weeks at birth,,39,weeks,mean,,,minmax,37.0,41.0,11,pediatric,,infants,0.26,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,417,2025-12-02T16:05:22.595023
21824458.0,gestational weeks at birth,,40,weeks,mean,,,minmax,38.0,41.0,10,pediatric,,infants,0.26,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,418,2025-12-02T16:05:22.595023
21824458.0,Apgar score,1 min,8.8,,mean,,,minmax,7.0,10.0,11,pediatric,,infants,0.44,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,419,2025-12-02T16:05:22.595023
21824458.0,Apgar score,1 min,9,,mean,,,minmax,9.0,9.0,10,pediatric,,infants,0.44,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,420,2025-12-02T16:05:22.595023
21824458.0,Apgar score,5 min,9.1,,mean,,,minmax,8.0,10.0,11,pediatric,,infants,0.16,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,421,2025-12-02T16:05:22.595023
21824458.0,Apgar score,5 min,9.3,,mean,,,minmax,9.0,10.0,10,pediatric,,infants,0.16,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,422,2025-12-02T16:05:22.595023
21824458.0,Apgar score,15 min,9.4,,mean,,,minmax,9.0,10.0,11,pediatric,,infants,0.11,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,423,2025-12-02T16:05:22.595023
21824458.0,Apgar score,15 min,9.3,,mean,,,minmax,9.0,10.0,10,pediatric,,infants,0.11,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,424,2025-12-02T16:05:22.595023
21824458.0,Umbilical artery pH,,7.27,,mean,,,minmax,7.15,7.4,11,pediatric,,infants,0.22,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,425,2025-12-02T16:05:22.595023
21824458.0,Umbilical artery pH,,7.33,,mean,,,minmax,7.22,7.47,10,pediatric,,infants,0.22,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,426,2025-12-02T16:05:22.595023
21824458.0,body temperature at birth,,37,,mean,,,minmax,36.6,37.7,11,pediatric,,infants,0.82,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,427,2025-12-02T16:05:22.595023
21824458.0,body temperature at birth,,37,,mean,,,minmax,36.3,37.5,10,pediatric,,infants,0.82,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,428,2025-12-02T16:05:22.595023
21824458.0,sex,female,6,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,429,2025-12-02T16:05:22.595023
21824458.0,sex,male,5,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,430,2025-12-02T16:05:22.595023
21824458.0,sex,female,6,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,431,2025-12-02T16:05:22.595023
21824458.0,sex,male,4,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,432,2025-12-02T16:05:22.595023
21824458.0,Delivery mode,vaginal,10,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,433,2025-12-02T16:05:22.595023
21824458.0,Delivery mode,cesarean,1,,N,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,434,2025-12-02T16:05:22.595023
21824458.0,Delivery mode,vaginal,9,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,435,2025-12-02T16:05:22.595023
21824458.0,Delivery mode,cesarean,1,,N,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,436,2025-12-02T16:05:22.595023
21824458.0,malformations,,,,,,,,,,11,pediatric,,infants,,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,437,2025-12-02T16:05:22.595023
21824458.0,malformations,,,,,,,,,,10,pediatric,,infants,,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,438,2025-12-02T16:05:22.595023
21824458.0,weight ,at birth,3460,g,mean,,,minmax,2830.0,4380.0,11,pediatric,,infants,0.62,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,439,2025-12-02T16:05:22.595023
21824458.0,weight ,at birth,10560,g,mean,,,minmax,11810.0,9420.0,10,pediatric,,infants,0.62,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,440,2025-12-02T16:05:22.595023
21824458.0,weight ,12 mo,3560,g,mean,,,minmax,3220.0,4260.0,11,pediatric,,infants,0.14,Citalopram,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,441,2025-12-02T16:05:22.595023
21824458.0,weight ,12 mo,9810,g,mean,,,minmax,10860.0,8900.0,10,pediatric,,infants,0.14,Control,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,442,2025-12-02T16:05:22.595023
3688386.0,Apgar score at 1 min,,5.8,,mean,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,447,2025-12-02T16:05:09.863062
3688386.0,Apgar score at 1 min,,6.5,,mean,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,448,2025-12-02T16:05:09.863062
3688386.0,Apgar score at 1 min,,7.5,,mean,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,449,2025-12-02T16:05:09.863062
3688386.0,Apgar score at 5 min,,7.8,,mean,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,450,2025-12-02T16:05:09.863062
3688386.0,Apgar score at 5 min,,8.8,,mean,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,451,2025-12-02T16:05:09.863062
3688386.0,Apgar score at 5 min,,8.9,,mean,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,452,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 1 min, <7",,5,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,453,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 1 min, <7",,8,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,454,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 1 min, <7",,4,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,455,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 1 min, >8",,3,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,456,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 1 min, >8",,2,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,457,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 1 min, >8",,8,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,458,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 5 min, <7",,2,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,459,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 5 min, <7",,6,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,460,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 5 min, <7",,0,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,461,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 5 min, >8",,10,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,462,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 5 min, >8",,0,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,463,2025-12-02T16:05:09.863062
3688386.0,"Apgar score at 5 min, >8",,12,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,464,2025-12-02T16:05:09.863062
3688386.0,Apgar score at 1 min,,5.8,,mean,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,447,2025-12-02T16:05:12.251790
3688386.0,Apgar score at 1 min,,6.5,,mean,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,448,2025-12-02T16:05:12.251790
3688386.0,Apgar score at 1 min,,7.5,,mean,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,449,2025-12-02T16:05:12.251790
3688386.0,Apgar score at 5 min,,7.8,,mean,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,450,2025-12-02T16:05:12.251790
3688386.0,Apgar score at 5 min,,8.8,,mean,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,451,2025-12-02T16:05:12.251790
3688386.0,Apgar score at 5 min,,8.9,,mean,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,452,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 1 min, <7",,5,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,453,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 1 min, <7",,8,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,454,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 1 min, <7",,4,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,455,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 1 min, >8",,3,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,456,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 1 min, >8",,2,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,457,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 1 min, >8",,8,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,458,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 5 min, <7",,2,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,459,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 5 min, <7",,6,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,460,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 5 min, <7",,0,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,461,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 5 min, >8",,10,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,462,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 5 min, >8",,0,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,463,2025-12-02T16:05:12.251790
3688386.0,"Apgar score at 5 min, >8",,12,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,464,2025-12-02T16:05:12.251790
3688386.0,Apgar score at 1 min,,5.8,,mean,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,447,2025-12-02T16:05:16.158507
3688386.0,Apgar score at 1 min,,6.5,,mean,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,448,2025-12-02T16:05:16.158507
3688386.0,Apgar score at 1 min,,7.5,,mean,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,449,2025-12-02T16:05:16.158507
3688386.0,Apgar score at 5 min,,7.8,,mean,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,450,2025-12-02T16:05:16.158507
3688386.0,Apgar score at 5 min,,8.8,,mean,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,451,2025-12-02T16:05:16.158507
3688386.0,Apgar score at 5 min,,8.9,,mean,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,452,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 1 min, <7",,5,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,453,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 1 min, <7",,8,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,454,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 1 min, <7",,4,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,455,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 1 min, >8",,3,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,456,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 1 min, >8",,2,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,457,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 1 min, >8",,8,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,458,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 5 min, <7",,2,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,459,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 5 min, <7",,6,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,460,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 5 min, <7",,0,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,461,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 5 min, >8",,10,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,462,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 5 min, >8",,0,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,463,2025-12-02T16:05:16.158507
3688386.0,"Apgar score at 5 min, >8",,12,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,464,2025-12-02T16:05:16.158507
3688386.0,Apgar score at 1 min,,5.8,,mean,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,447,2025-12-02T16:05:22.595023
3688386.0,Apgar score at 1 min,,6.5,,mean,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,448,2025-12-02T16:05:22.595023
3688386.0,Apgar score at 1 min,,7.5,,mean,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,449,2025-12-02T16:05:22.595023
3688386.0,Apgar score at 5 min,,7.8,,mean,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,450,2025-12-02T16:05:22.595023
3688386.0,Apgar score at 5 min,,8.8,,mean,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,451,2025-12-02T16:05:22.595023
3688386.0,Apgar score at 5 min,,8.9,,mean,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,452,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 1 min, <7",,5,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,453,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 1 min, <7",,8,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,454,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 1 min, <7",,4,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,455,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 1 min, >8",,3,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,456,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 1 min, >8",,2,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,457,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 1 min, >8",,8,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,458,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 5 min, <7",,2,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,459,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 5 min, <7",,6,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,460,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 5 min, <7",,0,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,461,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 5 min, >8",,10,,N,,,,,,12,pediatric,,neonates,,Labour  group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,462,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 5 min, >8",,0,,N,,,,,,18,pediatric,,neonates,,Caesarean section group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,463,2025-12-02T16:05:22.595023
3688386.0,"Apgar score at 5 min, >8",,12,,N,,,,,,20,pediatric,,neonates,,Awaiting Caesarean section,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,464,2025-12-02T16:05:22.595023
6851409.0,Quality of sleep,very good,2,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,465,2025-12-02T16:05:09.863062
6851409.0,Quality of sleep,good,6,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,466,2025-12-02T16:05:09.863062
6851409.0,Quality of sleep,moderately good,5,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,467,2025-12-02T16:05:09.863062
6851409.0,Quality of sleep,poor,0,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,468,2025-12-02T16:05:09.863062
6851409.0,Duration of sleep,,5.7,hr,mean,,,minmax,3.0,8.0,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,469,2025-12-02T16:05:09.863062
6851409.0,moderate apprehension or excitement,,2,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,470,2025-12-02T16:05:09.863062
6851409.0,no apprehension or excitement,,7,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,471,2025-12-02T16:05:09.863062
6851409.0,no apprehension or excitement,,3,,N,,,,,,6,maternal,delivery,,,Group 3,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,472,2025-12-02T16:05:09.863062
6851409.0,slight apprehension or excitement,,1,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,473,2025-12-02T16:05:09.863062
6851409.0,slight apprehension or excitement,,3,,N,,,,,,6,maternal,delivery,,,Group 3,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,474,2025-12-02T16:05:09.863062
6851409.0,Quality of sleep,very good,2,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,465,2025-12-02T16:05:12.251790
6851409.0,Quality of sleep,good,6,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,466,2025-12-02T16:05:12.251790
6851409.0,Quality of sleep,moderately good,5,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,467,2025-12-02T16:05:12.251790
6851409.0,Quality of sleep,poor,0,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,468,2025-12-02T16:05:12.251790
6851409.0,Duration of sleep,,5.7,hr,mean,,,minmax,3.0,8.0,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,469,2025-12-02T16:05:12.251790
6851409.0,moderate apprehension or excitement,,2,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,470,2025-12-02T16:05:12.251790
6851409.0,no apprehension or excitement,,7,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,471,2025-12-02T16:05:12.251790
6851409.0,no apprehension or excitement,,3,,N,,,,,,6,maternal,delivery,,,Group 3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,472,2025-12-02T16:05:12.251790
6851409.0,slight apprehension or excitement,,1,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,473,2025-12-02T16:05:12.251790
6851409.0,slight apprehension or excitement,,3,,N,,,,,,6,maternal,delivery,,,Group 3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,474,2025-12-02T16:05:12.251790
6851409.0,Quality of sleep,very good,2,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,465,2025-12-02T16:05:16.158507
6851409.0,Quality of sleep,good,6,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,466,2025-12-02T16:05:16.158507
6851409.0,Quality of sleep,moderately good,5,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,467,2025-12-02T16:05:16.158507
6851409.0,Quality of sleep,poor,0,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,468,2025-12-02T16:05:16.158507
6851409.0,Duration of sleep,,5.7,hr,mean,,,minmax,3.0,8.0,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,469,2025-12-02T16:05:16.158507
6851409.0,moderate apprehension or excitement,,2,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,470,2025-12-02T16:05:16.158507
6851409.0,no apprehension or excitement,,7,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,471,2025-12-02T16:05:16.158507
6851409.0,no apprehension or excitement,,3,,N,,,,,,6,maternal,delivery,,,Group 3,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,472,2025-12-02T16:05:16.158507
6851409.0,slight apprehension or excitement,,1,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,473,2025-12-02T16:05:16.158507
6851409.0,slight apprehension or excitement,,3,,N,,,,,,6,maternal,delivery,,,Group 3,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,474,2025-12-02T16:05:16.158507
6851409.0,Quality of sleep,very good,2,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,465,2025-12-02T16:05:22.595023
6851409.0,Quality of sleep,good,6,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,466,2025-12-02T16:05:22.595023
6851409.0,Quality of sleep,moderately good,5,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,467,2025-12-02T16:05:22.595023
6851409.0,Quality of sleep,poor,0,,N,,,,,,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,468,2025-12-02T16:05:22.595023
6851409.0,Duration of sleep,,5.7,hr,mean,,,minmax,3.0,8.0,13,maternal,delivery,,,Group 1,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,469,2025-12-02T16:05:22.595023
6851409.0,moderate apprehension or excitement,,2,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,470,2025-12-02T16:05:22.595023
6851409.0,no apprehension or excitement,,7,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,471,2025-12-02T16:05:22.595023
6851409.0,no apprehension or excitement,,3,,N,,,,,,6,maternal,delivery,,,Group 3,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,472,2025-12-02T16:05:22.595023
6851409.0,slight apprehension or excitement,,1,,N,,,,,,11,maternal,delivery,,,Group 2,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,473,2025-12-02T16:05:22.595023
6851409.0,slight apprehension or excitement,,3,,N,,,,,,6,maternal,delivery,,,Group 3,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,474,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,nausea,12,,N,%,57,,,,21,maternal,delivery,,0.14,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,475,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,nausea,8,,N,%,34,,,,23,maternal,delivery,,0.14,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,476,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe nausea,2,,N,%,9,,,,21,maternal,delivery,,0.22,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,477,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe nausea,0,,N,%,0,,,,23,maternal,delivery,,0.22,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,478,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,Vomiting,5,,N,%,24,,,,21,maternal,delivery,,0.35,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,479,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,Vomiting,3,,N,%,13,,,,23,maternal,delivery,,0.35,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,480,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe vomiting,1,,N,%,5,,,,21,maternal,delivery,,0.47,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,481,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe vomiting,0,,N,%,0,,,,23,maternal,delivery,,0.47,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,482,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,pruritus,16,,N,%,76,,,,21,maternal,delivery,,0.09,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,483,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,pruritus,22,,N,%,96,,,,23,maternal,delivery,,0.09,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,484,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe pruritus,2,,N,%,10,,,,21,maternal,delivery,,0.66,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,485,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe pruritus,4,,N,%,17,,,,23,maternal,delivery,,0.66,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,486,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,sedation,17,,N,%,81,,,,21,maternal,delivery,,0.58,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,487,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,sedation,17,,N,%,74,,,,23,maternal,delivery,,0.58,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,488,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe sedation,4,,N,%,19,,,,21,maternal,delivery,,0.04,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,489,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe sedation,0,,N,%,0,,,,23,maternal,delivery,,0.04,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,490,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,patients successfully contacted,16,,N,%,76,,,,21,maternal,delivery,,0.45,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,491,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,patients successfully contacted,20,,N,%,87,,,,23,maternal,delivery,,0.45,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,492,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,pateinets with any persistent pain,2/16,,N,%,12,,,,21,maternal,delivery,,0.67,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,493,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,pateinets with any persistent pain,4/20,,N,%,20,,,,23,maternal,delivery,,0.67,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,494,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,patients with any abnormal wound,3/16,,N,%,19,,,,21,maternal,delivery,,0.16,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,495,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,patients with any abnormal wound,9/20,,N,%,45,,,,23,maternal,delivery,,0.16,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,496,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,patients whose pain limited daily function,1/16,,N,%,6,,,,21,maternal,delivery,,1,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,497,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,patients whose pain limited daily function,1/20,,N,%,5,,,,23,maternal,delivery,,1,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,498,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,patients who required pain medication,0/16,,N,%,6,,,,21,maternal,delivery,,,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,499,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,patients who required pain medication,0/20,,N,%,0,,,,23,maternal,delivery,,,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,500,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,pain NRS,3,,median,,,minmax,1.0,4.0,21,maternal,delivery,,0.81,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,501,2025-12-02T16:05:09.863062
21081764.0,Persistent Pain at 3 Months After Delivery,pain NRS,2.5,,median,,,minmax,1.0,5.0,23,maternal,delivery,,0.81,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,502,2025-12-02T16:05:09.863062
21081764.0,weight ,,3520,g,mean,SD,407,,,,21,pediatric,,neonates,0.16,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,503,2025-12-02T16:05:09.863062
21081764.0,weight ,,33414,g,mean,SD,431,,,,23,pediatric,,neonates,0.16,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,504,2025-12-02T16:05:09.863062
21081764.0,1-minute Apgar,,9,,median,,,minmax,8.0,9.0,21,pediatric,,neonates,0.94,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,505,2025-12-02T16:05:09.863062
21081764.0,1-minute Apgar,,9,,median,,,minmax,8.0,9.0,23,pediatric,,neonates,0.94,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,506,2025-12-02T16:05:09.863062
21081764.0,5-minute Apgar,,9,,median,,,minmax,9.0,9.0,21,pediatric,,neonates,,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,507,2025-12-02T16:05:09.863062
21081764.0,5-minute Apgar,,9,,median,,,minmax,9.0,9.0,23,pediatric,,neonates,,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,508,2025-12-02T16:05:09.863062
21081764.0,Umbilical artery pH,,7.26,,mean,SD,0.04,,,,21,pediatric,,neonates,0.14,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,509,2025-12-02T16:05:09.863062
21081764.0,Umbilical artery pH,,7.29,,mean,SD,0.06,,,,23,pediatric,,neonates,0.14,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,510,2025-12-02T16:05:09.863062
21081764.0,NICU admission,,1,,N,%,5,,,,21,pediatric,,neonates,0.48,Gabapentin group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,511,2025-12-02T16:05:09.863062
21081764.0,NICU admission,,0,,N,%,0,,,,23,pediatric,,neonates,0.48,Placebo group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,512,2025-12-02T16:05:09.863062
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,nausea,12,,N,%,57,,,,21,maternal,delivery,,0.14,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,475,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,nausea,8,,N,%,34,,,,23,maternal,delivery,,0.14,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,476,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe nausea,2,,N,%,9,,,,21,maternal,delivery,,0.22,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,477,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe nausea,0,,N,%,0,,,,23,maternal,delivery,,0.22,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,478,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,Vomiting,5,,N,%,24,,,,21,maternal,delivery,,0.35,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,479,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,Vomiting,3,,N,%,13,,,,23,maternal,delivery,,0.35,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,480,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe vomiting,1,,N,%,5,,,,21,maternal,delivery,,0.47,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,481,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe vomiting,0,,N,%,0,,,,23,maternal,delivery,,0.47,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,482,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,pruritus,16,,N,%,76,,,,21,maternal,delivery,,0.09,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,483,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,pruritus,22,,N,%,96,,,,23,maternal,delivery,,0.09,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,484,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe pruritus,2,,N,%,10,,,,21,maternal,delivery,,0.66,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,485,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe pruritus,4,,N,%,17,,,,23,maternal,delivery,,0.66,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,486,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,sedation,17,,N,%,81,,,,21,maternal,delivery,,0.58,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,487,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,sedation,17,,N,%,74,,,,23,maternal,delivery,,0.58,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,488,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe sedation,4,,N,%,19,,,,21,maternal,delivery,,0.04,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,489,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe sedation,0,,N,%,0,,,,23,maternal,delivery,,0.04,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,490,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,patients successfully contacted,16,,N,%,76,,,,21,maternal,delivery,,0.45,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,491,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,patients successfully contacted,20,,N,%,87,,,,23,maternal,delivery,,0.45,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,492,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,pateinets with any persistent pain,2/16,,N,%,12,,,,21,maternal,delivery,,0.67,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,493,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,pateinets with any persistent pain,4/20,,N,%,20,,,,23,maternal,delivery,,0.67,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,494,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,patients with any abnormal wound,3/16,,N,%,19,,,,21,maternal,delivery,,0.16,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,495,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,patients with any abnormal wound,9/20,,N,%,45,,,,23,maternal,delivery,,0.16,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,496,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,patients whose pain limited daily function,1/16,,N,%,6,,,,21,maternal,delivery,,1,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,497,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,patients whose pain limited daily function,1/20,,N,%,5,,,,23,maternal,delivery,,1,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,498,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,patients who required pain medication,0/16,,N,%,6,,,,21,maternal,delivery,,,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,499,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,patients who required pain medication,0/20,,N,%,0,,,,23,maternal,delivery,,,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,500,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,pain NRS,3,,median,,,minmax,1.0,4.0,21,maternal,delivery,,0.81,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,501,2025-12-02T16:05:12.251790
21081764.0,Persistent Pain at 3 Months After Delivery,pain NRS,2.5,,median,,,minmax,1.0,5.0,23,maternal,delivery,,0.81,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,502,2025-12-02T16:05:12.251790
21081764.0,weight ,,3520,g,mean,SD,407,,,,21,pediatric,,neonates,0.16,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,503,2025-12-02T16:05:12.251790
21081764.0,weight ,,33414,g,mean,SD,431,,,,23,pediatric,,neonates,0.16,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,504,2025-12-02T16:05:12.251790
21081764.0,1-minute Apgar,,9,,median,,,minmax,8.0,9.0,21,pediatric,,neonates,0.94,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,505,2025-12-02T16:05:12.251790
21081764.0,1-minute Apgar,,9,,median,,,minmax,8.0,9.0,23,pediatric,,neonates,0.94,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,506,2025-12-02T16:05:12.251790
21081764.0,5-minute Apgar,,9,,median,,,minmax,9.0,9.0,21,pediatric,,neonates,,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,507,2025-12-02T16:05:12.251790
21081764.0,5-minute Apgar,,9,,median,,,minmax,9.0,9.0,23,pediatric,,neonates,,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,508,2025-12-02T16:05:12.251790
21081764.0,Umbilical artery pH,,7.26,,mean,SD,0.04,,,,21,pediatric,,neonates,0.14,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,509,2025-12-02T16:05:12.251790
21081764.0,Umbilical artery pH,,7.29,,mean,SD,0.06,,,,23,pediatric,,neonates,0.14,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,510,2025-12-02T16:05:12.251790
21081764.0,NICU admission,,1,,N,%,5,,,,21,pediatric,,neonates,0.48,Gabapentin group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,511,2025-12-02T16:05:12.251790
21081764.0,NICU admission,,0,,N,%,0,,,,23,pediatric,,neonates,0.48,Placebo group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,512,2025-12-02T16:05:12.251790
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,nausea,12,,N,%,57,,,,21,maternal,delivery,,0.14,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,475,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,nausea,8,,N,%,34,,,,23,maternal,delivery,,0.14,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,476,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe nausea,2,,N,%,9,,,,21,maternal,delivery,,0.22,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,477,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe nausea,0,,N,%,0,,,,23,maternal,delivery,,0.22,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,478,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,Vomiting,5,,N,%,24,,,,21,maternal,delivery,,0.35,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,479,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,Vomiting,3,,N,%,13,,,,23,maternal,delivery,,0.35,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,480,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe vomiting,1,,N,%,5,,,,21,maternal,delivery,,0.47,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,481,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe vomiting,0,,N,%,0,,,,23,maternal,delivery,,0.47,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,482,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,pruritus,16,,N,%,76,,,,21,maternal,delivery,,0.09,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,483,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,pruritus,22,,N,%,96,,,,23,maternal,delivery,,0.09,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,484,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe pruritus,2,,N,%,10,,,,21,maternal,delivery,,0.66,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,485,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe pruritus,4,,N,%,17,,,,23,maternal,delivery,,0.66,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,486,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,sedation,17,,N,%,81,,,,21,maternal,delivery,,0.58,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,487,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,sedation,17,,N,%,74,,,,23,maternal,delivery,,0.58,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,488,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe sedation,4,,N,%,19,,,,21,maternal,delivery,,0.04,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,489,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe sedation,0,,N,%,0,,,,23,maternal,delivery,,0.04,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,490,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,patients successfully contacted,16,,N,%,76,,,,21,maternal,delivery,,0.45,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,491,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,patients successfully contacted,20,,N,%,87,,,,23,maternal,delivery,,0.45,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,492,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,pateinets with any persistent pain,2/16,,N,%,12,,,,21,maternal,delivery,,0.67,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,493,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,pateinets with any persistent pain,4/20,,N,%,20,,,,23,maternal,delivery,,0.67,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,494,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,patients with any abnormal wound,3/16,,N,%,19,,,,21,maternal,delivery,,0.16,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,495,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,patients with any abnormal wound,9/20,,N,%,45,,,,23,maternal,delivery,,0.16,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,496,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,patients whose pain limited daily function,1/16,,N,%,6,,,,21,maternal,delivery,,1,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,497,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,patients whose pain limited daily function,1/20,,N,%,5,,,,23,maternal,delivery,,1,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,498,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,patients who required pain medication,0/16,,N,%,6,,,,21,maternal,delivery,,,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,499,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,patients who required pain medication,0/20,,N,%,0,,,,23,maternal,delivery,,,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,500,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,pain NRS,3,,median,,,minmax,1.0,4.0,21,maternal,delivery,,0.81,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,501,2025-12-02T16:05:16.158507
21081764.0,Persistent Pain at 3 Months After Delivery,pain NRS,2.5,,median,,,minmax,1.0,5.0,23,maternal,delivery,,0.81,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,502,2025-12-02T16:05:16.158507
21081764.0,weight ,,3520,g,mean,SD,407,,,,21,pediatric,,neonates,0.16,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,503,2025-12-02T16:05:16.158507
21081764.0,weight ,,33414,g,mean,SD,431,,,,23,pediatric,,neonates,0.16,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,504,2025-12-02T16:05:16.158507
21081764.0,1-minute Apgar,,9,,median,,,minmax,8.0,9.0,21,pediatric,,neonates,0.94,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,505,2025-12-02T16:05:16.158507
21081764.0,1-minute Apgar,,9,,median,,,minmax,8.0,9.0,23,pediatric,,neonates,0.94,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,506,2025-12-02T16:05:16.158507
21081764.0,5-minute Apgar,,9,,median,,,minmax,9.0,9.0,21,pediatric,,neonates,,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,507,2025-12-02T16:05:16.158507
21081764.0,5-minute Apgar,,9,,median,,,minmax,9.0,9.0,23,pediatric,,neonates,,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,508,2025-12-02T16:05:16.158507
21081764.0,Umbilical artery pH,,7.26,,mean,SD,0.04,,,,21,pediatric,,neonates,0.14,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,509,2025-12-02T16:05:16.158507
21081764.0,Umbilical artery pH,,7.29,,mean,SD,0.06,,,,23,pediatric,,neonates,0.14,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,510,2025-12-02T16:05:16.158507
21081764.0,NICU admission,,1,,N,%,5,,,,21,pediatric,,neonates,0.48,Gabapentin group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,511,2025-12-02T16:05:16.158507
21081764.0,NICU admission,,0,,N,%,0,,,,23,pediatric,,neonates,0.48,Placebo group,PRGLAC_PK_curation_Cleaned.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,512,2025-12-02T16:05:16.158507
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,nausea,12,,N,%,57,,,,21,maternal,delivery,,0.14,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,475,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,nausea,8,,N,%,34,,,,23,maternal,delivery,,0.14,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,476,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe nausea,2,,N,%,9,,,,21,maternal,delivery,,0.22,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,477,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe nausea,0,,N,%,0,,,,23,maternal,delivery,,0.22,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,478,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,Vomiting,5,,N,%,24,,,,21,maternal,delivery,,0.35,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,479,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,Vomiting,3,,N,%,13,,,,23,maternal,delivery,,0.35,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,480,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe vomiting,1,,N,%,5,,,,21,maternal,delivery,,0.47,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,481,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe vomiting,0,,N,%,0,,,,23,maternal,delivery,,0.47,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,482,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,pruritus,16,,N,%,76,,,,21,maternal,delivery,,0.09,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,483,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,pruritus,22,,N,%,96,,,,23,maternal,delivery,,0.09,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,484,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe pruritus,2,,N,%,10,,,,21,maternal,delivery,,0.66,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,485,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe pruritus,4,,N,%,17,,,,23,maternal,delivery,,0.66,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,486,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,sedation,17,,N,%,81,,,,21,maternal,delivery,,0.58,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,487,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,sedation,17,,N,%,74,,,,23,maternal,delivery,,0.58,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,488,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe sedation,4,,N,%,19,,,,21,maternal,delivery,,0.04,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,489,2025-12-02T16:05:22.595023
21081764.0,Maternal Adverse Reactions During the First 48 Postoperative Hours,severe sedation,0,,N,%,0,,,,23,maternal,delivery,,0.04,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,490,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,patients successfully contacted,16,,N,%,76,,,,21,maternal,delivery,,0.45,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,491,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,patients successfully contacted,20,,N,%,87,,,,23,maternal,delivery,,0.45,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,492,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,pateinets with any persistent pain,2/16,,N,%,12,,,,21,maternal,delivery,,0.67,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,493,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,pateinets with any persistent pain,4/20,,N,%,20,,,,23,maternal,delivery,,0.67,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,494,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,patients with any abnormal wound,3/16,,N,%,19,,,,21,maternal,delivery,,0.16,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,495,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,patients with any abnormal wound,9/20,,N,%,45,,,,23,maternal,delivery,,0.16,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,496,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,patients whose pain limited daily function,1/16,,N,%,6,,,,21,maternal,delivery,,1,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,497,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,patients whose pain limited daily function,1/20,,N,%,5,,,,23,maternal,delivery,,1,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,498,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,patients who required pain medication,0/16,,N,%,6,,,,21,maternal,delivery,,,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,499,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,patients who required pain medication,0/20,,N,%,0,,,,23,maternal,delivery,,,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,500,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,pain NRS,3,,median,,,minmax,1.0,4.0,21,maternal,delivery,,0.81,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,501,2025-12-02T16:05:22.595023
21081764.0,Persistent Pain at 3 Months After Delivery,pain NRS,2.5,,median,,,minmax,1.0,5.0,23,maternal,delivery,,0.81,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,502,2025-12-02T16:05:22.595023
21081764.0,weight ,,3520,g,mean,SD,407,,,,21,pediatric,,neonates,0.16,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,503,2025-12-02T16:05:22.595023
21081764.0,weight ,,33414,g,mean,SD,431,,,,23,pediatric,,neonates,0.16,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,504,2025-12-02T16:05:22.595023
21081764.0,1-minute Apgar,,9,,median,,,minmax,8.0,9.0,21,pediatric,,neonates,0.94,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,505,2025-12-02T16:05:22.595023
21081764.0,1-minute Apgar,,9,,median,,,minmax,8.0,9.0,23,pediatric,,neonates,0.94,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,506,2025-12-02T16:05:22.595023
21081764.0,5-minute Apgar,,9,,median,,,minmax,9.0,9.0,21,pediatric,,neonates,,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,507,2025-12-02T16:05:22.595023
21081764.0,5-minute Apgar,,9,,median,,,minmax,9.0,9.0,23,pediatric,,neonates,,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,508,2025-12-02T16:05:22.595023
21081764.0,Umbilical artery pH,,7.26,,mean,SD,0.04,,,,21,pediatric,,neonates,0.14,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,509,2025-12-02T16:05:22.595023
21081764.0,Umbilical artery pH,,7.29,,mean,SD,0.06,,,,23,pediatric,,neonates,0.14,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,510,2025-12-02T16:05:22.595023
21081764.0,NICU admission,,1,,N,%,5,,,,21,pediatric,,neonates,0.48,Gabapentin group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,511,2025-12-02T16:05:22.595023
21081764.0,NICU admission,,0,,N,%,0,,,,23,pediatric,,neonates,0.48,Placebo group,PRGLAC_PK_curation_SZ_By 91124.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,512,2025-12-02T16:05:22.595023
24134697.0,length,,49.84,cm,mean,SD,1.97,minmax,45.0,53.0,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,513,2025-12-02T16:05:09.863062
24134697.0,length,,48.43,cm,mean,SD,3.03,minmax,42.0,53.0,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,514,2025-12-02T16:05:09.863062
24134697.0,length,,49.43,cm,mean,SD,3.95,minmax,41.0,54.0,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,515,2025-12-02T16:05:09.863062
24134697.0,weight,,3.49,kg,mean,SD,0.51,minmax,2.27,4.54,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,516,2025-12-02T16:05:09.863062
24134697.0,weight,,3.12,kg,mean,SD,0.88,minmax,1.73,4.65,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,517,2025-12-02T16:05:09.863062
24134697.0,weight,,3.54,kg,mean,SD,0.75,minmax,1.83,4.5,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,518,2025-12-02T16:05:09.863062
24134697.0,BSA,,0.22,m2,mean,SD,0.002,minmax,0.1,0.17,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,519,2025-12-02T16:05:09.863062
24134697.0,BSA,,0.21,m2,mean,SD,0.004,minmax,0.13,0.14,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,520,2025-12-02T16:05:09.863062
24134697.0,BSA,,0.23,m2,mean,SD,0.003,minmax,0.13,0.14,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,521,2025-12-02T16:05:09.863062
24134697.0,Apgar score,1 min,8.97,,mean,SD,1.36,minmax,5.0,10.0,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,522,2025-12-02T16:05:09.863062
24134697.0,Apgar score,1 min,7.9,,mean,SD,1.33,minmax,5.0,10.0,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,523,2025-12-02T16:05:09.863062
24134697.0,Apgar score,1 min,8.79,,mean,SD,1.26,minmax,6.0,10.0,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,524,2025-12-02T16:05:09.863062
24134697.0,Apgar score,5 min,9.58,,mean,SD,0.83,minmax,7.0,10.0,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,525,2025-12-02T16:05:09.863062
24134697.0,Apgar score,5 min,8.83,,mean,SD,0.9,minmax,7.0,10.0,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,526,2025-12-02T16:05:09.863062
24134697.0,Apgar score,5 min,9.43,,mean,SD,0.82,minmax,7.0,10.0,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,527,2025-12-02T16:05:09.863062
24134697.0,gestational age,,39.6,weeks,mean,SD,0.8,minmax,39.0,42.0,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,528,2025-12-02T16:05:09.863062
24134697.0,gestational age,,37.9,weeks,mean,SD,2.38,minmax,32.0,41.0,30,pediatric,,neonates,<= 0.05 vs. control group,hypertension group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,529,2025-12-02T16:05:09.863062
24134697.0,gestational age,,38.3,weeks,mean,SD,0.81,minmax,37.0,39.0,14,pediatric,,neonates,<= 0.05 vs. control group,diabetes group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,530,2025-12-02T16:05:09.863062
24134697.0,gender,male/female,14/17,,N,,,,,,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,531,2025-12-02T16:05:09.863062
24134697.0,gender,male/female,22/8,,N,,,,,,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,532,2025-12-02T16:05:09.863062
24134697.0,gender,male/female,8/6,,N,,,,,,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,533,2025-12-02T16:05:09.863062
24134697.0,length,,49.84,cm,mean,SD,1.97,minmax,45.0,53.0,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,513,2025-12-02T16:05:12.251790
24134697.0,length,,48.43,cm,mean,SD,3.03,minmax,42.0,53.0,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,514,2025-12-02T16:05:12.251790
24134697.0,length,,49.43,cm,mean,SD,3.95,minmax,41.0,54.0,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,515,2025-12-02T16:05:12.251790
24134697.0,weight,,3.49,kg,mean,SD,0.51,minmax,2.27,4.54,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,516,2025-12-02T16:05:12.251790
24134697.0,weight,,3.12,kg,mean,SD,0.88,minmax,1.73,4.65,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,517,2025-12-02T16:05:12.251790
24134697.0,weight,,3.54,kg,mean,SD,0.75,minmax,1.83,4.5,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,518,2025-12-02T16:05:12.251790
24134697.0,BSA,,0.22,m2,mean,SD,0.002,minmax,0.1,0.17,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,519,2025-12-02T16:05:12.251790
24134697.0,BSA,,0.21,m2,mean,SD,0.004,minmax,0.13,0.14,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,520,2025-12-02T16:05:12.251790
24134697.0,BSA,,0.23,m2,mean,SD,0.003,minmax,0.13,0.14,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,521,2025-12-02T16:05:12.251790
24134697.0,Apgar score,1 min,8.97,,mean,SD,1.36,minmax,5.0,10.0,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,522,2025-12-02T16:05:12.251790
24134697.0,Apgar score,1 min,7.9,,mean,SD,1.33,minmax,5.0,10.0,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,523,2025-12-02T16:05:12.251790
24134697.0,Apgar score,1 min,8.79,,mean,SD,1.26,minmax,6.0,10.0,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,524,2025-12-02T16:05:12.251790
24134697.0,Apgar score,5 min,9.58,,mean,SD,0.83,minmax,7.0,10.0,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,525,2025-12-02T16:05:12.251790
24134697.0,Apgar score,5 min,8.83,,mean,SD,0.9,minmax,7.0,10.0,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,526,2025-12-02T16:05:12.251790
24134697.0,Apgar score,5 min,9.43,,mean,SD,0.82,minmax,7.0,10.0,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,527,2025-12-02T16:05:12.251790
24134697.0,gestational age,,39.6,weeks,mean,SD,0.8,minmax,39.0,42.0,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,528,2025-12-02T16:05:12.251790
24134697.0,gestational age,,37.9,weeks,mean,SD,2.38,minmax,32.0,41.0,30,pediatric,,neonates,<= 0.05 vs. control group,hypertension group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,529,2025-12-02T16:05:12.251790
24134697.0,gestational age,,38.3,weeks,mean,SD,0.81,minmax,37.0,39.0,14,pediatric,,neonates,<= 0.05 vs. control group,diabetes group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,530,2025-12-02T16:05:12.251790
24134697.0,gender,male/female,14/17,,N,,,,,,31,pediatric,,neonates,,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,531,2025-12-02T16:05:12.251790
24134697.0,gender,male/female,22/8,,N,,,,,,30,pediatric,,neonates,,hypertension group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,532,2025-12-02T16:05:12.251790
24134697.0,gender,male/female,8/6,,N,,,,,,14,pediatric,,neonates,,diabetes group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,533,2025-12-02T16:05:12.251790
7397084.0,injection-delivery interval,,367,seconds,mean,,,minmax,184.0,810.0,30,maternal,delivery,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,534,2025-12-02T16:05:09.863062
7397084.0,injection-delivery interval,,337,seconds,median,,,,,,30,maternal,delivery,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,535,2025-12-02T16:05:09.863062
7397084.0,injection-delivery interval,,367,seconds,mean,,,minmax,184.0,810.0,30,maternal,delivery,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,534,2025-12-02T16:05:12.251790
7397084.0,injection-delivery interval,,337,seconds,median,,,,,,30,maternal,delivery,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,535,2025-12-02T16:05:12.251790
699483.0,Injection-delivery (I-D) interval,,135,seconds,mean,SD,57,,,,15,maternal,labor,,,Group I,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,536,2025-12-02T16:05:09.863062
699483.0,Injection-delivery (I-D) interval,,151,seconds,mean,SD,74,,,,15,maternal,labor,,,Group II,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,537,2025-12-02T16:05:09.863062
699483.0,Injection-delivery (I-D) interval,,135,seconds,mean,SD,57,,,,15,maternal,labor,,,Group I,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,536,2025-12-02T16:05:12.251790
699483.0,Injection-delivery (I-D) interval,,151,seconds,mean,SD,74,,,,15,maternal,labor,,,Group II,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,537,2025-12-02T16:05:12.251790
7318882.0,Injection-delivery (I-D) interval,,343,seconds,mean,SD,116,,,,30,maternal,delivery,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,538,2025-12-02T16:05:09.863062
7318882.0,Injection-delivery (I-D) interval,,314,seconds,median,,,,,,30,maternal,delivery,,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,539,2025-12-02T16:05:09.863062
7318882.0,Injection-delivery (I-D) interval,,343,seconds,mean,SD,116,,,,30,maternal,delivery,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,538,2025-12-02T16:05:12.251790
7318882.0,Injection-delivery (I-D) interval,,314,seconds,median,,,,,,30,maternal,delivery,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,539,2025-12-02T16:05:12.251790
8244501.0,preterm,,11,,N,,,,,,25,pediatric,,neonates,,study group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,540,2025-12-02T16:05:09.863062
8244501.0,LBW,,13,,N,,,,,,25,pediatric,,neonates,,study group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,541,2025-12-02T16:05:09.863062
8244501.0,Apgar score at 1 min,,5.6,,mean,SD,1.68,,,,25,pediatric,,neonates,<0.001,study group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,542,2025-12-02T16:05:09.863062
8244501.0,Apgar score at 1 min,,8.2,,mean,SD,1.63,,,,25,pediatric,,neonates,<0.001,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,543,2025-12-02T16:05:09.863062
8244501.0,Apgar score at 5 min,,7.7,,mean,SD,1.24,,,,25,pediatric,,neonates,<0.001,study group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,544,2025-12-02T16:05:09.863062
8244501.0,Apgar score at 5 min,,9.3,,mean,SD,0.99,,,,25,pediatric,,neonates,<0.001,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,545,2025-12-02T16:05:09.863062
8244501.0,rectal temperature,,34.8,℃,,,,,,,25,pediatric,,neonates,<0.001,study group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,546,2025-12-02T16:05:09.863062
8244501.0,rectal temperature,,36.1,℃,,,,,,,25,pediatric,,neonates,<0.001,control group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,547,2025-12-02T16:05:09.863062
8244501.0,preterm,,11,,N,,,,,,25,pediatric,,neonates,,study group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,540,2025-12-02T16:05:12.251790
8244501.0,LBW,,13,,N,,,,,,25,pediatric,,neonates,,study group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,541,2025-12-02T16:05:12.251790
8244501.0,Apgar score at 1 min,,5.6,,mean,SD,1.68,,,,25,pediatric,,neonates,<0.001,study group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,542,2025-12-02T16:05:12.251790
8244501.0,Apgar score at 1 min,,8.2,,mean,SD,1.63,,,,25,pediatric,,neonates,<0.001,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,543,2025-12-02T16:05:12.251790
8244501.0,Apgar score at 5 min,,7.7,,mean,SD,1.24,,,,25,pediatric,,neonates,<0.001,study group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,544,2025-12-02T16:05:12.251790
8244501.0,Apgar score at 5 min,,9.3,,mean,SD,0.99,,,,25,pediatric,,neonates,<0.001,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,545,2025-12-02T16:05:12.251790
8244501.0,rectal temperature,,34.8,℃,,,,,,,25,pediatric,,neonates,<0.001,study group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,546,2025-12-02T16:05:12.251790
8244501.0,rectal temperature,,36.1,℃,,,,,,,25,pediatric,,neonates,<0.001,control group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,547,2025-12-02T16:05:12.251790
19657707.0,preterm delivery,,12,,N,%,26.7,,,,45,maternal,delivery,,<0.18,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,548,2025-12-02T16:05:09.863062
19657707.0,preterm delivery,,6,,N,%,13.3,,,,45,maternal,delivery,,<0.18,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,549,2025-12-02T16:05:09.863062
19657707.0,EGA at delivery,,38,mean,SD,2.5,,,,,45,maternal,delivery,,<0.15,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,550,2025-12-02T16:05:09.863062
19657707.0,EGA at delivery,,38.6,mean,SD,1.3,,,,,45,maternal,delivery,,<0.15,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,551,2025-12-02T16:05:09.863062
19657707.0,Low birth weight,,7,,N,%,15.6,,,,45,maternal,delivery,,<0.18,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,552,2025-12-02T16:05:09.863062
19657707.0,Low birth weight,,2,,N,%,4.4,,,,45,maternal,delivery,,<0.18,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,553,2025-12-02T16:05:09.863062
19657707.0,Birth weight,,3.18,kg,mean,SD,0.55,,,,45,pediatric,,neonates,<0.43,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,554,2025-12-02T16:05:09.863062
19657707.0,Birth weight,,3.26,kg,mean,SD,0.41,,,,45,pediatric,,neonates,<0.43,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,555,2025-12-02T16:05:09.863062
19657707.0,NICU admission,,4,,N,%,9.3,,,,45,pediatric,,neonates,<0.76,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,556,2025-12-02T16:05:09.863062
19657707.0,NICU admission,,6,,N,%,13.6,,,,45,pediatric,,neonates,<0.76,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,557,2025-12-02T16:05:09.863062
19657707.0,Respiratory difficulty,,10,,N,%,23.3,,,,45,pediatric,,neonates,<0.49,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,558,2025-12-02T16:05:09.863062
19657707.0,Respiratory difficulty,,14,,N,%,31.8,,,,45,pediatric,,neonates,<0.49,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,559,2025-12-02T16:05:09.863062
19657707.0,Lethargy,,1,,N,%,2.3,,,,45,pediatric,,neonates,<0.38,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,560,2025-12-02T16:05:09.863062
19657707.0,Lethargy,,4,,N,%,9.1,,,,45,pediatric,,neonates,<0.38,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,561,2025-12-02T16:05:09.863062
19657707.0,Hypotonia,,0,,N,%,0,,,,45,pediatric,,neonates,<0.13,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,562,2025-12-02T16:05:09.863062
19657707.0,Hypotonia,,4,,N,%,9.1,,,,45,pediatric,,neonates,<0.13,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,563,2025-12-02T16:05:09.863062
19657707.0,Apgar score at 1 min,,7.8,,mean,SD,1.4,,,,45,pediatric,,neonates,<0.14,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,564,2025-12-02T16:05:09.863062
19657707.0,Apgar score at 1 min,,7.3,,mean,SD,1.5,,,,45,pediatric,,neonates,<0.14,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,565,2025-12-02T16:05:09.863062
19657707.0,Apgar score at 5 min,,8.9,,mean,SD,0.4,,,,45,pediatric,,neonates,<0.1,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,566,2025-12-02T16:05:09.863062
19657707.0,Apgar score at 5 min,,8.7,,mean,SD,0.6,,,,45,pediatric,,neonates,<0.1,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,567,2025-12-02T16:05:09.863062
19657707.0,HTN/Preeclalmpsia,,3,,N,%,6.7,,,,45,pediatric,,neonates,1,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,568,2025-12-02T16:05:09.863062
19657707.0,HTN/Preeclalmpsia,,4,,N,%,9.1,,,,45,pediatric,,neonates,1,Matched group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,569,2025-12-02T16:05:09.863062
19657707.0,EGA,,38.8,weeks,mean,SD,1.3,,,,6,pediatric,,neonates,,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,570,2025-12-02T16:05:09.863062
19657707.0,Birth weight,,3.19,kg,mean,SD,0.52,,,,6,pediatric,,neonates,,Zolpidem-exposed group,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,571,2025-12-02T16:05:09.863062
19657707.0,preterm delivery,,12,,N,%,26.7,,,,45,maternal,delivery,,<0.18,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,548,2025-12-02T16:05:12.251790
19657707.0,preterm delivery,,6,,N,%,13.3,,,,45,maternal,delivery,,<0.18,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,549,2025-12-02T16:05:12.251790
19657707.0,EGA at delivery,,38,mean,SD,2.5,,,,,45,maternal,delivery,,<0.15,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,550,2025-12-02T16:05:12.251790
19657707.0,EGA at delivery,,38.6,mean,SD,1.3,,,,,45,maternal,delivery,,<0.15,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,551,2025-12-02T16:05:12.251790
19657707.0,Low birth weight,,7,,N,%,15.6,,,,45,maternal,delivery,,<0.18,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,552,2025-12-02T16:05:12.251790
19657707.0,Low birth weight,,2,,N,%,4.4,,,,45,maternal,delivery,,<0.18,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,553,2025-12-02T16:05:12.251790
19657707.0,Birth weight,,3.18,kg,mean,SD,0.55,,,,45,pediatric,,neonates,<0.43,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,554,2025-12-02T16:05:12.251790
19657707.0,Birth weight,,3.26,kg,mean,SD,0.41,,,,45,pediatric,,neonates,<0.43,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,555,2025-12-02T16:05:12.251790
19657707.0,NICU admission,,4,,N,%,9.3,,,,45,pediatric,,neonates,<0.76,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,556,2025-12-02T16:05:12.251790
19657707.0,NICU admission,,6,,N,%,13.6,,,,45,pediatric,,neonates,<0.76,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,557,2025-12-02T16:05:12.251790
19657707.0,Respiratory difficulty,,10,,N,%,23.3,,,,45,pediatric,,neonates,<0.49,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,558,2025-12-02T16:05:12.251790
19657707.0,Respiratory difficulty,,14,,N,%,31.8,,,,45,pediatric,,neonates,<0.49,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,559,2025-12-02T16:05:12.251790
19657707.0,Lethargy,,1,,N,%,2.3,,,,45,pediatric,,neonates,<0.38,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,560,2025-12-02T16:05:12.251790
19657707.0,Lethargy,,4,,N,%,9.1,,,,45,pediatric,,neonates,<0.38,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,561,2025-12-02T16:05:12.251790
19657707.0,Hypotonia,,0,,N,%,0,,,,45,pediatric,,neonates,<0.13,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,562,2025-12-02T16:05:12.251790
19657707.0,Hypotonia,,4,,N,%,9.1,,,,45,pediatric,,neonates,<0.13,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,563,2025-12-02T16:05:12.251790
19657707.0,Apgar score at 1 min,,7.8,,mean,SD,1.4,,,,45,pediatric,,neonates,<0.14,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,564,2025-12-02T16:05:12.251790
19657707.0,Apgar score at 1 min,,7.3,,mean,SD,1.5,,,,45,pediatric,,neonates,<0.14,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,565,2025-12-02T16:05:12.251790
19657707.0,Apgar score at 5 min,,8.9,,mean,SD,0.4,,,,45,pediatric,,neonates,<0.1,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,566,2025-12-02T16:05:12.251790
19657707.0,Apgar score at 5 min,,8.7,,mean,SD,0.6,,,,45,pediatric,,neonates,<0.1,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,567,2025-12-02T16:05:12.251790
19657707.0,HTN/Preeclalmpsia,,3,,N,%,6.7,,,,45,pediatric,,neonates,1,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,568,2025-12-02T16:05:12.251790
19657707.0,HTN/Preeclalmpsia,,4,,N,%,9.1,,,,45,pediatric,,neonates,1,Matched group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,569,2025-12-02T16:05:12.251790
19657707.0,EGA,,38.8,weeks,mean,SD,1.3,,,,6,pediatric,,neonates,,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,570,2025-12-02T16:05:12.251790
19657707.0,Birth weight,,3.19,kg,mean,SD,0.52,,,,6,pediatric,,neonates,,Zolpidem-exposed group,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,571,2025-12-02T16:05:12.251790
3208682.0,Birth weight,,3.5,kg,mean,SEM,0.3,,,,5,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,590,2025-12-02T16:05:09.863062
3208682.0,gestational age,,38.4,weeks,mean,SEM,0.5,,,,5,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,591,2025-12-02T16:05:09.863062
3208682.0,Apgar score (1 and 5 min),,8.6/9.8,,mean,SEM,0.5/0.4,,,,5,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,592,2025-12-02T16:05:09.863062
3208682.0,Birth weight,,3.5,kg,mean,SEM,0.3,,,,5,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,590,2025-12-02T16:05:12.251790
3208682.0,gestational age,,38.4,weeks,mean,SEM,0.5,,,,5,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,591,2025-12-02T16:05:12.251790
3208682.0,Apgar score (1 and 5 min),,8.6/9.8,,mean,SEM,0.5/0.4,,,,5,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,592,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,5 min after the first infection,140.3,beats/min,mean,SD,3.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,593,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,5 min after the first infection,136.8,beats/min,mean,SD,4.5,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,594,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,10 min after the first infection,138.5,beats/min,mean,SD,3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,595,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,10 min after the first infection,134.4,beats/min,mean,SD,4.5,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,596,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,15 min after the first infection,140,beats/min,mean,SD,3.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,597,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,15 min after the first infection,135.3,beats/min,mean,SD,3.7,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,598,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,30 min after the first infection,140.4,beats/min,mean,SD,1.4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,599,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,30 min after the first infection,138.9,beats/min,mean,SD,2.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,600,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,baseline,138.3,beats/min,mean,SD,3.2,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,601,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,baseline,138,beats/min,mean,SD,3.2,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,602,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,5 min after the first infection,90.8,mm Hg,mean,SD,4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,603,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,5 min after the first infection,88.8,mm Hg,mean,SD,2.9,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,604,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,10 min after the first infection,89,mm Hg,mean,SD,3.3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,605,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,10 min after the first infection,89.5,mm Hg,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,606,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,15 min after the first infection,88.1,mm Hg,mean,SD,2.8,,,,10,pediatric,,fetus,<0.01 vs. baseline,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,607,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,15 min after the first infection,83.1,mm Hg,mean,SD,2.8,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,608,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,30 min after the first infection,85.9,mm Hg,mean,SD,2.5,,,,10,pediatric,,fetus,<0.01 vs. baseline,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,609,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,30 min after the first infection,79,mm Hg,mean,SD,4.6,,,,12,pediatric,,fetus,<0.05 vs. baseline,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,610,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,baseline,95.3,mm Hg,mean,SD,4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,611,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,baseline,94.2,mm Hg,mean,SD,3.8,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,612,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,5 min after the first infection,79.7,beats/min,mean,SD,3.9,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,613,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,5 min after the first infection,80.1,beats/min,mean,SD,3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,614,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,10 min after the first infection,81.9,beats/min,mean,SD,4.6,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,615,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,10 min after the first infection,80.5,beats/min,mean,SD,2.7,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,616,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,15 min after the first infection,79.2,beats/min,mean,SD,3.4,,,,10,pediatric,,fetus,<0.05 vs. baseline,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,617,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,15 min after the first infection,78.6,beats/min,mean,SD,2.9,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,618,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,30 min after the first infection,78,beats/min,mean,SD,4.1,,,,10,pediatric,,fetus,<0.05 vs. baseline,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,619,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,30 min after the first infection,82.1,beats/min,mean,SD,3.8,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,620,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,baseline,84.2,beats/min,mean,SD,3.8,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,621,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,baseline,80.9,beats/min,mean,SD,2.9,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,622,2025-12-02T16:05:09.863062
7605757.0,SaO2,5 min after the first infection,97.9,%,mean,SD,0.2,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,623,2025-12-02T16:05:09.863062
7605757.0,SaO2,5 min after the first infection,97.4,%,mean,SD,0.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,624,2025-12-02T16:05:09.863062
7605757.0,SaO2,10 min after the first infection,97.6,%,mean,SD,0.2,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,625,2025-12-02T16:05:09.863062
7605757.0,SaO2,10 min after the first infection,97.5,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,626,2025-12-02T16:05:09.863062
7605757.0,SaO2,15 min after the first infection,98,%,mean,SD,0.3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,627,2025-12-02T16:05:09.863062
7605757.0,SaO2,15 min after the first infection,97.5,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,628,2025-12-02T16:05:09.863062
7605757.0,SaO2,30 min after the first infection,98.2,%,mean,SD,0.3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,629,2025-12-02T16:05:09.863062
7605757.0,SaO2,30 min after the first infection,97.4,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,630,2025-12-02T16:05:09.863062
7605757.0,SaO2,baseline,98.4,%,mean,SD,0.3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,631,2025-12-02T16:05:09.863062
7605757.0,SaO2,baseline,97.7,%,mean,SD,0.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,632,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,5 min after the second infection,84.2,mm Hg,mean,SD,2.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,633,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,5 min after the second infection,80.6,mm Hg,mean,SD,4.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,634,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,10 min after the second infection,86.5,mm Hg,mean,SD,1.7,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,635,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,10 min after the second infection,81.4,mm Hg,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,636,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,15 min after the second infection,86.5,mm Hg,mean,SD,1.7,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,637,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,15 min after the second infection,81.4,mm Hg,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,638,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,30 min after the second infection,83.5,mm Hg,mean,SD,1.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,639,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,30 min after the second infection,78.9,mm Hg,mean,SD,2.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,640,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,baseline,89.7,mm Hg,mean,SD,2.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,641,2025-12-02T16:05:09.863062
7605757.0,maternal mean arterial pressure,baseline,83.2,mm Hg,mean,SD,4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,642,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,5 min after the second infection,86.1,beats/min,mean,SD,5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,643,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,5 min after the second infection,76,beats/min,mean,SD,2.1,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,644,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,10 min after the second infection,88.2,beats/min,mean,SD,9.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,645,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,10 min after the second infection,76.1,beats/min,mean,SD,2.9,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,646,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,15 min after the second infection,88.1,beats/min,mean,SD,9.2,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,647,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,15 min after the second infection,72.8,beats/min,mean,SD,3.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,648,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,30 min after the second infection,86,beats/min,mean,SD,8.9,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,649,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,30 min after the second infection,74,beats/min,mean,SD,2.5,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,650,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,baseline,81.2,beats/min,mean,SD,4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,651,2025-12-02T16:05:09.863062
7605757.0,maternal heart rate,baseline,77.6,beats/min,mean,SD,2.2,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,652,2025-12-02T16:05:09.863062
7605757.0,SaO2,5 min after the second infection,97.5,%,mean,SD,0.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,653,2025-12-02T16:05:09.863062
7605757.0,SaO2,5 min after the second infection,97.7,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,654,2025-12-02T16:05:09.863062
7605757.0,SaO2,10 min after the second infection,97.6,%,mean,SD,0.4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,655,2025-12-02T16:05:09.863062
7605757.0,SaO2,10 min after the second infection,97.6,%,mean,SD,0.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,656,2025-12-02T16:05:09.863062
7605757.0,SaO2,15 min after the second infection,97.6,%,mean,SD,0.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,657,2025-12-02T16:05:09.863062
7605757.0,SaO2,15 min after the second infection,97.5,%,mean,SD,0.2,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,658,2025-12-02T16:05:09.863062
7605757.0,SaO2,30 min after the second infection,97.6,%,mean,SD,0.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,659,2025-12-02T16:05:09.863062
7605757.0,SaO2,30 min after the second infection,97.6,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,660,2025-12-02T16:05:09.863062
7605757.0,SaO2,baseline,98.5,%,mean,SD,0.4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,661,2025-12-02T16:05:09.863062
7605757.0,SaO2,baseline,97.2,%,mean,SD,0.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,662,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,5 min after the second infection,144.4,beats/min,mean,SD,4.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,663,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,5 min after the second infection,137,beats/min,mean,SD,3.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,664,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,10 min after the second infection,144.6,beats/min,mean,SD,2.4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,665,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,10 min after the second infection,133.5,beats/min,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,666,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,15 min after the second infection,140.7,beats/min,mean,SD,4.8,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,667,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,15 min after the second infection,132.3,beats/min,mean,SD,3.8,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,668,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,30 min after the second infection,142.3,beats/min,mean,SD,3.7,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,669,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,30 min after the second infection,134.5,beats/min,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,670,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,baseline,144.5,beats/min,mean,SD,3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,671,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,baseline,134.1,beats/min,mean,SD,2.5,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,672,2025-12-02T16:05:09.863062
7605757.0,fetal heart rate,5 min after the first infection,140.3,beats/min,mean,SD,3.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,593,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,5 min after the first infection,136.8,beats/min,mean,SD,4.5,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,594,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,10 min after the first infection,138.5,beats/min,mean,SD,3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,595,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,10 min after the first infection,134.4,beats/min,mean,SD,4.5,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,596,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,15 min after the first infection,140,beats/min,mean,SD,3.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,597,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,15 min after the first infection,135.3,beats/min,mean,SD,3.7,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,598,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,30 min after the first infection,140.4,beats/min,mean,SD,1.4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,599,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,30 min after the first infection,138.9,beats/min,mean,SD,2.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,600,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,baseline,138.3,beats/min,mean,SD,3.2,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,601,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,baseline,138,beats/min,mean,SD,3.2,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,602,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,5 min after the first infection,90.8,mm Hg,mean,SD,4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,603,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,5 min after the first infection,88.8,mm Hg,mean,SD,2.9,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,604,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,10 min after the first infection,89,mm Hg,mean,SD,3.3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,605,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,10 min after the first infection,89.5,mm Hg,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,606,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,15 min after the first infection,88.1,mm Hg,mean,SD,2.8,,,,10,pediatric,,fetus,<0.01 vs. baseline,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,607,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,15 min after the first infection,83.1,mm Hg,mean,SD,2.8,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,608,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,30 min after the first infection,85.9,mm Hg,mean,SD,2.5,,,,10,pediatric,,fetus,<0.01 vs. baseline,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,609,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,30 min after the first infection,79,mm Hg,mean,SD,4.6,,,,12,pediatric,,fetus,<0.05 vs. baseline,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,610,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,baseline,95.3,mm Hg,mean,SD,4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,611,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,baseline,94.2,mm Hg,mean,SD,3.8,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,612,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,5 min after the first infection,79.7,beats/min,mean,SD,3.9,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,613,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,5 min after the first infection,80.1,beats/min,mean,SD,3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,614,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,10 min after the first infection,81.9,beats/min,mean,SD,4.6,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,615,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,10 min after the first infection,80.5,beats/min,mean,SD,2.7,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,616,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,15 min after the first infection,79.2,beats/min,mean,SD,3.4,,,,10,pediatric,,fetus,<0.05 vs. baseline,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,617,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,15 min after the first infection,78.6,beats/min,mean,SD,2.9,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,618,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,30 min after the first infection,78,beats/min,mean,SD,4.1,,,,10,pediatric,,fetus,<0.05 vs. baseline,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,619,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,30 min after the first infection,82.1,beats/min,mean,SD,3.8,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,620,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,baseline,84.2,beats/min,mean,SD,3.8,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,621,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,baseline,80.9,beats/min,mean,SD,2.9,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,622,2025-12-02T16:05:12.251790
7605757.0,SaO2,5 min after the first infection,97.9,%,mean,SD,0.2,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,623,2025-12-02T16:05:12.251790
7605757.0,SaO2,5 min after the first infection,97.4,%,mean,SD,0.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,624,2025-12-02T16:05:12.251790
7605757.0,SaO2,10 min after the first infection,97.6,%,mean,SD,0.2,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,625,2025-12-02T16:05:12.251790
7605757.0,SaO2,10 min after the first infection,97.5,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,626,2025-12-02T16:05:12.251790
7605757.0,SaO2,15 min after the first infection,98,%,mean,SD,0.3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,627,2025-12-02T16:05:12.251790
7605757.0,SaO2,15 min after the first infection,97.5,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,628,2025-12-02T16:05:12.251790
7605757.0,SaO2,30 min after the first infection,98.2,%,mean,SD,0.3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,629,2025-12-02T16:05:12.251790
7605757.0,SaO2,30 min after the first infection,97.4,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,630,2025-12-02T16:05:12.251790
7605757.0,SaO2,baseline,98.4,%,mean,SD,0.3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,631,2025-12-02T16:05:12.251790
7605757.0,SaO2,baseline,97.7,%,mean,SD,0.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,632,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,5 min after the second infection,84.2,mm Hg,mean,SD,2.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,633,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,5 min after the second infection,80.6,mm Hg,mean,SD,4.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,634,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,10 min after the second infection,86.5,mm Hg,mean,SD,1.7,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,635,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,10 min after the second infection,81.4,mm Hg,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,636,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,15 min after the second infection,86.5,mm Hg,mean,SD,1.7,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,637,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,15 min after the second infection,81.4,mm Hg,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,638,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,30 min after the second infection,83.5,mm Hg,mean,SD,1.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,639,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,30 min after the second infection,78.9,mm Hg,mean,SD,2.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,640,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,baseline,89.7,mm Hg,mean,SD,2.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,641,2025-12-02T16:05:12.251790
7605757.0,maternal mean arterial pressure,baseline,83.2,mm Hg,mean,SD,4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,642,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,5 min after the second infection,86.1,beats/min,mean,SD,5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,643,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,5 min after the second infection,76,beats/min,mean,SD,2.1,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,644,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,10 min after the second infection,88.2,beats/min,mean,SD,9.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,645,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,10 min after the second infection,76.1,beats/min,mean,SD,2.9,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,646,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,15 min after the second infection,88.1,beats/min,mean,SD,9.2,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,647,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,15 min after the second infection,72.8,beats/min,mean,SD,3.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,648,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,30 min after the second infection,86,beats/min,mean,SD,8.9,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,649,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,30 min after the second infection,74,beats/min,mean,SD,2.5,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,650,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,baseline,81.2,beats/min,mean,SD,4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,651,2025-12-02T16:05:12.251790
7605757.0,maternal heart rate,baseline,77.6,beats/min,mean,SD,2.2,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,652,2025-12-02T16:05:12.251790
7605757.0,SaO2,5 min after the second infection,97.5,%,mean,SD,0.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,653,2025-12-02T16:05:12.251790
7605757.0,SaO2,5 min after the second infection,97.7,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,654,2025-12-02T16:05:12.251790
7605757.0,SaO2,10 min after the second infection,97.6,%,mean,SD,0.4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,655,2025-12-02T16:05:12.251790
7605757.0,SaO2,10 min after the second infection,97.6,%,mean,SD,0.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,656,2025-12-02T16:05:12.251790
7605757.0,SaO2,15 min after the second infection,97.6,%,mean,SD,0.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,657,2025-12-02T16:05:12.251790
7605757.0,SaO2,15 min after the second infection,97.5,%,mean,SD,0.2,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,658,2025-12-02T16:05:12.251790
7605757.0,SaO2,30 min after the second infection,97.6,%,mean,SD,0.5,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,659,2025-12-02T16:05:12.251790
7605757.0,SaO2,30 min after the second infection,97.6,%,mean,SD,0.4,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,660,2025-12-02T16:05:12.251790
7605757.0,SaO2,baseline,98.5,%,mean,SD,0.4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,661,2025-12-02T16:05:12.251790
7605757.0,SaO2,baseline,97.2,%,mean,SD,0.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,662,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,5 min after the second infection,144.4,beats/min,mean,SD,4.1,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,663,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,5 min after the second infection,137,beats/min,mean,SD,3.3,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,664,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,10 min after the second infection,144.6,beats/min,mean,SD,2.4,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,665,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,10 min after the second infection,133.5,beats/min,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,666,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,15 min after the second infection,140.7,beats/min,mean,SD,4.8,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,667,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,15 min after the second infection,132.3,beats/min,mean,SD,3.8,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,668,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,30 min after the second infection,142.3,beats/min,mean,SD,3.7,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,669,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,30 min after the second infection,134.5,beats/min,mean,SD,3.6,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,670,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,baseline,144.5,beats/min,mean,SD,3,,,,10,pediatric,,fetus,,bupivacaine ,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,671,2025-12-02T16:05:12.251790
7605757.0,fetal heart rate,baseline,134.1,beats/min,mean,SD,2.5,,,,12,pediatric,,fetus,,bupivacaine + clonidine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,672,2025-12-02T16:05:12.251790
12932617.0,QTc at the first day of life,,0.41,,mean,SD,0.035,minmax,0.35,0.47,18,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,673,2025-12-02T16:05:09.863062
12932617.0,birth weight,,3266,g,mean,SD,804,minmax,960.0,4280.0,18,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,674,2025-12-02T16:05:09.863062
12932617.0,died in utero,,1,,N,,,,,,18,pediatric,,fetus,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,675,2025-12-02T16:05:09.863062
12932617.0,died two days after delivery,,1,,N,,,,,,18,pediatric,,neonates,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,676,2025-12-02T16:05:09.863062
12932617.0,QTc at the first day of life,,0.41,,mean,SD,0.035,minmax,0.35,0.47,18,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,673,2025-12-02T16:05:12.251790
12932617.0,birth weight,,3266,g,mean,SD,804,minmax,960.0,4280.0,18,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,674,2025-12-02T16:05:12.251790
12932617.0,died in utero,,1,,N,,,,,,18,pediatric,,fetus,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,675,2025-12-02T16:05:12.251790
12932617.0,died two days after delivery,,1,,N,,,,,,18,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,676,2025-12-02T16:05:12.251790
7426541.0,birth weight,,2.8,kg,mean,,,,,,12,pediatric,,infants,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,677,2025-12-02T16:05:09.863062
7426541.0,birth weight,,2.8,kg,mean,,,,,,12,pediatric,,infants,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,677,2025-12-02T16:05:12.251790
23562958.0,sex,male,50.6,%,N,,,,,,567,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,678,2025-12-02T16:05:09.863062
23562958.0,sex,female,49.4,%,N,,,,,,567,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,679,2025-12-02T16:05:09.863062
23562958.0,birth weight,,3370,g,mean,SD,556,,,,564,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,680,2025-12-02T16:05:09.863062
23562958.0,body length,,50.2,cm,mean,SD,2.4,,,,557,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,681,2025-12-02T16:05:09.863062
23562958.0,length of gestation,,39.1,weeks,mean,SD,1.9,,,,551,pediatric,,newborn,,,PRGLAC_PK_curation_051925.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,682,2025-12-02T16:05:09.863062
23562958.0,sex,male,50.6,%,N,,,,,,567,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,678,2025-12-02T16:05:12.251790
23562958.0,sex,female,49.4,%,N,,,,,,567,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,679,2025-12-02T16:05:12.251790
23562958.0,birth weight,,3370,g,mean,SD,556,,,,564,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,680,2025-12-02T16:05:12.251790
23562958.0,body length,,50.2,cm,mean,SD,2.4,,,,557,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,681,2025-12-02T16:05:12.251790
23562958.0,length of gestation,,39.1,weeks,mean,SD,1.9,,,,551,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,682,2025-12-02T16:05:12.251790
26575635.0,unadjusted RR of a male birth ,,1.04,,,,,95% CI,0.91,1.19,213,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,683,2025-12-02T16:05:12.251790
26575635.0,adjusted RR of a male birth ,,1.06,,,,,95% CI,0.92,1.22,213,maternal,pregnancy,,,Adjusted for log-transformed urinary creatinine (continuous),PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,684,2025-12-02T16:05:12.251790
26575635.0,adjusted RR of a male birth ,,1.05,,,,,95% CI,0.91,1.21,213,maternal,pregnancy,,,"Adjusted for log-transformed urinary creatinine (continuous), research site (Michigan/Texas), age (continuous), annual household income (< $70,000/≥ $70,000), and maternal parity (nulliparous/parous)",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,685,2025-12-02T16:05:12.251790
26575635.0,unadjusted RR of a male birth ,,1.09,,,,,95% CI,0.96,1.23,212,paternal,,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,686,2025-12-02T16:05:12.251790
26575635.0,adjusted RR of a male birth ,,1.1,,,,,95% CI,0.97,1.24,212,paternal,,,,Adjusted for log-transformed urinary creatinine (continuous),PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,687,2025-12-02T16:05:12.251790
26575635.0,adjusted RR of a male birth ,,1.11,,,,,95% CI,0.98,1.24,212,paternal,,,,"Adjusted for log-transformed urinary creatinine (continuous), research site (Michigan/Texas), age (continuous), annual household income (< $70,000/≥ $70,000), and maternal parity (nulliparous/parous)",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,688,2025-12-02T16:05:12.251790
27037776.0,Unadjusted associations between benzophenone-3 concentrations and percent fat mass among overall children aged 4 to 9 years,,-1.13,,,,,95% CI,-2.24,0.0,173,pediatric,,children,,Adjusted only for natural log creatinine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,689,2025-12-02T16:05:12.251790
27037776.0,Unadjusted associations between benzophenone-3 concentrations and percent fat mass among girls aged 4 to 9 years,,-1.77,,,,,95% CI,-3.36,-0.2,79,pediatric,,children,,Adjusted only for natural log creatinine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,690,2025-12-02T16:05:12.251790
27037776.0,Unadjusted associations between benzophenone-3 concentrations and percent fat mass among boys aged 4 to 9 years,,-0.53,,,,,95% CI,-2.05,1.0,94,pediatric,,children,,Adjusted only for natural log creatinine,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,691,2025-12-02T16:05:12.251790
27037776.0,Adjusted associations between benzophenone-3 concentrations and percent fat mass among overall children aged 4 to 9 years,,-0.83,,,,,95% CI,-1.95,0.29,173,pediatric,,children,,"Adjusted for natural log creatinine and urine collection date; maternal race/ethnicity, age, education, work status, smoking during pregnancy, height, pre-pregnancy body mass index, and adequacy of gestational weight gain; prenatal summed di-(2-ethylhexyl) phthalate metabolite concentrations; breastfeeding; months of age and physical activity at follow-up; and, for overall models, child’s sex.",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,692,2025-12-02T16:05:12.251790
27037776.0,Adjusted associations between benzophenone-3 concentrations and percent fat mass among girls aged 4 to 9 years,,-1.51,,,,,95% CI,-3.06,0.01,79,pediatric,,children,,"Adjusted for natural log creatinine and urine collection date; maternal race/ethnicity, age, education, work status, smoking during pregnancy, height, pre-pregnancy body mass index, and adequacy of gestational weight gain; prenatal summed di-(2-ethylhexyl) phthalate metabolite concentrations; breastfeeding; months of age and physical activity at follow-up; and, for overall models, child’s sex.",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,693,2025-12-02T16:05:12.251790
27037776.0,Adjusted associations between benzophenone-3 concentrations and percent fat mass among boys aged 4 to 9 years,,-0.2,,,,,95% CI,-1.69,1.26,94,pediatric,,children,,"Adjusted for natural log creatinine and urine collection date; maternal race/ethnicity, age, education, work status, smoking during pregnancy, height, pre-pregnancy body mass index, and adequacy of gestational weight gain; prenatal summed di-(2-ethylhexyl) phthalate metabolite concentrations; breastfeeding; months of age and physical activity at follow-up; and, for overall models, child’s sex.",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,694,2025-12-02T16:05:12.251790
29294443.0,gestational age,female infants,39,weeks,median,,,minmax,33.0,42.0,72,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,695,2025-12-02T16:05:12.251790
29294443.0,gestational age,male infants,40,weeks,median,,,minmax,32.0,42.0,85,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,696,2025-12-02T16:05:12.251790
29294443.0,weight,female infants,3246,g,median,,,minmax,1351.0,4385.0,72,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,697,2025-12-02T16:05:12.251790
29294443.0,weight,male infants,3494,g,median,,,minmax,1560.0,4916.0,85,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,698,2025-12-02T16:05:12.251790
29294443.0,length ,female infants,50,cm,median,,,minmax,42.0,57.0,72,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,699,2025-12-02T16:05:12.251790
29294443.0,length ,male infants,51,cm,median,,,minmax,39.0,56.0,85,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,700,2025-12-02T16:05:12.251790
29294443.0,head cir,female infants,34,cm,median,,,minmax,29.0,38.0,72,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,701,2025-12-02T16:05:12.251790
29294443.0,head cir,male infants,35,cm,median,,,minmax,28.0,38.0,85,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,702,2025-12-02T16:05:12.251790
29294443.0,abdominal cir,female infants,32,cm,median,,,minmax,22.0,38.0,72,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,703,2025-12-02T16:05:12.251790
29294443.0,abdominal cir,male infants,33,cm,median,,,minmax,26.0,38.0,85,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,704,2025-12-02T16:05:12.251790
29458359.0,adjusted associations between Oxybenzone and performance IQ of boys at 5 years,,0.066,,β,,,95% CI,-0.025,0.156,452,pediatric,,children,0.16,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,705,2025-12-02T16:05:12.251790
29458359.0,adjusted associations between Oxybenzone and verbal IQ of boys at 5 years,,0.006,,β,,,95% CI,-0.105,0.118,452,pediatric,,children,0.91,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,706,2025-12-02T16:05:12.251790
29458359.0,adjusted associations between Oxybenzone and performance IQ of boys at 5 years,,0.044,,β,,,95% CI,-0.049,0.138,419,pediatric,,children,0.35,complete case analysis,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,707,2025-12-02T16:05:12.251790
29458359.0,adjusted associations between Oxybenzone and verbal IQ of boys at 5 years,,-0.048,,β,,,95% CI,-0.164,0.068,419,pediatric,,children,0.42,complete case analysis,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,708,2025-12-02T16:05:12.251790
29477955.0,unadjusted associations between Oxybenzone concentration and birth weight,,117,,β,,,95% CI,43.0,192.0,184,paternal,preconception,,0.002,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,709,2025-12-02T16:05:12.251790
29477955.0,covariate-adjusted associations between Oxybenzone concentration and birth weight,,137,,β,,,95% CI,60.0,214.0,184,paternal,preconception,,0.0005,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,710,2025-12-02T16:05:12.251790
29477955.0,co-exposure-adjusted associations between Oxybenzone concentration and birth weight,,153,,β,,,95% CI,74.0,234.0,184,paternal,preconception,,0.0002,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,711,2025-12-02T16:05:12.251790
29477955.0,unadjusted associations between Oxybenzone concentration and birth weight,,29,,β,,,95% CI,-17.0,75.0,364,maternal,preconception,,0.22,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,712,2025-12-02T16:05:12.251790
29477955.0,covariate-adjusted associations between Oxybenzone concentration and birth weight,,27,,β,,,95% CI,-18.0,72.0,364,maternal,preconception,,0.23,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,713,2025-12-02T16:05:12.251790
29477955.0,co-exposure-adjusted associations between Oxybenzone concentration and birth weight,,4,,β,,,95% CI,-40.0,88.0,364,maternal,preconception,,0.46,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,714,2025-12-02T16:05:12.251790
29477955.0,unadjusted associations between Oxybenzone concentration and birth weight,,-21,,β,,,95% CI,-65.0,23.0,364,maternal,pregnancy,,0.35,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,715,2025-12-02T16:05:12.251790
29477955.0,covariate-adjusted associations between Oxybenzone concentration and birth weight,,-12,,β,,,95% CI,-54.0,31.0,364,maternal,pregnancy,,0.32,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,716,2025-12-02T16:05:12.251790
29477955.0,co-exposure-adjusted associations between Oxybenzone concentration and birth weight,,-53,,β,,,95% CI,-120.0,14.0,364,maternal,pregnancy,,0.12,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,717,2025-12-02T16:05:12.251790
29477955.0,unadjusted associations between Oxybenzone concentration and head circumference,,0.29,,β,,,95% CI,-0.22,0.8,184,paternal,preconception,,0.26,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,718,2025-12-02T16:05:12.251790
29477955.0,covariate-adjusted associations between Oxybenzone concentration and head circumference,,0.11,,β,,,95% CI,-0.36,0.76,184,paternal,preconception,,0.64,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,719,2025-12-02T16:05:12.251790
29477955.0,co-exposure-adjusted associations between Oxybenzone concentration and head circumference,,0.14,,β,,,95% CI,-0.37,0.66,184,paternal,preconception,,0.59,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,720,2025-12-02T16:05:12.251790
29477955.0,unadjusted associations between Oxybenzone concentration and head circumference,,0.06,,β,,,95% CI,-0.26,0.38,364,maternal,preconception,,0.72,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,721,2025-12-02T16:05:12.251790
29477955.0,covariate-adjusted associations between Oxybenzone concentration and head circumference,,0.04,,β,,,95% CI,-0.26,0.34,364,maternal,preconception,,0.79,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,722,2025-12-02T16:05:12.251790
29477955.0,co-exposure-adjusted associations between Oxybenzone concentration and head circumference,,-0.15,,β,,,95% CI,-0.65,0.34,364,maternal,preconception,,0.55,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,723,2025-12-02T16:05:12.251790
29477955.0,unadjusted associations between Oxybenzone concentration and head circumference,,0.08,,β,,,95% CI,-0.22,0.39,364,maternal,pregnancy,,0.73,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,724,2025-12-02T16:05:12.251790
29477955.0,covariate-adjusted associations between Oxybenzone concentration and head circumference,,0.08,,β,,,95% CI,-0.22,0.38,364,maternal,pregnancy,,0.6,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,725,2025-12-02T16:05:12.251790
29477955.0,co-exposure-adjusted associations between Oxybenzone concentration and head circumference,,0.01,,β,,,95% CI,-0.48,0.5,364,maternal,pregnancy,,0.97,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,726,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with asthma,has a doctor or nurse ever said your child has asthma?,0.95,,OR,,,95% CI,0.6,1.51,164,pediatric,,children,0.3,overall,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,727,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with asthma,has a doctor or nurse ever said your child has asthma?,0.74,,OR,,,95% CI,0.38,1.44,,pediatric,,children,0.3,girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,728,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with asthma,has a doctor or nurse ever said your child has asthma?,1.18,,OR,,,95% CI,0.61,2.27,,pediatric,,children,0.3,boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,729,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with asthma,"In the past 12 months, has your child visited the emergency room because of an asthma attack?",0.58,,OR,,,95% CI,0.27,1.25,164,pediatric,,children,0.9,overall,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,730,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with asthma,"In the past 12 months, has your child visited the emergency room because of an asthma attack?",0.59,,OR,,,95% CI,0.22,1.6,,pediatric,,children,0.9,girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,731,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with asthma,"In the past 12 months, has your child visited the emergency room because of an asthma attack?",0.53,,OR,,,95% CI,0.18,1.54,,pediatric,,children,0.9,boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,732,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with wheeze,has your child ever had wheezing or whistling in the chest at any time in the past,0.88,,OR,,,95% CI,0.59,1.32,164,pediatric,,children,0.5,overall,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,733,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with wheeze,has your child ever had wheezing or whistling in the chest at any time in the past,0.76,,OR,,,95% CI,0.44,1.31,,pediatric,,children,0.5,girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,734,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with wheeze,has your child ever had wheezing or whistling in the chest at any time in the past,1.01,,OR,,,95% CI,0.55,1.87,,pediatric,,children,0.5,boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,735,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with wheeze,Has your child ever had wheezing or whistling in the chest at any time in the past 12 months?,0.65,,OR,,,95% CI,0.44,0.96,164,pediatric,,children,0.3,overall,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,736,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with wheeze,Has your child ever had wheezing or whistling in the chest at any time in the past 12 months?,0.52,,OR,,,95% CI,0.28,0.97,,pediatric,,children,0.3,girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,737,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with wheeze,Has your child ever had wheezing or whistling in the chest at any time in the past 12 months?,0.82,,OR,,,95% CI,0.48,1.4,,pediatric,,children,0.3,boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,738,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with atopic skin condition,"In the past 12 months, has your child had rashes, eczema or hives?",1.2,,OR,,,95% CI,0.85,1.7,164,pediatric,,children,0.8,overall,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,739,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with atopic skin condition,"In the past 12 months, has your child had rashes, eczema or hives?",1.17,,OR,,,95% CI,0.75,1.83,,pediatric,,children,0.8,girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,740,2025-12-02T16:05:12.251790
29550712.0,association of prenatal Oxybenzone concentration with atopic skin condition,"In the past 12 months, has your child had rashes, eczema or hives?",1.25,,OR,,,95% CI,0.76,2.06,,pediatric,,children,0.8,boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,741,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average Oxybenzone concentrations during pregnancy (specific gravity corrected) and neonatal TSH levels,,-2.13,,β,,,95% CI,-4.12,-0.1,451,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,742,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average Oxybenzone concentrations during pregnancy (specific gravity corrected) and neonatal TSH levels,"adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline",-2.01,,β,,,95% CI,-4.04,0.04,451,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,744,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average Oxybenzone concentrations during pregnancy (specific gravity corrected) and neonatal TSH levels,"Adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline, monocarboxyisononyl phthalate, the sum of di(2-ethylhexyl) phthalate metabolites, mono(3-carboxypropyl) phthalate, monocarboxyisooctyl phthalate, and triclosan ",-1.82,,β,,,95% CI,-4.06,0.48,451,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,746,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average Oxybenzone concentrations during pregnancy (specific gravity corrected) and neonatal TSH levels,"Adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline, monocarboxyisononyl phthalate, the sum of di(2-ethylhexyl) phthalate metabolites, mono(3-carboxypropyl) phthalate, monocarboxyisooctyl phthalate, and triclosan ",0.1273,,R-squared,,,,,,451,pediatric,,neonates,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,747,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal free thyroid hormone levels ,,-0.006,,β,,,95% CI,-0.014,0.003,314-316,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,748,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal free thyroid hormone levels ,,0.0056,,R-squared,,,,,,314-316,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,749,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal free thyroid hormone levels ,"adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline",-0.004,,β,,,95% CI,-0.013,0.004,314-316,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,750,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal free thyroid hormone levels ,"adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline",0.0775,,R-squared,,,,,,314-316,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,751,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal free thyroid hormone levels ,"Adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline, monocarboxyisononyl phthalate, the sum of di(2-ethylhexyl) phthalate metabolites, mono(3-carboxypropyl) phthalate, monocarboxyisooctyl phthalate, and triclosan ",-0.003,,β,,,95% CI,-0.012,0.005,272,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,752,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal free thyroid hormone levels ,"Adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline, monocarboxyisononyl phthalate, the sum of di(2-ethylhexyl) phthalate metabolites, mono(3-carboxypropyl) phthalate, monocarboxyisooctyl phthalate, and triclosan ",0.1679,,R-squared,,,,,,272,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,753,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal total thyroid hormone levels ,,-0.76,,β,,,95% CI,-2.7,1.23,317-319,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,754,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal total thyroid hormone levels ,,0.0018,,R-squared,,,,,,317-319,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,755,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal total thyroid hormone levels ,"adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline",-1.19,,β,,,95% CI,-3.12,0.77,317-319,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,756,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal total thyroid hormone levels ,"adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline",0.0639,,R-squared,,,,,,317-319,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,757,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal total thyroid hormone levels ,"Adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline, monocarboxyisononyl phthalate, the sum of di(2-ethylhexyl) phthalate metabolites, mono(3-carboxypropyl) phthalate, monocarboxyisooctyl phthalate, and triclosan ",0.13,,β,,,95% CI,-2.17,2.49,242-244,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,758,2025-12-02T16:05:12.251790
29803919.0,Associations of each two-fold increase in average urinary Oxybenzone concentrations during pregnancy (specific gravity corrected) with maternal total thyroid hormone levels ,"Adjusted for maternal age, maternal education, maternal country of birth, poverty index at baseline, monocarboxyisononyl phthalate, the sum of di(2-ethylhexyl) phthalate metabolites, mono(3-carboxypropyl) phthalate, monocarboxyisooctyl phthalate, and triclosan ",0.0997,,R-squared,,,,,,242-244,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,759,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in gestational age in relation to average exposure biomarker concentration across three time points during pregnancy ,change in days,1.9,,,,,95% CI,0.54,3.26,749,pediatric,,neonates,0.006,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,760,2025-12-02T16:05:12.251790
30412856.0,odds ratios of preterm birth in relation to average exposure biomarker concentration across three time points during pregnancy ,,0.54,,,,,95% CI,0.36,0.83,749,pediatric,,neonates,0.01,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,761,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in gestational age in relation to average exposure biomarker concentration ,visit 1,1.56,,,,,95% CI,0.18,2.93,611,pediatric,,neonates,0.03,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,762,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in gestational age in relation to average exposure biomarker concentration ,visit 2,1.44,,,,,95% CI,0.05,2.83,623,pediatric,,neonates,0.04,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,763,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in gestational age in relation to average exposure biomarker concentration ,visit 3,1.63,,,,,95% CI,0.15,3.12,470,pediatric,,neonates,0.03,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,764,2025-12-02T16:05:12.251790
30412856.0,odds ratios of preterm birth in relation to average exposure biomarker concentration ,visit 1,0.64,,,,,95% CI,0.42,0.98,611,pediatric,,neonates,0.04,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,765,2025-12-02T16:05:12.251790
30412856.0,odds ratios of preterm birth in relation to average exposure biomarker concentration ,visit 2,0.66,,,,,95% CI,0.43,1.02,623,pediatric,,neonates,0.06,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,766,2025-12-02T16:05:12.251790
30412856.0,odds ratios of preterm birth in relation to average exposure biomarker concentration ,visit 3,0.67,,,,,95% CI,0.41,1.07,470,pediatric,,neonates,0.1,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,767,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in birth weight z-scores associated with average exposure biomarker concentration across three time points during pregnancy ,change in z-score,0.08,,,,,95% CI,-0.04,0.2,737,pediatric,,neonates,0.17,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,768,2025-12-02T16:05:12.251790
30412856.0,odds ratios of small for GA in relation to average exposure biomarker concentration across three time points during pregnancy ,,0.91,,,,,95% CI,0.62,1.33,663,pediatric,,neonates,0.63,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,769,2025-12-02T16:05:12.251790
30412856.0,odds ratios of large  for GA in relation to average exposure biomarker concentration across three time points during pregnancy ,,1.38,,,,,95% CI,0.99,1.93,668,pediatric,,neonates,0.06,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,770,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in birth weight z-scores in relation to exposure biomarker concentration ,visit 1,0.06,,,,,95% CI,-0.06,0.18,601,pediatric,,neonates,0.31,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,771,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in birth weight z-scores in relation to exposure biomarker concentration ,visit 2,0.1,,,,,95% CI,-0.02,0.22,612,pediatric,,neonates,0.12,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,772,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in birth weight z-scores in relation to exposure biomarker concentration ,visit 3,0.06,,,,,95% CI,-0.07,0.2,462,pediatric,,neonates,0.35,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,773,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in small to GA odds in relation to exposure biomarker concentration ,visit 1,1.07,,,,,95% CI,0.74,1.55,528,pediatric,,neonates,0.7,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,774,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in small to GA odds in relation to exposure biomarker concentration ,visit 2,0.99,,,,,95% CI,0.67,1.49,547,pediatric,,neonates,0.98,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,775,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in small to GA odds in relation to exposure biomarker concentration ,visit 3,0.69,,,,,95% CI,0.44,1.08,431,pediatric,,neonates,0.11,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,776,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in large to GA odds in relation to exposure biomarker concentration ,visit 1,1.34,,,,,95% CI,0.96,1.89,533,pediatric,,neonates,0.09,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,777,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in large to GA odds in relation to exposure biomarker concentration ,visit 2,1.52,,,,,95% CI,1.09,2.13,555,pediatric,,neonates,0.01,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,778,2025-12-02T16:05:12.251790
30412856.0,Adjusted change in large to GA odds in relation to exposure biomarker concentration ,visit 3,1,,,,,95% CI,0.67,1.51,430,pediatric,,neonates,0.98,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,779,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in girls associated with a 2-fold increase in prenatal Oxybenzone concentrations. ,Thelarche,-0.1,months,mean shift,,,95% CI,-0.7,0.6,172-177,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,780,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in girls associated with a 2-fold increase in prenatal Oxybenzone concentrations. ,Pubarche,0.3,months,mean shift,,,95% CI,-0.4,1.0,172-177,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,781,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in girls associated with a 2-fold increase in prenatal Oxybenzone concentrations. ,Menarche,-0.3,months,mean shift,,,95% CI,-0.8,0.2,172-177,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,782,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in girls associated with a 2-fold increase in peripubertal Oxybenzone concentrations. ,Thelarche,-0.3,months,mean shift,,,95% CI,-1.3,0.7,155-157,pediatric,,peripubertal,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,783,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in girls associated with a 2-fold increase in peripubertal Oxybenzone concentrations. ,Pubarche,-0.5,months,mean shift,,,95% CI,-1.4,0.4,155-157,pediatric,,peripubertal,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,784,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in girls associated with a 2-fold increase in peripubertal Oxybenzone concentrations. ,Menarche,-0.6,months,mean shift,,,95% CI,-1.4,0.2,155-157,pediatric,,peripubertal,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,785,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in boys associated with a 2-fold increase in prenatal Oxybenzone concentrations. ,Gonadarche,0.5,months,mean shift,,,95% CI,-0.4,1.5,155-158,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,786,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in boys associated with a 2-fold increase in prenatal Oxybenzone concentrations. ,Pubarche,0.3,months,mean shift,,,95% CI,-0.5,1.1,155-159,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,787,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in boys associated with a 2-fold increase in peripubertal Oxybenzone concentrations. ,Gonadarche,-0.7,months,mean shift,,,95% CI,-1.8,0.4,139-140,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,788,2025-12-02T16:05:12.251790
30517665.0,Adjusted mean shift (95% confidence intervals) in age at pubertal milestones in boys associated with a 2-fold increase in peripubertal Oxybenzone concentrations. ,Pubarche,-0.3,months,mean shift,,,95% CI,-1.2,0.7,139-140,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,789,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth weight,1st trimester,-7.79,,,,,95% CI,-19.23,3.66,847,pediatric,,newborn,0.87,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,790,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth weight,2nd trimester,-4.98,,,,,95% CI,-16.86,-6.91,847,pediatric,,newborn,0.87,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,791,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth weight,3rd trimester,-9.48,,,,,95% CI,-21.48,2.52,847,pediatric,,newborn,0.87,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,792,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth weight,1st trimester,-8.77,,,,,95% CI,-25.45,7.91,445,pediatric,,newborn,0.86,Boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,793,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth weight,2nd trimester,-5.92,,,,,95% CI,-22.52,10.68,445,pediatric,,newborn,0.86,Boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,794,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth weight,3rd trimester,-2.18,,,,,95% CI,-18.64,14.28,445,pediatric,,newborn,0.86,Boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,795,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth weight,1st trimester,-7.37,,,,,95% CI,-23.06,8.33,402,pediatric,,newborn,0.52,Girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,796,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth weight,2nd trimester,-4.84,,,,,95% CI,-21.86,12.18,402,pediatric,,newborn,0.52,Girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,797,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth weight,3rd trimester,-19.75,,,,,95% CI,-37.31,-2.19,402,pediatric,,newborn,0.52,Girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,798,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth length,1st trimester,-0.03,,,,,95% CI,-0.08,0.01,847,pediatric,,newborn,0.93,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,799,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth length,2nd trimester,-0.02,,,,,95% CI,-0.06,0.02,847,pediatric,,newborn,0.93,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,800,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth length,3rd trimester,-0.03,,,,,95% CI,-0.08,0.01,847,pediatric,,newborn,0.93,All,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,801,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth length,1st trimester,-0.05,,,,,95% CI,-0.11,0.01,445,pediatric,,newborn,0.29,Boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,802,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth length,2nd trimester,-0.01,,,,,95% CI,-0.07,0.05,445,pediatric,,newborn,0.29,Boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,803,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth length,3rd trimester,0.02,,,,,95% CI,-0.05,-0.08,445,pediatric,,newborn,0.29,Boys,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,804,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth length,1st trimester,-0.02,,,,,95% CI,-0.07,0.04,402,pediatric,,newborn,0.5,Girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,805,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth length,2nd trimester,-0.03,,,,,95% CI,-0.09,0.03,402,pediatric,,newborn,0.5,Girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,806,2025-12-02T16:05:12.251790
30557721.0,regression coefficient for associations of ln-transformed SG-adjusted concentration of Oxybenzone with birth length,3rd trimester,-0.08,,,,,95% CI,-0.15,-0.02,402,pediatric,,newborn,0.5,Girls,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,807,2025-12-02T16:05:12.251790
30624098.0,Associations of phenol and phthalate metabolite concentrations with birth weight ,penalized effect estimates,2.52,,,,,95% CI,,,473,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,808,2025-12-02T16:05:12.251790
30624098.0,"Associations of phenol and phthalate metabolite concentrations with placental weight, and placental–to–birth weight ratio (PFR ",penalized effect estimates,0.65,,,,,95% CI,,,473,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,809,2025-12-02T16:05:12.251790
30624098.0,Associations of phenol and phthalate metabolite concentrations with placental–to–birth weight ratio (PFR ,penalized effect estimates,0,,,,,95% CI,,,473,pediatric,,newborn,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,810,2025-12-02T16:05:12.251790
30624098.0,Associations of phenol and phthalate metabolite concentrations with birth weight ,unpenalized effect estimates,21,,,,,95% CI,-3.45,45.5,473,pediatric,,newborn,0.09,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,811,2025-12-02T16:05:12.251790
30624098.0,"Associations of phenol and phthalate metabolite concentrations with placental weight, and placental–to–birth weight ratio (PFR ",unpenalized effect estimates,4.76,,,,,95% CI,-1.77,11.3,473,pediatric,,newborn,0.15,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,812,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Total oocyte yield,10.8,,mean,,,95% CI,9.8,11.9,304,maternal,pregnancy,,0.16,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,813,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Total oocyte yield,11.7,,mean,,,95% CI,10.6,12.9,304,maternal,pregnancy,,0.16,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,814,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Total oocyte yield,12.8,,mean,,,95% CI,11.5,14.2,304,maternal,pregnancy,,0.16,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,815,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Total oocyte yield,12.3,,mean,,,95% CI,11.0,13.8,304,maternal,pregnancy,,0.16,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,816,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Mil oocyte yield,9.5,,mean,,,95% CI,8.6,10.6,304,maternal,pregnancy,,0.3,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,817,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Mil oocyte yield,9,,mean,,,95% CI,8.2,10.0,304,maternal,pregnancy,,0.3,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,818,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Mil oocyte yield,9.6,,mean,,,95% CI,8.7,10.5,304,maternal,pregnancy,,0.3,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,819,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Mil oocyte yield,10.2,,mean,,,95% CI,9.2,11.2,304,maternal,pregnancy,,0.3,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,820,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Fertilizat ion,0.71,,mean,,,95% CI,0.67,0.76,304,maternal,pregnancy,,0.94,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,821,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Fertilizat ion,0.7,,mean,,,95% CI,0.65,0.74,304,maternal,pregnancy,,0.94,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,822,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Fertilizat ion,0.7,,mean,,,95% CI,0.66,0.75,304,maternal,pregnancy,,0.94,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,823,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Fertilizat ion,0.71,,mean,,,95% CI,0.66,0.75,304,maternal,pregnancy,,0.94,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,824,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Implantat ion,0.44,,mean,,,95% CI,0.29,0.47,304,maternal,pregnancy,,0.05,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,825,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Implantat ion,0.58,,mean,,,95% CI,0.39,0.57,304,maternal,pregnancy,,0.05,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,826,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Implantat ion,0.6,,mean,,,95% CI,0.44,0.63,304,maternal,pregnancy,,0.05,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,827,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Implantat ion,0.57,,mean,,,95% CI,0.44,0.62,304,maternal,pregnancy,,0.05,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,828,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Clinical pregnancy,0.37,,mean,,,95% CI,0.3,0.48,304,maternal,pregnancy,,0.01,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,829,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Clinical pregnancy,0.48,,mean,,,95% CI,0.37,0.56,304,maternal,pregnancy,,0.01,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,830,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Clinical pregnancy,0.53,,mean,,,95% CI,0.43,0.62,304,maternal,pregnancy,,0.01,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,831,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Clinical pregnancy,0.53,,mean,,,95% CI,0.44,0.62,304,maternal,pregnancy,,0.01,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,832,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,live birth,0.27,,mean,,,95% CI,0.19,0.36,304,maternal,pregnancy,,0.01,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,833,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,live birth,0.4,,mean,,,95% CI,0.31,0.5,304,maternal,pregnancy,,0.01,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,834,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,live birth,0.44,,mean,,,95% CI,0.35,0.54,304,maternal,pregnancy,,0.01,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,835,2025-12-02T16:05:12.251790
31077917.0,crude early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,live birth,0.43,,mean,,,95% CI,0.34,0.52,304,maternal,pregnancy,,0.01,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,836,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Total oocyte yield,11,,mean,,,95% CI,10.0,12.1,304,maternal,pregnancy,,0.3,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,837,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Total oocyte yield,11.1,,mean,,,95% CI,10.2,12.1,304,maternal,pregnancy,,0.3,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,838,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Total oocyte yield,12.3,,mean,,,95% CI,11.3,13.4,304,maternal,pregnancy,,0.3,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,839,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Total oocyte yield,11.4,,mean,,,95% CI,10.4,12.5,304,maternal,pregnancy,,0.3,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,840,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Mil oocyte yield,9.2,,mean,,,95% CI,8.3,10.1,304,maternal,pregnancy,,0.53,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,841,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Mil oocyte yield,9.4,,mean,,,95% CI,8.6,10.3,304,maternal,pregnancy,,0.53,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,842,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Mil oocyte yield,10.1,,mean,,,95% CI,9.2,11.1,304,maternal,pregnancy,,0.53,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,843,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Mil oocyte yield,9.4,,mean,,,95% CI,8.5,10.3,304,maternal,pregnancy,,0.53,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,844,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Fertilizat ion,0.71,,mean,,,95% CI,0.67,0.76,304,maternal,pregnancy,,0.95,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,845,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Fertilizat ion,0.7,,mean,,,95% CI,0.65,0.74,304,maternal,pregnancy,,0.95,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,846,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Fertilizat ion,0.7,,mean,,,95% CI,0.66,0.76,304,maternal,pregnancy,,0.95,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,847,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Fertilizat ion,0.71,,mean,,,95% CI,0.67,0.76,304,maternal,pregnancy,,0.95,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,848,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Implantat ion,0.44,,mean,,,95% CI,0.35,0.54,304,maternal,pregnancy,,0.06,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,849,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Implantat ion,0.57,,mean,,,95% CI,0.48,0.67,304,maternal,pregnancy,,0.06,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,850,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Implantat ion,0.61,,mean,,,95% CI,0.52,0.7,304,maternal,pregnancy,,0.06,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,851,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Implantat ion,0.58,,mean,,,95% CI,0.47,0.6,304,maternal,pregnancy,,0.06,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,852,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Clinical pregnancy,0.38,,mean,,,95% CI,0.3,0.48,304,maternal,pregnancy,,0.02,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,853,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Clinical pregnancy,0.46,,mean,,,95% CI,0.37,0.56,304,maternal,pregnancy,,0.02,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,854,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Clinical pregnancy,0.53,,mean,,,95% CI,0.43,0.62,304,maternal,pregnancy,,0.02,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,855,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,Clinical pregnancy,0.53,,mean,,,95% CI,0.44,0.62,304,maternal,pregnancy,,0.02,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,856,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,live birth,0.27,,mean,,,95% CI,0.2,0.37,304,maternal,pregnancy,,0.02,Q1,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,857,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,live birth,0.37,,mean,,,95% CI,0.29,0.47,304,maternal,pregnancy,,0.02,Q2,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,858,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,live birth,0.44,,mean,,,95% CI,0.34,0.53,304,maternal,pregnancy,,0.02,Q3,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,859,2025-12-02T16:05:12.251790
31077917.0,adjusted early developmental and pregnancy outcomes by quartiles of urinary Oxybenzone concentration,live birth,0.42,,mean,,,95% CI,0.33,0.52,304,maternal,pregnancy,,0.02,Q4,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,860,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and maternal age,<25 years,-0.11,,,,,95% CI,-0.25,0.03,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,861,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and maternal age,25-29 years,0.01,,,,,95% CI,-0.09,0.11,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,862,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and maternal age,>30 years,ref,,,,,95% CI,,,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,863,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and prepregnancy BMI,Under weight,-0.06,,,,,95% CI,-0.2,0.09,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,864,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and prepregnancy BMI,normal,-0.05,,,,,95% CI,-0.18,0.06,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,865,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and prepregnancy BMI,overweight,ref,,,,,95% CI,,,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,866,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and education,less than college,0.02,,,,,95% CI,-0.06,0.11,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,867,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and education,college or higher,ref,,,,,95% CI,,,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,868,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and employment,employed,0.08,,,,,95% CI,0.0,0.16,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,869,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and employment,unemployed,ref,,,,,95% CI,,,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,870,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and passive smoking during pregnancy,no,0.03,,,,,95% CI,-0.06,0.11,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,871,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and passive smoking during pregnancy,yes,ref,,,,,95% CI,,,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,872,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and household yearly income,100000 or less,-0.13,,,,,95% CI,-0.22,-0.05,941,maternal,pregnancy,,<0.05,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,873,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and household yearly income,more than 100000,ref,,,,,95% CI,,,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,874,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and home refurbishment,no,-0.16,,,,,95% CI,-0.25,-0.08,941,maternal,pregnancy,,<0.05,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,875,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and home refurbishment,yes,ref,,,,,95% CI,,,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,876,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and sampling season,spring,0.03,,,,,95% CI,-0.03,0.09,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,877,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and sampling season,summer,0.3,,,,,95% CI,0.23,0.36,941,maternal,pregnancy,,<0.05,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,878,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and sampling season,fall,0.16,,,,,95% CI,0.09,0.22,941,maternal,pregnancy,,<0.05,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,879,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and sampling season,winter,ref,,,,,95% CI,,,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,880,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and physical activity,none,0.05,,,,,95% CI,-0.38,0.47,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,881,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and physical activity,normal,0.07,,,,,95% CI,-0.26,0.4,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,882,2025-12-02T16:05:12.251790
31081626.0,association between SG-adjusted urinary Oxybenzone concentration and physical activity,everyday,ref,,,,,95% CI,,,941,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,883,2025-12-02T16:05:12.251790
31288179.0,Adjusted percent change in urinary 8-OHdG in association with an interquartile range difference in urinary Oxybenzone concentration.,,10,,,,,95% CI,5.46,14.8,481,maternal,pregnancy,,<0.01,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,884,2025-12-02T16:05:12.251790
31288179.0,Adjusted percent change in urinary 8-isoprostane in association with an interquartile range difference in urinary Oxybenzone concentration.,,9,,,,,95% CI,1.39,17.2,481,maternal,pregnancy,,0.02,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,885,2025-12-02T16:05:12.251790
31288179.0,Adjusted percent change in urinary 8-OHdG in association with an interquartile range difference in urinary Oxybenzone concentration.,visit 2,7.38,,,,,95% CI,-0.59,16.0,481,maternal,pregnancy,,0.07,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,886,2025-12-02T16:05:12.251790
31288179.0,Adjusted percent change in urinary 8-OHdG in association with an interquartile range difference in urinary Oxybenzone concentration.,visit 3,7.56,,,,,95% CI,-1.1,17.0,481,maternal,pregnancy,,0.09,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,887,2025-12-02T16:05:12.251790
31288179.0,Adjusted percent change in urinary 8-isoprostane in association with an interquartile range difference in urinary Oxybenzone concentration.,visit 2,13.3,,,,,95% CI,-4.44,34.3,481,maternal,pregnancy,,0.15,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,888,2025-12-02T16:05:12.251790
31288179.0,Adjusted percent change in urinary 8-isoprostane in association with an interquartile range difference in urinary Oxybenzone concentration.,visit 4,-16.1,,,,,95% CI,-27.2,-3.31,481,maternal,pregnancy,,0.02,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,889,2025-12-02T16:05:12.251790
32120140.0,RR for preterm birth per natural log-unit increase in maternal urinary Oxybenzone concentration,unadjusted,0.91,,,,,95% CI,0.7,1.19,417,maternal,pregnancy,,0.5,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,890,2025-12-02T16:05:12.251790
32120140.0,RR for preterm birth per natural log-unit increase in maternal urinary Oxybenzone concentration,adjusted for covariates,0.91,,,,,95% CI,0.68,1.22,417,maternal,pregnancy,,0.53,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,891,2025-12-02T16:05:12.251790
32120140.0,RR for preterm birth per natural log-unit increase in maternal urinary Oxybenzone concentration,adjusted for covariateds + prenantal biomarker exposure,0.93,,,,,95% CI,0.63,1.39,417,maternal,pregnancy,,0.74,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,892,2025-12-02T16:05:12.251790
32120140.0,RR for preterm birth per natural log-unit increase in maternal urinary Oxybenzone concentration,covariateds + prenantal preconception biomarker exposure,1.55,,,,,95% CI,0.89,2.7,417,maternal,pregnancy,,0.12,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,893,2025-12-02T16:05:12.251790
32120140.0,RR for preterm birth per natural log-unit increase in paternal urinary Oxybenzone concentration,unadjusted,1.01,,,,,95% CI,0.58,1.73,229,paternal,,,0.98,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,894,2025-12-02T16:05:12.251790
32120140.0,RR for preterm birth per natural log-unit increase in paternal urinary Oxybenzone concentration,adjusted for covariates,0.02,,,,,95% CI,0.53,1.99,229,paternal,,,0.95,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,895,2025-12-02T16:05:12.251790
32120140.0,RR for preterm birth per natural log-unit increase in paternal urinary Oxybenzone concentration,adjusted for covariateds + prenantal biomarker exposure,0.92,,,,,95% CI,0.44,1.94,229,paternal,,,0.83,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,896,2025-12-02T16:05:12.251790
32120140.0,RR for preterm birth per natural log-unit increase in paternal urinary Oxybenzone concentration,covariateds + prenantal preconception biomarker exposure,0.81,,,,,95% CI,0.39,1.69,229,paternal,,,0.58,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,897,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,specific gravity,0.03,,,,,95% CI,0.02,0.04,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,898,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,date of sampling,-0.04,,,,,95% CI,-0.18,0.1,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,899,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,sampling in spring,0.07,,,,,95% CI,-0.04,0.18,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,901,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,sampling in summer ,0.27,,,,,95% CI,0.14,0.4,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,902,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,sampling in autumn ,-0.09,,,,,95% CI,-0.21,0.04,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,903,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,defreeze time short,ref,,,,,95% CI,,,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,904,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,defreeze time long,0.17,,,,,95% CI,0.07,0.27,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,906,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,transport time,0.05,,,,,95% CI,-0.01,0.11,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,907,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,number of samples,-0.04,,,,,95% CI,-0.07,0.0,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,908,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,2nd trimester,ref,,,,,95% CI,,,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,909,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,3rd trimester,-0.18,,,,,95% CI,-0.26,-0.1,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,910,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,first child,ref,,,,,95% CI,,,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,911,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,second or more,-0.49,,,,,95% CI,-0.69,-0.28,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,912,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,maternal age,0.01,,,,,95% CI,-0.13,0.14,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,913,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,pre-pregnancy BMI,0.01,,,,,95% CI,-0.02,0.04,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,914,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,education high school + 5y,ref,,,,,95% CI,,,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,915,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,education high school + 1 to 4 y,-0.16,,,,,95% CI,-0.37,0.05,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,916,2025-12-02T16:05:12.251790
32248023.0,adjusted associations between subject and sampling characteristics and the box cox-transformed Oxybenzone urinary concentration,education high school or less,-0.02,,,,,95% CI,-0.45,0.41,477,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,917,2025-12-02T16:05:12.251790
32279061.0,Adjusted percent change (β) in the Oxybenzone urinary concentrations in relation to the total number of PCP applications in the last 0 to 6 hours ,,-23.4,,,,,95% CI,-42.6,2.2,8,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,918,2025-12-02T16:05:12.251790
32279061.0,Adjusted percent change (β) in the Oxybenzone urinary concentrations in relation to the total number of PCP applications in the last 6 to 12 hours ,,-16.5,,,,,95% CI,-37.0,10.7,8,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,919,2025-12-02T16:05:12.251790
32279061.0,Adjusted percent change (β) in the Oxybenzone urinary concentrations in relation to the total number of PCP applications in the last 12 to 24 hours ,,7,,,,,95% CI,-14.2,33.4,8,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,920,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q1 (<LOD to 58.7),114,mg/dl,mean,,,95% CI,106.4,122.1,178,maternal,preconception,,0.38,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,921,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q2 (58.7 to 153.3),113.9,mg/dl,mean,,,95% CI,106.4,121.9,178,maternal,preconception,,0.38,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,922,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q3 (153.8 to 494.5),1125,mg/dl,mean,,,95% CI,105.1,120.4,178,maternal,preconception,,0.38,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,923,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q4 (498.9 to 8313.8),109.5,mg/dl,mean,,,95% CI,102.2,117.3,178,maternal,preconception,,0.38,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,924,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q1 (<LOD to 58.7),111.9,mg/dl,mean,,,95% CI,103.0,121.6,178,maternal,preconception,,0.29,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,925,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q2 (58.7 to 153.3),113.7,mg/dl,mean,,,95% CI,103.5,124.9,178,maternal,preconception,,0.29,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,926,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q3 (153.8 to 494.5),107.1,mg/dl,mean,,,95% CI,97.2,118.0,178,maternal,preconception,,0.29,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,927,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q4 (498.9 to 8313.8),108,mg/dl,mean,,,95% CI,98.0,118.9,178,maternal,preconception,,0.29,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,928,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q1 (<LOD to 35.2),116.4,mg/dl,mean,,,95% CI,108.9,124.3,194,maternal,1st trimester,,0.06,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,929,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q2 (39 to 124),112.9,mg/dl,mean,,,95% CI,105.8,120.5,194,maternal,1st trimester,,0.06,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,930,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q3 (125.3 to 500.3),121.3,mg/dl,mean,,,95% CI,113.7,129.5,194,maternal,1st trimester,,0.06,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,931,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q4 (502.6 to 7888),104,mg/dl,mean,,,95% CI,97.4,111.1,194,maternal,1st trimester,,0.06,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,932,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q1 (<LOD to 35.2),114.6,mg/dl,mean,,,95% CI,105.8,124.2,194,maternal,1st trimester,,0.07,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,933,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q2 (39 to 124),111.9,mg/dl,mean,,,95% CI,102.6,121.9,194,maternal,1st trimester,,0.07,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,934,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q3 (125.3 to 500.3),118.9,mg/dl,mean,,,95% CI,109.1,129.4,194,maternal,1st trimester,,0.07,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,935,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q4 (502.6 to 7888),103.4,mg/dl,mean,,,95% CI,95.0,112.5,194,maternal,1st trimester,,0.07,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,936,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q1 (<LOD to 36.3),115.8,mg/dl,mean,,,95% CI,108.2,123.9,179,maternal,2nd trimester,,0.7,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,937,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q2 (40.1 to 167.5),107.2,mg/dl,mean,,,95% CI,100.2,114.7,179,maternal,2nd trimester,,0.7,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,938,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q3 (170.7 to 811.8),107.7,mg/dl,mean,,,95% CI,100.7,115.2,179,maternal,2nd trimester,,0.7,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,939,2025-12-02T16:05:12.251790
32345324.0,Unadjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q4 (855.2 to 17383.1),113,mg/dl,mean,,,95% CI,105.5,120.9,179,maternal,2nd trimester,,0.7,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,940,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q1 (<LOD to 36.3),110,mg/dl,mean,,,95% CI,100.9,119.9,179,maternal,2nd trimester,,0.28,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,941,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q2 (40.1 to 167.5),105.3,mg/dl,mean,,,95% CI,96.2,115.2,179,maternal,2nd trimester,,0.28,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,942,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q3 (170.7 to 811.8),103.2,mg/dl,mean,,,95% CI,94.4,112.8,179,maternal,2nd trimester,,0.28,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,943,2025-12-02T16:05:12.251790
32345324.0,Adjusted Population means of blood glucose level in mg/dL (95% CI) across quartiles of SG-adjusted BP-3 concentrations,Q4 (855.2 to 17383.1),104.9,mg/dl,mean,,,95% CI,95.7,114.9,179,maternal,2nd trimester,,0.28,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,944,2025-12-02T16:05:12.251790
32653713.0,OR for behavioral problems and prenatal and childhood exposure to BP-3,emotional symptoms,0.77,,,,,95% CI,0.37,1.61,386,maternal,pregnancy,0.493,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,945,2025-12-02T16:05:12.251790
32653713.0,OR for behavioral problems and prenatal and childhood exposure to BP-3,conduct problems,1.34,,,,,95% CI,0.74,2.42,386,maternal,pregnancy,0.327,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,946,2025-12-02T16:05:12.251790
32653713.0,OR for behavioral problems and prenatal and childhood exposure to BP-3,Hyperactivity/inattention,0.86,,,,,95% CI,0.57,1.3,386,maternal,pregnancy,0.472,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,947,2025-12-02T16:05:12.251790
32653713.0,OR for behavioral problems and prenatal and childhood exposure to BP-3,Peer problems,0.93,,,,,95% CI,0.68,1.27,386,maternal,pregnancy,0.644,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,948,2025-12-02T16:05:12.251790
32653713.0,OR for behavioral problems and prenatal and childhood exposure to BP-3,Prosocial behaivor,1.58,,,,,95% CI,1.04,2.39,386,maternal,pregnancy,0.032,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,949,2025-12-02T16:05:12.251790
32653713.0,OR for behavioral problems and prenatal and childhood exposure to BP-3,total difficulties,1.21,,,,,95% CI,0.7,2.09,386,maternal,pregnancy,0.485,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,950,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of total cholesterol by groups of urinary BP-3 concentration,tertile 1,234,mg/dl,mean,,,95% CI,220.0,248.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,951,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of total cholesterol by groups of urinary BP-3 concentration,tertile 2,228,mg/dl,mean,,,95% CI,214.0,241.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,952,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of total cholesterol by groups of urinary BP-3 concentration,tertile 3,237,mg/dl,mean,,,95% CI,224.0,251.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,953,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of HDL cholesterolby groups of urinary BP-3 concentration,tertile 1,67.9,mg/dl,mean,,,95% CI,63.6,72.3,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,954,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of HDL cholesterolby groups of urinary BP-3 concentration,tertile 2,70.9,mg/dl,mean,,,95% CI,66.7,75.1,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,955,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of HDL cholesterolby groups of urinary BP-3 concentration,tertile 3,72,mg/dl,mean,,,95% CI,67.6,76.3,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,956,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of Non-HDL cholesterolby groups of urinary BP-3 concentration,tertile 1,166,mg/dl,mean,,,95% CI,153.0,179.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,957,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of Non-HDL cholesterolby groups of urinary BP-3 concentration,tertile 2,157,mg/dl,mean,,,95% CI,144.0,169.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,958,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of Non-HDL cholesterolby groups of urinary BP-3 concentration,tertile 3,166,mg/dl,mean,,,95% CI,153.0,179.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,959,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of LDL cholesteroll by groups of urinary BP-3 concentration,tertile 1,125,mg/dl,mean,,,95% CI,113.0,136.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,960,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of LDL cholesteroll by groups of urinary BP-3 concentration,tertile 2,119,mg/dl,mean,,,95% CI,107.0,130.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,961,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of LDL cholesteroll by groups of urinary BP-3 concentration,tertile 3,128,mg/dl,mean,,,95% CI,116.0,139.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,962,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of Triglycerides by groups of urinary BP-3 concentration,tertile 1,207,mg/dl,mean,,,95% CI,184.0,230.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,963,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of Triglycerides by groups of urinary BP-3 concentration,tertile 2,190,mg/dl,mean,,,95% CI,167.0,212.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,964,2025-12-02T16:05:12.251790
35421480.0,adjusted serum level of Triglycerides by groups of urinary BP-3 concentration,tertile 3,188,mg/dl,mean,,,95% CI,165.0,211.0,175,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,965,2025-12-02T16:05:12.251790
35839910.0,Associations (crude OR) between SG-adjusted urinary concentrations of BP-3 per IQR and GDM,per IQR,1.57,,,,,95% CI,1.22,2.03,64,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,966,2025-12-02T16:05:12.251790
35839910.0,Associations (crude OR) between SG-adjusted urinary concentrations of BP-3 and GDM,<=7.4 ng/ml,1,,,,,95% CI,,,11,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,967,2025-12-02T16:05:12.251790
35839910.0,Associations (crude OR) between SG-adjusted urinary concentrations of BP-3 per IQR and GDM,7.41-22 ng/ml,1.28,,,,,95% CI,0.55,3.03,14,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,968,2025-12-02T16:05:12.251790
35839910.0,Associations (crude OR) between SG-adjusted urinary concentrations of BP-3 per IQR and GDM,>=22.01 ng/ml,3.41,,,,,95% CI,1.63,7.15,38,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,969,2025-12-02T16:05:12.251790
35839910.0,Associations (adjusted OR) between SG-adjusted urinary concentrations of BP-3 per IQR and GDM,per IQR,1.54,,,,,95% CI,1.15,2.08,64,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,970,2025-12-02T16:05:12.251790
35839910.0,Associations (adjusted OR) between SG-adjusted urinary concentrations of BP-3 per IQR and GDM,<=7.4,1,,,,,95% CI,,,11,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,971,2025-12-02T16:05:12.251790
35839910.0,Associations (adjusted OR) between SG-adjusted urinary concentrations of BP-3 per IQR and GDM,7.41-22,1.2,,,,,95% CI,0.44,3.23,14,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,972,2025-12-02T16:05:12.251790
35839910.0,Associations (adjusted OR) between SG-adjusted urinary concentrations of BP-3 per IQR and GDM,>=22.01,3.82,,,,,95% CI,1.6,9.08,38,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,973,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during first trimester, ng/ml",Tertile 1 (IQR 6.3-18.4),ref,,,,,95% CI,,,333,maternal,1st trimester,,0.34,adjusted for urinary creatinine level,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,974,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during first trimester, ng/ml",Tertile 2 (IQR 39.3-80.3),0.68,,,,,95% CI,0.39,1.21,333,maternal,1st trimester,,0.34,adjusted for urinary creatinine level,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,975,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during first trimester, ng/ml",Tertile 3 (IQR 175.7-821.5),0.79,,,,,95% CI,0.45,1.38,333,maternal,1st trimester,,0.34,adjusted for urinary creatinine level,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,976,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during first trimester, ng/ml",Per IQR increment,0.99,,,,,95% CI,0.97,1.02,333,maternal,1st trimester,,0.34,adjusted for urinary creatinine level,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,977,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during second trimester, ng/ml",Tertile 1 (IQR 5.6-15.6),ref,,,,,95% CI,,,333,maternal,2nd trimester,,0.13,adjusted for urinary creatinine level,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,978,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during second trimester, ng/ml",Tertile 2 (IQR 34.9-68.4),0.56,,,,,95% CI,0.37,1.26,333,maternal,2nd trimester,,0.13,adjusted for urinary creatinine level,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,979,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during second trimester, ng/ml",Tertile 3 (IQR 129.1-652.4),0.74,,,,,95% CI,0.45,1.56,333,maternal,2nd trimester,,0.13,adjusted for urinary creatinine level,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,980,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during second trimester, ng/ml",Per IQR increment,1,,,,,95% CI,0.95,1.05,333,maternal,2nd trimester,,0.13,adjusted for urinary creatinine level,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,981,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during first trimester, ng/ml",Tertile 1 (IQR 6.3-18.4),ref,,,,,95% CI,,,333,maternal,1st trimester,,0.34,"adjusted for urinary creatinine level, age, prepregnancy BMI, and race/ethnicity (White, Black, Hispanic, or other) among all and among non-Asians/Pacific Islanders",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,982,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during first trimester, ng/ml",Tertile 2 (IQR 39.3-80.3),0.68,,,,,95% CI,0.28,1.11,333,maternal,1st trimester,,0.34,"adjusted for urinary creatinine level, age, prepregnancy BMI, and race/ethnicity (White, Black, Hispanic, or other) among all and among non-Asians/Pacific Islanders",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,983,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during first trimester, ng/ml",Tertile 3 (IQR 175.7-821.5),0.84,,,,,95% CI,0.39,1.4,333,maternal,1st trimester,,0.34,"adjusted for urinary creatinine level, age, prepregnancy BMI, and race/ethnicity (White, Black, Hispanic, or other) among all and among non-Asians/Pacific Islanders",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,984,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during first trimester, ng/ml",Per IQR increment,1,,,,,95% CI,0.98,1.03,333,maternal,1st trimester,,0.34,"adjusted for urinary creatinine level, age, prepregnancy BMI, and race/ethnicity (White, Black, Hispanic, or other) among all and among non-Asians/Pacific Islanders",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,985,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during second trimester, ng/ml",Tertile 1 (IQR 5.6-15.6),ref,,,,,95% CI,,,333,maternal,2nd trimester,,0.13,"adjusted for urinary creatinine level, age, prepregnancy BMI, and race/ethnicity (White, Black, Hispanic, or other) among all and among non-Asians/Pacific Islanders",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,986,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during second trimester, ng/ml",Tertile 2 (IQR 34.9-68.4),0.66,,,,,95% CI,0.32,1.39,333,maternal,2nd trimester,,0.13,"adjusted for urinary creatinine level, age, prepregnancy BMI, and race/ethnicity (White, Black, Hispanic, or other) among all and among non-Asians/Pacific Islanders",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,987,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during second trimester, ng/ml",Tertile 3 (IQR 129.1-652.4),0.82,,,,,95% CI,0.39,1.71,333,maternal,2nd trimester,,0.13,"adjusted for urinary creatinine level, age, prepregnancy BMI, and race/ethnicity (White, Black, Hispanic, or other) among all and among non-Asians/Pacific Islanders",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,988,2025-12-02T16:05:12.251790
36227336.0,"Adjusted ORs (95% CIs) of GDM in association with urinary BP-3 during second trimester, ng/ml",Per IQR increment,0.99,,,,,95% CI,0.94,1.05,333,maternal,2nd trimester,,0.13,"adjusted for urinary creatinine level, age, prepregnancy BMI, and race/ethnicity (White, Black, Hispanic, or other) among all and among non-Asians/Pacific Islanders",PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,989,2025-12-02T16:05:12.251790
36346334.0,per-cycle odds ratio of conception associated with urinary BP-3 concentration (ug/g creatinine),Q2 (0.41-1.03),0.73,,,,,95% CI,0.47,1.16,42,maternal,pregnancy,,0.09,conceptions,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,990,2025-12-02T16:05:12.251790
36346334.0,per-cycle odds ratio of conception associated with urinary BP-3 concentration (ug/g creatinine),Q3 (1.04-2.6),1.07,,,,,95% CI,0.66,1.75,40,maternal,pregnancy,,0.09,conceptions,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,991,2025-12-02T16:05:12.251790
36346334.0,per-cycle odds ratio of conception associated with urinary BP-3 concentration (ug/g creatinine),Q4 (2.7-11.4),1.5,,,,,95% CI,0.87,2.59,42,maternal,pregnancy,,0.09,conceptions,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,992,2025-12-02T16:05:12.251790
36346334.0,per-cycle odds ratio of conception associated with urinary BP-3 concentration (ug/g creatinine),Q5 (>11.4),1.08,,,,,95% CI,0.65,1.78,49,maternal,pregnancy,,0.09,conceptions,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,993,2025-12-02T16:05:12.251790
36346334.0,odds ratio for early pregnancy loss associatied with urinary BP-3 concentration (ug/g creatinine),Q2 (0.41-1.03),1.92,,,,,95% CI,0.6,6.14,27,maternal,pregnancy,,0.34,early losses,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,994,2025-12-02T16:05:12.251790
36346334.0,odds ratio for early pregnancy loss associatied with urinary BP-3 concentration (ug/g creatinine),Q3 (1.04-2.6),1.03,,,,,95% CI,0.33,3.19,37,maternal,pregnancy,,0.34,early losses,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,995,2025-12-02T16:05:12.251790
36346334.0,odds ratio for early pregnancy loss associatied with urinary BP-3 concentration (ug/g creatinine),Q4 (2.7-11.4),0.55,,,,,95% CI,0.18,1.66,44,maternal,pregnancy,,0.34,early losses,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,996,2025-12-02T16:05:12.251790
36346334.0,odds ratio for early pregnancy loss associatied with urinary BP-3 concentration (ug/g creatinine),Q5 (>11.4),1.01,,,,,95% CI,0.29,3.48,33,maternal,pregnancy,,0.34,early losses,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,997,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome total oocyte yield ,concentration,-0.04,,,,,95% CI,-0.19,0.11,450,maternal,pregnancy,,0.58,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,998,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome total oocyte yield ,Q2,0.003,,,,,95% CI,-0.15,0.16,450,maternal,pregnancy,,0.97,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,999,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome total oocyte yield ,Q3,0.32,,,,,95% CI,-0.02,-0.17,450,maternal,pregnancy,,0.13,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1000,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome total oocyte yield ,Q4,-0.18,,,,,95% CI,-0.32,0.04,450,maternal,pregnancy,,0.56,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1001,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome MII oocyte count,concentration,-0.1,,,,,95% CI,-0.25,0.06,450,maternal,pregnancy,,0.22,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1002,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome MII oocyte count,Q2,0.04,,,,,95% CI,-0.11,0.19,450,maternal,pregnancy,,0.59,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1003,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome MII oocyte count,Q3,-0.09,,,,,95% CI,-0.24,0.06,450,maternal,pregnancy,,0.25,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1004,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome MII oocyte count,Q4,-0.04,,,,,95% CI,-0.28,0.194,450,maternal,pregnancy,,0.72,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1005,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome fertilization roate,concentration,-0.02,,,,,95% CI,-0.17,0.14,450,maternal,pregnancy,,0.81,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1006,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome fertilization roate,Q2,0.03,,,,,95% CI,-0.13,0.18,450,maternal,pregnancy,,0.75,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1007,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome fertilization roate,Q3,0.05,,,,,95% CI,-0.09,0.19,450,maternal,pregnancy,,0.51,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1008,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome fertilization roate,Q4,-0.03,,,,,95% CI,-0.27,0.21,450,maternal,pregnancy,,0.84,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1009,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome implantation rate,concentration,-0.02,,,,,95% CI,-0.18,0.13,450,maternal,pregnancy,,0.96,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1010,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome implantation rate,Q2,-0.04,,,,,95% CI,-0.19,0.12,450,maternal,pregnancy,,0.78,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1011,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome implantation rate,Q3,0.05,,,,,95% CI,-0.09,0.2,450,maternal,pregnancy,,0.65,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1012,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome implantation rate,Q4,-0.07,,,,,95% CI,-0.32,0.17,450,maternal,pregnancy,,0.53,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1013,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome clinical pregnancy,concentration,0.01,,,,,95% CI,-0.14,0.17,450,maternal,pregnancy,,0.87,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1014,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome clinical pregnancy,Q2,-0.12,,,,,95% CI,-0.28,0.03,450,maternal,pregnancy,,0.12,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1015,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome clinical pregnancy,Q3,-0.03,,,,,95% CI,-0.18,0.12,450,maternal,pregnancy,,0.69,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1016,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome clinical pregnancy,Q4,0.12,,,,,95% CI,-0.11,0.36,450,maternal,pregnancy,,0.3,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1017,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome live birth,concentration,-0.05,,,,,95% CI,-0.2,0.09,450,maternal,pregnancy,,0.51,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1018,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome live birth,Q2,-0.02,,,,,95% CI,-0.17,0.13,450,maternal,pregnancy,,0.77,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1019,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome live birth,Q3,0.03,,,,,95% CI,-0.13,0.18,450,maternal,pregnancy,,0.73,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1020,2025-12-02T16:05:12.251790
36701050.0,urinary c oncentration of BP-3 in relation to IVF outcome live birth,Q4,0.16,,,,,95% CI,-0.06,0.4,450,maternal,pregnancy,,0.16,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1021,2025-12-02T16:05:12.251790
36857904.0,effect estimate from adjusted urinary BP-3 standardized concentration and newborn total T4 concentration,,1.61,,,,,95% CI,0.19,3.02,434,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1022,2025-12-02T16:05:12.251790
36857904.0,effect estimate from adjusted urinary BP-3 standardized concentration and newborn TSH concentration,,-0.02,,,,,95% CI,-0.07,0.02,442,maternal,pregnancy,,,,PRGLAC_PK_curation_06232025.xlsx,PK curation_Shijun,Outcomes (summary),Outcomes_summary,1023,2025-12-02T16:05:12.251790
